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ABSTRACT 
Loss of appetite is frequently observed during ageing; termed the ‘anorexia of ageing’. Some evidence 
suggests that with advancing age there is an increase in satiety hormones, such as CCK and PYY, and 
a decrease in the hunger hormone ghrelin which may contribute to the anorexia of ageing. However, 
not all studies agree, emphasising the need for more in depth research to clarify age related changes.  
My first study developed a rat model to replicate the hormonal responses observed in humans. 
However, the results of this study did not replicate human studies; there were no alterations 
gastrointestinal hormones. I then designed a human study to examine more comprehensively, the 
effect of ageing on gastrointestinal peptide hormone release. Healthy human volunteers aged 20 to 92 
years were studied in fasting and post-prandial conditions. The results demonstrated an increase in 
PYY concentrations post-prandially in older volunteers. In order to understand the mechanism behind 
this, I followed this study with an investigation looking at the changes in gastrointestinal hormones in 
ageing mice colons. The data produced results conflicting with the human study, since no increase in 
PYY levels was observed.  
Dietary manipulation provides a good opportunity to alter gastrointestinal appetite hormone release, 
since release differs depending on the macronutrient content of the food consumed. My final studies 
focused on high protein diets. Results demonstrated that older volunteers were insensitive to the 
satiating effect of protein, where younger volunteers ate less following a high protein test meal but the 
older volunteers food intake did not change. Gastrointestinal appetite hormones concentrations did not 
change significantly between the high and low protein meals in the older and younger adults.  
These results suggest that age-associated reductions in appetite could be due to a resultant increase in 
the satiety hormone PYY. More studies need to be conducted to understand the role of protein on 
appetite and food intake in older adults. 
 
3 
 
TABLE OF CONTENTS 
 
 
TITLE PAGE…………………………………………………………………………………………...1 
ABSTRACT ............................................................................................................................................ 2 
TABLE OF CONTENTS ........................................................................................................................ 3 
LIST OF FIGURES .............................................................................................................................. 11 
LIST OF TABLES ................................................................................................................................ 15 
STATEMENT OF WORK PERFORMED BY AUTHOR .................................................................. 19 
ACKNOWLEDGEMENTS .................................................................................................................. 20 
PUBLICATIONS RELATED TO WORK IN THESIS ....................................................................... 21 
ABSTRACTS RELATED TO WORK IN THESIS ............................................................................. 21 
ABBREVIATIONS .............................................................................................................................. 22 
DEFINITIONS ...................................................................................................................................... 24 
Chapter 1 INTRODUCTION ................................................................................................................ 25 
1.1. Undernutrition ............................................................................................................................ 26 
1.2. The ‘Anorexia of Ageing’ .......................................................................................................... 27 
1.2.1. Appetite and weight loss in illness ...................................................................................... 30 
1.2.2. Summary ............................................................................................................................. 31 
1.3. Overview of the appetite regulatory system............................................................................... 31 
1.3.1. Ghrelin ................................................................................................................................ 34 
1.3.2. Peptide Tyrosine Tyrosine (PYY) ....................................................................................... 35 
1.3.3. Cholecystokinin (CCK)....................................................................................................... 36 
1.3.4. Glucagon-like peptide 1 (GLP-1) ....................................................................................... 37 
1.3.5. Pancreatic Polypeptide (PP) ................................................................................................ 37 
1.3.6. Oxyntomodulin (OXM) ...................................................................................................... 38 
1.3.7. Leptin .................................................................................................................................. 38 
1.3.8. Insulin ................................................................................................................................. 39 
1.4. Appetite gastrointestinal hormones in ageing and illness .......................................................... 39 
1.4.1. Ghrelin in illness and ageing ............................................................................................... 40 
1.4.2. PYY in illness and ageing ................................................................................................... 46 
1.4.3. CCK in illness and ageing ................................................................................................... 48 
1.4.4. Insulin in illness and ageing ................................................................................................ 50 
1.4.5. Leptin in illness and ageing ................................................................................................ 51 
1.4.6. Other hormones in illness and ageing ................................................................................. 52 
4 
 
1.5. Ageing and the gastrointestinal tract .......................................................................................... 61 
1.6. Other factors implicated in the loss of appetite in ageing and illness ........................................ 62 
1.6.1. Taste and smell ................................................................................................................... 62 
1.6.2. Cytokines ............................................................................................................................ 63 
1.7. Macronutrients, gastrointestinal hormone release and appetite ................................................. 63 
1.7.1. Ghrelin response to macronutrients .................................................................................... 64 
1.7.2. PP response to macronutrients ............................................................................................ 65 
1.7.3. PYY response to macronutrients ......................................................................................... 65 
1.7.4. CCK response to macronutrients ........................................................................................ 65 
1.7.5. GLP-1 response to macronutrients ...................................................................................... 66 
1.7.6 Macronutrients influence on satiety and energy intake ........................................................ 66 
1.7.7. Summary ............................................................................................................................. 68 
1.8. Thesis introduction summary ..................................................................................................... 69 
1.9. Thesis hypothesis ....................................................................................................................... 69 
1.10. Thesis aims and objectives ....................................................................................................... 70 
Chapter 2 METHODS ........................................................................................................................... 71 
2.1. Ethics ......................................................................................................................................... 72 
2.2. Recruitment ................................................................................................................................ 72 
2.3. Screening of participants ............................................................................................................ 72 
2.3.1. Anthropometrics.................................................................................................................. 74 
2.3.2. Blood pressure measurement .............................................................................................. 76 
2.3.3. Three Factors Eating Questionnaire (TFEQ) questionnaire – restraint only....................... 78 
2.3.4. Screening blood sample ...................................................................................................... 78 
2.3.5. The International Physical Activity Questionnaire (IPAQ) ................................................ 81 
2.3.6. Measurement of physical activity; the Actical monitor ...................................................... 83 
2.4. Ad libitum test meals .................................................................................................................. 84 
2.5. Sham visits ................................................................................................................................. 86 
2.6. Measurement of gastric emptying .............................................................................................. 86 
2.7. Measurement of blood parameters ............................................................................................. 87 
2.7.1. Radioimmunoassay ............................................................................................................. 87 
2.7.2. Analysis of total ghrelin ...................................................................................................... 88 
2.7.3. Plasma acyl ghrelin analysis ............................................................................................... 89 
2.7.4. Plasma PYY analysis .......................................................................................................... 89 
2.7.5. GLP-1 analysis .................................................................................................................... 89 
2.7.6. Insulin analysis .................................................................................................................... 90 
2.7.7. Glucose analysis .................................................................................................................. 90 
5 
 
2.7.8. Paracetamol/ gastric emptying analysis .............................................................................. 90 
2.8. Visual analogue scales ............................................................................................................... 91 
Chapter 3 THE EFFECT OF TRAUMA ON WEIGHT LOSS AND GASTROINTESTINAL 
APPETITE HORMONE RESPONSE IN RATS .................................................................................. 92 
3.1. Introduction ................................................................................................................................ 93 
3.2. Hypothesis.................................................................................................................................. 94 
3.3. Aim ............................................................................................................................................ 94 
3.4. Objectives .................................................................................................................................. 95 
3.5. Pilot Study .................................................................................................................................. 95 
3.5.1. Introduction ......................................................................................................................... 95 
3.5.2. Methodology ....................................................................................................................... 95 
3.5.3. Pilot study statistics ............................................................................................................. 97 
3.5.4. Pilot study results ................................................................................................................ 97 
3.6. Main study ................................................................................................................................. 99 
3.6.1. Introduction ......................................................................................................................... 99 
3.6.2. Methodology ....................................................................................................................... 99 
3.6.3. Procedure day .................................................................................................................... 100 
3.6.4. Procedure day methods ..................................................................................................... 101 
3.6.5. Measurement of outcomes ................................................................................................ 102 
3.6.6. Measurement of peptides .................................................................................................. 102 
3.6.7. Statistical analysis ............................................................................................................. 102 
3.7. Results ...................................................................................................................................... 103 
3.7.1. Body weight gain pre- and post-surgery ........................................................................... 103 
3.7.2. Food intake pre- and post-surgery..................................................................................... 105 
3.7.3. Plasma PYY ...................................................................................................................... 107 
3.7.4. Plasma GLP-1 ................................................................................................................... 108 
3.7.5. Plasma total ghrelin and acyl ghrelin ................................................................................ 109 
3.8. Discussion ................................................................................................................................ 110 
3.8.1. Overview ............................................................................................................................... 110 
3.8.2. Summary of findings ......................................................................................................... 110 
3.8.3. Is trauma associated with body weight loss and a reduction in energy intake in rodents? 110 
3.8.4. Is there an alteration in gastrointestinal appetite hormones in animals receiving trauma via 
a LV cannulation? ....................................................................................................................... 112 
3.8.5. Limitations ........................................................................................................................ 113 
3.8.6. Conclusion ........................................................................................................................ 113 
6 
 
Chapter 4 COMPARISON OF GASTROINTESTINAL APPETITE HORMONES IN OLDER AND 
YOUNGER HEALTHY VOLUNTEERS .......................................................................................... 115  
4.1. Introduction .............................................................................................................................. 116 
4.2. Hypothesis................................................................................................................................ 116 
4.3. Aims and Objectives ................................................................................................................ 117 
4.3.1. Aims .................................................................................................................................. 117 
4.3.2. Objectives ......................................................................................................................... 117 
4.4. Methodology ............................................................................................................................ 117 
4.4.1. Study design ...................................................................................................................... 117 
4.4.2. Study population ............................................................................................................... 117 
4.4.3. Study plan ......................................................................................................................... 118 
4.4.4. Measurement of outcomes ................................................................................................ 120 
4.4.5. Statistical analysis ............................................................................................................. 121 
4.5. Results ...................................................................................................................................... 123 
4.5.1. Descriptive statistics ......................................................................................................... 123 
4.5.2. Energy intake .................................................................................................................... 126 
4.5.3. Water consumption ........................................................................................................... 128 
4.5.4. Physical activity levels ...................................................................................................... 129 
4.5.5. Multiple linear regression to determine if age is a significant predictor of energy intake 
taking into account other factors ................................................................................................. 132 
4.5.6. Visual analogue scores ...................................................................................................... 133 
4.5.7. Plasma Hormone Analysis ................................................................................................ 140 
4.5.8. Insulin, glucose and gastric emptying measurements ....................................................... 146 
4.5.9. VAS following ad libitum test meal.................................................................................. 152 
4.6. Discussion ................................................................................................................................ 154 
4.6.1. Overview ........................................................................................................................... 154 
4.6.2. Findings ............................................................................................................................. 154 
4.6.3. Plasma PYY is elevated in ageing .................................................................................... 155 
4.6.4. Plasma GLP-1, total ghrelin and acyl ghrelin ................................................................... 158 
4.6.5. Body composition and activity levels ............................................................................... 160 
4.6.6. Energy intake .................................................................................................................... 161 
4.6.7. Water consumption ........................................................................................................... 162 
4.6.8. Visual analogue scales ...................................................................................................... 162 
4.6.9. Glucose, insulin and insulin resistance ............................................................................. 164 
4.6.10. Gastric emptying ............................................................................................................. 165 
4.6.11. Limitations ...................................................................................................................... 166 
7 
 
4.6.12. Summary ......................................................................................................................... 168 
4.6.13. Future Work .................................................................................................................... 169 
Chapter 5 COMPARISON OF GASTROINTESTINAL APPETITE HORMONES IN AGED AND 
YOUNG MICE COLONS .................................................................................................................. 171 
5.1. Introduction .............................................................................................................................. 172 
5.2. Hypothesis................................................................................................................................ 174 
5.3. Aims and objectives ................................................................................................................. 174 
5.3.1. Aims .................................................................................................................................. 174 
5.3.2. Objectives ......................................................................................................................... 174 
5.4. Methodology ............................................................................................................................ 174 
5.5. Outcomes ................................................................................................................................. 175 
5.5.1 Measurement of Outcomes ................................................................................................ 175 
5.6. Statistical analysis .................................................................................................................... 176 
5.7. Results ...................................................................................................................................... 177 
5.7.1. Descriptive statistics ......................................................................................................... 177 
5.7.2. Body weight ...................................................................................................................... 178 
5.7.3. Colonic PYY and GLP-1 concentrations .......................................................................... 179 
5.7.4. Stomach ghrelin concentrations ........................................................................................ 180 
5.8. Discussion ................................................................................................................................ 181 
5.8.1. Overview ........................................................................................................................... 181 
5.8.2. Summary of findings ......................................................................................................... 181 
5.8.3. Ghrelin is elevated in mice stomachs with age ................................................................. 182 
5.8.4. PYY and GLP-1 concentrations ........................................................................................ 183 
5.8.5. Limitations and future work .............................................................................................. 184 
5.8.6. Conclusions ....................................................................................................................... 186 
Chapter 6 THE ASSOCIATION BETWEEN HABITUAL PROTEIN INTAKE ON BMI AND 
HABITUAL ENERGY INTAKE IN OLDER AND YOUNGER ADULTS ..................................... 187 
6.1. Introduction .............................................................................................................................. 188 
6.2. Hypothesis................................................................................................................................ 189 
6.3. Aims and objectives ................................................................................................................. 189 
6.3.1. Aims .................................................................................................................................. 189 
6.3.2. Objectives ......................................................................................................................... 189 
6.4. Methodology ............................................................................................................................ 189 
6.4.1. Preparation of the NDNS datasheet .................................................................................. 190 
6.5. Outcomes ................................................................................................................................. 191 
6.6. Statistical analysis .................................................................................................................... 192 
8 
 
6.7. Results ...................................................................................................................................... 193 
6.7.1. Descriptive statistics ......................................................................................................... 193 
6.7.2. Correlations ....................................................................................................................... 196 
6.7.3. Habitual intake of macronutrients and BMI ...................................................................... 201 
6.7.4. Habitual intake of macronutrients and total energy intake ............................................... 206 
6.7.5. Habitual protein intake and body fat percentage ............................................................... 211 
6.7.6. Multiple linear regression ................................................................................................. 213 
6.8. Discussion ................................................................................................................................ 217 
6.8.1. Study overview ................................................................................................................. 217 
6.8.2. Summary of findings ......................................................................................................... 217 
6.8.3. Habitual protein intakes .................................................................................................... 219 
6.8.4. BMI and energy intake decrease’s in older adults ............................................................ 221 
6.8.5. Habitual fibre intakes ........................................................................................................ 221 
6.8.6. Habitual carbohydrate intakes ........................................................................................... 223 
6.8.7. Habitual fat intake ............................................................................................................. 223 
6.8.8. Limitations ........................................................................................................................ 224 
6.8.9. Conclusions ....................................................................................................................... 225 
Chapter 7 INVESTIGATION INTO THE EFFECT OF PROTEIN ON APPETITE SUPPRESSION 
AND GASTROINTESTINAL APPETITE HORMONE RESPONSE IN YOUNGER AND OLDER 
ADULTS ............................................................................................................................................. 226 
7.1. Introduction .............................................................................................................................. 227 
7.2. Hypothesis................................................................................................................................ 228 
7.3. Aims and objectives ................................................................................................................. 228 
7.3.1. Aims .................................................................................................................................. 228 
7.3.2. Objectives ......................................................................................................................... 228 
7.4. Methodology ............................................................................................................................ 229 
7.4.1. Study design ...................................................................................................................... 229 
7.4.2. Study plan ......................................................................................................................... 232 
7.4.3. Measurement of outcomes ................................................................................................ 235 
7.5. Statistical analysis .................................................................................................................... 236 
7.6. Results ...................................................................................................................................... 237 
7.6.1. Descriptive statistics ......................................................................................................... 237 
7.6.2. Physical activity levels ...................................................................................................... 238 
7.6.3. Energy intake at the ad libitum test meal .......................................................................... 239 
7.6.4. Food diaries ....................................................................................................................... 241 
7.6.5. Visual analogue scales ...................................................................................................... 246 
9 
 
7.6.6. Plasma gastrointestinal appetite hormone analysis ........................................................... 251 
7.6.7. Plasma insulin, glucose and insulin resistance .................................................................. 253 
7.6.8. Paracetamol method; gastric emptying ............................................................................. 257 
7.6.9. VAS following ad libitum test meal.................................................................................. 258 
7.7. Discussion ................................................................................................................................ 259 
7.7.1. Overview ........................................................................................................................... 259 
7.7.2. Findings ............................................................................................................................. 259 
7.7.3. Older adults are less sensitive to the effects of protein on reductions in energy intake 
compared to their younger counterparts. ..................................................................................... 262 
7.7.4. Gastrointestinal appetite hormone responses to different protein containing preloads. .... 265 
7.7.5. Subjective feelings of appetite in response to different protein containing preloads. ....... 269 
7.7.6. Glucose, insulin, insulin resistance, and gastric emptying in response to a high protein 
meal ............................................................................................................................................. 270 
7.7.7. Limitations ........................................................................................................................ 273 
7.7.8. Summary ........................................................................................................................... 275 
7.7.9. Future Work ...................................................................................................................... 275 
Chapter 8 GENERAL DISCUSSION AND FUTURE WORK ......................................................... 277 
8.1. Discussion and Future Work .................................................................................................... 278 
9.0. REFERENCES ............................................................................................................................ 288 
10.0. APPENDIX ................................................................................................................................ 325 
10.1. GP Letter sent out to participants, chapters 4 and 7 ............................................................... 326 
10.2. Three Factors Eating Questionnaire, restraint section only ................................................... 327 
10.3. The International Physical Activity Questionnaire ................................................................ 331 
10.4. Visual Analogue Scales ......................................................................................................... 334 
10.5. Participant Information Sheet, Chapter 4 ............................................................................... 335 
10.6. Participant Consent Form, Chapter 4 ..................................................................................... 340 
10.7. Chapter 3 plasma gastrointestinal appetite hormone results .................................................. 341 
10.8. Chapter 4 Tables and Results. ................................................................................................ 342 
10.8.1 Chapter 4 tables for AUC and IAUC Visual Analogue scores ........................................ 342 
10.8.2. Chapter 4 table for AUC and IAUC plasma hormone results ......................................... 343 
10.8.3 Chapter 4 table for AUC and IAUC insulin and Glucose and HOMA scores ................. 344 
10.8.4 Correlations between energy intake and final VAS score................................................ 345 
10.8.5. Chapter 4, separate statistics for males and females ....................................................... 346 
10.9. Chapter 7 Study Information Sheet ........................................................................................ 353 
10.10. Chapter 7 results .................................................................................................................. 358 
10.10.1. Energy intake ................................................................................................................ 358 
10 
 
10.10.2. Visual Analogue Scales ................................................................................................ 362 
10.10.3. Plasma hormone analysis .............................................................................................. 365 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
LIST OF FIGURES 
Chapter 1 – Introduction 
Figure 1.1. Mechanisms involved in the regulation of appetite………………………………….32 
Chapter 3 – The effect of trauma on weight loss and gastrointestinal hormone response in rats  
Figure 3.1.  Change in body weight following DMH cannulation………………………………..98 
Figure 3.2.  Change in food intake following DMH cannulation………………………………...98 
Figure 3.3.  Body weight change per day from days 1 to 8 in the control, anaesthetics and 
cannulated rats……………………………………………………………………...104 
Figure 3.4.  Total body weight change per day from days 1 to 8 in the control, anaesthetics and 
cannulated rats…………………………………………………………………...…104 
Figure 3.5. Food intake from days 1 to 8 in the controls, anaesthetics and cannulated rats……106 
Figure 3.6. Plasma PYY concentrations in the anaesthetics, cannulated and control rats……...107 
Figure 3.7. Plasma GLP-1 concentrations in the anaesthetics, cannulated and control rats……108 
Figure 3.8. Plasma total ghrelin (A) and acyl ghrelin (B) concentrations in the anaesthetics 
cannulated and control rats…………………………………………………………109 
Chapter 4 – Comparison of gastrointestinal appetite hormones in older and younger healthy 
volunteers 
Figure 4.1. Overview of study day. Participants were asked to attend two visits………………120 
Figure 4.2.  Flow chart of screening process…………………………………………………….123 
Figure 4.3. Food intake at the ad libitum test meal…………………………………………..…126 
Figure 4.4. Energy intake at the ad libitum test meal taking into account lean body 
mass…………………………………………………………………………………………………..127 
Figure 4.5. Water consumption at study visit…………………………………………………...128 
Figure 4.6. Three day average actical total energy expenditure (kcal)…………………………130 
Figure 4.7. Three day average actical activity energy expenditure (kcal)……………………...131 
Figure 4.8. VAS scores for how hungry in the 20-39, 40-59, 60-79 and 80+ age groups……...135 
12 
 
Figure 4.9. VAS scores for how sick do you feel in the 20-39, 40-59, 60-79 and 80+ age 
groups………………………………………………………………………………………………...136 
Figure 4.10. VAS scores for how pleasant to eat in the 20-39, 40-59, 60-79 and 80+ age groups 
………………………………………………………………………………………………………..137 
Figure 4.11. VAS scores for how much can you eat in the 20-39, 40-59, 60-79 and 80+ age groups 
………………………………………………………………………………………………………..138 
Figure 4.12. VAS scores for how full do you feel in the 20-39, 40-59, 60-79 and 80+ age 
groups………………………………………………………………………………………………...139 
Figure 4.13. Plasma PYY concentrations in the 20-39, 40-59, 60-79 and 80+ age groups……...142 
Figure 4.14.  Plasma GLP-1 concentrations in the 20-39, 40-59, 60-79 and 80+ age groups……143 
Figure 4.15. Plasma total ghrelin concentrations in the 20-39, 40-59, 60-79 and 80+ age 
groups………………………………………………………………………………………………...144 
Figure 4.16. Plasma acyl ghrelin concentrations in the 20-39, 40-59, 60-79 and 80+ age 
groups………………………………………………………………………………………………...145 
Figure 4.17. Plasma insulin concentrations in the 20-39, 40-59, 60-79 and 80+ age groups……148 
Figure 4.18. Plasma glucose concentrations in the 20-39, 40-59, 60-79 and 80+ age groups…...149 
Figure 4.19. HOMA scores in the 20-39, 40-59, 60-79 and 80+ age groups…………………….150 
Figure 4.20. HOMA PP scores in the 20-39, 40-59, 60-79 and 80+ age groups………………...150 
Figure 4.21. Gastric emptying time in the 20-39, 40-59, 60-79 and 80+ age groups……………151 
Figure 4.22. VAS how much can you eat following ad libitum test meal in the 20-39, 40-59, 60-79 
and 80+ age groups…………………………………………………………………153 
Figure 4.23.  Possible mechanisms in how alterations in gastrointestinal hormones may contribute 
to the anorexia of ageing……………………………………………………………170 
Chapter 5 – Comparison of gastrointestinal hormones in aged and young mice colons 
Figure 5.1. Body weights of mice in the three different age groups……………………………178 
Figure 5.2. PYY and GLP-1 concentrations in mice colons……………………………………179 
Figure 5.3. Total ghrelin concentrations in mice stomachs……………………………………..180 
13 
 
Chapter 6 – The association between habitual protein intake on BMI and habitual energy intake 
in older and younger adults 
Figure 6.1. Correlations between BMI and age in the 19-74 and 75+ years age groups……….197 
Figure 6.2. Correlations between Kcal intake and age in the 75+ year’s age group……………198 
Figure 6.3. Correlations between estimated body fat percentage and age in the 19-74 and 75+ 
year age groups……………………………………………………………………..200 
Figure 6.4. Correlations between percentage energy intake from protein and BMI in the 19-74 
and 75+ year age groups……………………………………………………………202 
Figure 6.5. Correlations between percentage energy intake from fat and BMI in the 19-74 and the 
75+ year age groups………………………………………………………………...203 
Figure 6.6. Correlations between percentage energy intake from carbohydrate and BMI in the 19-
74 and the 75+ year age groups…………………………………………………….204 
Figure 6.7. Correlations between fibre (g/1000kcal) and BMI in the 19-74 and the 75+ year age 
groups……………………………………………………………………………….205 
Figure 6.8. Correlations between percentage energy from protein and energy intake in the 19-74 
and 75+ year age groups……………………………………………………………207 
Figure 6.9. Correlations between percentage energy from fat and energy intake in the 19-74 and 
the 75+ year age groups…………………………………………………………….208 
Figure 6.10. Correlations between percentage energy from carbohydrate and energy intake in the 
19-74 and 75+ year age groups……………………………………………………..209 
Figure 6.11. Correlations between fibre (g/1000kcal) and energy intake in the 19-74 and 75+ years 
age groups…………………………………………………………………………..210 
Figure 6.12. Correlations between habitual protein intake (%kcal) and body fat percentage in the 
19-74 and 75+ year age groups……………………………………………………..212 
Chapter 7 – Investigation into the effect of protein on appetite suppression and gastrointestinal 
hormone response in younger and older adults 
Figure 7.1.  Diagram of overview of study day…………………………………………………235  
Figure 7.2. Energy intake (kcal) at the ad libitum test meal in the 20-39 and 65+ age groups 
following protein test meals B (15%), C (30%) and D (60%)……………………...239 
14 
 
Figure 7.3.  Total energy intake (kcal) consumed on the whole study day in the 20-39 and 65+ age 
groups following test meals B (15%), C (30%) and D (60%)……………………...241 
Figure 7.4. Time to eat next meal following protein preloads B (15%), C (30%) and D (60%) in 
the20-39 and 65+ age groups……………………………………………………….243 
Figure 7.5. Energy intake (kcal) on day two following protein preloads B (15%), C (30%) and D 
(60%) in the 20-39 and 65+ age groups…………………………………………….245 
Figure 7.6. AUC Visual analogue scores in the 20-39 and 65+ age group following protein test 
meal B (15%), C (30%) and D (60%)………………………………………………248 
Figure 7.7. AUC PYY, GLP-1 and acyl ghrelin in the 20-39 and 65+ age group following protein 
test meal B (15%), C (30%) and D (60%)………………………………………….252 
Figure 7.8. AUC insulin, AUC glucose and post-prandial insulin resistance in the 20-39 and 65+ 
age group following protein test meal B (15%), C (30%) and D (60%)…………...255 
Figure 7.9. Gastric emptying (time) using paracetamol method following protein test meal B 
(15%), C (30%) and D (60%) in the 20-39 and 65+ age group…………………….257 
 
 
 
 
 
 
 
 
 
15 
 
LIST OF TABLES 
 
Chapter 1 - Introduction 
Table 1.1. Summary of the characteristics of the main gastrointestinal appetite hormones…….33 
Table 1.2. Published studies exploring ageing and gastrointestinal appetite hormones in ageing 
in humans…………………………………………………………………………….53 
Table 1.3. Published studies exploring illness and gastrointestinal appetite hormones in 
humans……………………………………………………………………………….57 
Chapter 2 - Methods 
Table 2.1. Inclusion and exclusion criteria for human studies………………………………….74 
Table 2.2. Accepted criteria for blood pressure measurements…………………………………77 
Table 2.3. Healthy range for blood test results for urea and electrolyte, liver function and full 
blood count…………………………………………………………………………..80 
Table 2.4. Nutritional composition of ad libitum test meals per 100g………………………….85 
Chapter 3 - The effect of trauma on weight loss and gastrointestinal hormone response in rats  
Table 3.1. Body weights of the control, cannulated and anaesthetics rats from days 1 to 8…..103 
Table 3.2. Food intake from days 1 to 8 (post-surgery) in the control, anaesthetics and 
cannulated rats……………………………………………………………………...105 
Chapter 4 – Comparison of gastrointestinal appetite hormones in older and younger healthy 
volunteers 
Table 4.1. Nutritional composition of Ensure Plus provided at test meal……………………..119  
Table 4.2. Participants characteristics………………………………………………………….125 
Table 4.3. Multiple regression to determine the relationship between age and energy 
intake.............................................................................…...............................132 
Chapter 5 – Comparison of gastrointestinal hormones in aged and young mice colons 
Table 5.1. Body weights of mice………………………………………………………………177 
Chapter 6 –The association between habitual protein intake on BMI and habitual energy intake 
in older and younger adults 
Table 6.1. Descriptive data from the NDNS combined datasets in the 19-74 and 75+ years age 
range………………………………………………………………………………...194 
16 
 
Table 6.2. Multiple regression to determine if percentage energy from protein independently 
alters energy intake (combined age groups)………………………………………..214 
Table 6.3. Multiple regression to determine if percentage energy from protein independently 
alters energy intake in adults aged 19-74 years…………………………………….214 
Table 6.4. Multiple regression to determine if percentage energy from protein independently 
alters energy intake in adults aged 75+ years………………………………………215 
Table 6.5. Multiple regression to determine if percentage energy from protein independently 
alters BMI (combined age groups)…………………………………………………215 
Table 6.6. Multiple regression to determine if percentage energy from protein independently 
alters BMI in adults aged 19-74 years……………………………………………...216 
Table 6.7.  Multiple regression to determine if percentage energy from protein independently 
alters BMI in adults aged 75+ years………………………………………………..216 
Chapter 7 – Investigation into the effect of protein on appetite suppression and gastrointestinal 
hormone response in younger and older adults 
Table 7.1. Total and 40% estimated BMR estimates in males and females…………………...231 
Table 7.2. Nutritional composition of protein preload meals provided in the study visits in males 
and 
females……………………………………………………………………………...232 
Table 7.3.  Mean (SD) values for volunteer’s characteristics in the 20-39 and 65+ age group...237 
Table 7.4. Total and activity energy expenditure in the 20-39 and 65+ age groups…………...238 
Table 7.5. Percentage change in Kcal intake at ad libitum test meal between test conditions B 
(15%), C (30%) and D (60%) in the 20-39 and 65+ age groups…………………...240 
Table 7.6. Percentage change in how full do you feel AUC scores in test meal conditions B 
(15%), C (30%) and D (60%) in the 20-39 and 65+ age groups…………………...250 
Table 7.7. Percentage change in plasma insulin AUC concentrations in test meal conditions B 
(15%), C (30%) and D (60%) in the 20-39 and 65+ age groups…………………...256 
Chapter 10 - Appendix 
Table 10.1. Chapter 3 gastrointestinal appetite hormones in the cannulated, control and 
anaesthetics rats…………………………………………………………………….341 
17 
 
Table 10.2. Chapter 4 AUC and IAUC VAS scores in the 20-39, 40-59, 60-79 and 80+ age 
groups……………………………………………………………………………….342 
Table 10.3. Chapter 4 AUC and IAUC scores for GLP-1, PYY, acyl ghrelin and total ghrelin in 
the 20-39, 40-59, 60-79 and 80+ age groups……………………………………….343 
Table 10.4. Chapter 4 HOMA and HOMA-PP scores and AUC and IAUC scores for insulin and 
glucose in the 20-39, 40-59, 60-79 and 80+ age groups……………………………344 
Table 10.5. Chapter 4 correlations between energy intake and final VAS score in the 20-39, 40-
59, 60-79 and 80+ age groups………………………………………………………345 
Table 10.6. Chapter 4 energy intake at ad libitum test meal in males and females separately in the 
20-39, 40-59, 60-79 and 80+ age groups…………………………………………...346 
Table 10.7. Chapter 4 AUC VAS scores in males and females separately in the 20-39, 40-59, 60-
79 and 80+ age groups……………………………………………………………...347 
Table 10.8. Chapter 4 IAUC VAS scores in males and females separately in the 20-39, 40-59, 60-
79 and 80+ age groups……………………………………………………………...348 
Table 10.9. Chapter 4 AUC scores for PYY, GLP-1, total ghrelin and acyl ghrelin in males and 
females separately in the 20-39, 40-59, 60-79 and 80+ age groups………………..349 
Table 10.10. Chapter 4 IAUC scores for PYY, GLP-1, total ghrelin and acyl ghrelin in  males and 
females separately in the 20-39, 40-59, 60-79 and 80+ age groups………………..351 
Table 10.11. Chapter 7 ad libitum energy intake in the 20-39 and 65+ age groups following 15%, 
30% and 60% protein test meals……………………………………………………358 
Table 10.12. Chapter 7 Kcal consumed on the whole test day in the 20-39 and 65+ age 
groups……………………………………………………………………………….359 
Table 10.13. Chapter 7 percentage change in total energy intake between test day B (15%), C 
(30%) and D (60%) in the 20-39 and 65+ age groups……………………………...359 
Table 10.14. Chapter 7 time to eat next meal following protein test meals in the 20-39 and 65+ age 
groups……………………………………………………………………………….360 
Table 10.15. Chapter 7 percentage change in time to consume next meal between test meal B 
(15%), C (30%) and D (60%) in the 20-39 and 65+ age groups…………………...360 
18 
 
Table 10.16. Chapter 7 total energy intake on day 2 in the 20-39 and 65+ age group following 
protein test meal B (15%), C (30%) and D (60%)………………………………….361 
Table 10.17. Chapter 7 Mean (SEM) percentage change in kcal consumed on the day after the 
study visit (day 2) between test meal conditions B (15%), C (30%) and D (60%) in 
the 20-39 and 65+ age group……………………………………………………….361 
Table 10.18. Chapter 7 AUC VAS scores in the 20-39 and 65+ age groups following protein test 
meal b (15%), C (30%) and D (60%)………………………………………………362 
Table 10.19.  Chapter 7 percentage change in VAS scores following test meal conditions B (15%), 
C (30%) and D (60%) in the 20-39 and 65+ age groups…………………………...363 
Table 10.20. Chapter 7 AUC scores; PYY, GLP-1, acyl ghrelin, insulin and glucose following test 
meals B (15%), C (30%) and D (60%) in the 20-39 and 65+ age groups………….365 
Table 10.21. Chapter 7 percentage change in PYY, GLP-1, acyl ghrelin and glucose scores 
following test meal conditions B (15%), C (30%) and D (60%) in the 20-39 and 65+ 
age groups………………………………………………………………………..…367 
Table 10.22. Chapter 7 post-prandial insulin resistance scores following test meals B (15%), C 
(30%) and D (60%) in the 20-39 and 65+ age groups……………………………...368 
Table 10.23. Chapter 7 gastric emptying times following test meals B (15%), C (30%) and D 
(60%) in the 20-39 and 65+ age groups………………………………………….…368 
Table 10.24. Chapter 7 percentage change in peak paracetamol times in test meal conditions B 
(15%), C (30%) and D (60%) in the 20-39 and 65+ age groups…………………...369 
 
 
 
 
 
 
 
19 
 
STATEMENT OF WORK PERFORMED BY AUTHOR 
 
I undertook all aspects of the content of this thesis except the following; 
Chapter 3; The Department of Investigative Medicine Hypo Group, assisted in and undertook the 
sham cannulations in rats. Dr. Emma Leavy undertook the cannulations in the Pilot Study. Dr. Kevin 
Murphy assisted in RIA and ELISA measurements of gastrointestinal appetite hormones. 
Chapter 4; Ms. Jeanne Bottin assisted in the recruitment and running of the investigational study, 
including assistance in the measurement of gastrointestinal appetite hormones. Dr. Joseph Eliahoo, 
Statistical Advisory Service, Imperial College, provided guidance on power calculations and 
statistical analysis. 
Chapter 4 and 7; All human research studies were conducted in the Sir John McMichael Centre, 
Imperial College NHS trust and all cannulations were performed by the research nurses on site. For 
measurement of gastrointestinal hormones, Dr Paul Beck assisted in the radioimmunoassay 
measurements. 
Chapter 5; Department of Molecular Endocrinology, Imperial College London kindly donated the 
colons and stomachs from mice, and undertook cardiac puncture on the mice. Dr Michael Patterson 
assisted in tissue extraction and gastrointestinal hormone measurement. Michelle Sleeth assisted in the 
stomach and colon extraction. 
All chapters; Dr Michael Patterson provided assistance and advice for all in house radioimmunoassay 
carried out. Professor Mohammad Ghatei established  and maintained all the radioimmunoassays. 
 
 
 
20 
 
ACKNOWLEDGEMENTS 
 
 
I would like to thank my supervisors Dr Mary Hickson, Professor Gary Frost and Dr Waljit Dhillo for 
their support and guidance throughout completing my PhD.  
Special thanks to Ms. Jeanne Bottin for her hard work and enthusiasm, and to Dr. Michael Patterson, 
Professor Mohammad Ghatai and Professor Steve Bloom. 
I would like to thank the Hammersmith Hospital Trustees Charity for their funding of this PhD, and 
all the subjects who volunteered for my study. 
Finally, I would like to thank my family and friends for all their support. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21 
 
PUBLICATIONS RELATED TO WORK IN THESIS 
 
Review (content relates to information in chapter 1); 
Gastrointestinal hormones: the regulation of appetite and the anorexia of ageing (2012). C.Moss, W.S. 
Dhillo, G. Frost & M. Hickson. Journal of Human Nutrition and Dietetics, Volume 25, pages 3-15. 
ABSTRACTS RELATED TO WORK IN THESIS 
 
2010 Poster 
Ageing results in a reduction in energy intake and subjective feelings of appetite. Can this be 
attributed to gut appetite hormones? C.Moss, W. Dhillo, J. Bottin, G. Frost, & M.Hickson. 
NIHR BRC Experimental Medicine Summer School.  
Ashridge Business School, Berkhamstead,  
June 2010 
 
2011 Oral Communication 
Anorexia of ageing is associated with increased post-prandial secretion of the anorectic 
gastrointestinal hormone Peptide YY. C. Moss, W. Dhillo, J. Bottin, G. Frost & M. Hickson 
Nutrition Society Winter Meeting 
Royal College of Physicians, London 
December 2011 
22 
 
ABBREVIATIONS 
 
AGRP  Agouti-Related Peptide 
ANOVA Analysis of Variance 
ARC  Arcuate Nucleus 
AUC  Area Under Curve 
BIA  Bioelectical Impedance  
BMI  Body Mass Index 
BSA  Bovine Serum Albumin 
CCK  Cholecystokinin 
CNS  Central Nervous System 
DMH  Dorsomedial Hypothalamus 
EI  Energy Intake 
ELISA  Enzyme Linked Immunosorbent Assay 
FFM  Fat Free Mass 
g  Gram(s) 
GFR  Glomerular Filtration Rate 
GI  Gastrointestinal 
GLP-1  Glucagon-Like-Peptide-1 
GH  Growth Hormone 
GHS-R  Growth Hormone Secretagogue Receptor 
GOAT  Ghrelin O-Acyltransferase 
IAUC  Incremental Area Under Curve 
ICU  Intensive Care Unit 
ICV  Intracerebroventricular 
IL  Interleukin 
IPAQ  International Physical Activity Questionnaire 
IQR  Interquartile Range 
i.v.  Intravenous 
Kcal  Kilocalories 
LBM  Lean Body Mass 
23 
 
LH  Lateral Hypothalamus 
min  Minutes 
ml  Millilitres 
n  Number 
NHS  National Health Service 
NPY  Neuropeptide-Y 
OXM  Oxyntomodulin 
PBS  Phosphate Buffered Saline 
PEG  Polyethylene Glycol 
POMC  Proopiomelanocortin 
PP  Pancreatic Polypeptide 
PVN   Paraventricular Nucleus 
PYY  Peptide Tyrosine Tyrosine 
RIA  Radioimmunoassay 
SD  Standard Deviation 
SEM  Standard Error of the Mean 
TNF-α  Tumour Necrosis Factor alpha 
UK  United Kingdom 
VAS  Visual Analogue Scales 
WHO  World Health Organisation 
 
 
 
 
 
 
 
 
 
 
24 
 
DEFINITIONS 
 
Terminologies in my thesis are defined as follows; 
1. The ageing population in my study are defined as 65 years and above (weight loss has been 
demonstrated in adults aged 65 years and over). The old elderly will be defined as 75 years 
and over. 
2. Malnutrition is defined as being in a state of deficiency or excess, caused by either an excess 
of nutrients (over-nutrition) or a lack of one or more nutrients (under-nutrition). The content 
of this thesis focuses on under-nutrition. 
3. This thesis refers to a number of terms: satiety, satiation and hunger. Satiety is defined as the 
inhibition of eating following a meal. Satiation is defined as the process that brings a meal to 
an end. It could also represent an interval time before eating again. Hunger is the 
physiological drive to eat. 
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1.1. Undernutrition 
 
Undernutrition in the western society is prevalent, particularly in older people and in those who are of 
ill health (Elia and Russell, 2009).  Undernutrition is a public health issue because it results in a 
decline in functional status, impaired muscle function, decreased bone mass, immune dysfunction, 
anaemia, reduced cognitive function, poor wound healing, delayed recovery from surgery, higher 
hospital admission rates, and mortality (Corish and Kennedy, 2000; McWhirter and Pennington, 
1994).  
Undernutrition is an under recognised and under diagnosed problem in the UK (McWhirter and 
Pennington, 1994). Disease-related undernutrition in the UK in 2007 has been estimated to cost at 
around £13 billion per year (Elia and Russell, 2009). It has been suggested that around 3 million 
people in the UK are undernourished at any one time, with one of the explanations for these high 
levels due to an ageing population (Elia and Russell, 2009). In 2006, NICE guidelines were 
implemented to help the NHS identify patients and those living at home who are malnourished 
(NICE, 2006).  Since these guidelines were implemented, one study demonstrated in ICU patients, an 
increase in the use of enteral feeding. However, data still suggests that we are still far from integrating 
nutrition into care (Sharifi et al., 2011). It is still likely that people at higher risk of undernutrition are 
not being detected, and therefore effective care is not being provided to undernourished people in the 
hospital setting, institutions or in the community (Hickson, 2006). In a recent study, in a survey in 
hospitals in North East England, 44% of patients were at risk of undernutrition, and in those with high 
risk under nutrition, 37.8% of females and 24.5% of males over the age of 70 were at high risk of 
undernutrition (Lamb et al., 2009). 
Not only is undernutrition prevalent in the hospital setting, a substantial amount occurs in the 
community. It was estimated in 2007, that about 98% of undernutrition (using the malnutrition 
universal screening tool (MUST)) classed as of medium or high risk occurred outside of the hospital 
environment, in which 5% was in care homes, 2-3% in sheltered housing and 5-10% in the 
community (Elia and Russell, 2009). 
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The treatment of undernutrition is particularly difficult. A recent review of 62 trials, suggested that 
supplementation only produces a small but consistent weight gain in old people (Milne et al., 2009). 
Increasing nutritional intake by the use of nutrition supplements can be beneficial, but their use is not 
universally successful. Reasons may include poor compliance related to taste fatigue, their use of 
meal replacements rather than supplements (Milne et al., 2006) or the patients lack of appetite 
(Hickson et al., 2004). Pharmacological therapy can also reduce appetite, and older patients that are of 
ill health are more likely to be taking more medications (Freeman and Roubenoff, 1994; Womack and 
Breeding, 1998). 
The stimulation of appetite has been tried via pharmacological means, the currently available drugs, 
megestrol acetate and mirtazapine have limited use due to the serious adverse side-effects associated 
with them (Fox et al., 2009). Megestril acetate is a progesterone derivative used to increase appetite in 
cancer patients; the mechanisms of action of this appetite stimulant are unknown. Mirtazapine is a 
tetracyclic anti-depressant, and also improves appetite. It does this by increasing levels of 
noradrenaline and serotonin.  
Due to the lack of success of current therapies, alternative therapies need to be introduced for the 
prevention and treatment of under-nutrition. Causes of undernutrition are varied and can be caused by 
medical, social and psychological factors (Alibhai et al., 2005; Fischer and Johnson, 1990; Bouras et 
al., 2001; Hays and Roberts, 2006). Poor appetite has commonly been claimed as a contributing factor 
to undernutrition in ageing and age-associated illness (Schilp et al., 2011; Chen et al., 2001; Donini et 
al., 2003). 
1.2. The ‘Anorexia of Ageing’  
 
Throughout the developed world, the ageing population is increasing (Panel on Ageing and Social 
Development, 2000). Currently, about 16% of the population in the UK are over the age of 65 years, 
and 2% of the population are over the age of 85 years (Office for National Statistics, 2009) and in the 
next 30 years these proportions are set to increase. 
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Undernutrition increases with age, regardless of disease state (Hickson, 2006). In a study looking at 
the nutritional state of elderly people that were either recently hospitalised or  community living, it 
was demonstrated that a reduced nutritional status occurred frequently before disease, therefore 
suggesting that undernutrition may contribute to the development of disease (Mowe et al., 1994). This 
also suggests that a reduction in nutritional status cannot be caused by the disease alone.  This is not 
to say that disease cannot cause undernutrition; disease state can exacerbate malnutrition. In patients 
with cancer, there is a significant reduction in food intake and an increased risk of undernutrition (Del 
Fabbro et al., 2011; Palesty and Dudrick, 2003) (see section 1.2.1), which is associated with reduced 
survival rate (Vigano et al., 2000; Laviano et al., 2003). Therefore undernutrition and disease come 
hand in hand. 
Both low and high BMIs are associated with an increase in mortality in older persons (Kulminski et 
al., 2008; Janssen et al., 2005; Flegal et al., 2007). Optimal BMI for those over 60 years of age have 
been suggested to be around the range of 22-26kg/m
2  
(Gelber et al., 2007). Older people who lose 
weight are at higher risk of institutionalization and death (Payette et al., 2000; Morley, 2007) with an 
increased loss of bone and increased risk of hip fracture (Nguyen et al., 2007; Hannan et al., 2000; 
Arvat et al., 2001; Ensrud et al., 1997; Ensrud et al., 2006; Ensrud et al., 2005). In addition a poor 
appetite in older persons is associated with increased mortality (Kalantar-Zadeh et al., 2003; Kalantar-
Zadeh et al., 2004). These studies have led to the concept of reverse epidemiology which has stressed 
that in healthy older persons there is increased survival with higher body mass (Kalantar-Zadeh et al., 
2007).  
A loss of appetite is frequently observed with ageing: termed ‘anorexia of ageing’ (Morley and Silver, 
1988). People over the age of 80 years have a 5 fold increase in prevalence of undernutrition than 
people under the age of 50 years (Pirlich et al., 2005). The elderly, on average, consume smaller 
meals, eat more slowly and consume fewer snacks between meals than younger people (de Castro, 
1993; Morley and Silver, 1988a). In ageing, basal metabolic rate, diet-induced thermogenesis, and 
planned exercise all decrease with age (Roberts and Rosenberg, 2006; Wilson and Morley, 2003; 
Drewnowski and Evans, 2001), and so it would be expected that if food intake remains stable, there 
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would be weight gain. However, between the ages of 20 to 80 there is an average decline in energy 
intake of 30% in men and women (Wurtman et al., 1988). This reduction in energy intake may be 
partly due to reduced energy expenditure (Hauser and Neumann, 2005), but the reduction in energy 
expenditure is not large enough to balance the decrease in energy intake, and hence weight loss 
frequently occurs (Chapman, 2011; McMinn et al., 2011). The reasons for these observations are not 
clear. It could be related to either lean tissue loss (Dwyer et al., 1993), changes in the physiology of 
the gut, other unknown factors, an alteration in the regulation of appetite, but most likely, a 
combination of these factors. 
Research suggests that ageing is associated with the inability to appropriately control food intake after 
under-eating in the short- and long term (Moriguti et al., 2000; Roberts et al., 1994). This has been 
demonstrated by Roberts and colleagues (1994), where they underfed participants on a calorie 
restricted diet for a period of 21 days, and then followed this with a period of ad libitum feeding. 
Young and older participants lost weight in the underfed period, but unlike the young participants, the 
older participants did not regain their weight following the weight loss period (Roberts et al., 1994). 
This result has also been replicated in the longer term by Moriguti and colleagues (Moriguti et al., 
2000). They underfed young and older volunteers for a period of 6 weeks, and then measured changes 
in body weight and composition during a 6 month follow-up. Older volunteers lost significantly more 
weight during the underfeeding period than the young volunteers and did not gain back their weight 
initially lost at the 6 month follow-up. Additionally, the older volunteers reported significantly lower 
frequency of perceived hunger during the underfeeding period, and feelings of fullness were reached 
much earlier. This suggests an inability in older people to up-regulate appetite after periods of under-
nutrition and this may relate to changes in the sensations of hunger and fullness perceived by older 
adults. 
Changes in resting energy expenditure could also explain why older adults lose more weight during 
periods of underfeeding than young adults. Das and colleagues (2001) explored the effects of 
underfeeding on energy expenditure in older and young volunteers for 6 weeks. Resting energy 
expenditure (adjusted for fat-free mass and fat mass) was significantly lower in older subjects, and the 
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expected reduction in resting energy expenditure during negative energy balance was attenuated in the 
older volunteers (Das et al., 2001). This would explain increased weight loss during periods of 
undernutrition in older adults and supports the theory of a dysregulation in energy balance in older 
age. However, it does not explain why weight gain upon re-feeding is lower in older adults, or weight 
loss outside conditions of intentional underfeeding, and these observations could be explained through 
dysregulation of appetite control. 
1.2.1. Appetite and weight loss in illness 
 
In addition to reductions in appetite in older persons a poor appetite is also seen in persons with 
illness, such as renal failure (Kalantar-Zadeh et al., 2004; Kalantar-Zadeh et al., 2003). A large 
proportion of those suffering from illness are the elderly. Almost two thirds of general and acute 
hospital beds are used by adults over the age of 65 years (Office for National Statistics, 2004). 
Undernutrition could account for an additional 5 days admission for 10% of hospital patients 
(Lennard, 1992). Loss of appetite and weight are a major cause of morbidity and mortality affecting 
many patients with cancer, HIV, cardiac cachexia, inflammatory conditions such as sepsis and burns 
and in postoperative patients. Up to 40% of patients suffer from undernutrition throughout their illness 
(Witte and Clark, 2002; McWhirter and Pennington, 1994). Cardiac cachexia in heart failure consists 
of a loss of lean tissue, fat mass and bone mass (Springer et al., 2006). Up to 50% of cancer patients 
report changes in eating behaviour at the time of diagnosis, leading to weight loss (Dewys et al., 
1980). People suffering from undernutrition in illness are predominantly older people who are at risk 
of slower recovery from illness (Mudge et al., 2011). This data highlights the need for more effective 
appetite stimulatory therapies for many patient groups. 
A reduced nutritional status often seen in older cancer patients reduces quality of life (Nourissat et al., 
2008) demonstrating the importance of adequate nutrition in illness. Often patients that are ill suffer 
from nausea and vomiting, but there are those suffering with osteoarthritis who do not suffer from the 
symptoms of nausea who also have a marked reduction in nutritional status. This suggests that in 
illness there is a reduction in appetite due to a change in the appetite regulatory system.  
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1.2.2. Summary 
 
I am proposing that one of the key factors involved in undernutrition in the elderly and in age 
associated illness is a change in the appetite regulatory system. However, there is very limited work 
looking into undernutrition, ageing and illness and alterations in the appetite regulatory system, in 
particular gastrointestinal appetite hormones.  Thus a broad aim of my thesis is to explore the 
mechanisms and factors involved in this lack of appetite during ageing and illness. 
1.3. Overview of the appetite regulatory system 
 
Appetite has been defined as a global term used to describe a range of parameters associated with 
eating behaviours such as the drive for energy, the sensation of hunger, and selection of specific foods 
by their tastes, nutrients and cravings (King et al., 1997). It is influenced by the environment and can 
override the hunger sensation, resulting in food consumption regardless of hunger level.  
Peptide hormones released from the gastrointestinal tract are believed to be one of the major 
regulators of appetite, and they are released in response to nutritional stimuli. These hormones can be 
classed into anorexigenic (satiety hormones) and orexigenic (hunger hormones). Anorexigenic signals 
are released from the gastrointestinal tract following a meal; these include peptide YY (PYY), 
Glucagon-like peptide-1 (GLP-1), Pancreatic Polypeptide (PP) and Cholesystokinin (CCK). Leptin is 
also an anorexigenic hormone that increases feelings of satiety and reduces food intake, it is released 
from adipose tissue responding to changes in long-term energy status (Fei et al., 1997; Lee et al., 
1996). Insulin is thought to be anorectic and it is released from the β-cells of the pancreas after a meal 
(Polonsky et al., 1988). There is only one known peripheral orexigenic hormone, and that is ghrelin, 
released predominantly from the stomach (Date et al., 2000). The hypothalamus in the brain receives 
neural, metabolic and endocrine signals from the periphery. The arcuate nucleus (ARC) is located at 
the base of the hypothalamus and contains two types of neurons; Neuropeptide Y (NPY) and agouti 
related peptide (AgrP) releasing neurons (orexigenic), and melanocortin releasing neurons 
(anorexigenic) (Barsh et al., 2000). Alterations in the release of these neuropeptides can affect feeding 
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behaviour and energy expenditure (Schwartz et al., 2000). Both these neuropeptides and 
gastrointestinal hormones work to physiologically control appetite.  
Figure 1.1 represents the main mechanisms involved in the regulation of appetite and Table 1.1 
summarises the properties of these gastrointestinal peptide hormones. 
Figure 1.1.  Mechanisms involved in the regulation of appetite 
 
 
 
 
Outline of the main mechanisms involved in the regulation of appetite. PVN Para ventricular 
Nucleus; POMC, pro-opiomelanocortin; AgRP, Agouti-related peptide;  NPY, Neuropeptide Y; ARC, 
arcuate nucleus; PYY, peptide tyrosine tyrosine; GLP-1, glucagon like peptide-1; OXM, 
oxyntomodulin; CCK, cholecystokinin; PP, pancreatic polypeptide 
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Table 1.1.  Summary of the characteristics of the main gastrointestinal appetite hormones. (aa= amino acid) 
 Characteristics 
Gastrointestinal 
Hormones 
Biochemistry Identification 
and Discovery 
Action on 
appetite 
Time of release Half Life 
(minutes) 
Satiety Feeling Energy Intake 
Ghrelin 28-aa peptide 1999 
(Kojima et al., 
1999) 
Orexigenic Rises before meal  
(Cummings et al., 2001) 
Acylated form 
9-13; Total 27-
31 
(Akamizu et al., 
2004) 
Decreases 
(Wren et al., 
2000) 
 
Increases  
(Wren et al., 
2001a) 
Peptide YY 
(PYY) 
36-aa peptide 1980  
(Tatemoto and 
Mutt, 1980) 
Anorexigenic Rises to plateau 1 h after a 
meal  
(Adrian et al., 1985) 
8  
(Lluis et al., 
1989) 
Increases 
(Batterham et 
al., 2002) 
Decreases 
(Batterham et al., 
2002) 
Pancreatic 
Polypeptide 
(PP) 
36-aa peptide Early 1970’s Anorexigenic Rises 10-20 minutes after a 
meal  
(Adrian et al., 1976) 
6-9  
(Adrian et al., 
1976) 
Increases 
(Batterham et 
al., 2003b) 
Decreases 
(Batterham et al., 
2003b) 
Glucagon-like-
peptide -1 
(GLP-1) 
30-aa peptide 1980  
(Lund et al., 
1980) 
Anorexigenic Rises 5-15 minutes after a 
meal 
 
1.5-5  
(Hui et al., 
2002) 
Increases 
(Naslund et al., 
1999) 
Deceases 
(Naslund et al., 
1999) 
Cholecystokinin 
(CCK) 
58, 39, 33 
and 8-aa 
peptide 
Late 1920’s  Anorexigenic Rises rapidly and remains 
elevated for 5 hours  
(Koulischer et al., 1982) 
 
1-2  
(Gibbs et al., 
1973) 
Increases 
(Kissileff et al., 
1981) 
Decreases  
(Kissileff et al., 
1981) 
Oxyntomodulin 
(OXM) 
37-aa peptide 1981  
(Bataille et al., 
1981) 
Anorexigenic Rises 5-10 mins after a 
meal. Peaks 30 minutes 
after ingestion  
(Anini et al., 1999) 
11-13  
(Schjoldager et 
al., 1988) 
Increases 
(Cohen et al., 
2003) 
Decreases 
(Cohen et al., 
2003) 
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1.3.1. Ghrelin 
 
Ghrelin is a 28-amino acid peptide, secreted by the X/A-like cells of the gastric oxyntic glands, and to 
a lesser extent, the small intestine (Date et al., 2000). The receptors for ghrelin are found in the 
gastrointestinal tract, hypothalamus, pituitary, pancreas, myocardium, liver, adipose, kidney and the 
placenta (Hosoda et al., 2006). Ghrelin has a number of biological roles such as stimulation of growth  
hormone (GH) secretion (Takaya et al., 2000; Arvat et al., 2001; Hataya et al., 2001), gastrointestinal 
motility (Masuda et al., 2000; Trudel et al., 2002; Fujino et al., 2003), and appetite (Korbonits et al., 
2004). Ghrelin is the only known orexigenic peptide that relays information from the gut to the brain 
in both animals and humans (Wren et al., 2000; Wren et al., 2001a; Wren et al., 2001b). Ghrelin is 
thought to mediate its orexigenic effects through the stimulation of NPY, and agouti related proteins 
in the ARC (Kamegai et al., 2001; Wang et al., 2002; Kamegai et al., 2001; Wang et al., 2002). 
Ghrelin comes in two forms; desacyl and acyl ghrelin. Acyl ghrelin is the only known biologically 
active form of ghrelin (Yang et al., 2008). Levels of circulating ghrelin increase with fasting, and fall 
after consumption of a meal (Ariyasu et al., 2001; Cummings et al., 2001; Tschop et al., 2000), which 
suggests that the release of ghrelin is regulated by calories and nutritional signals (Sakata et al., 2002; 
Tschop et al., 2000).  Not only do ghrelin levels differ with nutritional status, but they also vary 
diurnally, where levels are high in the morning and low at night (Cummings et al., 2001). 
Intracerebroventricular (I.C.V) injection of ghrelin to rodents at suprophysiological doses increases 
food intake and weight gain (Nakazato et al., 2001). Subcutaneous administration of ghrelin daily also 
increases food intake and weight gain in fat mass and lean body mass in rodents (Tschop et al., 2000). 
Ghrelin also produces similar results in humans. Wren et al (2001a), demonstrated in healthy human 
volunteers, an increase in energy intake after intravenous administration of ghrelin by 28% in a buffet 
meal post infusion. Ghrelin also has been shown to correlate with subjective feelings of hunger as 
measured by visual analogue scales (VAS), where the higher the feelings of hunger, the higher the 
plasma concentrations of ghrelin in humans (Cummings et al., 2004). 
35 
 
The precise physiological role of ghrelin is not fully understood, but it appears in some literature that 
it may not be an essential regulator of appetite in animals. In a study by Sun et al, (2003) ghrelin null 
rats (confirmed by undetectable ghrelin concentrations in plasma) did not have an altered body weight 
nor altered food intake on a normal diet. However, the lack of alteration in body weight could be due 
to developmental compensation. Further study is required to understand the precise physiological role 
of ghrelin in appetite regulation. 
1.3.2. Peptide Tyrosine Tyrosine (PYY) 
 
PYY is a 36-amino acid that is a member of the pancreatic polypeptide family. It was first isolated 
from porcine intestine and is an endogenous Y2-receptor (Y2-R) agonist that also binds to the Y4 and 
Y5 receptors in the hypothalamus.  It is released from the L-cells of the gastrointestinal tract, 
primarily in the ileum, colon and the rectum (Ekblad and Sundler, 2002). There are two forms that are 
released endogenously by the gastrointestinal tract into the circulation; PYY1-36 and PYY3-36 (Eberlein 
et al., 1989; Grandt et al., 1994). PYY3-36 is the major form of circulating PYY and binds to the 
inhibitory presynaptic Y2 receptors in the hypothalamus with high affinity, whereas PYY1-36 binds to 
and activates the Y1, Y2 and Y5 NPY receptor subtype (Koda et al., 2005). PYY3-36 has many 
biological actions, including inhibition of gastric acid secretion (Yang, 2002), vasoconstriction 
(Zukowska-Grojec et al., 1986), reduction in intestinal and pancreatic secretion and inhibition of 
gastrointestinal motility (Layer and Groger, 1992). Little is known about the effect of PYY1-36, 
however it is known that it has very little effect on energy intake and appetite regulation (Sloth et al., 
2007). 
PYY3-36 is released in proportion to the amount of calories ingested (Adrian et al., 1985). Batterham et 
al. first reported PYY3-36 to exert an anorectic effect in rodents and humans (Batterham et al., 2002), 
which has been confirmed in a number of studies (Batterham et al., 2003b; Batterham et al., 2003a). 
PYY3-36 plasma concentrations increase significantly post ingestion of a meal (Cox, 2007) in 
proportion to the amount of calories consumed (Adrian et al., 1985). These levels rise to plateau at 1-2 
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hours from the ingestion of food and remain at these levels for up to 6 hours post consumption of a 
meal (Adrian et al., 1985). 
PYY3-36 can act directly though vagal nerves (Abbott et al., 2005; Koda et al., 2005). It has been 
suggested that the anorectic actions of PYY3-36 are mediated by the inhibition of NPY neurons 
(Batterham et al., 2002). In rodents peripheral administration of PYY3-36 inhibits food intake and 
reduces weight gain (Batterham et al., 2002; Challis et al., 2003). Batterham et al (2002), 
demonstrated in humans a 36% reduction in energy intake during a buffet meal 2 hours after 
intravenous infusion of PYY3-36. Similar findings have also been demonstrated in obese subjects 
versus lean controls (30% vs. 31%) (Batterham et al., 2003a). This reduction in energy intake, is also 
accompanied by a reduction in subjective feelings of hunger, which lasts up to 12 hours after infusion, 
despite the levels of PYY3-36 returning to normal (Batterham et al., 2002). 
1.3.3. Cholecystokinin (CCK) 
 
CCK is one of the most abundant neuropeptides found in the brain playing a role in reward behaviour, 
memory, anxiety and satiety (Crawley and Corwin, 1994). CCK is released from the duodenum, 
jejunum, and to a lesser extent the lower GI tract in response to nutrients (Larsson and Rehfeld, 1978) 
inhibiting food intake and reducing meal size (Kissileff et al., 1981).  
CCK was the first gastrointestinal hormone demonstrated to modulate appetite (Gibbs et al., 1973). 
CCK is released into the blood stream rapidly in response to nutrients, with its concentrations 
remaining elevated up to 5 hours post ingestion of a meal (Liddle et al., 1985). CCK, when released 
also stimulates the release of enzymes and pancreatic enzymes from the gall bladder, increases 
intestinal motility and inhibits gastric emptying (Liddle et al., 1985; Moran and McHugh, 1982), 
therefore helping digestion. 
There are two CCK receptor subtypes; CCK1 and CCK2 that are abundant in the brain, in particular 
the brainstem and the hypothalamus (Wank, 1995). The anorectic action of CCK seems to be mostly 
mediated though CCK1R on vagal afferents (Moran et al., 1997; Moran et al., 1998). In both animals 
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and humans CCK inhibits food intake and reduces meal size (Gibbs et al., 1973; Kissileff et al., 
1981), but its actions are brief and short lived due to its short half-life of 1-2 minutes (Gibbs et al., 
1973). 
1.3.4. Glucagon-like peptide 1 (GLP-1) 
 
GLP-1 is a pro-glucagon derived peptide and is co-secreted with PYY from the L-cells in the 
intestine. It acts as a potent stimulator of insulin secretion in a glucose dependent manner. GLP-1 is 
short lived in the circulation with a half-life of about 1-2 minutes (Vilsboll et al., 2003). There are two 
biologically active forms of GLP-1; GLP-1 (7-37) and GLP-1 (7-36) amide. GLP-1 (7-36) amide is 
the major circulating form in humans (Orskov et al., 1994). GLP-1 receptor expression is widely 
distributed in the brain, gastrointestinal tract and the pancreas (Holst, 2007; Yamato et al., 1997). 
GLP-1 concentrations rise with food consumption and decline in the non-fed state, and it has been 
suggested that concentrations also increase with meal anticipation (Vahl et al., 2010). GLP-1 
significantly reduces food intake and delays gastric emptying (Cummings and Overduin, 2007). 
Following infusion of GLP-1 there is a dose dependent reduction in food intake in both lean and obese 
human volunteers (Verdich et al., 2001), and increases in subjective feelings of fullness and satiety in 
humans (Naslund et al., 1999) . 
1.3.5. Pancreatic Polypeptide (PP) 
 
PP is produced by the cells at the periphery of the islets of the endocrine pancreas, colon and rectum 
(Larsson et al., 1975). It is released in response to ingestion of food in proportion to the amount of 
calories consumed, with its concentrations remaining elevated 6 hours post ingestion of food (Adrian 
et al., 1985). It has been suggested that the major site of PP action is in the brainstem (Whitcomb et 
al., 1990).  
Gastric distension, ghrelin, motulin and secretin increase levels of PP in the plasma (Christofides et 
al., 1979; Mochiki et al., 1997; Peracchi et al., 1999; Arosio et al., 2003). PP is known as the ileal 
brake, as it acts to slow the transit of food though the gut (Kojima et al., 2007). Infusion of PP in 
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normal weight volunteers demonstrated a decrease in appetite as measured by VAS and a 25% 
reduction in food intake over a 24 hour period (Batterham et al., 2003b).  
1.3.6. Oxyntomodulin (OXM) 
 
OXM is a 37-amino acid peptide that is another product of the pro-glucagon gene that is released from 
the L-cells of the distal gastrointestinal tract, alongside GLP-1 and PYY (Kieffer et al., 1995). The 
GLP-1 receptor is the only known receptor for OXM with OXM having a lower affinity for the GLP-1 
receptor than GLP-1 (Schjoldager et al., 1988). As with PYY and GLP-1, OXM is released into the 
circulation after the ingestion of food, which rises in proportion to the number of calories consumed 
(Ghatei et al., 1983). OXM has additional physiological roles such as inhibition of gastric acid 
secretion and gastric emptying (Schjoldager et al., 1988). 
In healthy human volunteers, chronic administration of OXM reduces food intake at a buffet meal by 
approximately 19% causing weight loss (Cohen et al., 2003). OXM also increases energy expenditure 
in both humans and rodents (Dakin et al., 2001; Wynne et al., 2006). Pre-prandial subcutaneous 
injections of OXM to obese subjects for 4 weeks produced an average of 2.3kg weight loss compared 
to 0.5kg with placebo (Wynne et al., 2006). 
1.3.7. Leptin  
 
Leptin is a peptide hormone secreted by adipose tissue that regulates adipose tissue mass and energy 
balance. Leptin was discovered in 1995 as a product of the ob gene, and a hormonal signal that 
regulates energy balance (Zhang et al., 1994; Halaas et al., 1995; Pelleymounter et al., 1995; 
Campfield et al., 1995). Leptin circulates in plasma as a ≈16-kD protein with a single disulphide bond 
that is required for its bioactivity (Halaas et al., 1995). Leptin release is diurnal and in a pulsatile 
pattern, peaking at night (Saad et al., 1998).  By shifting meal patterns by 6-7 hours, there is a 
subsequent shift in leptin secretion, suggesting that its release is not through the circadian clock 
(Schoeller et al., 1997; Schoeller et al., 1997). Evidence suggests that leptin acts directly on the 
hypothalamus in order to regulate food intake and body mass (Lee et al., 1996; Fei et al., 1997). 
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Leptin inhibits NPY/AgRP neurons and activates POMC/CART neurons (Huszar et al., 1997; Sahu, 
2003) which results in reduced food intake (Huszar et al., 1997) and an increase in energy expenditure 
(Pelleymounter et al., 1995). 
It is well established that leptin reduces food intake and body weight in humans (Air et al., 2002; 
Halaas et al., 1995; Licinio et al., 2004). With weight loss, fat mass decreases and so does leptin 
concentrations (Maffei et al., 1995). Normally, low leptin concentrations are sensed and it induces a 
state of positive energy balance by increasing appetitive behaviour and reducing energy expenditure 
in order to restore fat mass as an adaptive response to starvation. 
1.3.8. Insulin 
 
Insulin is synthesised in the β cells of the pancreas and is secreted rapidly after a meal (Polonsky et 
al., 1988). Circulating insulin crosses the blood brain barrier (BBB) in a dose-dependent manner by a 
saturable receptor mediated mechanism (Pardridge et al., 1985) and acts at the ARC where insulin 
receptors are highly expressed (Marks et al., 1990). Administration of antisense 
oligodeoxynucleotides targeting the insulin receptor precursor protein in the ARC results in 
hyperphagia and increased fat mass in rats (Obici et al., 2002). Central administration of insulin 
suppresses the fasting induced increase in NPY mRNA levels (Schwartz et al., 1992) and increases 
POMC mRNA expression (Benoit et al., 2002). 
Circulating levels of leptin and insulin are positively correlated with adiposity and body weight 
(Woods and Seeley, 2000) and they deliver information on peripheral energy stores to the central 
nervous system (CNS). Insulin has also been suggested to suppress ghrelin concentrations (Kim et al., 
2007). Intracerebroventricular injection (i.c.v) of insulin or intranasal application of insulin decreases 
food intake in animals (Brown et al., 2006) and man (Hallschmid et al., 2004).  
1.4. Appetite gastrointestinal hormones in ageing and illness 
 
The lack of success in the treatment of undernutrition has led to the investigation of the aetiology of 
unintentional weight loss in ageing and illness. A topic of particular interest is the alterations in 
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gastrointestinal appetite hormones that have an influence on hunger and satiety. Evidence suggests 
that alterations in gastrointestinal appetite hormones may play a role in appetite reduction during 
ageing, but the data is ambiguous. The literature shows a consistent finding that there is a loss of 
appetite above the age of 65 years, but how this loss is mediated is not yet clear. Some evidence 
suggests that with advancing age there is an increase in satiety hormones, such as CCK and PYY, and 
a decrease in the hunger hormone, ghrelin. However, not all studies agree, emphasising the need for 
more in-depth research to clarify age related changes. This knowledge will potentially enable us to 
develop therapies to help prevent under-nutrition during ageing. 
This section explores the alterations in the release of gastrointestinal hormones during illness and 
ageing, specifically CCK, PYY, GLP-1, oxyntomodulin, insulin and ghrelin. Other hormones and 
neuropeptides may be involved in the observed reduction in appetite, but most available evidence in 
humans is in these hormones. Table 2 and 3 summarise the main studies investigating ageing, illness 
and gastrointestinal hormone release.  
1.4.1. Ghrelin in illness and ageing 
 
A reduction in ghrelin release and/or reduction in sensitivity to the action of ghrelin may explain age 
and illness related reductions in appetite. 
Ghrelin and other gastrointestinal hormones are measured using radio-immuno assays (RIAs) and a 
large number of factors can falsify the results of RIAs, for example, ghrelin circulates in two forms; 
desacyl and acyl ghrelin. Antibodies used in RIAs to measure ghrelin cross reacts with both forms of 
ghrelin. Recently, new RIAs have been developed to specifically measure acyl ghrelin alone, since it 
is thought to be the only biologically active form. This is important to note since researchers need to 
measure acyl ghrelin levels in order to accurately investigate the hormones actions. A lack of acyl 
ghrelin measurement in previously published studies means these results need to be interpreted with 
caution. 
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Ghrelin alterations with ageing have been investigated in a number of studies (see table 2), with the 
evidence for a decrease in ghrelin release or sensitivity during ageing being limited and equivocal. 
Results from studies have varied depending on fasting or post-prandial measurements of the hormone 
and the methodological design of the study. Even taking this into consideration it is difficult to define 
with any certainty the changes in ghrelin levels and sensitivity, with ageing. From the eight studies 
reviewed, three studies demonstrated there to be no alteration in total ghrelin levels both fasting and 
post-prandially in the short term (Di Francesco et al., 2006; Schneider et al., 2008; Sturm et al., 2003). 
One demonstrated there to be a reduction in fasting acyl ghrelin (Di Francesco et al., 2008), one 
showed there to be a lack of decline in acyl ghrelin following a meal (Bauer et al., 2010) and another 
demonstrated a conflicting results where ghrelin concentrations decline initially, but did not recover 
and increase following a meal (Serra-Prat et al., 2009). Also in a long term study no alterations in 
ghrelin levels were observed in advancing age (Yukawa et al., 2006) 
It is now known that measurement of acyl ghrelin is critical to assess the biological activity of this 
peptide. Previous studies do not measure this and so these results must be viewed with significant 
caution. Of the eight studies only three (Schneider et al., 2008; Di Francesco et al., 2008; Bauer et al., 
2010) measured acyl ghrelin. Two of these used the same acyl ghrelin assay kit (Schneider et al., 
2008; Bauer et al., 2010), but the other used a different assay (Di Francesco et al., 2008). Different 
assays may report different values due to inter-assay variation. In addition, differences in epitope (part 
of an antigen) recognized by the antibody can also produce different values, which may mean that 
acyl ghrelin values using different assays are not comparable. These three studies do not provide a 
consistent picture, showing either; no difference in fasting ghrelin between young and old (Schneider 
et al., 2008), lower fasting and post-prandial ghrelin in older adults (Di Francesco et al., 2008), and no 
difference in fasting but higher overall ghrelin release in older adults (Bauer et al., 2010). 
Nevertheless, there are other significant variations in study design including the calorie content of the 
study meals provided, time of day, and the matching of groups on age range, BMI and gender. In 
addition, small study numbers were used in these studies with a lack of the use of power calculations, 
therefore these studies are not properly powered for acyl ghrelin. 
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The calorie content of meals is important since gastrointestinal hormone release is proportional to the 
calorie content of the meal. Test meals need to be high in calories (>500) to stimulate a significant 
hormonal response from the gastrointestinal tract. In the studies looking at acyl ghrelin, Di Francesco 
et al. (2008) used a breakfast of 800kcal which should have maximized hormonal response. Schneider 
at al. (2008) allowed an ad libitum breakfast, which would have resulted in each subject consuming 
different energy loads, in particular, the older participants would be expected to consume less than the 
younger ones, potentially confounding the results. Finally, Bauer et al (2010) used a small 245kcal 
breakfast followed by a 4 hour fast, then a 420kcal (relatively small) test meal. These testing 
conditions differ considerably from the other two studies, with hormone levels being assessed at 
midday rather than the morning. Since ghrelin is produced diurnally (Cummings et al., 2001) and 
concentrations are highest in the morning and lowest at night time, morning testing is preferable, and 
studies should be consistent in order to compare different studies. These factors may explain the 
differing results between the three studies, and point to the Di Francesco et al (2008) study as the most 
robust methodology. This study demonstrated that older adults had lower fasting and post-prandial 
acyl ghrelin release compared to younger subjects. 
No human studies to date have investigated if elderly patients have reduced sensitivity to the effects 
of circulating ghrelin concentrations. If sensitivity declines in older adults, a larger ghrelin production 
would be required to elicit the same orexigenic biological response in the elderly compared to the 
young. Animal studies provide some evidence to this theory.  In a study by Ariyasu and colleagues 
(2008), 75 week old rats were fasted for 72 hours and then were resumed with normal feeding with 
subcutaneous administration of saline or ghrelin at 360µg/kg twice daily for 4 days. Food intake was 
increased, with increased body weight recovery in the ghrelin compared to the saline group. 
In another study Yukawa (2008) gave peripheral ghrelin treatment to aged rats. Treatment with 
ghrelin stabilized body weight, but contrary to the other studies, food intake did not increase (Yukawa 
et al., 2008). The reasons for the lack of increased food intake but the maintenance of body weight 
may have been due to ghrelin’s ability to reduce metabolic rate (Nakazato et al., 2001). This was a 2 
week study compared to 4 days and a 1 off injection used in the other studies. It may have been that 
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the body had time to adjust to the ghrelin levels. As these studies were conducted in animals it is 
difficult to extrapolate these results to humans. 
Animal studies suggest that ageing is associated with the general down regulation of receptors 
involved in the stimulation of food intake, and a lack of alterations in receptors in the anorexigenic 
pathways (Kmiec, 2006). Specifically, ageing in rats is associated with a down regulation of NPY 
expression in the hypothalamus that stimulates food intake. It has already been reported in humans 
that older volunteers are less sensitive to the GH-releasing effects of intravenous ghrelin than young 
adults (Broglio et al., 2003).  
Other studies have been conducted in different disease states in humans; in elderly cancer, renal and 
chronic heart failure patients that are all associated with the anorexia of ageing. These studies have 
shown results similar to that of the studies observing healthy older adults, with the results being 
limited and equivocal.  However, there are a number of studies that have demonstrated an 
improvement in appetite after administration of ghrelin in the short term, in a number of disease states 
(Neary et al., 2004; Ashby et al., 2009; Nagaya et al., 2001). 
Few studies to date have investigated acyl ghrelin levels in illness.  Cetinkaya (2009) looked at 
possible relations between serum and saliva acyl ghrelin concentrations before and after surgery in 
patients with acute appendicitis and cholelithiasis when compared to healthy controls. Preoperative 
levels of ghrelin in saliva and serum in people with appendicitis were significantly lower than those 
with choelithiasis. This suggests that low ghrelin levels may be a causative factor of reduced appetite 
observed in inflammatory conditions such as appendicitis. Although acyl ghrelin was measured, this 
study compared groups that were significantly different in age and BMI, with no measurements of 
food intake and subjective feelings of hunger taken. This makes the comparison between different 
illness states invalid, as it is well known that BMI can alter gut hormone production and 
concentrations, for example obese adults have lower circulating ghrelin than normal weight adults 
(Tschop et al., 2001). In another study, in 36 patients with chronic kidney disease there was a 
significant reduction in acyl ghrelin concentrations compared to healthy controls (Oner-Iyidogan et 
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al., 2011). These studies taken together suggest that acyl ghrelin may contribute to the illness 
observed reductions in appetite; more studies however need to be conducted with the use of acyl 
ghrelin. 
Alterations in total ghrelin release have been observed in patients with severe heart failure. Nine 
patients with severe heart failure awaiting heart transplant with seven of these followed up post heart 
transplant and seven healthy controls were looked at (Lund et al., 2009). Ghrelin concentrations were 
elevated in heart failure patients and 12.7 ± 8.6 months post heart transplant compared to controls. 
Ghrelin AUC was elevated in heart failure patients compared to controls, which declined following 
heart transplant. Koch (2010) looked at 120 critically ill patients (122 with sepsis and 48 without) in 
ICU compared to 60 healthy controls. Fasting ghrelin concentrations were also elevated in the 
critically ill regardless if sepsis was present or not. This demonstrates that there might be a ghrelin 
resistance in critical illness and heart failure resulting in a failure of ghrelin to stimulate appetite and a 
consequential reduction in food intake. 
Marchesini et al (2004) looked at ghrelin levels in liver failure. Using 43 cirrhotic and 50 controls 
serum ghrelin and self-assessed food intake were measured. Ghrelin concentrations were not altered 
with cirrhosis.  Le Roux et al (2005) also observed similar results; nine patients with primary 
pulmonary hypertension and cardiac cachexia and nine control subjects were given a 720kcal 
breakfast following an overnight fast, with blood samples being taken every 30 minutes post meal for 
the measurement of ghrelin. In the patient group there was no difference in ghrelin response compared 
to the control group.  
Kadoglou et al (2010) looked at 355 patients (80 with unstable angina, 115 with acute myocardial 
infarction, 88 asymptomatic CAD) and 72 controls. Blood samples were taken on patient’s admittance 
and were measured for ghrelin, apelin, C-Reactive-Protein (CRP), and HOMA-IR. All patients had 
significantly lower ghrelin and apelin compared to the control group and a significantly higher CRP 
and HOMA-IR than the controls. If there is a decline in ghrelin concentration then this would result in 
a reduced appetite and food intake. However, patients on admittance were not under specific fed or 
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fasted states, therefore conditions were not standardized. Similar results were seen in cachectic cancer 
patients, alongside a significant increase in cytokines, there was also a significant reduction in ghrelin 
in patients (Kemik et al., 2010). 
This small set of data demonstrates that there is no definitive answer if ghrelin alters with age or 
during illness. New studies need to be developed in these different disease states that include the 
measurement of acyl ghrelin and the use of post-prandial measurements to improve the validity of the 
results. Study results may also vary due to the methodology of the study; whether samples were taken 
in the fed or fasted state, time of day ghrelin measurement was taken, disease state and disease 
severity. Conditions also need to be standardized so that patients’ characteristics such as BMI, age and 
gender are matched between the groups. 
An obvious target for appetite stimulation is ghrelin. Studies have been conducted in patients with 
illness associated with anorexia of ageing, e.g. patients with cancer, renal disease or chronic heart 
failure. These studies report that IV administration of ghrelin improves appetite and weight gain in the 
short term (Nagaya et al., 2004; Neary et al., 2004; Ashby et al., 2009) suggesting ghrelin 
administration may be a novel approach for age-related weight loss. However, progress has been 
limited by the need to infuse ghrelin (as it is rapidly broken down when administered orally) rather 
than oral administration. 
A recent study has been conducted using a new oral ghrelin mimetic (MK-677, which mimics the 
actions of ghrelin but can be taken orally) in healthy elderly adults to study the effect on growth 
hormone, insulin-like-growth factor 1 (IGF-1), fat-free mass, and abdominal visceral fat. Nass and 
colleagues (2008) undertook a 2 year double blind, randomized, placebo-controlled, modified-
crossover clinical trial in 65 healthy adults ranging from 60-81 years. The ghrelin mimetic 
significantly increased growth hormone and IGF-1 levels to those of healthy young adults without 
serious adverse effects. Mean fat-free mass decreased in the placebo group, but increased in the 
ghrelin mimetic group. Only a small number of volunteers were recruited for this study and a more 
detailed evaluation needs to be conducted looking into the adverse events seen such as; reductions in 
46 
 
bone mass, oedema, and muscle pain. Thus, there remains an opportunity for successful appetite 
stimulation though the use of hormonal mechanisms.  
To conclude, it is unclear if there is any alteration in ghrelin in ageing and in illness; more studies 
need to be conducted. It is clear that ghrelin could prove to be a good therapeutic agent in the 
treatment of undernutrition providing its administration limitations can be resolved and no unforeseen 
adverse effects materialise. 
1.4.2. PYY in illness and ageing 
 
An increase in PYY or an increased sensitivity to PYY may explain elevated feelings of fullness 
causing the cessation of food intake, and may explain the changes in appetite seen in illness and 
ageing. 
Very few studies have studied the effect of ageing and illness on the release of PYY in humans in 
ageing, and none have explored the sensitivity of PYY, therefore, there is no consensus on whether 
PYY is an important factor in the changes in appetite control in old age. The two studies conducted in 
healthy elderly suggest that there is an increase in post-prandial PYY release in ageing (Di Francesco 
et al., 2005), but fasting levels do not change (MacIntosh et al., 1999). 
When food is malabsorbed in the intestine, or when there is an intestinal dysfunction there is resultant 
higher circulating level of anorexigenic hormones (such as PYY) resulting in suppression of appetite 
and reductions in food intake (Nightingale et al., 1996; Wahab et al., 2001). As ageing is associated 
with higher levels of malabsorption in the gut and a dysregulation in the intestine (Morley, 1997), this 
may be a possible reason why older adults have a lower appetite due to a resultant increase in the 
release in the appetite suppressing hormone PYY . 
Research by Di Francesco (2005) demonstrated in ten elderly versus nine younger adults’ plasma 
PYY levels to be raised post-prandially following a test meal. MacIntosh (1999) however, when 
investigating fasting plasma PYY levels, did not detect any differences between eight old and seven 
young volunteers. This study also looked at the effect of an isoenergetic intraduodenal lipid infusion 
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and glucose infusions on PYY release in comparison to younger adults. No effect was seen. This 
refutes the data from Di Francesco where there was a higher concentration of circulating PYY in older 
people post-prandially. However, infusions are not representative of normal eating patterns, as food 
bypasses the stomach and is delivered directly to the duodenum. PYY is released predominantly from 
the colon, and if food and nutrients do not reach the colon, like with an infusion, this would affect 
PYY release. As no effect was seen in an infusion, but an effect was observed following a meal, it 
may be that the intestinal regulation when digesting food in ageing causes the alteration in PYY 
release rather than the sensitivity of the individual to nutrients. It may be that the differences that 
occur in PYY release in old versus young people are more prominent post ingestion of food, which 
may also be the reasoning for the early termination of eating seen in elderly people and the intestinal 
dysregulation observed. In aged rats, there is an increase in NPY and PYY positive cells in the colon 
(Sweet et al., 1996), suggesting that there could possibly be a resultant increase in the volume of PYY 
release, subsequently reducing appetite. 
Larger studies using standardized protocols are required to clarify the effect that ageing may have on 
PYY. Not enough studies in humans have been conducted with large enough samples. It may be 
intestinal dysregulation, rather than nutrients, causing an increased release in the peptide in ageing. 
Sensitivity studies are particularly challenging since the side effects of high PYY levels are nausea 
and vomiting. The margin between physiological and adverse events is small so the PYY infusions 
required to test sensitivity are very difficult to control to avoid such side effects. 
There is a clearer understanding that PYY concentrations are higher in older ill people. Out of the four 
studies that have looked at PYY concentrations in illness, they have all demonstrated that there is an 
increase in PYY concentrations in fasting or postprandial conditions (Nematy et al., 2006a; Nematy et 
al., 2006b; Le Roux et al., 2005; Nguyen et al., 2006) in a number of different disease states. 
In a study by Nematy (2006a) fasting plasma PYY concentrations were elevated in the first week of 
admission to the intensive care unit (ICU) which normalized after three weeks. In 19 critically ill 
patients, Ensure (a nutritional replacement meal) was given via a nasogastric tube at either 1kcal/min 
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or 2kcal/min, with blood samples taken intermittently. Both fasting and nutrient stimulated plasma 
PYY concentrations were elevated, with an elevated CCK response compared to controls. In another 
study by Nematy et al (2006b) 17 elderly patients with femoral neck fracture and 17 elderly controls 
were studied. Fasting samples were taken from femoral neck fracture patients on day 1, 4, 7, 14, 21 
and 28 or on discharge. Samples were compared to control volunteers. PYY levels were not 
significantly different on admission, but were significantly higher over the hospital stay. 13 of the 
femoral neck fracture patients consumed a standard test meal for the measurement of post-prandial 
PYY release in comparison to controls. Post-prandial PYY release was significantly raised in the 
femoral neck fracture patients demonstrating that in trauma states there is a reduction in appetite 
which may be mediated via an increase in plasma PYY concentrations. 
Le Roux et al (2005) investigated nine patients with primary pulmonary hypertension and cardiac 
cachexia and nine control subjects, who were given a 720kcal breakfast following an overnight fast, 
with blood samples being taken every 30 minutes post meal for the measurement of PYY. In the 
patient group there was an exaggerated and early PYY response compared to the control group.  
Nguyen et al (2006) studied 19 mechanically ventilated critically ill patients and 24 healthy controls 
who received a 60 minute duodenal infusion of Ensure at either 1 or 2kcal/minute. Fasting and post 
infusion blood samples were taken for PYY and CCK. Fasting and post-infusion PYY levels were 
higher in critically ill patients than controls. Infusions however, are not representative of normal 
eating behaviour, since food bypassed the stomach and was delivered directly into the duodenum. 
This provides good evidence that illness is associated with elevated PYY, which could result in 
anorexia and play a role in the reduction in appetite seen in sick people. In healthy older adults more 
studies need to be conducted in order to come to a firm conclusion on PYY alterations in ageing. 
1.4.3. CCK in illness and ageing 
 
The majority of studies conducted into the age related effects of CCK on appetite have come to a 
conclusion that CCK plays a role in reducing appetite in older adults. Fasting and post-prandial levels 
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of CCK have been demonstrated to be elevated in older adults (MacIntosh et al., 1999; Sturm et al., 
2003; Di Francesco et al., 2005), with an increased sensitivity to CCK (MacIntosh et al., 2001). 
However, research by Serra-Prat and colleagues found conflicting results, with no increase in plasma 
CCK in older adults (Serra-Prat et al., 2009), but nutritional loads given to stimulate the post-prandial 
effect may have been too small to detect a difference. 
Research by MacIntosh et al (1999) in 8 healthy older and 7 younger adults demonstrated that fasting 
CCK levels were higher in older versus younger volunteers, and when infusing these volunteers with 
an intraduodenal infusion of lipid there was a greater rise  in the levels of CCK in the older adults 
creating an anorectic effect. However, these results need to be taken with caution. An infusion of lipid 
does not represent normal eating patterns. Sturm and colleagues looked at plasma CCK levels before 
and after a 280kcal preload consisting of vanilla ice cream (Sturm et al., 2003). Plasma CCK levels 
were elevated to a greater extent in older than young participants, with old well-nourished and 
undernourished participants levels of CCK not significantly different to one another (Sturm et al., 
2003). Di Francesco (2005) has also demonstrated an increase in CCK levels with age following an 
800kcal preload consisting of 15% protein, 45% fat and 40% carbohydrates. 
Serra Prat et al (2009) and colleagues, when observing old subjects, frail and non-frail demonstrated 
no alteration in plasma CCK levels in ageing. However, post-prandially CCK concentrations were 
slightly higher in young participants, which is contradictory to other studies investigating CCK in 
ageing. This study’s test meals contained carbohydrate as the highest proportion of energy content, 
but it is well known that lipids stimulate CCK release to a greater extent (Hopman et al., 1985). 
An increased satiating effect of CCK could also be a causal effect of the anorexia of ageing. After IV 
infusions of CCK to older and younger volunteers, older participants ate less than younger volunteers 
and food intake was suppressed by 21.6% with CCK infusion than the control day. CCK 
administration also suppressed food intake to a greater extent in the older volunteers than the younger 
volunteers (32% vs. 16%). Baseline CCK concentrations were also higher in older volunteers 
(MacIntosh et al., 2001). Therefore, if there is an increased sensitivity to CCK levels and an increased 
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baseline CCK concentration, this would increase feelings of satiety and reduce food intake to a greater 
extent in older people, therefore, could be a factor involved in the anorexia of ageing. 
Studies that have looked into the role that CCK may have in appetite reduction in illness have 
demonstrated an elevation in CCK levels both fasting and post prandially (Nguyen et al., 2006; 
Nguyen et al., 2007b). 
As previously mentioned (PYY section 1.3.2.) Nguyen et al (2006) studied critically ill patients and  
healthy controls who received a 60 minute duodenal infusion of Ensure. Fasting and post infusion 
blood samples were taken for PYY and CCK. Fasting and post-infusion CCK levels were higher in 
critically ill patients than controls. Infusions however, are not representative of normal eating 
behaviour so these results need to be interpreted with caution. In another study by Nguyen (2007b) in 
23 critically ill patients and 28 healthy subjects, they received two 60 minute duodenal infusions of 
Ensure. Both fasting and nutrient stimulated plasma CCK concentrations were increased in critically 
ill patients. 
No one to date has assessed if there is an alteration in the sensitivity to CCK in ill people, but it is 
likely that it would follow the same pattern to the changes in the sensitivity seen in healthy older 
people, because in both healthy ageing and illness there are similar alterations in fasting and post-
prandial CCK responses. This demonstrates that CCK may play a role in appetite reduction in healthy 
elderly and in age-associated illness.  An increase in basal CCK and an increase in the sensitivity to 
the actions of CCK have been seen in healthy ageing. In illness there is also an increase in both 
baseline and fasting CCK with a possibility of an increase to the sensitivity of CCK, which will 
ultimately decrease appetite. 
1.4.4. Insulin in illness and ageing 
 
Insulin is a well-known regulator of glucose metabolism that is synthesised in the β-cells of the 
pancreas and is secreted rapidly after a meal (Polonsky et al., 1988). Circulating concentrations of 
insulin, alongside leptin are positively correlated with adiposity and body weight (Woods and Seeley, 
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2000). Intracerebroventricular injection of insulin or intranasal application of insulin decreases food 
intake in animals (Brown et al., 2006) and male humans (Hallschmid et al., 2004). However, the 
evidence for insulin playing a direct role in appetite suppression in humans is limited. The increase in 
insulin levels in older adults has been demonstrated to be mainly associated with insulin resistance 
caused by increased adiposity (Colman et al., 1995). 
Blood glucose concentrations have been hypothesised to be a cause of hunger signals (Bergmann et 
al., 1992; Campfield and Smith, 2003). In hypoglycaemia, there is a resultant feeling of hunger 
(Melanson et al., 1998). Human ageing is characterised by increased fasting and postprandial insulin 
resistance (Fraze et al., 1987; Colman et al., 1995) and reduced glucose tolerance. It could be that this 
combination is a cause of reduced food intake in older people (Gutzwiller et al., 1999). Insulin also 
stimulates leptin centrally (Doucet et al., 2000), therefore the higher circulating concentrations of 
plasma insulin seen in older adults may stimulate the signal of leptin. 
Low plasma concentrations of ghrelin are associated with high insulin and glucose concentrations. 
High concentrations of insulin my inhibit ghrelin expression and sensitivity in the elderly (Murdolo et 
al., 2003), therefore reducing appetite. 
There is very little evidence for the effect of insulin on appetite regulation in illness. There is an 
increase in insulin resistance in critical illness (Dhar and Castillo, 2011), and an increase in circulating 
insulin levels in sepsis (Tzanela et al., 2006), therefore if there are higher circulating levels this could 
result in increased feelings of fullness and reduced food intake.  
1.4.5. Leptin in illness and ageing 
 
Leptin has been suggested to be a causal factor in the anorexia of ageing. In one study serum leptin 
has been found to be significantly higher in older adults in comparison to younger adults (Di 
Francesco et al., 2006). However, this study did not take into account body fat mass. When body fat 
has been taken into account, fasting leptin has been found to be elevated in one study (Zamboni et al., 
2004), but in others the effect was removed in males and females (Mann et al., 2003) and females 
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only (Baumgartner et al., 1999). It has even been suggested in some studies that leptin may be lower 
than expected when body fat is taken into account in ageing (Blanton et al., 1999). No studies to date 
have investigated alterations in leptin sensitivity in ageing. 
Leptin is implicated in the neuroendocrine stress response (Flier, 1998). Leptin concentrations have 
been investigated in a number of different disease states. Evidence suggests that leptin concentrations 
are raised in acute sepsis (Tzanela et al., 2006; Torpy et al., 1998) which returned to normal after 
prolonged sepsis (Tzanela et al., 2006). Leptin concentrations are also higher in COPD patients 
(Kythreotis et al., 2009). However, in 137 critically ill patients and in cancer cachexia (Smiechowska 
et al., 2010), there is a reduction in leptin levels, associated with weight loss. 
Together this data is unclear on the alterations, if any in leptin concentrations with ageing and in 
illness. Additional studies need to be conducted on larger study populations to determine if there is an 
alteration. 
1.4.6. Other hormones in illness and ageing 
 
The remaining gut hormones; GLP-1, PP and oxyntomodulin are relatively understudied in terms of 
ageing. Of the few studies available, none to date have shown an effect of ageing on GLP-1 
(MacIntosh et al., 1999). MacIntosh and colleagues administered an intra-duodenal infusion of lipid to 
young and old participants; GLP-1, PYY and CCK were measured. There was no significant 
difference in GLP-1 between groups. However, there was an inverse relationship between GLP-1 and 
hunger in the young but not the older volunteers (MacIntosh et al., 1999). This suggests an alteration 
in sensitivity of the older volunteers to the actions and release of GLP-1, but further study is required 
to confirm this hypothesis. No studies to date have looked at the changes in PP or oxyntomodulin in 
ageing. As both these hormones decrease food intake and appetite in humans (Cohen et al., 2003), it 
would be useful to determine if levels of either change with age. 
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Table 1.2. Published studies exploring ageing and gastrointestinal appetite hormones in humans 
Author 
 
Sample Experimental method Significant difference in 
gastrointestinal hormones 
between young and older 
Non-significant difference in 
gut hormones in young and 
older 
Critique of study 
 
MacIntosh et al, 
1999 
 
 
 
8 older (65-80years) 
8 young (20-34 
years) 
Males only 
 
Fasting blood sample 
following 12hr fast 
Intra-duodenal infusion of 
either glucose or lipid, 
followed by buffet style 
test meal. 
 
Baseline CCK higher in older 
volunteers, with higher 
concentrations throughout the 
infusion. 
 
No significance in GLP-1 and 
PYY concentrations fasting 
and post infusion. 
 
Infusions not 
representative of normal 
eating. 
Participants anaesthetized 
for the placement of the 
infusion.  
 
Rigamonti et al, 
2002 
 
12 Young normal-
weight (27-39 years) 
7 Older normal-
weight (67-91 years) 
7 Obese (16-36 yrs) 
6 Anorexic (17-18 
yrs) 
 
Compared fasting plasma 
total ghrelin levels. 
 
Lower ghrelin concentrations in 
normal weight older compared to 
young normal weight 
  
No postprandial ghrelin 
measured. 
 No acyl ghrelin 
measurements. 
Small sample size 
 
MacIntosh et al, 
2001 
 
12 young (18-33 
years), 12 older (67-
83 years) males and 
females 
 
 
 
Compared food intake 
following CCK infusion in 
older and younger 
volunteers 
 
 
 
Food intake was suppressed to a 
greater extent after CCK infusion 
in the older than younger adults 
CCK concentrations increased to 
a greater extent in older 
volunteers during the CCK 
infusions. 
  
Small sample size. 
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Author 
 
Sample Experimental method Significant difference in 
gastrointestinal hormones 
between young and older 
Non-significant difference in 
gastrointestinal hormones in 
young and older 
Critique of study 
 
Sturm et al, 
2003 
 
8 Under-nourished 
older (67-87 years) 
8 well-nourished 
older (72-80 years) 
8 well-nourished 
young (18-29 years) 
 
 
2 Visits 
1. Overnight fast with 
Vanilla ice cream preload 
(280kcal) followed by 
buffet meal 90 minutes 
later 
2. Overnight fast. No 
preload. Followed by 
buffet meal 90 minutes 
later. 
Measured plasma GLP-1, 
total ghrelin, CCK and 
VAS 
 
CCK higher in well-nourished 
and undernourished older than 
young in fasting and following 
meal. 
Fasting total ghrelin higher in 
undernourished older compared to 
well-nourished older and well-
nourished young 
 
No significance in fasting and 
postprandial ghrelin in well-
nourished older and well-
nourished young 
No difference in GLP-1 levels 
 
The preload test meal 
size may not be large 
enough 
90 minute a short time to 
record post-prandial 
hormone release. 
Small sample size and 
did not measure acyl 
ghrelin 
 
Di Francesco et al, 
2005 
 
10 older (72-82 
years) and 9 young 
(25-53 years) males 
and females 
 
Compared fasting blood 
concentrations and 
following an 800kcal 
preload. Measured gastric 
emptying, CCK and PYY 
 
Fasting CCK and postprandial 
CCK higher in older volunteers 
PYY higher 2 hours following 
preload. Prolonged gastric 
emptying in older adults. 
  
Small population sample 
size 
 
Yukawa et al, 
2006 
 
21 young (18-35 
years) 
18 older (>70 years) 
males and females 
 
Diet intervention study. 2 
weeks weight maintaining 
diet followed by 2 weeks 
20% calorie restriction, 
then 4 weeks ad libitum 
diet. 24 hr blood sampling 
for total ghrelin 
  
No difference in ghrelin 
concentrations  in each diet 
between the two age ranges 
 
Short duration of diets. 
Problems with adherence 
to diets? 
Only looked at total 
ghrelin 
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Author 
 
Sample Experimental method Significant difference in 
gastrointestinal hormones 
between young and older 
Non-significant difference in 
gastrointestinal hormones in 
young and older 
Critique of study 
 
Di Francesco et al, 
2006 
 
8 older (74-82 years) 
8 Young (25-38 
years) males and 
females 
 
 
Compared fasting blood 
concentrations and 
following an 800kcal 
preload 
Measured leptin and total 
ghrelin concentrations 
 
Fasting leptin significantly higher 
in older 
 
No significant difference in 
basal and post-prandial ghrelin 
concentrations 
 
Small sample size 
Did not measure  acyl 
ghrelin 
 
Schneider et al, 
2008 
 
11 older 
undernourished (71-
89 years) 
9 older well 
nourished (65-88 yrs) 
10 young 
undernourished (19-
34 years) 
10 young well 
nourished (23-49 
years) 
 
Fasting blood 
concentrations and 
following an ad libitum 
breakfast. 
 
Measured acyl ghrelin, 
total ghrelin and leptin 
 
Fasting ghrelin higher in young 
malnourished  than well 
nourished 
 
AUC ghrelin elevated in 
undernourished young compared 
to well-nourished young 
 
Leptin higher in well-nourished 
old than well-nourished young 
 
No difference in ghrelin 
between young and older, and 
well-nourished and 
malnourished older 
 
 
Small numbers 
 
Mainly females in the 
malnourished groups. 
 
Undernourished old are 
older than well-nourished 
old 
 
Di Francesco et al,  
2008 
 
11 older (75.2yrs 
±1.8 years)  
11 young (21 ± 0.7 
years) 
 
Compared fasting blood 
levels and following 
800kcal meal in older and 
younger volunteers. 
Measured acyl ghrelin 
 
Acyl ghrelin significantly lower 
in older 
  
Slightly different BMI in 
each group 
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Author Sample Experimental method Significant difference in 
gastrointestinal hormones 
between young and older 
Non-significant difference in 
gastrointestinal hormones in 
young and older 
Critique of study 
 
Serra Prat et al, 
2009 
 
15 older frail (>75 
years) 
10 older non-frail (> 
75 years) 
17 Young (<30 years) 
 
 
Compared fasting blood 
concentrations and 
following 380kcal test 
meal. 
Measured total ghrelin and 
CCK 
 
Older (frail and non-frail) had 
poorer post-prandial ghrelin 
recovery. 
Frail older had lower fasting 
ghrelin than non-frail older and 
young 
Lower post-prandial CCK release 
in older (frail and non-frail) 
 
No difference in fasting CCK 
 
Preload test meal may not 
have been large enough 
to detect an effect. 
Did not measure acyl 
ghrelin 
 
Bauer et al, 
2010 
 
19 older  (71-89 
years) 
15 young (25-45 
years) 
 
Light 285kcal breakfast on 
arrival. 4 hours following 
breakfast (midday) test 
meal administered 
420kcal. Blood samples 
before and following test 
meal for total ghrelin and 
acyl ghrelin. 
 
Poorer post-prandial ghrelin 
decline in older people. 
AUC acyl ghrelin higher in older 
volunteers. 
 
No difference in basal ghrelin 
concentrations 
 
Different time of day to 
other studies. Difficult to 
make a comparison. 
Test meal size relatively 
small. 
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Table 1.3. Published studies exploring illness and gastrointestinal appetite hormones in humans 
Author Sample Experimental method Significant difference in 
gastrointestinal hormones in 
illness compared to controls 
Non-significant difference in 
gastrointestinal hormones in 
illness compared to controls 
Critique of study 
 
Le Roux et al, 
2005 
 
9 patients with 
primary pulmonary 
hypertension and 
cardiac cachexia 
and 9 control 
subjects 
 
Given a 720kcal breakfast 
following an overnight fast, 
fasting blood sample and 
samples every 30 minutes 
post meal for measurement 
of  PYY and Ghrelin 
 
Exaggerated and early PYY 
response in hypertension 
group compared to controls 
 
No difference in ghrelin 
 
Small sample size used 
No measurement of acyl 
ghrelin 
 
Lund et al, 
2009 
 
12 patients with 
severe heart failure 
awaiting heart 
transplant (7 
followed up post 
heart transplant) 
and 7 controls 
 
Measured ghrelin, hunger 
sensation in heart failure and 
12.7 ± 8.6 months post heart 
transplant compared to 
controls 
 
Ghrelin AUC was higher in 
heart failure compared to 
controls, which declined 
following heart transplant. 
  
No measurement of acyl 
ghrelin 
No measurements 
following meal. 
Small sample size 
 
Marchesini et al, 
2004 
 
 
 
43 cirrhotic patients 
(liver failure) and 
50 controls 
 
Fasting ghrelin and self-
assessed food intake 
measured 
 
Ghrelin concentrations 
increased with decreasing 
hunger 
 
Ghrelin concentrations not 
increased with cirrhosis 
 
Self-assessed food intake. 
An ad libitum meal 
would have been more 
ideal. 
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Author Sample Experimental method Significant difference in 
gastrointestinal hormones in 
illness compared to controls 
Non-significant difference in 
gastrointestinal hormones in 
illness compared to controls 
Critique of study 
 
Nagaya et al, 
2004 
 
18 patients with 
chronic heart failure 
 
Human synthetic ghrelin 
administered IV to 10 CHF 
patients for 3 weeks. Looked 
at effects on LV function, 
muscle wasting, exercise 
capacity compared to 8 CHF 
controls 
 
Ghrelin increased LV ejection 
fraction with association with 
increase in LV mass. 
Increased muscle strength and 
LBM, and exercise capacity, 
unchanged in controls 
  
Short term effects, did 
not look at the long term 
effects of administration 
and effect on food intake. 
 
Nguyen et al, 
2006 
 
19 mechanically 
ventilated critically 
ill patients and 24 
healthy controls 
 
Received 60 minute 
duodenal infusion of Ensure 
at either 1 or 2kcal/minute. 
Fasting and post infusion 
blood samples for PYY and 
CCK 
 
Fasting and post-infusion 
PYY concentrations higher in 
critically ill patients than 
controls 
Fasting and post-infusion 
CCK concentrations higher in 
critically ill patients than 
controls 
 
  
Infusions not 
representative of normal 
eating patterns. 
 
Neary et al, 
2004 
 
 
7 cancer patients 
with loss of appetite 
 
 
Energy intake at a buffet 
meal following a ghrelin 
infusion versus a saline 
solution. 
 
Increase in energy intake 
observed with ghrelin infusion 
in every patient compared 
with saline. Meal appreciation 
greater with ghrelin treatment.  
  
Small study numbers 
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Author Sample Experimental method Significant difference in 
gastrointestinal hormones in 
illness compared to controls 
Non-significant difference in 
gastrointestinal hormones in 
illness compared to controls 
Critique of study 
 
Nematy et al, 
2006 
 
16 ICU patients and 
36 healthy control 
volunteers 
 
 
ICU patients underwent 
fasting blood samples at day 
1, 3, 5, 14, 21 and 28 of stay 
in hospital for measurement 
of ghrelin and PYY. 
Samples compared to 
control volunteers. 
 
 
ICU patients significantly 
lower ghrelin concentrations 
during stay which tended to 
rise to normal during last 3 
weeks of hospital stay. 
ICU patients had significantly 
higher concentrations of PYY 
with a downward trend to 
normal though out the stay. 
  
No post prandial 
measurements or 
comparisons with energy 
intake. 
 
Wynne at al, 
2005 
 
9 peritoneal dialysis 
patients with mild 
to moderate 
malnutrition 
 
Subcutaneous administration 
of ghrelin on food intake, Bp 
and heart rate compared to 
saline. 
 
Energy intake higher after 
ghrelin administration with a 
fall in Bp 
  
Small study numbers 
 
Nematy et al, 
2006 
 
 
17 elderly patients 
with femoral neck 
fracture (FNF) and 
17 elderly control 
 
 
 
Fasting blood samples taken 
for PYY from FNF patients 
on day 1,4,7,14,21 and 28 or 
on discharge and compared 
to healthy control. 13 FNF 
patients consumed standard 
test meal, post prandial 
samples taken for PYY 
 
PYY levels increased 
significantly over hospital 
stay. 
Post prandial PPY increased 
compared to control. 
  
Only 1 post prandial 
PYY measurement taken. 
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Author Sample Experimental method Significant difference in 
gastrointestinal hormones in 
illness compared to controls 
Non-significant difference in 
gastrointestinal hormones in 
illness compared to controls 
Critique of study 
 
Koch et al, 
2010 
 
120 critically ill 
patients (122 with 
sepsis, 48 without) 
in ICU and 60 
healthy controls 
 
Fasting blood samples for 
ghrelin 
 
Ghrelin serum concentrations 
elevated in critically ill 
patients compared to healthy 
controls with no difference 
between sepsis and non-sepsis 
  
No post prandial 
measurements 
 
Kadoglou et al, 
2010 
 
355 patients (80 
unstable angina, 
115 acute 
myocardial 
infarction, 88 
asymptomatic  
CAD)  72 controls 
 
Blood samples taken on 
admittance for ghrelin, 
apelin, CRP, HOMA-IR 
 
All patients had significantly 
lower ghrelin  and apelin 
compared to the control group 
and significantly higher CRP 
and HOMA-IR than the 
controls. 
  
Fasting and postprandial 
measurement would be  
more accurate. 
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1.5. Ageing and the gastrointestinal tract 
 
Gastrointestinal physiology alters with ageing, and these changes may play a role in the ‘anorexia of 
ageing.’ Changes in gastric function can lead to malabsorption, delayed gastric emptying and 
constipation. 
Morley and Silver (1988) suggested that the ‘anorexia of ageing’ could be due, in part, to alterations 
in the response of the upper gastrointestinal tract to food. They suggested that the alteration in the 
physiology of the gastrointestinal tract could lead to an altered release of gastrointestinal hormones 
and activation of ascending vagal fibres. 
There have been a number of studies that have demonstrated that there is a slowing of gastric 
emptying after the consumption of large solid and liquid meals in older persons (Brogna et al., 2006; 
Horowitz et al., 1984; Clarkston et al., 1997; O'Donovan et al., 2005; Moore et al., 1983), and a delay 
in a large liquid meal using a wide array of techniques such as dual radioisotopic method, and 
radiopaque markers. It has been demonstrated in older adults that gastric emptying (measured using 
antral area) is slower than in younger people, and that emptying is correlated with appetite sensations, 
suggesting that greater distension and slower emptying results in greater satiety (Sturm et al., 2004). If 
there is a slowing of food through the gastrointestinal tract, the presence of food could result in 
prolonged activation of ascending vagal fibres and thus an increase in satiety hormone release.  
However, not all literature has demonstrated a reduction in gastric emptying times with age. In a study 
by Kupfer et al (1985), gastric emptying following a liquid meal was found to be accelerated in the 
early post-pradial phase. Other studies have found no change in gastric emptying time (Madsen and 
Graff, 2004; Gainsborough et al., 1993). Therefore it remains to be understood if a delay in gastric 
emptying is a characteristic of ageing and if it could cause to the age associated reductions in appetite.  
Results from different studies are likely to be due to differences in methodology; technique for 
measurement of gastric emptying, size of test meal administered, volume and consistency of meal 
provided.  
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There is some animal evidence to support this idea that changes in the ageing gastrointestinal tract 
result in increased satiety; in rat colons the number of PYY and NPY positive cells increased with age 
(Sweet et al., 1996). However, a study of human rectum tissue samples demonstrated no difference 
between the numbers of PYY and PP containing cells in young versus older (Sandstrom and El-Salhy, 
1999b) but, this study only examined adults in the 60-69 years age group. Since anorexia of ageing is 
more prevalent in those over 75 years, more data is required to establish what happens in humans. 
There are other factors that occur more commonly in older adults and could contribute to age related 
weight loss; helicobacter pylori infection (Portnoi, 1997) and gallstones (Lissoos et al., 1993). 
However, there is limited evidence that either of these may alter gut hormone release. 
In summary, the scant data available does not allow any firm conclusion about the effect of ageing on 
gastrointestinal function and its response to food, highlighting the need for more extensive research. 
1.6. Other factors implicated in the loss of appetite in ageing and illness 
1.6.1. Taste and smell 
Taste and smell senses make food enjoyable to consume and it is also part of the initiation of the 
digestive process. Thus reductions in smell and taste could theoretically influence appetite. It is well 
established that with age there is a decline in taste and smell sensitivity (Doty et al., 1984; Finkelstein 
and Schiffman, 1999; Schiffman, 1994; Schiffman, 1977; Schiffman, 1997). In a review, in people 
between the ages of 65- 80 years; 60% had developed a reduced sense of smell and taste. In adults 
over the age of 80 years, this was even higher with more than 80% with a reduced sense of taste and 
smell (Boyce and Shone, 2006). 
This reduction in sensitivity is associated with a reduced interest in the intake of food, which 
subsequently results in a less varied diet and micronutrient deficiencies. The taste and smell senses 
appear to be necessary for the cephalic phase of digestion. This includes the initial increase in 
salivary, gastric, pancreatic and intestinal secretions that initiate digestion (Sawaya et al., 1995; 
Schiffman, 1997), which ultimately could alter the secretions of gastrointestinal hormones. 
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1.6.2. Cytokines 
Cytokine concentrations are increased in response to significant stress such as during injury, infection 
and long term inflammation. Cytokines known to have an involvement in appetite reduction include 
interleukin 1 (IL-1), interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF-α) (Yeh and Schuster, 
1999; Plata-Salaman, 1995; Langhans and Hrupka, 1999). They act to reduce feelings of hunger and 
body weight via a number of central and peripheral pathways, with the exact mechanism of their role 
unknown (Asarian and Langhans, 2010; Hermann and Rogers, 2009; Gautron and Laye, 2009; Inui, 
1999). 
Ageing is associated with an increase in the concentration of cortisol and catecholamine 
concentrations and a decrease in sex hormones and growth hormone (GH). The alteration in cortisol 
and catecholamine levels promote the release of IL-6 and TNF-α (Yeh and Schuster, 1999), 
subsequently reducing food intake. IL-6 and TNF-α are also increased in patients with cancer and 
AIDs that are cachectic (Moldawer et al., 1992; Noguchi et al., 1996). An increase in these cytokines 
would result in appetite suppression and subsequent weight loss. However, there are no specific 
studies looking at cytokines role in appetite control in healthy ageing and it is unclear whether their 
effect will be acute or chronic. 
1.7. Macronutrients, gastrointestinal hormone release and appetite 
The evidence suggests that with ageing there is an alteration in gastrointestinal hormone release and / 
or sensitivity. A method in order to modulate the release of these different hormones could be through 
a change in macronutrient content of the diet. Diet provides a good opportunity to manipulate 
gastrointestinal appetite hormones, which may help to gain optimal nutrition for elderly adults and 
patients. Gastrointestinal appetite hormone release differs depending on macronutrient content of the 
food consumed. However, evidence around gastrointestinal release in response to macronutrients is 
limited and sometimes contradictory. There is currently only one study that has been conducted to 
compare gastrointestinal hormone release and appetite response to the macronutrient fat (Di 
Francesco et al., 2010), where they found that older people were significantly more sensitive to the 
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satiating effects of dietary fat and had a larger GLP-1 release in response to a high fat diet than 
younger volunteers. No research has been conducted to observe if there is a different effect in older 
people than younger people on protein and carbohydrates in gastrointestinal appetite hormone release 
and appetite.  
1.7.1. Ghrelin response to macronutrients 
Among the macronutrients, carbohydrates create the largest effect in ghrelin suppression. Glucose is 
the most potent form of carbohydrate in ghrelin suppression, which has been shown orally (Shiiya et 
al., 2002; Caixas et al., 2002), intravenously (Tschop et al., 2000; Shiiya et al., 2002) and using 
intragastric administration (Williams et al., 2003). Glucose administered orally reduces ghrelin 
(Shiiya et al., 2002) and active ghrelin (Nakai et al., 2003) to nadir at 60 minutes, which returns to 
normal baseline levels after 190 minutes (Shiiya et al., 2002; Gottero et al., 2003). Interestingly when 
fructose is administered orally, there is no ghrelin suppression (Teff et al., 2004) ). Even over a 3 hour 
period, a high carbohydrate meal is more effective in suppressing ghrelin than a high fat meal 
(Monteleone et al., 2003).  
Studies investigating the influence of protein on ghrelin suppression have been contradictory. Ghrelin 
has been shown to be unchanged after a protein rich meal (Greenman et al., 2004). However, it has 
also been demonstrated that ghrelin release increased after a high protein enriched meal (Bauer et al., 
2010; Bauer et al., 2010; Erdmann et al., 2003; Erdmann et al., 2006). A few studies have also 
opposed this result and have demonstrated a reduction in acyl ghrelin (Al Awar et al., 2005) and total 
ghrelin (Blom et al., 2006) release post-prandially after a high protein meal. 
Lipid infusion has little effect on acyl ghrelin (Nakai et al., 2003) and total ghrelin (Mohlig et al., 
2002; Murray et al., 2006) concentrations. Results investigating ghrelin response to lipids have been 
contradictory where lipids have been shown to increase ghrelin concentrations (Erdmann et al., 2004) 
and decrease ghrelin concentrations (Greenman et al., 2004).  
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In summary, carbohydrates are the most potent in ghrelin suppression, with glucose the most 
influential form of carbohydrate on ghrelin suppression. More studies need to be conducted to 
determine the role of lipids and protein in ghrelin suppression. 
1.7.2. PP response to macronutrients 
Data around PP response to macronutrients is very limited. Carbohydrate, protein and dietary fat have 
been shown to stimulate PP release (Sive et al., 1979; Taylor et al., 1985; Lawson et al., 1983; Schmid 
et al., 1992; Zipf et al., 1983). However data on dietary fats role in PP suppression is not clear, where 
a decrease in PP concentrations has been observed following a high fat meal (Robertson et al., 2004). 
1.7.3. PYY response to macronutrients 
All macronutrients (protein, fat and carbohydrate) stimulate PYY release, but with different degrees 
of intensity and time courses. The hierarchy of macronutrients on PYY release appear to follow the 
order of protein>fat>carbohydrate. Carbohydrates appear to have little effect on PYY release 
compared to other macronutrients. Essah et al (2007) in a randomised cross over study fed volunteers 
a high fat low carbohydrate diet and a low fat high carbohydrate diet for one week with a one week 
wash out period between test conditions. The high fat diet produced the highest post-prandial PYY 
response compared to the high carbohydrate test meals. However, when high fat diets are compared to 
high protein diets, protein appears to be the most potent in elevating PYY concentrations (El Khoury 
et al., 2010; Pedersen-Bjergaard et al., 1996; Leidy et al., 2010). In a study by Batterham et al (2006) 
a high protein meal compared to high fat meal resulted in the highest elevation in PYY response 
compared to the other macronutrients. This has not been demonstrated in all studies, where fat elicited 
the largest PYY response compared to protein  (Adrian et al., 1985). 
1.7.4. CCK response to macronutrients 
Carbohydrates have very little effect on CCK release (Brown et al., 2006), with its effects very short 
lasting (Bowen et al., 2006b). Fat and protein are the macronutrients that produce the greatest 
postprandial CCK response. Protein is a strong stimuli for the satiety gastrointestinal hormones PYY, 
GLP-1 and CCK. CCK has been demonstrated to be elevated following a high protein meal (Blom et 
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al., 2006; Bowen et al., 2006b; Bowen et al., 2006a). However out of all the macronutrients lipids 
appear to have the largest effect on CCK release, with its effects long lasting (Hopman et al., 1985; 
Liddle et al., 1985). Robertson et al (2002) demonstrated that after a high fat evening meal CCK 
plasma concentrations remained elevated until the following morning.  
1.7.5. GLP-1 response to macronutrients 
GLP-1 is released in response to all macronutrients, but its concentrations in plasma decrease after a 
relatively short time due to its short half-life (Hui et al., 2002). Carbohydrate is a stimulator of GLP-1 
(Elliott et al., 1993; Herrmann et al., 1995; Brubaker and Anini, 2003; Holst, 2007), with different 
types of carbohydrates exerting different effects on GLP-1 release (Elliott et al., 1993; Kong et al., 
1999). Carbohydrates are not the most potent in exerting a GLP-1 response. Protein produces more of 
a substantial response in GLP-1 release than carbohydrates (Blom et al., 2006; Lejeune et al., 2006). 
Lipids also stimulate GLP-1 release (Herrmann et al., 1995), but this response is slower in comparison 
to carbohydrates (Elliott et al., 1993). 
1.7.6 Macronutrients influence on satiety and energy intake 
The satiating power of the macronutrients have been suggested to follow the oxidation hierarchy; 
alcohol>protein>carbohydrate>fat (Johnstone et al., 1996; Stubbs et al., 2000a; Blundell and 
MacDiarmid, 1997). However, evidence around the satiating power of carbohydrate and fats is still 
limited and often contradictory. The majority of research has suggested that protein is the most 
satiating macronutrient. 
There is a relatively large body of evidence to suggest that high intakes of protein have a substantial 
effect on satiety and energy intake. Protein is a highly satiating macronutrient (Poppitt and Swann, 
1998; Johnstone et al., 1996; Blundell and MacDiarmid, 1997; de Castro, 1999; Marmonier et al., 
2000; Nickols-Richardson et al., 2005), in which has been shown to exert a higher effect on both 
intra-meal satiation and post-ingestive satiety than high fat foods (Porrini et al., 1997). Protein creates 
the largest post-prandial score in fullness and reductions in hunger (Johnstone et al., 1996; Blundell 
and MacDiarmid, 1997; de Castro, 1999; Marmonier et al., 2000; Nickols-Richardson et al., 2005) 
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compared to the other macronutrients lipid and carbohydrates. In the longer term, protein has been 
suggested to aid weight maintenance and body weight loss. Skov et al (1999) studied 65 healthy 
volunteers and investigated the effect of a high carbohydrate vs. a high protein (25%) diet over 6 
months. Weight loss in the high protein group was significantly higher than the high carbohydrate 
group (Skov et al., 1999). Similar results have been observed in other studies in which demonstrated 
that protein has an improved effect on weight loss than high carbohydrate diets and high fat diets (Due 
et al., 2004; Weigle et al., 2005). Very few studies have proved otherwise, where protein has no 
influence on food intake. Raben et al (2003) using a 32% protein meal found opposing results, where 
there was no difference in food intake compared to equal energy content carbohydrate and fat meals. 
Conflicting results may be due to differences in methodology, compliance, palatability of the diets 
and food form. 
Most of the data looking into the satiating effect of carbohydrate and fat, and which one exerts the 
largest effect on appetite suppression is unclear. The uncertainty may partly be due to different types 
of carbohydrates and fats that may exert different effects on appetite. It has already been described in 
this section that different types of carbohydrates have different effects on gastrointestinal appetite 
hormone release (Elliott et al., 1993; Kong et al., 1999). Blundell et al (1993) demonstrated that high-
fat foods have little effect on satiation compared with sucrose. Contradicting this, high carbohydrate 
meals have also been shown to provide the smallest effect on feelings of satiety compared to high fat 
meals and high protein meals. Although it has been observed that high fat diets produce a substantial 
CCK and PYY response, high fat diets do not have a significant effect on satiety. High fat diets 
compared to low fat diets result in lower feelings of satiety and increased food intake. Clegg and 
Shafat (2010) fed volunteers a high fat breakfast or a low fat breakfast of equal energy density. 
Feelings of fullness were higher following the low fat breakfast and energy intake seven hours 
following the high fat meal was significantly higher. A review by Astrup et al (2002) suggested that a 
low fat diet is more favourable for body weight loss than a high fat diet. The relevance of high fat and 
high carbohydrate diets on satiety and food intake is still yet to be fully elucidated, and it is beyond 
the scope of this thesis to concentrate on. 
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No studies to date have investigated the differences in effects of satiety on high protein meals between 
older and younger volunteers. However, Di Francesco et al (2010) investigated the differences in 
gastrointestinal appetite hormone response and subjective feelings of appetite in 12 healthy older and 
12 young volunteers between two different fat containing meals. Volunteers attended two study visits, 
on one visit they were required to consume a 20% fat meal, and on the other occasion a 40% fat meal. 
Plasma GLP-1 levels were higher following the 40% fat than the 20% fat meal in the older but not the 
younger volunteers. There was also a reduction in hunger following the 40% fat meal in the older but 
not the younger volunteers. The flaw to this study is that ad libitum food intake was not measured, 
and so remains unknown if the reduction in hunger observed would result in a reduction in food 
intake. There was no difference in ghrelin (total and acyl) response with a lack of measurement of 
PYY. In another study, Ryan et al (2004) gave patients either a high fat or a high carbohydrate 
supplement over 3 days and measured energy intake and subjective feelings of appetite during the 3 
day period. There was an increase in cumulative energy intake following supplementation of both the 
carbohydrate and fat supplements, but there was no difference between the kcal consumed between 
the two macronutrient supplements. This suggests that a high intake in fat in the older population via a 
supplement increases cumulative daily energy intake, suggestive that high fat intake does not reduce 
long term energy intake. More studies need to be conducted in older people to determine if there is a 
difference in response in older people to high fat meals. 
1.7.7. Summary  
In summary, different macronutrients exert different effects on gastrointestinal hormone release. One 
macronutrient in particular; protein, seems to have potent effects on appetite suppression and on all 
gastrointestinal hormones, with the exception of ghrelin. It has also been demonstrated that a diet high 
in protein compared to other macronutrients increases feelings of satiety and reduces food intake more 
substantially than both high fat and high carbohydrate diets (Johnstone et al., 1996; Blundell and 
MacDiarmid, 1997; de Castro, 1999; Marmonier et al., 2000). A meta-analysis also demonstrated that 
out of 10 studies, eight showed a larger reduction in food intake following a high protein meal than a 
high fat or high carbohydrate meal (Eisenstein et al., 2002). It has also been shown that in the longer-
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term, those who consumed a high protein diet maintained their weight better than a high carbohydrate 
diet (Skov et al., 1999). Studies have investigated the satiating effect of high fat diets in on appetite 
and gastrointestinal hormone release in older people compared to younger people, but no studies to 
date have looked at the satiating effect of a high protein meal in older people compared to younger 
people. If there is an altered profile in gastrointestinal appetite hormones sensitive to protein 
consumption in younger adults, the effect of protein on satiation and reductions in energy intake and 
gastrointestinal appetite hormones may even be substantially larger in older people, and provide 
further insight into the alterations in appetite regulation and undernutrition in older people. 
1.8. Thesis introduction summary 
The ageing population is increasing. Under-nutrition in the UK is a common problem in the ageing 
population, and in those that are of ill health. An explanation for the reduction in appetite observed 
could be explained by an alteration in gastrointestinal appetite hormones. However, preliminary 
evidence has failed to come to definite conclusion in the alterations that may occur with ageing. 
Different macronutrients exert diverse post-prandial effects on gastrointestinal appetite hormone 
release. This could potentially suggest that diet in older people could be manipulated to create 
different post-prandial appetite hormone effects and satiety. Protein is a potent stimulator of satiety 
gastrointestinal hormones; and older people may be more sensitive to the satiating effect of protein. 
No studies to date have investigated the effects of high protein intake on satiety in older people 
compared to younger people. More studies need to be conducted in order to define the alterations that 
occur. If there is an increase in satiety hormones and a reduction in the orexigenic hormone ghrelin, 
and an increased sensitivity to satiating macronutrients, this would help to explain the age-associated 
and illness associated reductions in appetite observed. 
1.9. Thesis hypothesis 
In ageing there will be an altered gastrointestinal appetite hormone release and an alteration in 
sensitivity to the satiating effect of protein. 
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1.10. Thesis aims and objectives 
The aim of the thesis is to study the role of gastrointestinal hormones involved in the regulation of 
appetite in undernutrition in ageing and illness. This thesis will study the following objectives; 
1. To develop an animal model that replicates the gastrointestinal hormone response seen in 
humans in illness. 
2. To explore the alterations in gastrointestinal hormone release in older and younger healthy 
human volunteers 
3. To determine if the changes seen in gastrointestinal appetite hormone concentrations in plasma 
in ageing correlates with an alteration in appetite hormone concentrations in the 
gastrointestinal tract.  
4. To establish, using the NDNS dataset, if there is an effect of protein and other macronutrients 
on body weight 
5. To investigate the effect of a high protein meal on short-term energy intake appetite responses 
and gastrointestinal hormone release in aged and young adults.  
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Chapter 2 
METHODS 
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This methods section describes the main protocols and techniques used in more than one of the 
investigations in this thesis. Chapters in this thesis will also contain protocols and procedures unique 
to that study in more detail. All methodologies in this chapter were performed by me unless stated 
otherwise. 
2.1. Ethics 
All human studies had gained ethical approval prior to the study commencing. The riverside research 
ethics committee granted ethical approval for the studies; REC No 08/H0706/128 Comparison of gut 
appetite hormones in healthy older and young adults, and REC No 10/H0706/80 The effect of protein 
on appetite and gut hormone response in older and younger volunteers. All volunteers gave informed 
written consent. The study was explained in detail to potential volunteers and the information sheet 
for the study was given to them, any questions and concerns they may have had were answered prior 
obtaining consent. Participants were given at least 24 hours to decide if they were interested in taking 
part in the study. Only once potential volunteers were satisfied with the information given to them 
they signed the consent form. Participants were able to withdraw from the study at any time without 
giving a reason. 
2.2. Recruitment 
Potential participants were recruited via poster adverts, newspaper adverts and on the local intranet. 
Due to recruitment difficulties the older volunteers were also recruited via local general practices. 
Letters of invitation were sent by the GP to potential participants (see appendix 10.1) who fitted the 
inclusion and exclusion criteria, and anyone interested was asked to contact the investigator for 
further details. The inclusion and exclusion criteria are explained in further detail in section 2.3. 
2.3. Screening of participants 
In chapter 4 and 7 participants that were recruited into the study were screened prior to taking part. At 
this visit participants had their weight and height measured to calculate their BMI, and body fat 
percentage calculated by Bioelectrical Impedance. Any participants at the extremes of BMI (see 
section 2.3.1) were excluded from the study in order the match the participants BMI as closely as 
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possible. Potential volunteers also had a blood sample taken to check for any blood abnormalities (see 
section 2.3.4). 
Participants were asked about any current medications that they were taking and any recent illnesses. 
Volunteers were unable to take part in the study if they had a history of, or any current major 
haematological, renal, gastrointestinal, hepatic, respiratory, cardiovascular or any other illness. This is 
because illness is known to interfere with gastrointestinal appetite peptide hormone release (Nguyen 
et al., 2006; Le Roux et al., 2005; Nematy et al., 2006a; Nematy et al., 2006b). Potential participants 
were also excluded if they were taking any over the counter medications thought to interfere with the 
results of the study for example, medications that may inhibit gastrointestinal hormone release or 
excretion from the body. Due to the large number of older people with high blood pressure, older 
volunteers were accepted to take part in the study if they were on anti-hypertensive tablets, with their 
blood pressure maintained on their tablets within a normal range according to the American Heart 
Association standards (described in table 2.2 and section 2.3.2). 
Participants received training on how to fill out the 24 hour food diary and 3-day food diary 
accurately, and were asked to fill in the restraint section in the Three Factors Eating Questionnaire. 
Participants were then also given the opportunity to taste an example of the test meal to ensure they 
were able and willing to consume it at the study sessions. 
Providing the participant was eligible and had consented to take part in the study, they were asked to 
wear an activity monitor for a period of 3 days (with one day a weekend day). Training on how to use 
this monitor was provided on the screening visit. The activity monitor consists of an elasticated 
waistband with a small device attached to it. The device enables the measurement of movement and 
therefore physical activity levels (see section 2.3.5. for further details). 
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Table 2.1. Inclusion and Exclusion criteria for human studies 
Inclusion 
· Adults aged over 20 years of age 
·Healthy with no diagnosed acute disease, and no chronic disease or drugs known to interfere with gut 
peptide secretion.  
· Matched age groups by sex and BMI (within ±3kg/M²)  
Exclusion 
· History of alcoholism or substance abuse within the last 12 months 
· History of, or current illness thought to affect study results 
·Medical or psychological condition or social circumstances which would interfere with ability to     
participate in the study 
· Without access to a telephone 
· Women who are pregnant, breastfeeding or unable to maintain adequate contraception for the 
duration of the study and for one month afterwards 
· Treatment with an investigational drug within the preceding 2 months 
· Volunteers who have donated, intend to donate blood within 3 months before or following study 
completion 
· Current smokers 
‧ Weight loss of more than 3kg in the last 3 months 
‧ Restrained eater 
‧ Dislike for the study test meal 
 
2.3.1. Anthropometrics 
Height and weight were measured in the screening in order to calculate BMI. Participants were 
recruited according to BMI where they were required to be within the range of 21-26 (i.e. within 
±3kg/M²). Body weight and obesity may be a limiting factor to study results; obesity has been shown 
to influence gastrointestinal hormone release (Tschop et al., 2001; Carlson et al., 2009). Due to the 
marked differences in adiposity in older and younger people, it was not feasible to match younger and 
older people recruited within the study on adiposity levels; BMI was the next best option. 
Height was measured using a standometer fixed to the wall. The participant was asked to remove 
shoes and to stand up-right with their frankfort plane horizontal. The horizontal bar was lowered until 
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it was resting on the participants head. The participant was asked to stand as tall as possible. A 
reading was then taken to the nearest centimetre.  
Weight was measured on bioelectrical impedance machine scales, to the nearest 0.1kg, with the 
average value from duplicate measurements taken. Volunteers are asked to stand on the scales in their 
bare feet. Additional weight was taken off the measurements to take into account clothing. 1kg was 
taken off if the volunteer was wearing light clothing such as linen or cotton; 2kg was taken off for 
heavy clothing such as denim and jumpers. 
Using the height and weight measurements the body mass index (BMI) could be measured. BMI, also 
known as the quetelet index is a proxy for body fat based on a person’s height and weight. BMI is 
defined as the individuals body weight divided by the square of his or her height.  
BMI = Mass (kg) / (height (m)) ² 
A BMI of 21-26 was used in this study. The aim was to have normal weight volunteers within the 
BMI range of 20-25 as volunteers in this category are less likely to express abnormal gastrointestinal 
hormone response to a test meal. As the majority of the applicants were within the BMI range of 21-
26, this was chosen in order to aid recruitment.  
Body fat percentage was measured using bioelectrical impedance analysis (BIA). The principle of the 
technique is that lean tissue is a good conductor of electrical current whilst fat tissue is a non-
conductor.  The method is based on the relationship between the volume of the human body, the 
subject’s height, the components of the participant (i.e. fat or fat-free mass) and its impedance. This 
BIA method has been validated with magnetic resonance imaging assessment of body fat (Xu et al., 
2011), and also in comparison to DEXA (Thomson et al., 2007) with a coefficient of variation of 1.4 
± 6.3%. The BIA analysis used multi-frequency segmental analysis on the Tanita Body Composition 
Analyser (Marsden). Although BIA does not produce results to an accuracy of DEXA, this was the 
most convenient option, and body fat percentage wasn’t a primary outcome, therefore it was deemed 
as acceptable. 
76 
 
To measure body fat percentage, the machine was switched on and the participant’s height, gender, 
age and an allowance for clothing (2kg heavy clothing, 1kg light clothing) was entered into the 
machine. Once the machine was ready, the volunteer stepped onto the machine with their bare feet on 
top of the electrode plates. The volunteer was given the hand held electrodes and asked to ensure that 
all their fingers were in contact with the electrodes. The volunteer stood still ensuring that there was 
no contact between their arms and body whilst the machine was taking a reading. Once the reading 
was taken, the volunteer steps off the machine. Readings were taking in duplicate in order for an 
average value to be calculated. 
2.3.2. Blood pressure measurement 
Blood pressure was measured in the screening visit in order to ensure that their blood pressure 
measurement is within the healthy range to take part. Blood pressure was compared to the American 
Heart Association standards (see table 2.2). Older adults generally have higher blood pressure 
compared to their younger counterparts, and are often on medication for high blood pressure. In order 
to aid recruitment, participants were able to enter the study if their blood pressure was within the 
desirable and pre-hypertension category. Because hypertensive medication does not have a known 
effect on any of my primary end points, volunteers were also allowed to take part if they were on 
blood pressure lowering medication, as long as their blood pressure was within the normal/ pre-
hypertension range whilst on the medication. Those within the pre-hypertension range were advised to 
consult their GP on this matter and, the medic on duty during the study visits was made aware of their 
moderately raised blood pressure. 
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Table 2.2. Accepted criteria for blood pressure measurements. 
Category Systolic, mmHg Diastolic, mmHg 
Hypotension <90 <60 
Desirable 90-119 60-79 
Prehypertension 120-139 Or 80-89 
Stage 1 hypertension 140-159 Or 90-99 
Stage 2 hypertension 160-179 Or 100-109 
Hypertensive crisis ≥ 180 Or ≥ 120 
 
American heart association blood pressure standards. Volunteers were recruited within the 
categories ‘desirable’ and ‘prehypertension’. 
 
Participants with high blood pressure were excluded because I not aware of the influence that high 
blood pressure would have on gut appetite hormone release. As described in chapter 1, alterations in 
gut appetite hormones are observed in those with poor health. 
Participants had duplicate measurements of their blood pressure taken to obtain an average value 
using an electric monitor. Electric monitors use a microphone that can detect the pulse of the blood 
flowing though the artery. Blood pressure was taken whilst the participant had been sat relaxed for 
around 5 minutes. The cuff was wrapped around the upper arm, with the bottom of the cuff 1 inch 
above the crease of the elbow. The arm is then placed on a table or an object of an equivalent height 
so that their arm is level with the heart. The machine is turned on and the cuff automatically inflates. 
The screen will automatically take a reading and the cuff then deflates. The recording of the blood 
pressure will be noted down and checked to see if it is a normal reading (see table 2.2). Blood 
pressure monitors are a quick and convenient method for the measurement of blood pressure, and are 
often the preferred method of measurement by health professionals, and have been clinically approved 
in a number of patient groups (Altunkan et al., 2007). 
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2.3.3. Three Factors Eating Questionnaire (TFEQ) questionnaire – restraint only 
The TFEQ measures restraint, disinhibition and hunger. The aim was to eliminate just the restrained 
eaters, not disinhibition or hunger, as these two factors could be seen as a measurement of hunger in 
which I did not want to eliminate in the human studies. The TFEQ is a validated questionnaire 
(Stunkard and Messick, 1985). The participant is required to answer the 21 restraint questions during 
the screening visit to ensure that they are not a restrained eater. 
The restraint section of the TFEQ comprised of two parts; part one includes 12 questions with true or 
false answers. The answer that is defined as a restrained characteristic ‘+’ will be given a score of 1 
and an answer that is defined as an unrestrained eating behaviour ‘–’ will be given a score of 0. Part 2 
includes a further 9 questions requiring a rating between 1 to 4. For questions marked with a ‘+’ 
scores 1 point (restrained characteristic), for questions marked with ‘–’, response scores 0 points 
(unrestrained characteristic) as marked on the answer sheet. Participants given a score of 15 or more 
were classed as high restraint as seen on the answer sheet (see appendix 10.2). A cut off score of 15 
was used for participation in the study as it was deemed as low enough to eliminate the restrained 
eaters without  the score being too low in which it hinders recruitment.  
2.3.4. Screening blood sample 
Blood samples were taken from potential volunteers in the screening visit; this was to ensure that 
participants were healthy enough to take part in the study. The tests taken were a full blood count 
(FBC) to ensure the volunteer didn’t have any signs of anaemia, a liver function test (LFT) to ensure 
that it is safe to prescribe paracetamol to volunteers, and the liver functions efficiently to eliminate the 
drug from the body, and finally a urea and electrolyte test to ensure there is good renal function. 
Healthy volunteers were required for their own safety (blood sampling and paracetamol) and for the 
purpose of the study which was to investigate healthy volunteers. 
The process of blood taking is as follows; a tourniquet is tightened around the upper arm to partially 
restrict the blood flow in veins so that they stand out. The tourniquet is released as soon as practicable 
and will not be left on the arm for more than 5 minutes. The blood is collected by piercing a vein with 
79 
 
a needle with an evacuated blood collecting system. When the blood has been collected, it is labelled 
appropriately and sent off to the lab for analysis. Participants were only allowed to participate in the 
study if their blood sample results are within the healthy range (see table 2.3). 
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Table 2.3. Healthy range for blood tests results for urea and electrolyte, liver function and full blood 
count. 
Investigation/ Test Range Units 
FBC   
White Blood Cells (WBC) 4.0 – 11.0 x10 
Red Blood Cells (RBC) 3.74 – 4.99 x10 
Hemoglobin (Hgb) 11.4 – 15.0 g/dl 
Haemarocrit 0.357 – 0.460 Ratio 
Mean Corpuscular Volume (MCV) 83.0 – 101.0 fl 
Mean Corpuscular Hemoglobin (MCH) 26.7 – 32.9 Pg 
Mean Corpuscular Hemoglobin Concentration 
(MCHC) 
31.4 – 35.0 g/dl 
Red blood cell distribution width (RDW) 8.3 – 17.5 % 
Platelets 120 – 400 x10 
MPV 8.0 – 12.0 fl 
Neutrophils 2.0 – 7.5 x10 
Lymphocytes 1.0 – 3.5 x10 
Monocytes 0.3 – 1.0 x10 
Eosinophils 0.0 – 0.4 x10 
Basophils 0.0 – 0.1 x10 
UE Profile   
Soduim 135 – 145 mmol/L 
Potassium 3.5 – 5.3 mmol/L 
Chloride 95 – 108 mmol/L 
Urea 2.5 – 7.0 mmol/L 
Creatinine 60 – 110 umol/L 
LFT Profile   
Alanine Transaminase 0 – 40 IU/L 
Bilirubin 0 – 17 umol/L 
Alkaline Phosphatase 30 – 130 IU/L 
Total Protein 64 – 83 g/L 
Albumin 33 – 47 g/L 
Globulin 19 – 35 g/L 
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Blood sample results that were out of the normal range were checked by the study medic, and the 
volunteers GP was contacted to inform them of these results. Occasionally, blood samples were very 
slightly out of the normal range, but it was regarded by the study medic to be within healthy enough 
range for the participant to take part and the study, as it would not cause detriment to their health, or 
to the study results. The participants GP would however still be informed, and a repeat blood sample 
will be taken. 
2.3.5. The International Physical Activity Questionnaire (IPAQ) 
Participants are asked to complete a short validated questionnaire on their physical activity levels in 
the past 7 days on the screening visit. This is to get an estimate of their energy expenditure. The IPAQ 
short 7 day activity questionnaire can be seen in appendix 10.3. 
The International Physical Activity Questionnaire (IPAQ) short form is used as a standardised 
measure to estimate habitual practice of physical activities of populations from different countries and 
socio-cultural contexts. It has been developed and tested for the use in adults with an age range of 15 
to 69 years (Craig et al., 2003). This questionnaire is only valid on individuals up to the age of 69 
years, however, it was the only questionnaire to my knowledge that encompassed a large age range, 
that has been reported with high validity and reliability (Mader et al., 2006). The IPAQ questionnaire 
assesses physical activity undertaken in the past 7 days across a set of the following domains; leisure 
time physical activity, domestic and gardening, work-related physical activity and transport related 
physical activity. The IPAQ short form that was administered to the participants asks about three 
specific types of activity undertaken in those four domains.  The IPAQ questionnaire provides 
metabolic equivalent (MET) values as a measurement of energy expenditure. One MET is equivalent 
to the energy you expend at resting. Therefore, if a score has four MET you would be expending four 
times the energy expended at rest. The MET values that are obtained from this questionnaire were 
derived from work undertaken during the IPAQ Reliability study (Craig et al., 2003).  MET values 
were calculated for three activities on the questionnaire; walking, moderate activity and vigorous 
activity. 
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Once the participant filled out the questionnaire, the three different activities could then have a MET 
score calculated for it using the calculations provided in the IPAQ questionnaire; 
 
Walking MET- minutes/week = 3.3 X walking minutes X walking days 
Moderate MET –minutes/week = 4.0 X moderate-intensity activity minutes X moderate days 
Vigorous MET- minutes/week = 8.0 X vigorous-intensity activity minutes X vigorous intensity days 
 
Total physical activity could then be calculated using the formula; 
Total MET-minutes/week = Walking + Moderate + Vigorous MET-minutes/week scores. 
 
The scores were then classified into three activity levels; high, medium or low activity levels using the 
IPAQ questionnaires criteria. 
● Classification of high activity: 
In order to classify people with a high level of physical activity, the criteria participant had to fulfil 
was as follows; 
1. Vigorous-intensity activity on at least 3 days achieving a minimum total physical activity of at least 
1500MET-minutes/week, or 
2. Seven or more days of any combination of walking, moderate-intensity or vigorous-intensity 
activities achieving a minimum of total physical activity of at least 3000 MET-minutes/week. 
 
● Classification of moderate activity: 
In order to classify people with a moderate level of physical activity, the criteria the participant had to 
fulfil was as follows: 
1. Three or more days of vigorous-intensity activity of at least 20 minutes per day, or 
2. Five or more days of moderate-intensity activity and/or walking of at least 30 minutes per day, or 
3. Five or more days of any combination of walking, moderate-intensity or vigorous intensity 
activities achieving a minimum total physical activity of at least 600 MET-minutes/week. 
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● Classification of low physical activity; 
These participants were those who did not fulfil the criteria of high or medium activity with their 
responses to the questionnaire. 
 
In order to eliminate over-reporting respondents to the questionnaire, the questionnaire also had a set 
exclusion criteria. Those who reported over 960 minutes of combined activity were excluded. 
 
The final scores calculated from the questionnaire can be converted into kcal per day though the 
following equation;  
Kcal/day = MET/WEEK x (weight(kg)/ 60) 
The IPAQ questionnaire can be seen in appendix 10.3. 
2.3.6. Measurement of physical activity; the Actical monitor 
Physical activity was also measured using an activity monitor. The IPAQ questionnaire, as described 
above, is only validated for those up to the age of 69 years. A large proportion of the participants 
recruited to take part in the study were of the age of 70 and above, therefore it was necessary to use a 
form of measurement that could be measured accurately in this population. The actical monitor is a 
more reliable estimate of energy expenditure than physical activity questionnaires, as it can create a 
measurement of physical activity and total energy expenditure from the body’s movement. The CV of 
the actical monitor is relatively large at 31.1% (Welk et al., 2004), however the actical is frequently 
used in research as it is able to track intensity, duration and frequency of the free living physical 
activity, and it is able to estimate energy expenditure with minimal participant burden. Physical 
activity levels were also not the main outcome of the studies, it would have been inappropriate to use 
a higher burden form of measurement of physical activity. 
Participants were asked to wear the actical activity monitor for a period of three days (with one day 
being a weekend day). The actical was a compact, lightweight, waist worn activity monitor that is 
used to assess human gross motor activity. From this caloric expenditure and energy expenditure can 
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be calculated. The actical monitor estimates this by quantifying physical motion. The actical 
calculates and records active energy expenditure, metabolic equivalents per time (METs) and step 
counts.  
The monitor was fitted to an elasticated waist strap which could be worn under or over clothing. The 
belt was mounted on the body so that the Actical device rests on iliac creast of the hip, as this is the 
site in which will produce the most accurate readings. The iliac crest is the uppermost and widest of 
the 3 bones constituting either of the lateral halves of the pelvis. The belt was worn at all times in 
order to get 3 full consecutive days of energy expenditure. The monitor is also water-proof and so 
participants were able to wear the monitor in the shower and whilst swimming. Participants were 
allowed to take the activity monitor off whilst showering, as the belt would be unpleasant to wear 
underneath clothing whilst wet, however because swimming involves a lot of gross motor movement, 
they were asked to wear it whilst swimming, and not to avoid it because of the activity monitor. 
2.4. Ad libitum test meals 
The most commonly used method for the measurement of short-term appetite is the pre-load test meal 
followed by an ad libitum test meal. 
The use of the pre-load test meal involves the consumption of a food with a standard content of 
energy and nutrients under investigation. This is often used in studies with a within subjects repeated 
measures design (Kissileff, 1985).  An ad libitum test meal is usually pre-weighed food that is re-
weighed after the subject has finished consuming the required amount until they  are ‘comfortably 
full’ to allow for the calculation of macronutrient consumption by the individual (Hill et al., 1995). 
Test-meal conditions need to be standardised, by using the same room, with constant light, free of 
odours, sounds and other disturbing factors, as well as to keep subjects in separate cubicles during test 
meals, in order to avoid social interaction. This is because eating behaviours and therefore energy 
compensation can be affected by many factors. These factors include the environment (location, 
weather conditions, noises); temporal (hour of the day, day of the week, season of the year); social 
(presence of other people); psychological (subjective state of anger and anxiety) and the properties of 
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the foods presented (palatability, energy content etc) (de Castro, 1997; Kissileff, 1985; Stubbs et al., 
2000a). 
Participants were offered a choice of ad libitum test meals to maximise recruitment and account for 
food preferences. However, the meal choices needed to be matched for macronutrient content, 
because macronutrients have different effects on gut hormone release, as described in chapter 1.7. 
The meals also need to be of a homogenous consistency (no large pieces of food so different parts of 
the dish could be eaten in preference to another i.e. participants couldn’t pick out the chunks of 
chicken and therefore consume disproportionately higher amounts of protein). There were three meals 
on offer to the participants; Bolognese bake, Chicken Tikka Masala, and Macaroni Cheese. The 
nutritional composition of the meals can be seen in the table 2.4. Although there were minor 
differences in macronutrient content, these differences were not likely to significantly affect gut 
hormone response. 
Table 2.4. Nutritional Composition of ad libitum test meals per 100g 
 
 
 
 
 
 
 
 
 
On the screening visit participants were given a small sample of each of the test meals to try and were 
asked to score it on a 100mm visual analogue scale where 0 is where they really dislike the food and 
100 is where they like the test meal extremely. The meal for the use in the study was chosen to avoid 
Typical Values  Bolognese 
bake 
Chicken Tikka 
Masala 
Macaroni 
Cheese 
Energy 665kj 
160kcal 
665kj 
160kcal 
631kj 
151kcal 
Protein 8.5g 7.3g 7.0g 
Carbohydrate 
of which sugars 
15.6g 
1.5g 
16.6g 
3.6g 
14.0g 
1.0g 
Fat 
of which saturates 
Mono-unsaturates 
Poly-unsaturates 
6.8g 
3.5g 
2.7g 
0.3g 
6.9g 
2.4g 
3.0g 
1.1g 
7.4g 
4.8g 
2.3g 
0.3g 
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preferences on the extreme ends of the scale. This is because I wanted to ensure that they didn’t enjoy 
the meal too much, potentially resulting in over consumption beyond comfortable levels of fullness, 
nor dislike it so much that they didn’t eat enough to reach their comfortable levels of fullness. 
Vegetarians were only given the macaroni cheese to try, but were still required to score a mid-rage 
preference rating for the meal, or they will be excluded. 
2.5. Sham visits 
Participants were required to attend a sham visit (chapter 4 and 7).  On these study visits a reduced 
amount of blood samples were taken as the samples were not analysed. It is not clear if stress from 
having blood samples taken would affect gastrointestinal hormone release, therefore participants were 
required to attend the sham visit in order for them to get accustomed to the environment. The aim of 
the sham visit was to introduce the volunteer to the study protocol with the aim to reduce stress in the 
volunteers for the true study days when the data was collected.  It is important that the volunteers had 
experienced cannulation prior to the study day.  If the volunteer was to feel faint or have a vasovagal 
reaction this would have rendered results from that volunteer un-usable. 
2.6. Measurement of gastric emptying 
Gastric emptying was measured by the paracetamol method. 1.5g of soluble paracetamol 
(acetaminophen) in 250mls of water was given to participants with their breakfast meal for the 
measurement of gastric emptying. Paracetamol is not absorbed in the stomach, but when it reaches the 
small intestines it is absorbed rapidly. By measuring the paracetamol levels in subsequent blood 
samples, gastric emptying can be measured using the peak paracetamol concentration. The 
paracetamol method is an easy to use and non-invasive method for gastric emptying. This method was 
chosen as it has been demonstrated to be comparable to gastric emptying scintography (Glerup et al., 
2007), and other methods such as gastric emptying scintography, are more invasive and stressful for 
the participants, which may subsequently affect gastrointestinal hormone response and appetite 
ratings. 
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2.7. Measurement of blood parameters 
Blood samples on study visits were taken from a cannula. Blood was collected in 10ml lithium 
heparin tubes containing trasylol (200ul trasylol for 10ml blood). The blood was spun immediately for 
10 minutes to separate the plasma. The plasma was removed and pipetted into assay tubes and 
transferred immediately to dry ice for freezing. Acyl ghrelin samples had 50ul 1M HCL to 1ml 
plasma and 2 mM AEBSF to 1ml plasma added to them. After the procedure/ study visits blood 
samples were stored in a -20 freezer until they were ready to use. 
All radioimmunoassays in this thesis were measured in duplicate and in a single assay to eliminate the 
effects of inter-assay variation. 
The physiology of all gut peptides measured are described in chapter one. 
2.7.1. Radioimmunoassay 
All peptide hormones (ghrelin, acyl ghrelin, GLP-1, PYY, Oxyntomodulin) and Insulin were 
measured by radioimmunoassay. The principle behind this technique is as follows; An immunoassay 
is the qualitative or quantitative measurement of a substance (Ag) that uses antibody (Ab) complexes 
as a means of generating a measureable result. A radioimmunoassay (RIA) works on the basis of 
competition between radioactively [125I] labelled [Ag*] and unlabelled antigen [Ag], for the binding 
site of an antibody to create an antibody-antigen complex [AgAb]. 
Ag + Ab + Ag*»AgAb + Ag*Ab + Ag +Ab +Ag* 
The labelled antigen (peptide) and antibody are added at known concentrations to allow determination 
of the amount of unlabelled antigen (peptide). If the plasma peptide is present in low concentrations 
then the amount of labelled peptide is high and vice versa. The only molecules measured are the 
radioactive tracers; therefore a method of separation is required to distinguish the unbound labelled 
antigen [Ag*] from the bound labelled antigen [Ag*+Ab]. A standard curve is plotted of known 
concentrations of pure peptide against the radioactive count and is used to estimate the unknown 
concentration of peptide in the plasma. 
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The radioimmunoassay of a hormone depends on the competition between radio-actively labelled and 
unlabelled hormone for the specific binding site of an antibody. The amounts of antibody and labelled 
hormone are fixed, the only variable being the unlabelled hormone concentration. The higher the 
concentration of unlabelled hormone, the less radioactively labelled hormone will be bound to 
antibody. After separation of the bound from the free hormone, the amount of labelled hormone 
bound to antibody can be assessed by counting the radioactivity. By using known quantities of pure 
hormone, a standard curve can be prepared with which unknown samples can be compared. 
Sensitivity is important for assays involving plasma because of low hormone concentrations; a long 
incubation period is used. 
The most widely used methods of separation are immunoprecipitation (e.g. anti-rabbit antibody), 
chemical precipitation (alcohol, polyethylene glycol or ammonium sulphate) and adsorption 
(cellulose, talc or charcoal). 
Adequate assay sensitivity can be achieved as long as the label possesses an affinity for its specific 
antibody which is similar to that of the unlabelled antigen. Assay sensitivity is of particular 
importance for the gut hormones as they circulate at very low concentrations. Thus the assay detecting 
limit is a major limiting factor for their successful measurement. 
2.7.2. Analysis of total ghrelin 
Ghrelin like immunoreactivity was measured with a specific and sensitive RIA as previously 
described (Patterson et al., 2005). The antisera (SC-10368, obtained from Santa Cruz biotechnology) 
was used at a final dilution of 1:50,000. The 125I-labelled ghrelin was prepared with Bolton and 
Hunter reagent (Amersham International) and purified by high-pressure liquid chromatography using 
a linear gradient from 10 to 40% acetonitrile and 0.05% trifluoroacetic acid over 90 minutes. The 
specific activity of ghrelin label was approximately 48Bq/fmol. The assay was performed in a total 
volume of 0.7ml of 0.06M phosphate buffer, pH7.2, containing 0.3% BSA and then incubated for 3 
days at 4°C before separation of free and antibody-bound label by charcoal absorption. The assay 
detects changes of 20pmol/l of plasma ghrelin with a 95% confidence limit. This assay cross-reacts 
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(100%) with both octanoyl and des-octanoyl ghrelin but does not cross react with any other known 
gastrointestinal or pancreatic hormones. The intra- and interassay coefficients of variation are 6.9 and 
5.5% respectively (Parkinson et al., 2008). 
2.7.3. Plasma acyl ghrelin analysis 
Acyl ghrelin was measured using a commercially available sandwich ELISA kit (Millipore, USA), 
using kits specific for human acyl ghrelin (section 4 and 7) and rat/mouse acyl ghrelin (section 3) 
according to the manufacturer’s protocol, with intra- and interassay coefficients of variation of 1-6% 
and 1-5% respectively. There is no cross-reactivity to des-octanoyl-ghrelin. 
2.7.4. Plasma PYY analysis 
PYY-like immunoreactivity was measured with a specific sensitive RIA as previously described 
(Adrian et al., 1987). Briefly, the antiserum (Y21, produced in a rabbit against synthetic porcine PYY 
(Bachem) and coupled to BSA by gluteraldehyde), then used at a final dilution of 1:50,000. This 
antibody cross-reacts fully with both the hormone fragment (PYY3-36) and the full length hormone 
(PYY1-36) but not with pancreatic polypeptide, NPY, or other known gastrointestinal hormones. 
125I-labelled PYY was prepared by the iodogen method and purified by high-pressure liquid 
chromatography. The specific activity of the 125I-labelled PYY was approximately 54Bq/fmol. The 
assay was performed in a total volume of 0.7ml of 0.06M phosphate buffer, pH7.3, containing 0.3% 
BSA. The sample was incubated for 3 days at 4°C before the separation of free and antibody bound 
label by sheep antirabbit antibody. Unextracted plasma (200ul) will be assayed. The assay detects 
changes of 2pmol/l, with intra- and interassay coefficients of variation of 5.8 and 9.8, respectively 
(Parkinson et al., 2008). 
2.7.5. GLP-1 analysis 
GLP-1 immunoreactivity was measured with a specific and sensitive RIA as previously described 
(Kreymann et al., 1987). Briefly, bovine serum albumin (0.3%) was added to veronal buffer and used 
to dilate the antibody 1:190,000, which fully cross reacts with GLP-1(1-36) amide but does not cross 
react with GLP-1 (1-37) or (7-37). 125I-labelled GLP-1 (7-36) was prepared by the iodogen method 
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and purified by high-pressure liquid chromatography. The specific activity of the 125I-labelled GLP-
1(7-36) was approximately 54Bq/fmol. The assay was performed in a total volume of 0.7ml of 0.06M 
phosphate buffer, containing 0.3% BSA. The sample will be incubated for 3 days at 4°C before the 
separation of free and anti-body bound label by charcoal absorption. The assay detect changes of 
2pmol/l, with intra- and inter-assay co-efficient of variation of 6.1 and <8%, respectively. 
2.7.6. Insulin analysis 
Insulin was measured by commercially available RIA (Millipore, USA) using kits specific to human 
insulin. The procedure was performed according to the manufacturer’s instructions. The intra and 
interassay coefficients of variation were 2.7 – 5.8% and 3.8 – 10.8% respectively.  
2.7.7. Glucose analysis 
Glucose was measured using hexokinase and G-6-PDH using Abbott ci8200 analysers (Abbott 
Diagnostics, Maidenhead, UK). Glucose was phosphorylated by hexokinase in the presence of 
adenosine triphosphate (ATP) and magnesium ions producing glucose-6-phosphate (G-6-P) and ADP. 
G-6-P dehydrogenase (G-6-PDH) oxidises G-6-P to 6-phosphogluconate with the simultaneous 
reduction of nicotinamide adenine dinucleotide (NADH). One micromole of NADH is produced for 
each micromole of glucose consumed. The NADH absorbs light at 340nm and can be detected as an 
increased absorbance by spectrophotometry. The intra-assay coefficient of variation is 1.0-5.0%.  
2.7.8. Paracetamol/ gastric emptying analysis 
Paracetamol was measured using Enzymatic/Colorimetric method using Abbott ci800 analysers 
(Abbott Diagnostics, Maidenhead, UK). Acyl Acylamidase enzyme cleaves acetaminophen 
(paracetamol) molecules amide bond producing p-aminophenol and acetate. 8-hydroxyquinoline-5-
sulfonic acid is added in the presence of manganese ions to react with p-aminophenol which forms a 
coloured compound, 5,-(4-iminophenol)-8-quinolone. The formation of 5,-(4-iminophenol)-8-
quinolone results in increased absorbance at 615nm which is directly proportional to the concentration 
of acetaminophen (paracetamol) in the sample. The intra-assay coefficient of variation is 1.0-5.0%. 
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2.8. Visual analogue scales 
Visual Analogue Scales (VAS) are commonly used in studies on appetite, hunger and energy intake. 
Stubbs et al, (2000b) reviewed the reliability and validity of visual analogue scales in terms of their 
ability to predict feeding behaviour, their sensitivity to experimental manipulations and their 
reproducibility. It was suggested that VAS correlate with, but do not reliably predict energy intake to 
the extent that they could be used as a proxy for energy intake. Under laboratory conditions, 
subjective motivation to eat measured by VAS is sensitive to experimental manipulations and is 
reproducible (Stubbs et al., 2000b). Another limitation of VAS, is that subjects tend to rate their 
feelings at the extreme ends of the scale despite them being told that they represent the extreme 
sensations (Hill et al., 1995). VAS are best used in conjunction with food preference lists (Stubbs et 
al., 2000b). 
Just before each blood sample is taken in section 4 and 7 participants will have to answer a number of 
questions on a visual analogue scale (VAS). These are lines drawn on a piece of paper with a measure 
of extreme ratings at each end, for example ranging from 'I am as hungry as I could possibly be' to 'I 
am as full as I could possibly be.' Participants will have to mark a point on the scale to indicate how 
they feel. Subjective appetite scores were taken for hunger, nausea, fullness, desire to eat and how 
much they can eat. Following test meals participants were also asked to fill in a questionnaire on food 
palatability. The VAS provides a score out of 100 from where participant marks on the scale (see 
appendix 10.4). Participants were advised in all study visits that each end of the VAS scale represents 
the extreme end of the scale, to try and prevent extreme appetite reporting’s. 
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Chapter 3 
THE EFFECT OF TRAUMA ON WEIGHT LOSS AND 
GASTROINTESTINAL APPETITE HORMONE 
RESPONSE IN RATS 
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3.1. Introduction 
In chapter 1 section 1.6, I outlined the available data supporting the theory that appetite reductions 
observed in illness and ageing are potentially related to gastrointestinal appetite hormone alterations. 
Several issues have been highlighted with the research to date, specifically a lack of consistent 
methodology, with many studies conducted with small sample sizes without controlling for 
confounding factors. Additionally, only until recently, has there been the ability to measure the active 
form of ghrelin; acyl ghrelin. 
In states of age-related disease and trauma there is more convincing evidence that the putative satiety 
hormone PYY is elevated. Out for the four studies that have investigated PYY concentrations in 
illness, all of them demonstrated an increase in PYY concentrations in fasting or post-prandial 
conditions (Nematy et al., 2006b; Nematy et al., 2006a; Le Roux et al., 2005; Nguyen et al., 2006) in 
a number of different disease states. In states of trauma, in elderly patients with femoral neck fracture, 
there is an elevation in PYY serum concentrations in comparison to controls (Nematy et al., 2006b). 
Currently, there is no literature that has investigated the role of GLP-1 and its alterations in illness. 
Considering this hormone can induce a reduction in food intake (Verdich et al., 2001), it is pivotal to 
understand its role, if any, in appetite reduction in under-nutrition in illness. 
Research has also demonstrated that there may be an alteration in ghrelin response in illness, but the 
data to date is unclear, with more observations needed using the analysis of acyl ghrelin. Studies 
looking at acyl ghrelin concentrations in illness have shown a reduction  in appendicitis (Cetinkaya et 
al., 2009) and in kidney disease (Oner-Iyidogan et al., 2011). The study by Cetinkaya (2009) which 
demonstrated a reduction in acyl ghrelin concentrations in appendicitis is particularly flawed. This 
study compared groups that were significantly different in age and BMI, with no measurements of 
food intake and subjective feelings of hunger taken. This makes the comparison between groups 
invalid, as it is well known that BMI can alter gut hormone production and concentrations, for 
example obese adults have lower circulating ghrelin than normal weight adults (Tschop et al., 2001). 
The above described studies did not standardise conditions such as fasting and post-prandial state, and 
therefore comparisons between healthy controls are difficult. Other studies have been conducted using 
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the analysis of total ghrelin. Data is conflicting where either an increase in ghrelin has been 
demonstrated in critically ill patients (Koch et al., 2010), a reduction in cardiac cachexia (Kadoglou et 
al., 2010), or an absence of an alteration observed in liver failure (Marchesini et al., 2004). Due to the 
different disease states investigated, the flawed methodology and the few studies measuring acyl 
ghrelin it is difficult to determine the alterations that may occur in ghrelin in illness. 
However, even taking this into consideration, ghrelin has proved to be a useful therapy in patients. 
Studies have been conducted in patients with illness associated with the anorexia of ageing e.g. 
patients with cancer, renal disease or chronic heart failure. IV administration increased food intake 
and appetite in the short term which would subsequently help speed recovery from illness and aid 
weight gain following the initial weight loss (Nagaya et al., 2004; Neary et al., 2004; Ashby et al., 
2009).  
Due to the difficulties in human studies an animal model of trauma would assist in the investigation of 
trauma related alterations in gastrointestinal hormones. This chapter describes the study I designed to 
try and develop such a model and to test whether ghrelin and PYY are altered during trauma. 
3.2. Hypothesis 
My hypothesis was;  
There will be a reduction in acyl and total ghrelin, and raised PYY and GLP-1 gastrointestinal 
appetite hormone response leading to a greater weight loss in rats that have received trauma compared 
to controls and rats receiving anaesthetics only. 
3.3. Aim 
To develop an animal model of trauma that replicates the gastrointestinal appetite hormone response 
seen in humans following illness and trauma. 
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3.4. Objectives 
1. To establish the effect of trauma via a left ventricle (LV) sham cannulation on fasting levels of 
ghrelin (total and acyl), PYY, and GLP-1 in rats compared to control rats and rats receiving 
anaesthesia only 
2. To establish the effect of trauma on weight loss and food intake compared to controls and rats 
receiving anaesthesia only. 
3.5. Pilot Study 
3.5.1. Introduction 
Before the main investigation was undertaken, I wanted to be assured that rats followed the same 
pattern as humans following trauma and demonstrated a reduction in food intake and body weight. I 
also wanted to determine at what point post-operatively that the largest substantial change in body 
weight occurred. To do this I collaborated with other researchers on a study already in planning in the 
Diabetes, Endocrinology and Metabolism Department within the section of Investigative Medicine at 
Imperial College. 
3.5.2. Methodology 
Cannulation was being carried out on the dorsal medial hypothalamus (DMH) of the brain in 35 rats.  
35 male wistar rats (specific pathogen free; Charles River, Margate, Kent, UK) were maintained in 
individual cages at a constant room temperature of 21-23°C on a 12 hour light/dark cycle (7am – 
7pm). Rats were allowed ad libitum access to rat chow (Rat and Mouse 1 (RM1) diet, Special Diet 
Service Ltd, Witham, Essex, UK) and water. Cage dimensions were 245 (width) x 415 (length) x 185 
(depth) mm. Animals and procedures undertaken were approved by the British Home Office Animals 
(scientific procedures) Act 1986. 
 
 
96 
 
3.5.2.1. Cannulation procedure 
Rats were placed in an induction chamber and were anaesthetized with 2L/minute oxygen and 4% 
inhaled isoflourane (Abbott Laboratories Ltd, Queenborough, Kent, UK) until they lost their pedal 
reflex. Following anaesthetisation rats were administered prophylactic antibiotics (amoxicillin 
37.5mg/kg and flucloxacillin 37.5mg/kg) intra-peritoneally to prevent post-operative infection. The 
head was cleaned with a 10% w/v providine/iodine solution (Ecolabs Ltd, Leeds, Yorkshire, UK) and 
the rats were positioned on a stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA) with the 
incisor bar 3mm below the interaural line. A 1.5cm longitudinal incision was made. A hole was 
drilled using a stereotactically mounted electric drill (Department of Medical Engineering, Imperial 
College London, UK). Stereotactic coordinates calculated from the Rat Brain Atlas (Paxinos and 
Watson, 2007) were as follows; 2.8mm posterior to the bregma in the midline and 10mm below the 
surface of the skull. A 22-gauge cannula (Plastics One Inc, Roanoke, VI, USA) projecting into the 
dorsal medial hypothalamus was implanted.  Screws were inserted into the skull and dental cement 
was then used to cover them over (Associated Dental Products Ltd, Swindon, Wiltshire, UK) to hold 
the cannula in place. Animals were administered subcutaneous analagesia (Buprenorphine 45mg/kg, 
Schering-Plough Corp, Welwyn Garden City, Hertfordshire, UK)  and saline and allowed to recover. 
A cap was placed on the cannula to prevent blockage. 
 
Weight before cannulation and 6 days post-cannulation was recorded. Food intake was also measured 
at days 2, 3 and 4 post-surgery.  Food intake was not measured at days 0 and 1 due to the cage in 
provision of wet rat chow. In normal conditions rats are fed standard dry rat chow, but in order to aid 
recovery, wet rat chow was administered within the rat cage, rather than in the food hopper, where it 
is normally kept, making it difficult to weigh the food consumed.  
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3.5.3. Pilot study statistics 
As this was a study that was performed by another member of the department, a power calculation 
was not conducted. The data was analysed using SPSS 18.0 for Windows (SPSS Science, Apache 
Software Foundation, Chicago, IL, USA). 
All data was checked for normality and presented as mean ± standard error or the mean (SEM). Data 
was analysed using a One Way ANOVA to compare groups against baseline, followed by a Tukey 
post-hoc test.  
3.5.4. Pilot study results 
Results demonstrated that there was a substantial decrease in body weight gain (g) per day following 
cannulation (Mean (SEM) -2.42 (1.64) g per day) occurring 24 hours post operation (p<0.001) (see 
figure 3.1). Following this loss, body weight gain started to increase from day 2. Data (figure 3.2) also 
demonstrated that there was a significant reduction in food intake (p=0.018) following the cannulation 
in comparison to pre-surgery food intake with a mean (SEM) 29.46 (0.95) (g) food intake at day -1 
and mean (SEM) 20.8 (0.72) (g) food intake at day 2 (p=0.024). Day 2 was the earliest point 
measured following surgery, with food intake increasing following day 2 (figure 3.2). 
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Figure 3.1. Change in body weight following DMH cannulation 
 
 
 
 
 
 
 
Mean ± SEM change in body weight (g per day) in rats receiving DMH surgery (n=35) at days –2 
and -1 pre surgery, and days 0 (baseline), 1, 2, 3, 4, 5 post surgery. Cannulation at day 0. Difference 
detected between days (p<0.001). *p=<0.001, **p=0.008, ***p=0.031, ****p=0.001 vs. day 0 
(n=35). 
 
Figure 3.2.  Change in food intake following DMH cannulation 
 
 
 
 
 
 
 
 
Mean ± SEM in food intake (g) in rats receiving DMH cannulation (n=35) on day -1 (baseline) pre-
surgery and days 2, 3, 4, and 5 post-surgery. Difference detected between days (p=0.018) *p=0.024 
vs. day -1(n=35). 
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This data suggests that a cannulation to the brain in rats induces weight loss and reductions in food 
intake, therefore this would be an appropriate animal model for trauma. However, since the 
hypothalamus is known to be important in the regulation of appetite, a cannulation to the left ventricle 
would be preferable to the dorsal medial hypothalamus. The greatest amount of weight loss was 
observed at 24 hours post procedure, therefore this is the point at which I decided gastrointestinal 
hormone measurement should be taken in the main study. 
3.6. Main study 
3.6.1. Introduction 
Following this pilot study, I undertook the investigation to determine the effect of trauma on weight 
loss and gastrointestinal appetite hormone release. 
3.6.2. Methodology 
24 male Wistar rats (specific pathogen free; Charles River, Margate, Kent, UK) were maintained in 
the same conditions as described in section 3.5.2. Animals and procedures undertaken were approved 
by the British Home Office Animals (scientific procedures) Act 1986. On arrival to the animal house, 
rats were given 7 days to acclimatize to the environment before any procedures or measurements were 
undertaken.  
Following the initial acclimatisation week, body weight and food intake in the rats were measured 
daily at the same time each day for seven days. On the 7
th
 day the rats were randomized into the 
following groups; eight controls, eight that underwent anaesthesia only, since it is not known if 
anaesthesia can result in body weight loss, and eight that had left lateral ventricle (LV) surgery as per 
the pilot study. LV cannulation was chosen as it did not penetrate the hypothalamus, which is known 
to have an important influence on appetite, but should provide sufficient trauma to demonstrate a 
change in body weight as was demonstrated in the pilot study. 
Randomization was conducted using the body weights of the rats. Body weights of the rats from the 
7
th
 day were listed in ascending order. The first rat in the list was allocated to group 1 (cannulation), 
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the second allocated to group 2 (anaesthetics) and the third allocated to group 3 (control), the 
following rat body weights in the list were allocated to the following groups using the following 
sequence; 3,2,1,1,2,3 etc etc. Following randomization, mean body weights of the groups and food 
intake were calculated to ensure the mean values between the groups were close in value. 
3.6.3. Procedure day 
On the morning of the procedure day (day seven), body weights and food intake were measured and 
rats were allocated to their procedure groups (described in section 3.6.1) either the cannulation, 
anaesthetics or control group. Food was removed from all of the rats in all procedure groups’ cages 
prior to the procedure throughout the duration of the cannulations to standardize conditions. 
3.6.3.1. Cannulation group 
Eight rats were to receive a sham cannulation to the left lateral ventricle of the hypothalamus. A sham 
cannulation is where the methodology is identical to a normal cannulation (see section 3.5.2.1), but 
the cannula is removed immediately before the screws are then inserted. This means that the animals 
have received some form of trauma which would be substantial enough to produce a weight loss. It is 
not necessary to keep the cannula inside the ventricle due to the increased risk of infection and the 
possibility of accidental removal of the cannula by the rats. 
Cannulation rats were anaesthetized one at a time and were administered with prophylactic antibiotics 
(see section 3.5.2). The head was cleaned with a 10% w/v providine/iodine solution (Ecolabs Ltd, 
Leeds, Yorkshire, UK) and the rats were positioned on a stereotaxic frame (David Kopf Instruments, 
Tujunga, CA, USA) with the incisor bar 3mm below the interaural line. A 1.5cm longitudinal incision 
was made. A hole was drilled using a stereotactically mounted electric drill (Department of Medical 
Engineering, Imperial College London, UK). Stereotactic coordinates calculated from the Rat Brain 
Atlas (Paxinos and Watson, 2007) were as follows; 0.5mm posterior to the bregma in the midline, 
+1.2mm ML (left) and 2.5mm below the surface of the skull. A 22-gauge cannula (Plastics One Inc, 
Roanoke, VI, USA) projecting into the left ventricle was then implanted and then immediately 
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removed  Screws were inserted into the skull and dental cement was then used to cover them over 
(Associated Dental Products Ltd, Swindon, Wiltshire, UK). Animals were administered subcutaneous 
analagesia (Buprenorphine 45mg/kg, Schering-Plough Corp, Welwyn Garden City, Hertfordshire, 
UK) and saline and allowed to recover.  Time was recorded from the time that the rat was 
anaesthetized to the time when the sham cannulation procedure ended. Following cannulation, rats 
were returned to their cage. 
3.6.3.2. Anaesthesia only group 
The anaesthetics only group was anaesthetized with the same procedure as the cannulated rats. They 
were partnered to a cannulation rat and were positioned in the stereotaxic frame and were under 
anaesthesia for the exact timing to standardize conditions. The rats were administered analgesia and 
saline to keep the conditions consistent to the cannulation group. Following anaesthetics, rats were 
also returned to their cage. 
3.6.3.3. Control group 
The control group underwent no procedures but received an injection of analgesia to standardize 
conditions (both the anaesthetics and cannulation groups received analgesia), as it is not known if the 
painkiller or the stress from receiving injections have an influence on appetite.  
3.6.4. Procedure day methods 
Animals were decapitated 24 hours post-surgery for the measurement of gastrointestinal appetite 
hormones (largest weight loss was seen in the DMH rats at day 1 post surgery). Food was removed 
two hours prior to decapitation in order to standardize gastrointestinal hormone levels. Following the 
two hour fast animals had a final body weight check exactly 24 hours after surgery. The animals were 
decapitated and blood was taken for the measurement of PYY, GLP-1, total ghrelin and acyl ghrelin. 
The rats were decapitated in order of surgery from the previous day (i.e. the rat that was cannulated 
first was decapitated first) in the sequence of control, anaesthetics, cannulation, control etc.  
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Blood was collected in 10ml lithium heparin tubes containing trasylol (200ul trasylol for 10ml blood). 
The blood was spun immediately for 10 minutes to separate the plasma. The plasma was removed and 
pipetted into assay tubes and transferred immediately to dry ice for freezing. Acyl ghrelin samples had 
50ul 1M HCL to 1ml plasma and 2 mM AEBSF to 1ml plasma added to them. After the procedure 
blood samples were stored in a -20 freezer until they were ready to use. 
3.6.5. Measurement of outcomes 
Primary Outcome: Plasma ghrelin levels (total and acyl).  
Secondary Outcome: Plasma PYY and GLP-1 levels and body weight following the procedure. 
3.6.6. Measurement of peptides 
Plasma samples were defrosted when needed and plasma GLP-1, PYY and ghrelin (total and acyl) 
were analysed using Radio Immunoassay and ELISAS as described in chapter 2.6. 
3.6.7. Statistical analysis 
As this study was a pilot study, a power calculation was not conducted. The data was analysed using 
SPSS 18.0 for Windows (SPSS Science, Apache Software Foundation, Chicago, IL, USA). All data 
was checked for normality and presented as Mean ± Standard Error of the Mean (SEM). Data was 
analyzed using a One Way ANOVA, with difference between groups detected by a Tukey post-hoc 
test. 
Data was tested for normality using the Kolmogorov-Smirnov test for normality. All data was 
normally distributed with the exception of plasma PYY levels. PYY data was log-transformed and 
tested for normality again using the Kolmogorov-Smirnov test and was normal. Parametric analysis 
was applied to all variables as they were normally distributed. 
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3.7. Results 
3.7.1. Body weight gain pre- and post-surgery 
The anaesthetics, cannulation and control groups total body weights and body weight gain was similar 
in the 7 days leading up to the procedure. Both the anaesthetics and the cannulation groups lost weight 
following the procedure day on day 8 (table 3.1). 
Results demonstrate significant alterations in body weight change (g) per day (p=0.002) occurring 
between the anaesthetics (p=0.003) and cannulated (p=0.015) rats in comparison to the controls at day 
8 post surgery (figure 3.3). Significant alterations in total body weight change (g) was also detected 
(p<0.001), occurring between the anaesthetics (p<0.001) and the cannulation (p=0.006) groups in 
comparison to the control group (figure 3.4) at day 8 post-surgery. 
Table 3.1. Body weights of the control, cannulated and anaesthetics rats from days 1 to 8. 
 
 Cannulation (n=8) Anaesthetics (n=8) Controls (n=8) 
Day Weight gain 
per day (g) 
Mean (SEM) 
Body weight 
(g) Mean 
(SEM) 
Weight gain 
per day (g) 
Mean (SEM) 
Body 
weight (g) 
Mean 
(SEM) 
Weight gain 
per day (g) 
Mean 
(SEM) 
Body 
weight (g) 
Mean 
(SEM) 
1 8.6 (0.52) 232.8 (2.53) 8.2 (0.81) 234.1 (3.46) 9.1 (0.81) 232.7 (3.45) 
2 9.7 (0.78) 242.4 (2.64) 10.3 (0.62) 244.4 (3.47) 9.9 (0.62) 242.6 (3.47) 
3 9.4 (0.86) 251.8 (2.83) 8.9 (0.93) 253.3 (3.85) 9.4 (0.93) 252.0 (3.85) 
4 6.9 (0.67) 258.7 (2.69) 7.1 (1.29) 260.4 (3.69) 8.3 (1.29) 260.3 (3.69) 
5 6.5 (0.97) 265.2 (3.12) 5.5 (0.94) 265.9 (3.51) 6.3 (0.94) 266.6 (3.51) 
6 10.9 (0.97) 276.1 (3.42) 10.5 (1.22) 276.4 (3.74) 10.3 (1.22) 276.9 (3.74) 
7 11.2 (0.66) 287.3 (3.71) 10.9 (1.09) 287.3 (3.77) 10.9 (1.09) 287.8 (3.77) 
8 (post 
surgery) 
-11.4 (3.56) 275.9 (3.60) -14.2 (2.80) 273.1 (5.09) 1.3 (2.80) 289.0 (5.09) 
 
Mean (SEM) body weight change (g) and total body weight (g) for each group from days 1 to 8 (post-
surgery)  in the control, anaesthetics and cannulated rats (n24) 
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Figure 3.3. Body weight change per day from days 1 to 8 in the control, anaesthetics and cannulated 
rats. 
 
 
 
 
 
 
 
Mean ± SEM body weight change per day (g) in control, anaesthetics, and cannulated rats on days 1 
to 8. Significant difference detected at day 8 (post surgery) (p=0.002) between the groups. 
Significance detected between controls and anaesthetics (*) (p=0.003) and controls and cannulated 
rats (**) (p=0.015)(n=24) 
 
Figure 3.4.  Total body weight change per day from days 1 to 8 in the control, anaesthetics and 
cannulated rats  
 
 
 
 
 
 
 
 
Mean ± SEM total body weight (g) per day in controls, anaesthetics, and cannulated rats in days 1 to 
8. Significant difference detected at day 8 (post-surgery) (p<0.001) between the groups. Significance 
detected between control and anaesthetic rats (*) (p<0.001) and between controls and cannulated 
rats (**) (p=0.006) (n=24) 
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3.7.2. Food intake pre- and post-surgery 
The anaesthetics and control group had a similar food intake the 7 days leading up to the procedure. 
The anaesthetics, cannulation and the control rats consumed less food on day 8 following the 
procedure than the control rats. The difference in food intake between groups at day 8 reached 
significance (p=0.012). Tukey post-hoc test detected this difference between the anaesthetics and 
control group (p=0.011). No significance was detected between the controls and the cannulation 
group. Table 3.2 and figure 3.5 present the data investigating changes in food intake for each 
procedure group from days 1 to 8. 
Table 3.2. Food intake from days 1 to 8 (post-surgery) in the control, anaesthetics and cannulated 
rats 
 Cannulation (n=8) Anaesthetics (n=8) Controls (n=8) 
Day Food Intake (g) 
Mean (SEM) 
Food Intake (g) 
Mean (SEM) 
Food Intake (g) 
Mean (SEM) 
1 31.54 (0.79) 29.00 (1.07) 31.55 (1.07) 
2 31.30 (0.66) 31.03 (0.93) 31.34 (0.93) 
3 31.64 (0.84) 30.79 (0.73) 33.00 (0.73) 
4 31.34 (0.64) 30.55 (0.71) 32.05 (0.71) 
5 31.24 (0.76) 32.61 (1.42) 32.40 (1.42) 
6 31.41 (0.80) 30.39 (0.68) 31.96 (0.68) 
7 32.09 (0.61) 30.81 (0.78) 32.96 (0.78) 
8 (post-surgery) 16.04 (1.68) 13.89 (1.90) 21.20 (1.90) 
 
Mean (SEM) changes in food intake (g) in each group from days 1 to 8 in the cannulated, anaesthetics 
and control rats (n24). 
 
 
 
 
 
106 
 
0 2 4 6 8 10
0
10
20
30
40
Controls Anaesthetics Cannulated
*
Day
F
o
o
d
 W
e
ig
h
t 
(g
)
Figure 3.5. Food Intake from days 1 to 8 in the controls, anaesthetics and cannulated rats. 
 
 
 
 
 
 
 
 
Mean ± SEM food weight (g) consumed per day in controls, anaesthetics and cannulated rats in days 
1 to 8. Significance was detected at day 8 (post-surgery) (p=0.012) between the groups. Difference 
detected between the control and anaesthetics groups (*) (p=0.011) (n=24) 
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3.7.3. Plasma PYY 
There was no alteration in plasma PYY concentrations detected between the 3 test conditions. Table 
10.1 in appendix 10.7 and figure 3.6 present the plasma PYY concentrations on day 8 following the 
procedure.  
Figure 3.6. Plasma PYY concentrations in the anaesthetics, cannulated and control rats. 
 
 
 
 
 
 
 
 
Mean ±SEM plasma PYY concentrations pmol/L on log
10
 transformed y axis on day 8 (post-surgery) 
in the anaesthetics, cannulated and control rats (n=24). No significance detected between groups. 
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3.7.4. Plasma GLP-1 
Plasma GLP-1 concentrations were slightly lower in the cannulation group at day 8 post-surgery. 
There was an absence of a significant alteration in GLP-1 concentrations in the cannulated and 
anaesthetics group compared to controls. Mean (SEM) GLP-1 concentrations can be seen in table 10.1 
in appendix 10.7. Figure 3.7 presents the data between groups. 
 
Figure 3.7. Plasma GLP-1 concentrations in the anaesthetics, cannulated and control rats 
 
 
 
 
 
 
 
 
Mean ±SEM plasma GLP-1 concentrations (pmol/L) on day 8 in the anaesthetics, cannulated and 
control rats (n=24). No significance detected between groups. 
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3.7.5. Plasma total ghrelin and acyl ghrelin 
Plasma total ghrelin concentrations were similar in all test conditions. Plasma acyl ghrelin 
concentrations appeared to be moderately lower in the cannulation group. No significant differences 
between the 3 test groups in total and acyl ghrelin concentrations were detected.  Results are presented 
in figure 3.8. and in table 10.1 in appendix 10.7. 
 
Figure 3.8. Plasma total ghrelin (A) and acyl ghrelin (B) concentrations in the anaesthetics, 
cannulated and control groups. 
(A)               (B) 
 
 
 
 
 
 
A. Mean ±SEM plasma total ghrelin (pmol/L) concentrations on day 8 in the anaesthetics, 
cannulation, and control rats (n=24). No significance detected between groups. 
B. Mean ±SEM plasma acyl ghrelin (pmol/L) concentrations on day 8 in the anaesthetics, 
cannulation, and control rats (n=24). No significance detected between groups. 
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3.8. Discussion 
3.8.1. Overview 
The objective of this study was to try to develop an animal model that replicates what is seen in 
humans, where there is an abnormal gastrointestinal appetite hormone profile and body weight loss in 
periods of illness and trauma. 
3.8.2. Summary of findings 
This study has demonstrated that following trauma in rats receiving a sham LV cannulation, there is a 
significant reduction in body weight in comparison to controls. Food intake decreased in the 
cannulated rats compared to the control rats, but did not reach significance in this group. These results 
were also seen to a very similar degree in rats that received the anaesthetics alone in comparison to 
controls, although interestingly reductions in energy intake reached significance. The lack of 
significance in the cannulated group may be due to small study numbers. This reduction in body 
weight observed mirrors what is seen in humans in illness, where there is a reduction in energy intake 
and subsequent loss in body weight (Witte and Clark, 2002; McWhirter and Pennington, 1994). This 
demonstrates that with trauma in rats, there is an inability to regulate appetite to normal levels. 
Unexpectedly, there was an absence of an alteration in gastrointestinal appetite hormones; PYY, GLP-
1, total ghrelin and acyl ghrelin following trauma compared to the controls opposing my proposed 
hypothesis. This demonstrates that this particular model carries no relevance when trying to elucidate 
the gastrointestinal appetite hormonal changes that occur in illness and trauma in humans and their 
role on appetite reduction and weight loss. 
3.8.3. Is trauma associated with body weight loss and a reduction in energy intake 
in rodents? 
In the rats receiving the sham LV cannulation and the anaesthetics alone group, body weight change 
was significantly lower post procedure day than in the control rats. Both the anaesthetics and control 
groups lost weight following the procedure, whereas the control group gained weight. The weight loss 
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observed in the cannulation group was expected, but was unexpected in the rats receiving anaesthetics 
alone. 
It was also observed in the study, although not significant, a reduction in food intake in the control 
rats compared to food intake prior to the procedure day and a weight gain that was not as substantial 
to the previous days. A possible explanation for the body weight loss observed in the cannulation and 
anaesthetics group and the absence of a weight gain in the control group could be explained by the 
stress that was inflicted upon the rodents. The procedures that were carried out on the rodents would 
have been a stressful experience, as it is a procedure the rats were not familiar with. It has been 
regularly observed that stress causes a reduction in energy intake and body weight in rodents (Diane 
et al., 2008; Torres and Nowson, 2007). The rodents all received some form of stress, i.e. 
cannulations, anaesthesia and injections. The control rats received an i.p. injection of analgesia to 
standardise conditions, as this was administered to the anaesthetics and the cannulation groups as 
well. This would be stressful for the rats, and could have possibly prevented them from eating their 
normal energy intake. 
The reduction in appetite and body weight loss mirrors what is observed in humans in trauma and 
illness (Witte and Clark, 2002; McWhirter and Pennington, 1994). What is surprising is the weight 
loss that is seen in the anaesthetics group. No studies have been conducted in humans that have 
looked into the effects of anaesthetics on food intake and body weight loss. It is difficult to pinpoint 
the reasoning for this weight loss in the anaesthetics group, but if this weight loss is observed in 
humans, it is important that particular care is taken with patients undergoing anaesthesia due to the 
reductions in body weight and appetite observed. Anaesthetics have a major influence in the neuronal 
activity in the brain and therefore neurotransmitters such as NPY, AgRP and melanocortin releasing 
neurones may also be affected by anaesthetics. Considering these neurotransmitters play a role in the 
regulation of appetite, it may be via this route that the reduction in food intake and body weight was 
observed in the rats. If the appetite stimulating neurotransmitters NPY and AgRP became inhibited by 
the effects of the anaesthetics, appetite and subsequent food intake will decline. It is thought that the 
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effects of anaesthetics could cause neurodegeneration (Bianchi et al., 2008; Jevtovic-Todorovic et al., 
2003), but the mechanisms of how it causes this is unclear.  
3.8.4. Is there an alteration in gastrointestinal appetite hormones in animals 
receiving trauma via a LV cannulation? 
The plasma gastrointestinal hormone profiles of the rats were not statistically different between 
treatment groups for any of the hormones; PYY, GLP-1, total ghrelin and active ghrelin. This lack of 
alteration in gastrointestinal appetite hormones does not correlate with the weight loss that was 
observed. This also does not reflect what is seen in humans in illness where there is an increase in 
PYY observed (Nematy et al., 2006a; Nematy et al., 2006b) and possible reductions in total and acyl 
ghrelin (Oner-Iyidogan et al., 2011; Yoshimoto et al., 2002). There were only a small number of rats 
used in the study which may have not given enough for statistical power to demonstrate a difference. 
However, observing the results there does not appear to be a trend towards a difference between the 
groups.  
There has only ever been an effect seen in animals in gastrointestinal appetite hormones in trauma in 
gastric-bypass models (Le Roux et al., 2006) which has also been confirmed in humans (Pournaras et 
al., 2009). As no other studies have found an altered gastrointestinal hormone response so far in rats 
in trauma, it may be that a rat is not a good model to demonstrate changes in gastrointestinal appetite 
hormones. A longer term illness might have been more appropriate for an effect to be seen. In the 
studies that alterations have been shown in humans, the participants have been from the ageing 
population. The illnesses which have provided a change in gut appetite hormones in humans were 
either a fracture of the neck of femur, ITU patients, renal failure or cancer patients (Nematy et al., 
2006a; Nematy et al., 2006b; Le Roux et al., 2005; Nguyen et al., 2006; Neary et al., 2004; Ashby et 
al., 2009; Nagaya et al., 2001). Although fracture of the neck is classed as trauma, it was in an older 
age group (Mean age 81 years) (Nematy et al., 2006b) and therefore may be reasoning for why no 
effect on gastrointestinal hormones was detected in rodents. The rats were not old in this study as this 
was only a pilot study, but this suggests that a longer term illness on older rodents might be more 
appropriate to use to demonstrate an effect on gastrointestinal appetite hormones. 
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3.8.5. Limitations 
This study was a pilot study to develop an animal model that replicates the alterations observed in 
humans, therefore only small numbers were used. A power calculation was not conducted because it 
was a pilot study. A model needs to be developed that demonstrates the desired effects in order to 
decide on therapeutics that will increase the appetite in illness in older patients. 
The procedures carried out on the animals would have created a substantial amount of stress to the 
rodents. Although the rats were given one week to acclimatise to the environment, they were not 
accustomed to the administration of injections. In order to acclimatise conditions the rats would need 
to have daily i.p. injections of saline for a period of days in order to alleviate the stress for the rodents 
on the procedure day. Unfortunately due to the nature of the study, I could not relieve the stress for 
the animals completely, as I could not justify giving the rodents daily anaesthesia and daily injections 
and sham cannulations to enable the rat to become accustomed. Stress is known to reduce food intake 
in rodents (Diane et al., 2008). Every effort was made to reduce the stress for the animals. Animals 
were handled for the shortest possible amount of time and were administered anaesthesia for the 
shortest amount of time.  
3.8.6. Conclusion 
This study was a pilot study to find out if there was any alteration in gastrointestinal appetite 
hormones in trauma to see if I could replicate what is observed in humans. This study found no 
significant alterations in gastrointestinal appetite hormones. A different effect might have been 
observed in aged animals due to older animals/humans being unable to adapt and recover as rapidly 
after surgery than younger people (Watters et al., 1993). There is an alteration in gastrointestinal 
appetite hormones in humans, where the majority of patients were over the age of 60 years, for 
example PYY has been observed to be higher in elderly patients with femoral neck fracture (Nematy 
et al., 2006b), as this proportion of the population are at higher risk of developing an illness than 
younger individuals. It is difficult to come to a firm conclusion as I cannot extrapolate results from 
humans to rats due to species variation. Due to the results of this study, this line of enquiry was halted 
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and efforts focussed on exploring alterations in humans since the rat model required further 
exploration. 
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Chapter 4 
COMPARISON OF GASTROINTESTINAL APPETITE 
HORMONES IN OLDER AND YOUNGER HEALTHY 
VOLUNTEERS 
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4.1. Introduction 
 
In healthy ageing, data is unclear on what gastrointestinal appetite hormone changes occur. Published 
data reviewed in chapter 1 shows a consistent finding that there is a loss of appetite over the age of 65 
years, but how this loss is mediated is not yet clear. Some evidence suggests that with advancing age 
there is an increase in the satiety hormone PYY (Di Francesco et al., 2005) and a decrease in the 
anorectic hormone ghrelin (Rigamonti et al., 2002; Di Francesco et al., 2005), but a lot of the 
literature demonstrates opposing results suggesting that there is a lack of alteration in PYY 
(MacIntosh et al., 1999) and ghrelin (Yukawa et al., 2006). Only one study to date has investigated 
GLP-1 alterations in ageing in a small sample of volunteers, where GLP-1 concentrations were 
observed to not be altered (MacIntosh et al., 1999). One of the explanations for the lack of 
consistency in findings could be due to differences in methodology, for example, the time of day and 
kcal load of the test meals (see chapter 1).  
This chapter explores how age may influence gastrointestinal appetite hormone release which would 
subsequently enable me to determine if gastrointestinal hormones contribute to age related under-
nutrition. 
4.2. Hypothesis 
 
Increasing age will be associated with alterations in fasting and post-prandial ghrelin (total and acyl), 
PYY and GLP-1 concentrations which will favour a reduction in appetite and a decrease in energy 
intake. 
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4.3. Aims and Objectives 
 
4.3.1. Aims 
 
To investigate the alterations that occur with ageing in fasting and post-prandial levels of ghrelin, 
PYY and GLP-1 in plasma and their association with energy intake and appetite. 
4.3.2. Objectives 
 
1. To determine the effect of ageing on fasting and post-prandial concentrations of ghrelin (total 
and acyl), PYY and GLP-1. 
2. To determine the effect of ageing on energy intake from an ad libitum meal following a 
standard breakfast. 
3. To investigate the effect on reported appetite scores during the test meal process 
4. To determine whether insulin, glucose, or gastric emptying explain any of the observed age 
related differences in appetite or energy intake. 
4.4. Methodology 
 
4.4.1. Study design 
 
This investigation is a comparative experimental design, using a cross-sectional sample of ages from a 
healthy population. Differences in fasting and postprandial levels of ghrelin (total and acyl), PYY and 
GLP-1 were compared between different age ranges. 
4.4.2. Study population 
 
Using a power calculation (described in section 4.4.4.1) 72 participants were required to participate in 
this study. Participants were recruited in age groups; 20-39, 40-59, 60-79 and 80+ years, with the aim 
of recruiting 18 volunteers in each group in order to obtain an even spread of age ranges. 
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4.4.3. Study plan 
 
4.4.3.1. Recruitment 
The recruitment process is detailed in section 2.2. 
4.4.3.2. Screening of participants 
Participants were screened prior to taking part in the study. A detailed description of the screening 
process is described in section 2.2 
4.4.3.3. Study visits 
Participants are required to attend two study visits lasting 4 hours. The first study visit was a practice 
visit (sham visit) where exactly the same tests were undertaken as the second visit. A reduced amount 
of blood samples were taken as the samples were not analysed. Gastrointestinal hormones are easily 
influenced by stress, therefore participants were required to attend the sham visit in order for them to 
become accustomed to the environment (for more information please see chapter 2). The second study 
visit was identical to the sham visit, with the exception that larger blood samples were taken for 
gastrointestinal hormone analysis. 
4.4.3.4. Study day protocol 
Participants that were eligible to take part in the study signed a consent form and had read the 
information sheet sent to them (see appendix 10.5 and 10.6), only once they had done this, they were 
allowed to participate in the study. 
Participants attended two ½ day visits lasting around 4 hours, arriving at 8.30am. Participants were 
fasted, having not eaten from 9pm the night before, and had not consumed alcohol and avoided 
excessive exercise the night prior to the study visit. Participants were allowed to drink water. 
On arrival to the study, participants had an i.v. (intra-venous) cannula placed in a vein in their arm for 
blood sampling. Following this, participants were given 30 minutes to become accustomed to the 
environment before any tests were undertaken. After the 30 minute acclimatisation period, the first 
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blood sample was taken at baseline (0min) for comparison of fasting gastrointestinal hormone 
concentrations. A blood pressure reading was also taken (see section 2.3.2.) as a precautionary 
monitor of the volunteers health. Participants were also asked to fill in VAS to assess feelings of 
hunger, nausea, appetite and satiety (see section 2.8.). Immediately following the first blood sample 
participants were asked to consume a standard test meal of two Ensure Plus meal replacement drinks 
(table 4.1.). Participants were required to consume all of the test meal within 15 minutes for a 
standard intake of energy and macronutrients. At the same time that the test meal was consumed, 
participants were also required to drink 250ml of water containing 1.5g of soluble paracetamol which 
is used for the measurement of gastric emptying. 
Table 4.1. Nutritional composition of Ensure Plus provided at test meal.  
 Per 100g Per 440g provided at test meal 
Kcal 150 660 
KJ 632 2,781 
Protein (g) 6.25 27.5 
Carbohydrate (g) 20.2 88.88 
Fat (g) 4.92 21.648 
Fibre (g) 0 0 
Sodium (mg) 92 404.8 
 
The remaining blood samples were then taken at 15, 30, 60, 120 and 180 minutes post standard test 
meal for comparison of release of gastrointestinal appetite hormones. The timeline of the study visit 
can be seen in figure 4.2. Participants were also asked to fill in VAS to assess feelings of hunger, 
nausea, food palatability, appetite and satiety immediately before each blood sample is taken (see 
chapter 2.8.). Blood pressure readings were also taken at every time point. 
At 180 minutes, following the final blood sample, the cannula was removed. Participants were 
presented with a large ad libitum test meal and were invited to eat until they felt comfortably full. 
Comfortably full was described to the participants as a feeling of satisfaction without feeling that they 
have eaten too much or too little. Water was also provided in excess at the ad libitum test meal and at 
the participants request throughout the duration of the study. Water intake was measured and 
monitored throughout the study. A final VAS was filled in following the ad libitum test meal for 
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subjective feelings of hunger and satiety. Nutritional composition and description of the test meals are 
described in section 2.4. 
 
Figure 4.1. Overview of study day. Participants were asked to attend two study days 
 
 
 
 
 
 
 
 
 
 
4.4.4. Measurement of outcomes 
 
Primary outcomes: Ghrelin concentrations (acyl and total). 
Secondary outcomes: PYY, GLP-1, Insulin, Glucose, Gastric Emptying, Energy Intake and 
subjective feelings of appetite. 
Collection of blood; Detailed in section 2.7 
Measurement of hormones, glucose and gastric emptying; Detailed in section 2.7 
Subjective feelings of appetite; Detailed in section 2.8 
 
 
 
121 
 
4.4.4.1. Power Calculation 
Assuming a power of 90% and α=0.05, with a sd=256.6 (Neary et al., 2004) and to detect a difference 
of 100pmol/L (difference in ghrelin levels seen in previous work in the department and previously 
shown to result in altered food intake) 72 participants are needed in total. 
4.4.5. Statistical analysis 
 
All data was tested for normality using the Kolmogorov-Smirnov test for normality. Data that was not 
normally distributed was log transformed to a power of 10 and tested for normality once again. If data 
was normal, parametric analysis was applied and was presented as mean with standard error of the 
mean (SEM). Descriptive data was presented as mean with standard deviation (SD). It has been 
described previously by (Sedgwick, 2011), that descriptive data should ideally be presented as mean 
(SD). Log transformed data is presented in graphs with the original values on a log transformed axis, 
and in tables as geometric mean and inter-quartile range.  
Data that was not normally distributed following log transformation, or contained negative values 
which prevented log transformation, was analysed using non-parametric analysis and presented as 
median and inter-quartile range in graphs and tables. 
Data was analysed using age categories; 20-39, 40-59, 60-79 and 80 + years. Parametric data was 
analysed using a One-Way ANOVA followed by a Tukey Post-Hoc test to determine where the 
significance lies. For non-parametric data, a non-parametric Kruskall Wallis test was used to compare 
between groups, followed by a Mann Whitney U test to see where the alterations lie between groups. 
Data will also be analysed using correlations and regression. 
For measurements over time, the area under curve (AUC) and the incremental area under the curve 
(IAUC) were used. The IAUC was used because it takes into account the baseline value.  Although 
the IAUC is the preferred method to determine changes over time, AUC was also used as this enabled 
me to look at the overall effect of ageing, For example, hunger levels may not decrease significantly 
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more in ageing in response to a test meal, but overall hunger levels may be consistently lower, 
demonstrating an overall effect of ageing rather than just a response to a test meal.  
Some values from the insulin assay were excluded from the insulin analysis due to haemolysis (see 
section 4.6.11). IAUC and AUC could not be calculated for participants that had a missing baseline 
value or final value. Furthermore, if more than two insulin samples were excluded from the 
participant’s insulin profile, then the IAUC and AUC was also not calculated. The IAUC and AUC 
calculation was amended for the time points that were not included in the analysis. 
Males and females were analysed combined due to the effect of splitting the data into males and 
females reducing the statistical power of the study. Males and females individual statistics are 
presented in appendix 10.8.4. 
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4.5. Results 
 
58 volunteers were recruited in total (27 male, 31 female), a flow chart of the screening process can 
be seen in figure 4.2. Due to recruitment difficulties, I was unable to recruit any males over the age of 
80 years that were healthy enough to participate in the study. Only 6 females in the over 80’s category 
were healthy enough to take part. I was unable to recruit all the females in the 60-79 age group (7 
females instead of 9), due to lack of interest in this particular age groups willingness to take part.  
 
Figure 4.2. Flow chart of screening process 
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Telephone Screenings 
76 Full Screenings 
62 Recruited 
58 Completed 
58 Excluded: 
(25) Illness/ Medication 
(24) Incorrect BMI 
(3) Withdrawal Participation 
(2) Availability 
(2) Participation in other studies 
14 Excluded: 
(4) Illness/ Medication 
(5) Incorrect BMI 
(5) Withdrawal Participation  
 4 Withdrawals: 
(2) Tolerability blood sampling 
(2) Non Attendance 
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4.5.1. Descriptive statistics 
 
Table 4.2 presents the volunteers characteristics. BMI and body weight (kg) across the age ranges 
were not significantly different to one another. As would be expected in an ageing population, there 
was a significant difference in body fat percentage (p=0.012) and lean body mass percentage 
(p=0.005), post hoc analysis revealed this significance to be between the 20-39 and 80+ age group for 
both body fat percentage (p=0.010) and lean mass percentage (p=0.003) between the 4 age groups. 
The older age groups had higher body fat percentage and lower lean body mass percentage than 
younger volunteers. There was a positive correlation with age and body fat percentage (p=<0.001, 
r=0.47), and a negative correlation with age and lean body mass (p=0.002, r=-0.413). 
Body fat percentage was not measured in one of the volunteers due to the BIA machine unable to 
work on the volunteer for some unforeseen reason. 
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Table 4.2. Participants Characteristics 
 Mean (SEM) 
 20-39 years 40-59 years 60-79 years 80+ years 
 
Age (years) 
 
26 (4.29) 
 
(n=18) f=9, m=9 
 
50 (6.47) 
 
(n=18) f=9, m=9 
 
67 (5.65) 
 
(n=16) f=7, m=9 
 
85 (4.82) 
 
(n=6) f=6 
 
BMI (kg/m
2
) 
 
22.63 (1.58) 
 
(n=18) f=9, m=9 
 
23.71 (1.70) 
 
(n=18) f=9, m=9 
 
24.13 (1.96) 
 
(n=16) f=7, m=9 
 
23.47 (2.69) 
 
(n=6) f=6 
 
Weight (kg)* 
 
 
66.19 (60.7-72.5) 
 
(n=18) f=9, m=9 
 
74.99(64.2-73.1) 
 
(n=18) f=9, m=9 
 
70.35 (61.4-80.2) 
 
(n=16) f=7, m=9 
 
61.38 (57.2-65.9) 
 
(n=6) f=6 
 
Body Fat (%) 
 
19.17 (10.08) 
 
(n=18) f=9, m=9 
 
23.42 (11.87) 
 
(n=18) f=9, m=9 
 
25.98 (7.23) 
 
(n=15) f=6, m=9 
 
33.98 (4.17) 
 
(n=6) f=6 
 
Lean Mass 
(%) 
 
21.44 (10.59) 
 
(n=18) f=9, m=9 
 
21.12 (12.06) 
 
(n=18) f=9, m=9 
 
19.68 (7.46) 
 
(n=15) f=6, m=9 
 
17.69 (4.14) 
 
(n=6) f=6 
 
Mean (SEM) subject characteristics; Age, BMI, Weight, Body fat % and Lean Mass % in age 
categories; 20-29, 40-59, 60-79 and 80+ years. 
*Geometric Mean (Interquartile range) 
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4.5.2. Energy intake 
 
Mean energy intake at the ad libitum test meal declined with increasing age. Mean (SEM) energy 
intakes in the groups are as follows; 1018.9 (±83.03) kcal in the 20-39 age range, 801.1 (±64.89) kcal 
in the 40-59 age range, 638.7 (±75.54) kcal in the 60-79 age range and 415.62 (±72.43) kcal in the 
80+ years age range. Significance was detected in energy intake between the age categories 
(p<0.001). Difference was detected between the 20-39 and the 60-79 age group (p=0.003), the 20-39 
and the 80+ age group (p=0.001) and between the 40-59 and 80+ age group (p=0.044) (figure 4.3A). 
A Pearson correlation detected a significant negative correlation between age and energy intake at test 
meal (p<0.001, r=-0.593) (figure 4.3B). 
Figure 4.3. Food intake at the ad libitum test meal 
(B) 
    (A)                                                                                         
  
 
 
 
 
 
 
 
 
A. Mean ± SEM food intake (kcal) at ad libitum test meal in age groups 20-39 (n18), 40-59 (n18), 60-
79 years, and 80+ (n6) years. Significance detected between age groups (p<0.001). *p=0.003, 
**p=0.001 vs 20-39 age group. 
$
p=0.044 vs 40-59 age group. 
B. Scatter plot with linear regression correlating Kcal consumed at ad libitum test meal against age. 
Significant negative correlation (p<0.001, r=-.593)(n=58). 
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4.5.2.1. Energy intake taking into account lean body mass 
 
To determine if a reduction in energy intake at the ad libitum meal occurred independent of lean body 
mass, energy intake was divided by lean body mass (kg) for each participant, these values were then 
analysed against age. Mean (SEM) values for energy intake/ lean body mass (kg) are; 71.24 (5.15) in 
the 20-39 group, 55.51 (4.63) in the 40-59 group, 42.18 (4.41) in the 60-79 group and 37.50 (5.52) in 
the 80+ age group. A significant effect was observed with age groups and energy intake/ lean body 
mass (p<0.001) where as age increased, energy intake/ lean body mass decreased. Post-Hoc tests 
detected this difference to be between the 20-39 and the 60-79 age groups (p<0.001) and between the 
20-39 and the 80+ age group (p=0.003) (figure 4.4A). A Pearson correlation was applied to the data. 
There was a significant negative correlation between age and energy intake/lean body mass (p<0.001, 
r=-.566) (figure 4.4B). This demonstrates that the reduction in food intake in older adults compared to 
younger adults occurs despite the reduction in lean body mass (metabolically active tissue). 
Figure 4.4. Energy intake at the ad libitum test meal taking into account lean body mass. 
                                                                       (B)   
 (A) 
 
 
 
 
 
 
 
 
A. Mean ± SEM kcal consumed at test meal/lean body mass (kg) in the 20-39 (n18), 40-59 (n18), 60-
79 (n15), and 80+ (n6)age group. Significance detected in age groups (p<0.001). *p<0.001, 
*p=0.003 vs. 20-39 age group 
B Scatter plot with linear regression correlating kcal consumed at test meal/Lean body mass (kg) with 
age. Significant negative correlation (p<0.001, r=-0.566) (n=58) 
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4.5.3. Water consumption 
 
Water consumption at the study visit decreased with age. Mean (SEM) water intake (g) in the 
different age groups are as follows; 294.9 (41.2) in the 20-39 group, 316.6 (48.8) in the 40-59 group, 
197.8 (24.5) in the 60-79 and 66.0 (17.08) in the 80+ age group.  There was a significant difference in 
water consumption between the age ranges (p=0.007). This significance was detected between the 20-
39 and the 80+ age group (p=0.023) and the 40-59 and 80+ age group (p=0.011) (figure 4.5A). There 
was also a significant negative correlation detected with water intake at the study visit with age 
(p=0.001, r=-.423) (figure 4.5B). 
 
Figure 4.5. Water consumption at study visit 
                                                                                       (B)                  
 
(A) 
 
 
 
 
 
 
 
 
 
A. Mean± SEM water consumption (g) in the 20-39 (n18), 40-59 (n18), 60-79 (n16) and 80+ (n6) age 
groups. Significance detected between age groups (p=0.007). *p=0.023 vs. 20-39, **p=0.011 vs. 40-
59. 
B Scatter plot with linear regression correlating water consumed at test meal with age. Significant 
negative correlation (p=0.001, r=-0.423) (n=58). 
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4.5.4. Physical activity levels 
 
The IPAQ questionnaire provides an estimate of activity energy expenditure. 18 volunteers were 
excluded from the analysis using this questionnaire. This was due to the volunteers recording their 
physical activity levels too high according to the questionnaires criteria (see chapter 2.4). Due to this, 
data was excluded from this questionnaire and was not included in this thesis. 
The actical monitor measures total energy expenditure as well as activity energy expenditure (see 
chapter 2). Fewer participants (25) had their energy expenditure measured using this measurement 
due to this method of energy expenditure only commencing half way through the study. Total energy 
expenditure and activity energy expenditure decreased with age. Total energy expenditure was 
significantly different between the age groups for both total energy expenditure (p=0.001) and activity 
energy expenditure (p<0.001). This significance was detected between the 20-39 and the 80+ age 
group (p=0.001) and the 40-59 and the 80+ age group (p<0.001) for total energy expenditure, and in 
the 20-39 and 80+ age group (p<0.001), the 40-59 and the 80+ age group (p=<0.001) and the 60-79 
and the 80+ age group (p<0.001) in activity energy expenditure (figure 4.6A and 4.7A). 
There was a significant negative correlation between total energy expenditure (kcal) with age 
(p=0.001, r=-0.555) and for activity energy expenditure (kcal) with age (p=0.005, r=-0.541) (figure 
4.6B and 4.7B). 
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Figure 4.6. Three day average actical total energy expenditure (kcal). 
                                                                      
                                                                               (B) 
(A) 
 
 
 
 
 
 
 
 
 
 
A. Mean ± SEM average actical total energy expenditure (kcal) per day measured over 3 days 
presented on a log
10
 transformed y axis between the 20-39 (n5), 40-59 (n11), 60-79 (n5) and 80+ (n4) 
age groups. Significance detected between age groups (p=0.001). *p<0.001 between 20-39 vs. 80+, 
**p<0.001 between 40-59 vs. 80+ years. 
B. Scatter plot with linear regression correlating average actical total energy expenditure (kcal) per 
day measured over 3 days presented on a log
10
 transformed y axis and age. Significant negative 
correlation (p=0.004, r=-0.555) (n=25). 
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Figure 4.7. Three day average actical activity energy expenditure (kcal). 
                                                                                 (B) 
 
 
(A) 
 
 
 
 
 
 
 
 
 
 
A. Mean ± SEM average actical activity energy expenditure (kcal) per day measured over 3 days on a 
log
10
 transformed y axis between the 20-39 (n5), 40-59 (n11), 60-79 (n5) and 80+ (n4) age groups. 
Significance detected in age groups p<0.001. *p<0.001 between 20-39 vs. 80+, **p<0.001 between 
40-59 vs. 80+ years, ***p<0.001 between 60-79 vs. 80+ years 
B. Scatter plot with linear regression correlating average actical activity energy expenditure (kcal) 
per day measured over 3 days presented on a log
10
 transformed y axis and age. Significant negative 
correlation (p=0.005, r=-0.541) n=25. 
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4.5.5. Multiple linear regression to determine the relationship between age and 
energy intake taking into account other factors.  
 
Given the interesting observation that energy intake declined significantly taking into consideration 
lean body mass, a multiple linear regression was performed to determine the relationship between age 
and energy intake taking into account body composition and total energy expenditure (actical). The 
dependent variable; energy intake at the ad libitum test meal (kcal), and the independent variables; 
age (years), lean body mass percentage, gender and total energy expenditure measured using the 
actical monitor were added to the regression. The model demonstrated that only age and gender had 
were significant predictors for energy intake at the ad libitum test meal. Results from the linear 
regression can be seen in table 4.3. 
Table 4.3. Multiple regression to determine the relationship between age and energy intake. 
 
 Unstandardised Coefficients Standardised 
coefficients 
t Significance 
β Std Error Beta 
Age -12.821 3.094 -.595 -4.144 p<0.001 
Gender -339.59 146.79 -.332 -2.313 p=0.030 
 
Final model summary from the multiple linear regression (p<0.001, adjusted R
2
 = 0.369). Age and 
gender were significant predictors of energy intake. Total energy expenditure (kcal) (p=0.152), lean 
mass percentage (p=0.858) and water (p=0.862) have no significant effect on energy intake. 
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4.5.6. Visual analogue scores 
 
Subjective feelings of appetite were recorded at every time point during the study for measurements 
of hunger, satiety and satiation. This next section describes the results for VAS measurements 
between the four age groups. Tables for AUC scores and IAUC scores for each age group can be seen 
in table 10.2 in section 10.8.1. in appendix. 
4.5.6.1. VAS how hungry 
Hunger measured by VAS was lower both fasting and post-prandially in older volunteers. VAS for 
how hungry at each time point can be seen in figure 4.8A.  Significance was detected between AUC 
scores between the age groups (p=0.004). This significance was detected between the 20-39 and 60-
79 age group (p=0.027) and the 20-39 and 80+ age group (p=0.007) (figure 4.8B). There was no 
significant difference in IAUC scores between age groups (figure 4.8C)   
4.5.6.2. VAS how sick 
VAS scores for how sick at each time point can be seen in figure 4.9A. AUC scores for how sick 
declined with age. However, no significance was detected between the age groups AUC scores (figure 
4.9B) and IAUC scores (figure 4.9C).  
4.5.6.3. VAS how pleasant to eat 
How pleasant to eat VAS scores were lower both fasting and post-prandially in older volunteers. VAS 
scores for how pleasant to eat declined with age. Significance was detected (p<0.001) in AUC scores 
for how pleasant to eat between the age groups. This significance was detected between the 20-39 and 
40-59 (p=0.019), 60-79 (p=0.003) and the 80+ (p<0.001) age groups (figure 4.10B) There was no 
significant difference in IAUC scores between age groups (figure 4.10C). 
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4.5.6.4. VAS how much can you eat 
How much can you eat VAS scores were also lower both fasting and post-prandially in older 
volunteers. VAS for how much can you eat at each time point can be seen in figure (figure 4.11A). 
AUC scores for how much can you eat declined with age. Significance was detected in AUC values 
between the age groups (p<0.001). This significance was detected between the 20-39 and 40-59 
(p=0.006), 60-79 (p=0.002) and the 80+ (p<0.001) age groups (figure 4.11B). There was no 
significant difference in IAUC scores between age groups (figure 4.11C).  
4.5.6.5. VAS how full do you feel 
How full do you feel VAS scores were higher both fasting and post-prandially in older volunteers. 
VAS for how full do you feel at each time point can be seen in figure 4.12A. AUC scores increased 
with age. Significance was detected between age groups (p=0.047). There was no statistical 
significance between groups, but it was approaching significance between the 20-29 and 40-59 age 
group (p=0.069) (figure 4.12B). There was no significant difference in IAUC scores between age 
groups using (figure 4.12C).  
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Figure 4.8. VAS scores for how hungry in the 20-39, 40-59, 60-79 and 80+ age groups 
(A)            (B) 
 
 
 
    
 
                                 
 
 
 
  (C) 
 
 
 
 
 
 
 
A. Median (IQ Range) how hungry VAS (mm) at each time point (0,15,30,60,120 and 180 minutes) in 
the 20-39, 40-59, 60-79 and 80+ age groups. 
B. Mean ± SEM AUC how hungry between the 20-39, 40-59, 60-79 and 80+ age groups. Significance 
detected between age groups (p=0.004). *p=0.027, **p=0.007 vs. 20-39 age group. 
C. Mean ± SEM IAUC how hungry VAS between 20-39, 40-59, 60-79 and 80+ age groups. No 
significance detected 
20-39 age group (n=18), 40-59 age group (n=18), 60-79 age group (n=16), 80+ age group (n=6) 
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Figure 4.9. VAS scores for how sick do you feel in the 20-39, 40-59, 60-79 and 80+ age groups. 
(A)       (B) 
 
 
 
 
 
 
 
   
(C) 
       
 
 
 
 
A. Median ± IQ Range how sick VAS (mm) at each time point (0,15,30,60,120 and 180 minutes) in the 
20-39, 40-59, 60-79 and 80+ groups.  
B. Median ± IQ Range AUC how sick between the 20-39, 40-59, 60-79 and 80+ age groups. No 
significance detected 
C. Median ± IQ range IAUC how sick between the 20-39, 40-59, 60-79 and 80+ age groups. No 
significance detected 
20-39 age group (n=18), 40-59 age group (n=18), 60-79 age group (n=16), 80+ age group (n=6). 
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Figure 4.10. VAS scores for how pleasant to eat in the 20-39, 40-59, 60-79 and 80+ age groups 
(A)                                                                       (B) 
 
 
 
 
 
                         
 
(C)  
 
 
                           
 
 
 
 
 
A. Median ± IQ Range how pleasant to eat VAS (mm) at each time point (0,15,30,60,120 and 180 
minutes) in the 20-39, 40-59, 60-79 and 80+ groups.  
B. Mean ± SEM AUC how pleasant to eat between the 20-39, 40-59, 60-79 and 80+ age groups. 
Significance detected between groups p<0.001. *p=0.019, **p=0.003, ***p<0.001 vs. 20-39 age 
group. 
C. Mean ± SEM IAUC how pleasant to eat VAS scores between 20-39, 40-59, 60-79 and 80+ age 
groups. No significance detected. 
20-39 age group (n=18), 40-59 age group (n=18), 60-79 age group (n=16), 80+ age group (n=6). 
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Figure 4.11. VAS scores for how much can you eat in the 20-39, 40-59, 60-79 and 80+ age groups 
 
(A)                                                                      (B) 
 
 
 
 
 
 
                        
(C) 
 
                     
 
 
 
 
 
 
A. Median ± IQ Range how much can you eat VAS (mm) at each time point (0,15,30,60,120 and 180 
minutes) in the 20-39, 40-59, 60-79 and 80+ groups.  
B. Mean ± SEM AUC how much can you eat between the 20-39, 40-59, 60-79 and 80+ age groups. 
Significance detected between age groups (p<0.001) *p=0.006, **p=0.002, ***p<0.001 vs. 20-39 
age group. 
C. Mean ± SEM IAUC how much can you eat VAS scores between 20-39, 40-59, 60-79 and 80+ age 
groups. No significance detected. 
20-39 age group (n=18), 40-59 age group (n=18), 60-79 age group (n=16), 80+ age group (n=6). 
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Figure 4.12. VAS scores for how full do you feel in the 20-39, 40-59, 60-79 and 80+ age groups 
(A)       (B) 
 
 
 
 
 
 
                  
 
 (C) 
 
 
 
 
 
 
 
 
A. Median ± IQ Range how full do you feel VAS (mm) at each time point (0,15,30,60,120 and 180 
minutes) in the 20-39, 40-59, 60-79 and 80+ groups.  
B. Mean ± SEM AUC how full do you feel between the 20-39, 40-59, 60-79 and 80+ age groups. 
Significance detected between age groups (p=0.047). 
C. Mean ± SEM IAUC how full do you feel VAS scores between 20-39, 40-59, 60-79 and 80+ age 
groups. No significance detected. 
20-39 age group (n=18), 40-59 age group (n=18), 60-79 age group (n=16), 80+ age group (n=6). 
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4.5.7. Plasma Hormone Analysis 
 
This next section describes the results for the gastrointestinal hormones PYY, GLP-1, acyl and total 
ghrelin in the four age groups. Tables for AUC scores and IAUC scores for each age group can be 
seen in table 10.3 in section 10.8.2 in appendix. 
4.5.7.1.  Plasma PYY concentrations 
Plasma PYY concentrations were higher post-prandially in the older volunteers. Plasma PYY 
concentrations at each time point can be seen in figure 4.13A. AUC scores were higher in the over 
80’s age group. However, no significance was detected between AUC scores between the age groups 
(figure 4.13B).  
IAUC scores were higher in the over 80’s age group. Significance was detected between age groups 
(p=0.021) IAUC scores, this significance was detected between the 20-39 and 80+ age group 
(p=0.018), the 40-59 and 80+ age group (p=0.018) and the 60-79 and 80+ age group (p=0.010), where 
the over 80’s category had a significantly higher incremental area under curve for PYY values over 
time (see figure 4.13C).  
4.5.7.2. Plasma GLP-1 concentrations 
Plasma GLP-1 results were similar between age groups. Plasma GLP-1 concentrations at each time 
point can be seen in figure 4.14A. There was no significant difference between plasma AUC and 
IAUC GLP-1 scores between the age groups (figure 4.14B and 4.14C). 
All plasma GLP-1 concentrations were higher than expected. The concentrations presented are still 
able to demonstrate if there was an alteration in GLP-1 concentrations in age groups. As no alteration 
was seen in plasma GLP-1 levels, the GLP-1 analysis was not repeated. 
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4.5.7.3. Plasma total ghrelin concentrations 
Plasma total ghrelin concentrations at each time point can be seen in figure 4.15A. Plasma total 
ghrelin concentrations were similar between the age ranges. There was no significant difference in 
AUC and IAUC scores for total ghrelin levels between the age groups (figure 4.15B, and 4.15C).  
4.5.7.4 Plasma acyl ghrelin 
Plasma acyl ghrelin concentrations at each time point can be seen in figure 4.16A. There was no 
significant difference between the age groups for acyl ghrelin AUC and IAUC scores (figure 4.16B 
and 4.16C).  
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Figure 4.13. Plasma PYY concentrations in the 20-39, 40-59, 60-79 and 80+ age groups. 
(A)            (B) 
  
 
 
 
 
 
                                
 
       (C) 
                        
                           
 
 
 
 
 
 
 
A. Mean ± SEM PYY pmol/l on a log
10
 transformed y axis at each time point (0,15,30,60,120 and 180 
mins) in the 20-39, 40-59, 60-79 and 80+ age groups. 
B. Mean ± SEM PYY AUC presented on a log
10
 transformed y axis in the 20-39, 40-59, 60-79 and 
80+ age groups. No Significance detected. 
C. Median ± IQ Range IAUC PYY in the 20-39, 40-59, 60-79 and 80+ age groups. Significance 
detected between age groups (p=0.021). *p=0.018, **p=0.018, ***p=0.010. 
20-39 age group (n=18), 40-59 age group (n=18), 60-79 age group (n=16), 80+ age group (n=6). 
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Figure 4.14. Plasma GLP-1 concentrations in the 20-39, 40-59, 60-79 and 80+ age groups 
(A)      (B) 
 
 
 
 
 
 
 
 
                        
           (C) 
 
 
 
 
 
 
 
 
 
A. Mean ± SEM GLP-1 pmol/l at each time point (0,15,30,60,120 and 180 mins) in the 20-39, 40-59, 
60-79 and 80+ age groups. 
B. Mean ± SEM GLP-1 AUC in the 20-39, 40-59, 60-79 and 80+ age groups. No Significance 
detected. 
C. Mean ± SEM GLP-1 IAUC in the 20-39, 40-59, 60-79 and 80+ age groups. No Significance 
detected. 
20-39 age group (n=18), 40-59 age group (n=18), 60-79 age group (n=16), 80+ age group (n=6). 
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Figure 4.15. Plasma total ghrelin concentrations in the 20-39, 40-59, 60-79 and 80+ age groups 
 
(A)      (B) 
 
 
 
 
 
 
             
 
(C) 
 
                    
 
 
 
 
 
A. Mean ± SEM total ghrelin concentrations (pmol/L) presented on a log
10
 transformed Y axis at each 
time point (0,15,30,60,120 and 180 minutes) in 20-39, 40-59, 60-79 and 80+ age groups.  
B. Mean ± SEM total ghrelin AUC on a log
10
 transformed y axis in the 20-39, 40-59, 60-79 and 80+ 
age groups. No Significance detected. 
C. Median ± IQ Range total ghrelin IAUC in the 20-39, 40-59, 60-79 and 80+ age groups. No 
Significance detected. 
20-39 age group (n=18), 40-59 age group (n=18), 60-79 age group (n=16), 80+ age group (n=6). 
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Figure 4.16. Plasma acyl ghrelin concentrations in the 20-39, 40-59, 60-79 and 80+ age groups. 
(A)             (B) 
 
 
 
 
 
 
 
           
 
 
      (C) 
 
 
 
 
 
 
 
 
A. Mean ± SEM acyl ghrelin concentrations (pmol/L) presented on a log
10
 transformed Y axis at each 
time point (0,15,30,60,120 and 180 minutes) in 20-39, 40-59, 60-79 and 80+ age groups.  
B. Mean ± SEM acyl ghrelin AUC on a log
10
 transformed y axis in the 20-39, 40-59, 60-79 and 80+ 
age groups. No Significance detected. 
C. Median ± IQ Range total ghrelin IAUC in the 20-39, 40-59, 60-79 and 80+ age groups. No 
Significance detected. 
20-39 age group (n=18), 40-59 age group (n=18), 60-79 age group (n=16), 80+ age group (n=6). 
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4.5.8. Insulin, glucose and gastric emptying measurements 
 
This next section describes the results for glucose, insulin, insulin resistance and gastric emptying 
times between the four age groups. Tables for mean scores, AUC scores and IAUC scores for each 
age group can be seen in table 10.4. in section 10.8.3. in appendix. 
4.5.8.1. Plasma insulin 
Plasma insulin concentrations at each time point can be seen in figure 4.17A. AUC scores for insulin 
increased with age. Significance in insulin AUC scores was detected between age groups (p=0.035). 
Post-Hoc tests detected this difference to be between the 20-39 and 80+ (p=0.047) age group and the 
40-59 and 80+ age group (p=0.031) (figure 4.17B), where the 80+ age group had higher mean insulin 
AUC values. IAUC scores also increased with age, but this failed to reach significance (p=0.408) 
between the age groups (figure 4.17C).  
4.5.8.2. Plasma glucose 
Plasma glucose concentrations at each time point can be seen in figure (4.18A). Plasma glucose AUC 
scores increased with age. Significance was detected (p=0.024) between age groups for AUC scores. 
Post-hoc tests detected this significance between the 20-39 and 80+ age groups (p=0.021) (figure 
4.18B), where the 80+ age group had a significantly higher AUC score. IAUC scores were the highest 
in the 80+ age group. No significance was detected between age categories for IAUC glucose scores 
(figure 4.18C).  
4.5.8.3. Insulin resistance 
An index of fasting insulin resistance (HOMA) was measured using the following equation; 
HOMA = (glucose mmol/L * Insulin mU/L) / 22.5  
mU/L = pmol/7.5 (Raben et al., 2001). 
Significance was detected between age groups (p=0.032) HOMA scores. This significance was 
detected between the 20-39 and 40-59 age group (p=0.048), the 20-39 and 60-79 age groups 
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(p=0.004), and the 20-39 and 80+ age groups (p=0.006) (see figure 19), where HOMA scores were 
significantly higher in the older age groups. 
An Index of post-prandial Insulin resistance (HOMA-PP) can be calculated using the following 
equation; 
HOMA-PP =  (IAUC Glucose nmol/L * IAUC Insulin mU/L) / 22.5 (Brynes et al., 2003). 
Although HOMA-PP scores increased with age, no significance was detected (p=0.131) between age 
groups in HOMA-PP scores (see figure 4.20). 
4.5.8.4. Paracetamol method- gastric emptying 
The peak concentration for paracetamol was used as a measurement of gastric emptying. Peak 
paracetamol concentrations did not change with age, no significance was detected between the 4 age 
groups for peak paracetamol concentrations (figure 4.21) 
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Figure 4.17. Plasma insulin concentrations in the 20-39, 40-59, 60-79 and 80+ age groups 
(A)                                                                           (B) 
 
 
 
                                                               
 
 
                                                 
 
 
        (C) 
 
 
 
 
 
 
 
A. Mean ± SEM insulin concentrations (pmol/L) presented on a log
10
 transformed y axis at each time 
point (0,15,30,60,120 and 180 minutes) in 20-39, 40-59, 60-79 and 80+ age groups.  
B. Mean ± SEM insulin AUC in the 20-39, 40-59, 60-79 and 80+ age groups. Significance detected 
between groups (p=0.035). *p=0.047 between 20-39 and 80+, **p=0.031 between 40-59 and 80+ 
age groups.  
C.  Mean ± SEM insulin IAUC in the 20-39, 40-59, 60-79 and 80+ age groups. No significance 
detected. 
20-39 age group (n=12), 40-59 age group (n=12), 60-79 age group (n=12), 80+ age group (n=5) 
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Figure 4.18. Plasma glucose concentrations in the 20-39, 40-59, 60-79 and 80+ age groups 
 
(A)                                                                       (B) 
 
 
 
 
 
 
 
                        
  
(C) 
 
 
 
 
 
 
 
A. Mean ± SEM Glucose concentrations (pmol/L) presented on a log
10
 transformed Y axis at each 
time point (0,15,30,60,120 and 180 minutes) in 20-39, 40-59, 60-79 and 80+ age groups.  
B. Mean ± SEM Glucose AUC on a log
10
 transformed y axis in the 20-39, 40-59, 60-79 and 80+ age 
groups. Significance detected between groups (p=0.024) *p=0.021 
C.  Mean ± SEM Glucose IAUC in the 20-39, 40-59, 60-79 and 80+ age groups. No Significance 
detected. 
20-39 age group (n=18), 40-59 age group (n=18), 60-79 age group (n=16), 80+ age group (n=6). 
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Figure 4.19. HOMA scores in the 20-39, 40-59, 60-79 and 80+ age groups 
 
 
 
 
 
 
 
 
 
Median ± IQ Range HOMA scores between 20-39, 40-59, 60-79 and 80+ age groups. Significance 
detected between groups (p=0.032). *p=0.006, **p=0.004, ***p=0.048. 
20-39 age group (n=17), 40-59 age group (n=16), 60-79 age group (n=12), 80+ age group (n=6). 
 
Figure 4.20. HOMA PP scores in the 20-39, 40-59, 60-79 and 80+ age groups 
 
 
 
 
 
 
 
 
 
Mean ± SEM HOMA-PP scores between 20-39, 40-59, 60-79 and 80+ age groups. No significance 
detected. 
20-39 age group (n=12), 40-59 age group (n=12), 60-79 age group (n=12), 80+ age group (n=5). 
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Figure 4.21. Gastric emptying time in the 20-39, 40-59, 60-79 and 80+ age groups. 
 
 
 
 
 
 
 
 
 
 
Mean ± SEM peak paracetamol concentrations presented on a log
10
 transformed y axis between the 
20-39, 40-59, 60-79 and 80+ age groups. No significance detected. 
20-39 age group (n=18), 40-59 age group (n=18), 60-79 age group (n=16), 80+ age group (n=6). 
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4.5.9. VAS following ad libitum test meal 
 
Following the ad libitum test meal participants were asked fill in the normal VAS questionnaire but 
with two additional questions; ‘how tasty was this meal?’ and ‘how pleasant was this meal?’  
All VAS (how hungry, how full, how much can you eat, how pleasant to eat, how sick, how tasty was 
this meal and how pleasant was this meal) following the ad libitum meal were analysed to determine 
if there was any significance in scores between the four age groups.  
There was no significant difference between age groups in scores for ‘how hungry’, ‘how full’, ‘how 
pleasant to eat’ and ‘how sick’ and ‘how tasty’ VAS scores following the ad libitum test meal. 
Significance was detected between age groups for ‘how much can you eat’ (p=0.011). Using a post-
hoc test, this significance was detected between 20-39 and 80+ age group (p=0.012), 40-59 and 80+ 
age group (p=0.012), 20-39 and 60-79 age group (p=0.027) and the 40-59 and 60-79 age group 
(p=0.042) (see figure 4.24). The older age groups scores for how much can you eat were significantly 
lower than the younger volunteers scores. 
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Figure 4.22. VAS How much can you eat following ad libitum meal in the 20-39, 40-59, 60-79 and 
80+ age groups 
 
 
 
 
 
 
 
 
 
Median ± IQ Range VAS following ad libitum meal for ‘How much can you eat’ scores between the 
20-39, 40-59, 60-79 and 80+ age groups. Significance detected between groups (p0.011). *p=0.027 
vs 20-39, **p=0.012 vs 20-39, $p=0.027 vs 40-59, $$p=0.012 vs 40-59. 
20-39 age group (n=18), 40-59 age group (n=18), 60-79 age group (n=16), 80+ age group (n=6). 
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4.6. Discussion 
 
4.6.1. Overview 
 
The objective of this investigation was to determine if there is an alteration in gastrointestinal appetite 
hormone release and energy intake in healthy older volunteers compared to healthy young volunteers. 
Data so far has been highly conflicting, mainly due to a large variation in methodology between 
studies. This study was designed with a larger study population sample and a wide range of age-
groups recruited to try and elucidate if there is an alteration in gastrointestinal appetite hormones with 
age. 
4.6.2. Findings 
 
This comparative study demonstrated that with ageing, there is a raised post-prandial plasma PYY 
response in the very old age group (80+ years) measured by IAUC following a standard preload test 
meal. The older adults also had a significant reduction in food intake which was independent to 
reductions in physical activity compared to the younger adults. There were also significant increases 
in AUC glucose, insulin and insulin resistance (HOMA), but no difference in IAUC scores in the 
older age group. Ageing was also associated with lower AUC subjective feelings of hunger and desire 
to eat and an increased perception of fullness measured by visual analogue scales, but again no 
significance was detected in IAUC scores. The lack of significance in IAUC suggests that the 
alterations are not due to a difference in response to a test meal (because IAUC, which adjusts for the 
baseline value was not significant), but rather an overall effect of ageing (AUC does not adjust for 
baseline values). 
Only one other study to date has demonstrated an elevation in PYY concentrations with healthy 
ageing (Di Francesco et al., 2005). An absence of an alteration in GLP-1, total ghrelin, acyl ghrelin 
and gastric emptying with ageing was also observed in this investigation, opposing my proposed 
hypothesis. 
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These findings are complimentary to that of others where a reduction of appetite is observed (Bhutto 
and Morley, 2008) and a reduction in hunger and desire to eat (Clarkston et al., 1997) as measured by 
VAS with ageing. This study also compliments studies other studies (Di Francesco et al., 2005; 
Colman et al., 1995; Fraze et al., 1987) where older volunteers demonstrated an elevation in glucose, 
insulin and fasting insulin resistance in comparison to younger counterparts. 
4.6.3. Plasma PYY is elevated in ageing 
 
The main outcome of this study was to determine if there is an age associated alteration in 
gastrointestinal appetite hormone response in older adults. This study found that in the 80+ age group 
there was a significant elevation in plasma IAUC PYY concentrations post standard test meal. This 
increase in the putative satiety hormone PYY may explain the age observed reductions in food intake. 
There was no significant alteration in AUC PYY concentrations suggesting that the age observed 
alterations in PYY are post ingestion of food (AUC includes baseline value whereas IAUC is adjusted 
for the baseline). However, AUC scores were higher in the over 80’s age group. With higher 
participant numbers, a significant effect may have been seen. This substantial increase in PYY 
following the test meal may also explain why there is earlier termination in eating in older adults and 
increased length of time between consumption of their next meal (de Castro, 1993; Morley and Silver, 
1988). 
This present investigation confirms data from Di Francesco et al (2005) where a significant increase 
in post-prandial PYY concentrations was seen, but disputes data from MacIntosh et al (1999) were no 
age associated alterations in PYY were observed.  Di Francesco et al, (2005) recruited 19 volunteers 
in total, 10 healthy elderly (72-82 years) and 9 young adult controls (25-53 years). Participants were 
subject to a similar protocol to this current study where they had to fast over-night and consumed a 
standard preload test meal breakfast the following morning. Blood samples were taken over a period 
of 240 minutes. In contrast to this, MacIntosh et al, (1999) studies protocol was different, 15 
volunteers were recruited; 8 older (65-80 years) and 7 younger (20-34) males only. Participants were 
also subject to an overnight fast, but instead of receiving a standard preload breakfast test meal, a tube 
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was inserted into their stomach and they received an intraduodenal infusion of glucose or lipid for 120 
minutes. The invasive procedures that were placed onto the participants in MacIntosh et al, (1999) 
study may provide an explanation as to why different PYY responses were seen. Participants (older 
and young) may have been substantially more stressed in this study during the intraduodenal infusion, 
as it is reported that stress can influence gastrointestinal appetite hormone response (Chandarana et 
al., 2009). I am also unaware from this study whether participants were subject to a sham visit to 
enable the participants to become accustomed to the environment, and to attenuate the amount of 
stress subjected to the participants. Another issue with MacIntosh et al (1999) study was that because 
intraduodenal infusion was used, there was no mastication of food to initiate the digestion process. It 
could be that the process of chewing, digesting and breaking down food matrixes in the intestine that 
plays a role in the alteration in PYY release. In addition an intraduodenal infusion may not have 
activated the ascending vagal fibres and thus affect food intake and appetite. The lack of significance 
seen with an infusion suggests that it could be the food reaching the intestine that is a causing the 
increase in PYY release with ageing rather than its sensitivity to nutrients. Finally MacIntosh et al 
(1999) only recruited males, and only in the age range of 65-80 years. This current study only found 
significant alterations in PYY release in the oldest adults aged 80 years and over. Also, this current 
study did not have any males in the over 80’s age group where the effect was seen in PYY release. 
We do not know from this study if there was a gender effect in the over 80’s group, however the 
median values (data was not normally distributed) for PYY IAUC for males and females in the 60-79 
age group were 1078 for males and 1330 for females, which were not significantly different from one 
another. When females were analysed alone, there still remained a significant difference (p=0.007) 
between the younger and older adults, also suggesting that the males in the younger age groups did 
not skew the results. In conclusion the study by MacIntosh at al. (1999) is not comparable to this 
present study and would therefore explain the difference in results to this present study. 
The reduction in appetite observed in this study may have been mediated, in part by PYY, but it is 
likely that other factors were involved, because a reduction in appetite was seen in the 60-79 age 
group without an alteration in PYY. In a number of studies it has been observed that fasting and post-
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prandial levels of CCK are elevated in older adults (MacIntosh et al., 1999; Sturm et al., 2003; Di 
Francesco et al., 2005), with older adults also having an increased sensitivity to CCK (MacIntosh et 
al., 2001). CCK was not measured in this study, but it could be that it is a combination of altered 
gastrointestinal hormones, PYY and CCK that have an inhibitory effect on appetite in ageing. Not 
only may gastrointestinal hormones change with age, there may also be a change in the hedonic 
control of appetite (discussed in 4.6.4). 
PYY has been demonstrated to inhibit gastric emptying at supraphysiological doses, and this has been 
postulated to be the reason for the reduction in food intake (Witte et al., 2009). There was no 
alteration in gastric emptying between age groups in this study, despite an increase in post-prandial 
PYY in the older volunteers. This suggests that the increase in post-prandial PYY seen in this study is 
not due to a slower transit of food through the gastrointestinal tract, and that other factors are 
mediating this alteration. It could be that the levels of PYY were not high enough in the older adults 
to create such an effect. 
It is possible that the elevation in PYY observed in the study could be due to a delayed clearance in 
the plasma. Participants recruited into this study were screened for their glomerular filtration rate 
(GFR), which is a test for renal function, prior to taking part. Therefore, only participants within a 
normal range were recruited, in an attempt to eliminate the effect of reduced kidney function, which is 
a common characteristic of ageing. Thus a difference in PYY clearance seems unlikely. 
It has also been hypothesised that PYY plays a role in hedonic mechanisms. Batterham at al, (2007) 
using functional magnetic resonance imaging, suggested that although PYY has its main effect on the 
hypothalamus, it also effects higher cortical areas. It is therefore possible that PYY may affect the 
higher cortical areas and the feelings of desire to eat in the older people. This hypothesis is supportive 
of the VAS data in which the older volunteers rated their desire to eat significantly lower than the 
younger volunteers. 
It is difficult to determine in this study if the older volunteers were more sensitive to the effects of 
PYY on food intake. No studies to date have investigated PYY sensitivity in aged humans. Sensitivity 
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studies are particularly challenging since the side effects of high PYY levels are nausea and vomiting, 
and the amount of PYY inducing these symptoms varies considerably. Thus, infusions of PYY are 
very difficult to undertake avoiding such effects. If there was an increased sensitivity alongside 
increased concentrations of PYY, it would strongly support why in ageing there is a substantial 
amount of unintentional weight loss in adults above 80 years of age. 
This current study recruited more participants (58) over a larger age range, with the measurement of a 
larger number of gastrointestinal appetite hormones measured than any other published study 
investigating gastrointestinal appetite hormones with age. This is the first study to my knowledge that 
has demonstrated an increase in PYY with corresponding alterations in food intake irrespective of 
activity levels and alterations in subjective feelings of appetite. No alterations in other gastrointestinal 
hormones total ghrelin, acyl ghrelin and GLP-1 were detected. 
4.6.4. Plasma GLP-1, total ghrelin and acyl ghrelin  
 
In this investigation there was no difference in the gastrointestinal appetite hormones GLP-1, acyl 
ghrelin and total ghrelin, in ageing, suggesting that these gastrointestinal appetite hormones do not 
play a significant role in the reductions in food intake seen in older adults. 
Only one study to date has investigated the alterations in GLP-1 concentrations in ageing (MacIntosh 
et al., 1999). Although a different methodological design, this present study supports the data from 
MacIntosh et al (1999) where plasma GLP-1 concentrations are constant between the different age 
ranges. MacIntosh and colleagues (1999) infused nutrients via a duodenal infusion for a period of 120 
minutes and compared change in GLP-1 and hunger ratings to find a reduction in hunger but no 
change in plasma GLP-1 concentrations. This study and MacIntosh study suggests that GLP-1 does 
not contribute to the age associated reduction in appetite. Studies will need to focus on the use of 
infusions of GLP-1 to determine if there is an alteration in older adults to the satiating effects of GLP-
1. 
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Total and acyl ghrelin release did not differ between age groups in this present study. Literature 
reviewed in chapter one (p40) described how total and acyl ghrelin proved to have the largest amount 
of controversy determining whether there is an alteration with ageing. Reasons for this lack of 
consensus are mainly due to the inconsistencies in the study design. Acyl ghrelin measurement is 
regarded as a more valid measure, as this method only measures the active ghrelin concentrations. 
Only three other studies have measured acyl ghrelin in ageing to date. These three studies do not 
provide a consistent picture, showing either; no difference in fasting ghrelin between young and old 
(Schneider et al., 2008), lower fasting and post-prandial ghrelin in older adults (Di Francesco et al., 
2008), and no difference in fasting but higher overall ghrelin release in older adults (Bauer et al., 
2010). Bauer et al (2010) and Schneider et al (2008) used different methodology and ELISA kits for 
analysis of acyl ghrelin, providing an additional reason for the difference in results. 
Di Francesco et al (2008) used a similar methodology to this present study where volunteers were 
subject to an overnight fast, followed by 800kcal preload test meal. Di Francesco et al (2008) study 
found that acyl ghrelin levels were lower fasting and postprandially in older adults compared to 
younger adults. Di Francesco et al (2008) measured acyl ghrelin up to 240 minutes post-test meal, 
rather than at 180 minutes, which was the time frame that acyl ghrelin was measured in this present 
study. The largest alteration in acyl ghrelin levels were seen at 240 minutes in Di Francesco et al 
(2008) study. This study did not measure up to 240 minutes but the ghrelin values at 180 minutes did 
not appear to be different to younger volunteers. Therefore, it remains unclear why different results 
were seen, the difference in calorie content of the meals (Di Francesco et al 800kcal vs. 660kcal in 
this present study) could provide a potential explanation or it could be that different ELISA kits were 
used for the measurement of acyl ghrelin. This study, unlike the studies by Di Francesco et al (2008), 
Bauer et al (2010) and Schneider et al (2008) that have measured acyl ghrelin with ageing, recruited 
more volunteers, with more standardised conditions; sham visit and strict recruitment criteria to create 
a more robust methodology. The three other studies that have investigated acyl ghrelin alterations 
with age did not report to use a sham visit, and in addition their recruitment criterion was not as strict. 
For example, Bauer et al (2010) only excluded volunteers with a significant illness, other factors such 
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as hypertension, gastrointestinal problems and minor illnesses could have impacted on the 
gastrointestinal appetite hormone response.  
It is not known if there is an alteration in sensitivity to ghrelin with ageing. If there is a reduction in 
sensitivity to ghrelin, this would result in reductions in food intake. No human studies to date have 
investigated sensitivity to ghrelin in aged adults. Animal studies suggest that ageing is associated with 
the general down regulation of receptors involved in the stimulation of food intake, and a lack of 
alterations in receptors in the anorexigenic pathways (Kmiec, 2006). Specifically, ageing in rats is 
associated with a down regulation of NPY expression in the hypothalamus that stimulates food intake. 
It has already been reported in humans that older volunteers are less sensitive to the GH-releasing 
effects of intravenous ghrelin than young adults (Broglio et al., 2003). It has however been seen with 
a ghrelin mimetic, that there is weight gain in lean tissue mass in older adults (Nass et al., 2008) 
suggesting that although there are no significant alterations in ghrelin concentrations with age, ghrelin 
could still prove to be useful as a therapeutic approach to increasing lean mass.  
In summary there was no alteration in release of GLP-1, total ghrelin and acyl ghrelin in older 
compared to younger adults, suggesting that these gastrointestinal appetite hormones do not play a 
role in the age associated reductions in food intake. Further study is required to determine if there is 
an alteration in sensitivity to the actions of these peptide hormones with ageing. 
4.6.5. Body composition and activity levels 
 
Results from this present study demonstrate that there is an alteration in body composition with 
ageing. Body fat percentage increased with age as demonstrated by a positive correlation (p<0.001, 
r=0.470). Lean body mass percentage also decreased with age shown by a negative correlation 
(p=0.002, r= -0.413). This demonstrates that the compositional make-up of the older volunteers were 
different to younger volunteers. This fits in with current well documented literature where changes in 
body composition are a common feature of ageing. 
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This study also replicated what is observed in the literature where, in older individuals there is a 
reduction in physical activity levels (p<0.001) and total energy expenditure (p=0.001) using the 
actical monitor. The IPAQ questionnaire however, provided conflicting results, where there was an 
absence in significance in activity levels between age ranges. The results from the IPAQ questionnaire 
were disregarded due to the high volumes of participants scoring their activity levels too high based 
on the questionnaires exclusion criteria. The questionnaire is also only validated on people aged up to 
69 years (see section 2); a large proportion of this study population was over the age of 69 years. The 
actical monitor is perceived as a more accurate method of energy expenditure measurement (see 
section 2) therefore this questionnaire was regarded as unsuitable for this particular study. 
Unfortunately there were a limited number of measurements using the actical (25 respondents) due to 
the late commencement of the measurement. 
4.6.6. Energy intake 
 
There was a significant negative correlation in energy intake (kcal) at the ad libitum test meal 
observed with age (p<0.001, r= -.593). Significance was also demonstrated between age groups 
(p<0.001) where food intake at the ad libitum test meal decreased with age, with the old elderly (80+ 
years) consuming the least amount of calories. Energy intake was expressed per unit of lean body 
mass to take into account metabolically active tissue. Taking this into consideration, there was still a 
negative correlation with age (p<0.001, r= -.566) and between age groups (p<0.001). I.e. energy 
intake when taking into account lean tissue declined with age. The reduction in food intake in adults 
fits in with current literature (de Castro, 1993; Morley and Silver, 1988). 
Furthermore, when calorie intake at the ad libitum test meal was added as a predictor to a multiple 
regression, age and gender proved to be significant predictors of energy intake, but total energy 
expenditure measured by the actical monitor did not significantly predict energy intake. This fits in 
with the current literature that shows that energy intake declines in older adults above and beyond 
their reductions in energy expenditure (see chapter 1). 
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VAS were taken following the consumption of the ad libitum test meal, for measurement of hunger 
and satiety to determine if volunteers ate beyond fullness or did not consume enough based on the 
VAS scores. There was no difference in VAS scores between age groups with the exception of VAS 
for how much can you eat. The older age groups scored the VAS significantly lower than the younger 
volunteers (p=0.011). This suggests that the older population felt that they could eat a lot less 
following the ad libitum meal, which could be interpreted that they ate to a higher level of fullness 
than the younger volunteers at the ad libitum test meal. However, VAS for how full was not 
significantly different, which would suggest that the older volunteers did not eat beyond fullness, and 
that it may just be an effect of ageing where they have a consistent feeling that they can eat less. 
4.6.7. Water consumption 
 
In addition to reductions in food intake, water consumption decreased significantly in the over 80’s 
age group (p=0.007). Water intake has been demonstrated to reduce subsequent energy intake at a 
meal in older individuals but not younger (Van Walleghen et al., 2007). The older volunteers 
consumed less water than the younger volunteers in this study. This means that water intake could not 
have been an influencing factor for why older adults ate less. The water provided in the study was at 
the participants request and they were all given the same amount of water at the test meal. The 
reduction in water intake observed in the older age groups is interesting. Reductions in thirst 
sensations and reduced hydration is a serious risk factor for elderly patients (Naitoh and Burrell, 1998; 
Sheehy et al., 1999; Ferry, 2005). 
4.6.8. Visual analogue scales 
 
VAS was used as a proxy for hunger and appetite. Results of this investigation showed that the older 
age group felt significantly more full, less hungry, less desire to eat, and lower scores for how 
pleasant to eat. No significances were detected between the age groups for appetite ratings for nausea. 
The alterations in PYY concentrations with age may have contributed to the alterations in subjective 
feelings of appetite and energy intake with age. 
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There was a significant reduction in hunger (p=0.004), how pleasant to eat (p<0.001) and desire to eat 
(p<0.001) in older volunteers using AUC. IAUC also decreased in the older age groups in hunger and 
desire to eat scores, but did not reach significance. There was a large variation in IAUC scores which 
could be an explanatory reason for the non-significance. The reduction in hunger and desire to eat in 
this study confirms what has been investigated by Clarkston et al (1997) where lower feelings of 
hunger in older volunteers were demonstrated. Decline in desire to eat in the ageing population could 
suggest that in ageing, there may be an effect on the higher cortical areas on feelings of pleasure to 
eat, which as mentioned earlier in this discussion, PYY has been suggested to affect higher cortical 
areas of the brain (Batterham et al., 2007). AUC scores for fullness also increased with age, 
(p=0.047), however this difference did not reach significance between groups, which is likely to be 
due to the large variation in fullness scores seen between participants. AUC fullness scores were 
approaching significance between the 20-39 and 40-59 age groups (p=0.069). Although the over 80’s 
age group had a higher  mean AUC value (10503) than the 40-59 age group (9708), the over 80’s age 
group did not reach significance, most probably due to the high SEM (2026.2 in over 80’s group vs. 
808.0 in 40-59 age group). Other studies have demonstrated an increase in fullness in older volunteers 
(Sturm et al., 2003; Sturm et al., 2004), however Clarkston et al (1997) demonstrated no alteration in 
fullness. The lack of ability of the older participants to increase hunger after long periods of low 
energy intake is comparative to the increase in satiety seen in the study by Roberts et al (1994), where 
after periods of deprivation, older people are unable to increase their appetite. 
The final hunger score before the ad libitum test meal was correlated with energy intake (see appendix 
10.8.4.). There was a significant positive correlation (p<0.001, r=.597), where as hunger increased, 
food intake at the ad libitum meal increased. There was also a positive correlation (p<0.001, r=.704) 
between food intake at the ad libitum test meal and the desire to eat VAS score immediately before 
the ad libitum meal and a significant negative correlation (p=0.005, r-.360) in fullness scores at the 
final time point and energy intake at the ad libitum test meal (appendix 10.8.4.) This suggests that 
hunger and desire to eat and fullness measured by VAS are good predictors of energy intake at an ad 
libitum test meal.  
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There was an absence of an alteration in feelings of nausea in this study in both the AUC and IAUC 
scores. The scores for how sick were also relatively low in all the age groups, suggesting that the test 
meal was palatable to the participants and did not cause nausea or sickness. When observing how sick 
IAUC scores in males and females separately, however, older males (60-79 years) felt significantly 
more sick following a standard preload, which follows a different pattern to females, where the 
younger females felt significantly more sick. These observations are likely to be a result of a few 
individuals in the study reporting sickness at the extreme ends, although they appeared well, maybe 
suggesting that a few individuals had a strong dislike for the test meal. 
In this investigation only the AUC presented significance between age groups. The IAUC takes into 
consideration the baseline value, therefore it is looking at the appetite response to a test meal. The 
AUC includes the baseline value, therefore it is looking at the whole overall curve. Fasting values for 
the older age group were different to the young age group, and it is important to take this into account 
when analysing results. As the AUC was only significant in this study, I can conclude that it is an 
overall effect of ageing rather than the response to a test meal (IAUC) that alters with age in VAS 
scores as the curves remained consistently elevated in the older volunteers for fullness, and 
consistently lower for hunger, desire to eat and pleasantness to eat scores.  
4.6.9. Glucose, insulin and insulin resistance  
 
A significant increase in AUC glucose and insulin, and fasting insulin resistance (HOMA) 
concentrations observed in ageing in this present study is in line with current literature (Fraze et al., 
1987; Colman et al., 1995; Di Francesco et al., 2006). Insulin resistance, the inability to respond to 
available insulin, often accompanies age related glucose intolerance, as seen in this study, but not all 
studies have shown circulating insulin to be elevated compared to the young (Chang and Halter, 
2003). Under some conditions, insulin levels can be lower because the pancreas is unable to produce 
as much insulin (Chang and Halter, 2003). This study recruited only healthy volunteers, thus 
potentially eliminating this problem. IAUC insulin scores also increased with age, but did not reach 
significance. Unfortunately, due to the number of haemolysed samples, I was unable to have a 
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complete set of insulin results. The measurement of insulin is very sensitive to haemolysed blood 
samples (Pasic et al., 1991) (discussed further in section 4.6.12). The reduction in the number of 
insulin samples analysed would subsequently reduce the power of the analysis.  
Glucose concentrations have been hypothesised to contribute to hunger signals (Bergmann et al., 
1992; Campfield and Smith, 2003), where low levels are associated with a resultant feeling of hunger 
(Melanson et al., 1998). Insulin has also been demonstrated to decrease food intake in males but not 
females (Hallschmid et al., 2004). Therefore the combination of the increase in insulin and glucose 
levels could play a contributory role in appetite suppression and reduction in food intake in the older 
volunteers in this study. However, the evidence for insulin and glucose playing a direct role in 
appetite suppression is limited. 
Post-prandial insulin resistance (HOMA-PP) also increased with age, but did not reach significance. A 
likely explanation for the lack of alteration detected in this study may be due to the small study 
numbers due to the number of haemolysed insulin samples that had to be removed from the analysis. 
4.6.10. Gastric emptying  
 
Another suggested feature of ageing is a slowing of gastric emptying after the consumption of large 
solid and liquid meals (Brogna et al., 2006; Clarkston et al., 1997; Horowitz et al., 1984; Moore et al., 
1983) using a wide array of techniques. In this present study there was no significant difference in 
gastric emptying time between the young and older volunteers. Not every study has found a 
significant difference in gastric emptying times in the older populations. Studies have found no 
significant difference in gastric emptying time (Madsen and Graff, 2004; Gainsborough et al., 1993), 
and even an accelerated gastric emptying time in the early post-pradial phase in healthy elderly 
volunteers (Kupfer et al., 1985). The volume of the meal may provide an explanation why differences 
in gastric emptying rate has been noticed in some studies but not others. This present study used a 
liquid meal, that was calorie dense but in a small volume in order to the make the meal easier for the 
older volunteers with smaller appetites to consume. The study by Madsen and Graff (2004) also used 
small volume meals. Whereas a large proportion of the studies that have found a slowing of gastric 
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emptying time have used larger volume meals e.g. Clarkston et al (1997) used a 100g meal of beef 
patties in which would have been a larger volume than this present study with more complex food 
matrices. Thus potentially providing an explanation for the discrepancy in results. Currently little 
information is known about ageing on the gastrointestinal function, it may be that the volunteers in 
this study were too healthy for an alteration in gastric emptying to be seen, as those who described 
issues with the gastrointestinal tract were excluded from entering the study. More research is required 
to understand the mechanisms behind the contradictory results.  
The results from this present study suggest that gastric emptying rate does not provide an explanation 
for the age-associated decline in food intake. Previous studies have suggested that a delay in gastric 
emptying is related to an increase in fullness (Sturm et al., 2003), however the results from this study 
suggest that older adults have a reduced energy intake, which is not related to alterations in gastric 
emptying time.  
4.6.11. Limitations 
 
As with all appetite studies there are limitations. The control of appetite is affected by many factors, 
in which many are difficult to control for, including the surroundings. In this study every effort was 
made to standardise the conditions so that the participants were not affected by the surroundings. 
Participants were subject to quiet conditions, away from other people and were in total seclusion 
when it came to the consumption of the meal. The laboratory conditions that the participants were 
subject to does not necessarily reflect normal eating behaviour, and their appetite may have been 
influenced by these conditions. Nevertheless, strict control of the environment was essential to allow 
comparisons between volunteers. The eating setting was not ideal (eating in a simulated hospital 
setting), since it could have an effect on subjective feelings of hunger and appetite and energy intake. 
Although the participants consumed their meals on the same hour of the day, the amounts ingested 
can vary with the week of the month and the month of the year, and can be markedly be altered by an 
individual’s physiological state (de Castro, 1997). Thus despite care in controlling conditions, some 
factors may still have varied and would be difficult to standardise. 
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Participant’s familiarity with the test meals given in the study may have had an effect upon the 
amount of the test meal consumed. Preference for the meal was rated prior to the study and following 
the meal on the test day. It is of note that the test meal (Ensure Plus) may have been unpleasant to 
consume, as some of the participants commented on the dislike for the product. This may have altered 
the participants subjective feelings of hunger and appetite after the test meal, nevertheless all 
participants consumed all of the amounts provided. Ensure Plus was chosen as it provides an exact 
amount of calories in a given volume, and since it is energy dense it provides a large amount of 
calories (enough to see a clear gastrointestinal hormone response) without the meal being too large. 
Older adults are thought to have an intestinal dysregulation (Clarkston et al., 1997) that may result in 
intolerance to large quantities of food, therefore energy dense Ensure Plus product would have been 
easier for the older volunteers to tolerate. 
Food intake is influenced by mood states. Mood states were not measured in this study, but they can 
be in terms of happiness, stress and anxiety using VAS scores. Stress may have had an effect on 
amount of food consumed. A sham visit was introduced to try and eliminate the stress levels of the 
participants so that they know what to expect in the main visit, therefore it was considered as not 
essential to measure mood states in VAS as this effect should have been alleviated. A measurement of 
cortisol as a measure of stress will be a useful measure to eliminate this confounding factor in the 
future. 
The presence of other participants in the study and different nurses used who varied from week to 
week may have an influence appetite and energy intake. This is not ideal, as the familiarity effect on 
the study mornings would have been low. However, due to time restraints, participants availability, 
and the number of volunteers needed to be recruited in this study, I was not able to overcome this. 
Although a power calculation was conducted for this study, I was unable to recruit the required 
amount. The over 80’s population was particularly difficult to recruit due to the amount of 
medications taken and illness that may have had an influence on gastrointestinal hormone release. 
Due to this, there was also an unequal ratio of males and females in the age groups. Males and 
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females were analysed separately (see appendix 4), although it is difficult to discern if males and 
females have a different response due to low study numbers. The majority of significance was seen in 
the 80+ age group which makes comparisons difficult as there were no males in this age group.  
The measurement of insulin is very sensitive to haemolysed blood samples (Pasic et al., 1991). 
Haemolysis can lead to insulin levels that are undetectable or unusually abnormal. Even the slightest 
haemolysis can lead to insulin degradation and a reduction in insulin concentrations (Chevenne et al., 
1998). Unfortunately, in this study there were many haemolysed samples, which resulted in 
undetectable levels or unusually abnormal insulin levels. All haemolysed results were excluded from 
the analysis to ensure that the insulin levels were correct. Haemolysis in blood samples is where the 
red blood cells break down during the sampling process. It is not known why blood samples become 
haemolysed when sampling blood from humans using a cannula. Haemolysed samples are also 
difficult to avoid completely, but every effort was made to reduce haemolysis as much as possible. 
Samples were separated immediately after they were taken, and participants were kept warm with 
blankets so that veins did not vasoconstrict. It is not common for haemolysed samples to interfere 
with gastrointestinal hormone analysis, but it is common for it to interfere with insulin analysis.  
This study only recruited healthy volunteers. This does not represent the ageing population as a 
whole, since a large proportion of the ageing population are on medications or suffer from some form 
of illness. This study wanted to determine if alterations in gastrointestinal hormones in ageing are 
independent to illness and medication, thus it was reasonable to exclude on this criteria, but does not 
help us to understand how different illness and drugs may alter appetite control. 
4.6.12. Summary 
 
In summary, results from this study demonstrated that in older age groups there is a reduction in food 
intake, irrespective of activity levels, at an ad libitum test meal following a standard breakfast, and 
subsequent reductions in subjective feelings of hunger, appetite and desire to eat. The loss of appetite 
and lower food intake may be due, in part, to increases in PYY release in response to the test meal in 
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the older age group. Increases in glucose, insulin and insulin resistance may also play a contributory 
role. 
The absence in a difference between younger and older volunteers GLP-1 levels suggests that the 
reduction in food intake observed is not due to this particular hormone.  Contrary to some published 
literature, there was no significant difference in total and acyl ghrelin concentrations between the age 
groups. The difference in results to previous studies is likely to be due to the more robust 
methodology adopted in this study. Studies in rodents suggest that in ageing there could be an 
alteration in sensitivity to the actions of ghrelin and so more studies are needed in humans to 
determine these effects. 
4.6.13. Future Work 
4.6.13.1. Measurement of leptin 
Leptin is a peptide hormone that is produced and secreted predominantly from adipose tissue. It 
circulates in amounts in proportion to adipose stores (Maffei et al., 1995). Leptin levels reflect energy 
intake. The measurement of this hormone was not originally planned as data on leptin in ageing is 
limited. However, as older participants had a higher amount of adipose tissue than younger 
volunteers, this may mean they have higher levels of circulating leptin. Age has been demonstrated to 
be correlated with leptin levels (Ganji et al., 2009), but data so far is rather conflicting. I hypothesise 
that in addition to PYY, leptin may also play a contributory role in the longer term reductions in 
appetite in older adults. 
4.6.13.2. Regression analysis 
Regression analysis would need to be performed on the data to determine if PYY has an independent 
effect on the reduction in food intake observed in this study. Due to the number of interactions and 
cofactors that may contribute to the reduction in food intake seen in this study, this would require a 
statistician to perform. Also study numbers may be too small to detect an effect as there are several 
factors to control for e.g. body weight, body fat mass, activity levels, other hormones etc. 
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4.6.13.3. Infusion studies 
Two main positive mechanisms in how alterations in gastrointestinal hormones may contribute to the 
anorexia of ageing have been hypothesised (see figure 4.23). Either by an alteration in the release of 
gastrointestinal hormones, or an alteration in their sensitivity. Infusion studies need to be conducted to 
determine if there is an alteration in sensitivity to appetite hormones with ageing. It is not known in 
humans if there is an alteration in sensitivity to the effects of gastrointestinal hormones ghrelin and 
PYY on appetite and food intake. Alterations in sensitivity to CCK have been demonstrated in 
humans. After IV infusions of CCK to older and younger volunteers, older participants ate less than 
younger volunteers and food intake was suppressed by 21.6% compared to CCK infusion than the 
control day. CCK administration also suppressed food intake to a greater extent in the older 
volunteers than the younger volunteers (32% vs. 16%) (MacIntosh et al., 2001). 
Animal studies suggest that ageing is associated with the general down-regulation of receptors 
involved in the stimulation of food intake, and a lack of alterations in receptors in the anorexigenic 
pathways (Kmiec, 2006). As yet there have been no studies looking at the sensitivity to appetite 
regulating hormones as humans age.  
 
Figure 4.23. Possible mechanisms in how alterations in gastrointestinal hormones may contribute to 
the anorexia of ageing 
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5.1. Introduction 
 
Results described in chapter 4 and data reviewed in chapter 1 suggest that in older humans there is a 
post-prandial elevation of the gastrointestinal satiety hormone PYY without an alteration in any other 
gastrointestinal appetite hormones.  
PYY is released to a large extent in the colon, ileum and rectum (Ekblad and Sundler, 2002). 
Evidence suggests that in the ageing rat colon, numbers of PYY and NPY positive cells increase with 
age (Sweet et al., 1996). This has also been replicated in mice, where there was an increase in PYY-
IR cells in older mice aged 12-24 months (Sandstrom et al., 1998). Only one human study has 
investigated PYY alterations with age in the gastrointestinal tract (Sandstrom and El-Salhy, 1999b). In 
this study, PYY containing cells in the ageing human rectum were compared to their younger 
counterparts. Results demonstrated that PYY containing cells in ageing human rectum were not  
significantly different to their younger counterparts (Sandstrom and El-Salhy, 1999b). However, this 
study only looked at human rectum samples, which may not be representative to the total PYY 
concentrations in the gastrointestinal tract, since PYY is also released from the colon and the ileum. 
Additionally, the oldest age group was 60-69 years, which may not be old enough. Findings in section 
4, showed an alteration in plasma PYY concentrations in volunteers over the age of 80 years only.  
The number of PYY containing cells in the colon does not reflect the release of PYY into the colon. 
The cell secretory index (CSI) provides an indication for secretory activity of the PYY containing 
cells. Sandstrom et al (1998) and Sandstrom and El-Salhy (1999b) studies mentioned above measured 
the CSI in older and younger mice and humans. These studies did not detect an alteration in the CSI 
of PYY with ageing in mice colons and human rectum. These results suggest that there is a lack of 
alteration in PYY release in aged and young colons and rectum but an increase in PYY containing 
cells in rats and mice only. Further studies need to be conducted to clarify the changes that may occur. 
Another method in which to measure PYY content in colons is via the use of acetic acid to extract the 
PYY content out of the colon in order to measure PYY content per gram of tissue. For an accurate 
result, the whole colon needs to be used for the analysis; this would mean that rodents would need to 
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be used. If an alteration in PYY concentrations can be seen in the ageing colon, this could provide a 
good model in order to develop therapeutics in older adults. No study to date has determined the total 
PYY concentrations contained within the aged colon. 
Only one study to date has investigated GLP-1 alterations in human ageing in a small sample of 
volunteers. There were no observed alterations in GLP-1 concentrations with age (MacIntosh et al., 
1999). No studies to my knowledge have investigated the effect of ageing on GLP-1 colonic 
concentrations in both rodents and humans. Considering the lack of an alteration in GLP-1 
concentrations described in chapter 4, it would be expected that there would be no alteration in 
colonic GLP-1 concentrations with age.  
The stomach is the primary production site of ghrelin in the gastrointestinal tract (Lee et al., 2002). In 
the stomach, ghrelin is produced in mucosal enteroendocrine cells called X/A cells (Date et al., 2000; 
Tomasetto et al., 2000).  Data from my previous study (chapter 4), and others (Sturm et al., 2003; 
Yukawa et al., 2006; Di Francesco et al., 2006; Schneider et al., 2008) have demonstrated that there is 
a lack of alteration in plasma ghrelin concentrations with ageing, therefore it would be expected that 
there would be no alteration in ghrelin concentrations contained within the stomach of older and 
younger humans. There are no methods currently available to measure ghrelin concentrations in the 
stomachs of living humans, therefore rodents are required. One study has investigated the effect of 
ageing on ghrelin concentrations in the stomach of rodents. This study demonstrated an increase in the 
production of ghrelin in the stomach of older rats (Englander et al., 2004), opposing the majority of 
literature investigating ghrelin plasma concentrations in humans. Rats are not the ideal animal model 
of ageing, mice are thought as a more ideal model of ageing as they follow a growth pattern that is not 
identical (as with age they are known to gain weight) but follows a pattern closer to humans than 
those of rats. A study needs to be conducted in mice to confirm the data from Englander (2004) in 
order to provide a clearer picture on the alterations in ghrelin with ageing. 
This investigation will explore the alterations in gastrointestinal hormone concentrations within the 
stomach and colon in aged and young mice. The aim is to determine if alterations show a similar 
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pattern to human ageing. This would provide a useful animal model to investigate age associated 
alterations in gastrointestinal hormones in order to create therapies to increase food intake in older 
humans. 
5.2. Hypothesis 
 
Increasing age will be associated with an increase in the concentration of PYY in the gastrointestinal 
tract. There will be no change in GLP-1 and acyl ghrelin concentrations with age. 
5.3. Aims and objectives 
 
5.3.1. Aims 
 
To investigate the alterations that may occur with ageing in ghrelin, PYY and GLP-1 concentrations 
in young and aged mice stomachs and colons. 
5.3.2. Objectives 
 
1. To compare total ghrelin concentrations in older and younger mice stomachs. 
2. To compare PYY and GLP-1 concentrations in young and old mice colons 
5.4. Methodology 
 
This study was a comparative study design comparing concentrations of ghrelin, PYY and GLP-1 in 
old (300+days), middle aged (100-299 days) and young (28-99 days) mice stomachs and colons. This 
was a pilot study, using colons and stomachs donated from the department of Molecular 
Endocrinology, Imperial College London, who have an interest in ageing and bone health. 
Colons and stomachs were extracted from 21 TRβ Flox Flox and 20 Rosa D3C8 mice. These mice 
demonstrate a normal phenotype because an abnormal phenotype would only be expressed once the 
targeted gene has been excised.  Mice were kept under conditions according to the Department of 
Molecular Endocrinology labs protocol; mice were singly housed at a constant room temperature of 
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21-23°C on a 12 hour light/dark cycle (7am – 7pm). The mice were fed on a standard mice chow diet. 
The study and procedures were approved by the Home Office under a project license. 
Body weight of the mice was measured and noted down prior to the commencement of any 
procedures. The mice were killed by cardiac puncture, by a member of the Molecular Endocrinology 
department, prior to extraction of colons and stomachs. Sections of the colon (tissue taken 
immediately after the caecal junction to the rectum) and stomach were taken from the mice. Colons 
and stomachs were cleaned out and washed with PBS solution (87g NaCl, 2.7g KH2PO4, 14.1g 
Na2HPO4.H2O in 1 litre H2O). Clean samples were weighed, placed in 4.5ml Cyro Tube Vials (Nunc, 
Denmark), and then placed immediately into liquid nitrogen. Samples were stored at -80 following the 
study procedure. 
Prior to hormone analysis, GLP-1, ghrelin and PYY were extracted from the stomach and colonic 
tissues using a method used previously by Le Roux et al (2006). Briefly 0.5M acetic acid was added 
to the Cyro tubes containing the mice colons and stomachs at a volume of 10ml per gram net weight 
of the tissue. The tubes containing the tissue and acetic acid were then boiled in a water bath for 15 
minutes. Following this, the Cyro tubes containing the tissue and the acetic acid were added 
immediately to ice to cool down. Once the Cyro tubes had cooled down, they are then stored in -20 
freezer until ready to use for hormone analysis. 
5.5. Outcomes 
 
Primary Outcomes: Colonic PYY concentrations 
Secondary Outcomes: Stomach ghrelin concentrations and colonic GLP-1 concentrations 
5.5.1 Measurement of Outcomes 
 
Measurement of hormones: PYY, GLP-1 and ghrelin were measured in 1 in 100 dilution according to 
the protocol detailed in section 2.7. 
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5.6. Statistical analysis 
 
Data was tested for normality using Kolminov-Smirnov test for normality. All data was normally 
distributed with the exception of GLP-1 and body weight. Non-normally distributed data was log-
transformed and tested for normality again. If data was normally distributed following log 
transformation it was presented as mean ± SEM on a log-transformed axis with parametric analysis 
applied, and presented as geometric mean (IQ range) in tables. Log transformed data was presented as 
geometric mean (IQ Range) in table in order for the values to be easily compared to data presented in 
graphs on a log transformed axis. Geometric mean is a measure of central tendency. Where data was 
normally distributed (without log-transformation), it was presented as mean ± SEM (SD for 
descriptive data). Data was analysed using age categories 1-99 days, 100-299 days and 300+ days old. 
Comparisons between age groups were measured using a One-Way ANOVA. 
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5.7. Results 
 
41 male and female mice stomachs and colons were donated for use in this study. I was unable to 
standardize conditions such as the male to female ratio and an equal number of mice in age ranges, as 
colons and stomachs were a donation. There appears to be little data to suggest that males and females 
have different PYY, GLP-1 and ghrelin responses in mice, therefore the different ratios of males to 
females in the age groups was thought to not be an issue. Data was analysed in age groups; Group 1; 
young: 1-99 days, Group 2; middle age: 100-299 days and Group 3; old; 300+ days. 
5.7.1. Descriptive statistics 
 
Body weights between the different mouse strains in each group were not statistically different from 
one another. Descriptive statistics for age and weight of mice can be seen in table 5.1. The body 
weights of the mice increased with age. 
Table 5.1.  Body weights and age of mice. 
 Age Group Strain Mean SD 
Age 
(Days) 
1 (1-99 days) 
f=25 n=25 
12 Rosa 
13 TRβ 
40 2.64 
2 (100-299 days) 
 f=4 n=4 
4 Rosa 107 1.17 
3 (300+ days) 
f=2 m=10 n=12 
4 Rosa 
8 TRβ 
334 5.64 
 Age Group Strain Geometric Mean IQ Range 
Weight 
(g) 
1 (1-99 days) 
f=25 n=25 
12 Rosa 
13 TRβ 
18.75 17-21 
2 (100-299 days)  
f=4 n=4 
4 Rosa 23.45 22-24 
3 (300+ days) 
f=2 m=10 n=12 
4 Rosa 
8 TRβ 
38.06 35-42 
 
Mean and Standard Deviation for age (days) and  Geometric mean and Interquartile Range for 
weight(g) between age ranges 1-99 days, 100-199 days and 300+ days 
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5.7.2. Body weight 
 
Body weight increased with age. Significance was detected between the age groups (p<0.001), this 
difference was detected between group 1 (1-99 days) and group 2 (100-299 days) (p=0.012) and 
between group 1 (1-99 days) and group 3 (300+ days) (p<0.001) see figure 5.1. 
 
Figure 5.1. Body weights of mice in the three different age groups 
 
 
 
 
 
 
 
 
 
 
Mean ± SEM body weight (g) on a log transformed axis in group 1 (1-99 days n=25), group 2 (100-
299 days n=4) and group 3 (300+ days n=12).Significance detected between groups (p<0.001) 
*p=0.012 vs. group 1, **p<0.001 vs. group 1 
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5.7.3. Colonic PYY and GLP-1 concentrations 
Colonic PYY and GLP-1 concentrations were similar in all age groups. There was no significant 
alteration in PYY concentrations between the three different age groups (p=0.566). Data is presented 
in figure 5.2. 
Figure 5.2. PYY and GLP-1 concentrations in mice colons 
(A)                                                                         (B) 
 
 
 
 
 
 
 
 
A. Mean ± SEM PYY nmol per gram tissue (nmol/g) contained in mice colons in group 1 (1-99 days 
old, n=25), group 2 (100-299 days old, n=4) and group 3 (300+ days old, n=12). No significance 
detected between groups. 
B. Mean ± SEM GLP-1 nmol per gram tissue (nmol/g) contained in mice colons on a log
10
 
transformed axis in group 1 (1-99 days old, n=25), group 2 (100-299 days old, n=4) and group 3 
(300+ days old, n=12). No significance detected between groups 
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5.7.4. Stomach ghrelin concentrations 
The two oldest age groups (2 and 3) had higher stomach ghrelin concentration compared to the 
youngest age group, this reached significance between the 3 age groups (p=0.006). A post-hoc test 
detected this significance between group 1 and 2 (p=0.006), and group 1 and 3 (p=0.025). Data is 
presented in figure 5.3. 
Figure 5.3. Total ghrelin concentrations in mice stomachs. 
 
 
 
 
 
 
 
 
 
 
 
Mean ± SEM ghrelin nmol per gram tissue (nmol/g) contained in mice stomachs between group 1 (1-
99 days old, n=25), group 2 (100-299 days old, n=4) and group 3 (300+ days old, n=12). *p=0.006 
vs group 1, **p=0.025 vs group 1 
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5.8. Discussion 
 
5.8.1. Overview 
 
The objective of this study was to determine if there are alterations in gastrointestinal appetite 
hormone concentrations contained within the gastrointestinal tract in aged and young mice to see if 
they reflected human observations in plasma. 
Evidence from chapter 4 suggests that there is an elevation in post-prandial PYY concentrations and 
an absence of an alteration in plasma ghrelin and GLP-1 concentrations in humans with age. This 
study aimed to determine if the increase in PYY observed in human ageing can be replicated in 
colonic tissue in mice, and to determine if a lack of an alteration in GLP-1 and ghrelin observed in 
humans correlates with concentrations in older mice stomachs and colons. 
5.8.2. Summary of findings 
 
In aged mice there is an absence of an alteration in colonic PYY and GLP-1 concentrations, but  an 
elevation in stomach ghrelin concentrations in middle aged (100-299 days) and old senescent (300+ 
days) mice. 
Chapter one reviews the studies investigating ghrelin alterations in ageing, studies described were 
inconclusive providing no definitive answer on what alterations occur with age. Section four 
suggested that there was a lack of an alteration in plasma ghrelin concentrations with ageing. This 
study did not replicate results seen in humans, but confirms data from Englander at al (2004) where an 
elevation in ghrelin concentrations was observed in aged rats.  
PYY has been demonstrated to be significantly higher in healthy elderly humans (see section 4) (Di 
Francesco et al., 2005). In rodents, investigations have also demonstrated that there is an increase in 
PYY positive cells in rats (Sweet et al., 1996) and mice (Sandstrom et al., 1998) in ageing, with a lack 
of alteration in the CSI in ageing mice colons (Sandstrom et al., 1998). This study did not demonstrate 
an increase in PYY concentrations in ageing mice colons, which remains in line with data where there 
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was a lack of an alteration in CSI activity (Sandstrom et al., 1998), suggesting an absence of an 
alteration in PYY concentrations in ageing in rodents. This is the first study to my knowledge that has 
investigated GLP-1 concentrations contained within colons of aged mice, the lack in alteration of 
colonic GLP-1 concentrations observed in this study remains in line with previous data investigating 
plasma GLP-1 alterations in humans (see section 4) (MacIntosh et al., 1999). 
The results observed in this investigation do not replicate what is observed in human studies, 
opposing my proposed hypothesis, but remains in line with previous animal data. This suggests that 
rodents may not be a suitable model for ageing human research.  
5.8.3. Ghrelin is elevated in mice stomachs with age 
 
In the middle-aged mice aged 100-299 days and the senescent mice 300+ days there was a significant 
increase in stomach ghrelin concentrations in comparison to the young aged mice (p=0.006). This 
observation replicates the data from Englander et al (2004), where there was an increase in stomach 
ghrelin concentrations in aged rats. Unfortunately, I was unable to take plasma samples from the aged 
mice but it was seen in the investigation by Englander et al (2004)  that there was also an increase in 
plasma ghrelin concentrations in the aged rats, and therefore it would be expected that the older mice  
in this study would replicate these alterations. It is not clear why in rodents there is an elevation in 
ghrelin stomach concentrations. A possible explanation could be due to a reduced biological activity 
of ghrelin, therefore an increased production of ghrelin in the stomach would be needed to elicit the 
same hunger responses observed in the young. Sohn et al (2002) demonstrated in male brown norway 
rats NPY mRNA levels were 6 times lower in the hypothalamus of old rats compared to young. 
Fasting increases hypothalamic NPY expression in young animals, however, in old rats this response 
is suppressed (Gruenewald et al., 1996). Ghrelin strongly stimulates NPY, therefore, if there is a down 
regulation of NPY expression, this may result in an increase in the production and release of ghrelin. 
It could be that that there is a difference in ghrelin secretion in humans and rodents as a reflection of 
species variation. It is well established in human ageing that there is a reduction in body weight, 
however in rodents, especially rats, body weight still increases with age, as demonstrated in my study, 
183 
 
and in a study by Pu et al (2000). This may result in an altered secretion of gastrointestinal hormones 
due to body weight rather than age. This would therefore make the model of ageing in rodents invalid. 
In addition in the middle aged mice, where you wouldn’t expect an alteration to be seen in ghrelin 
concentrations, there was an elevation in comparison to the young aged mice, thus the increases in 
body weight seem like the most likely explanation. 
The regulation of stomach ghrelin is obscure, and the concentrations of ghrelin that are contained 
within the mice stomachs may not represent the amount in the circulation. The biologically active 
form of ghrelin was also not measured in this investigation, it could be possible that the high amounts 
of ghrelin detected in the stomach in the mice may have been the inactive form (desacyl ghrelin). For 
a more reliable measurement of ghrelin concentrations in the stomach, acyl ghrelin needs to be 
measured.  
5.8.4. PYY and GLP-1 concentrations 
 
There were no alterations in PYY and GLP-1 concentrations contained in aged mice colons in this 
study. Previous work has seen increase in PYY-IR cells in mice (Sandstrom et al., 1998)  and an 
increase in PYY positive cells in rats (Sweet et al., 1996), but these studies look at cell numbers not 
PYY concentration. This study looked at the total content of PYY per gram of colonic tissue in order 
to provide a more accurate measure of total PYY in the colon. A more comparable data is that 
described by Sandstrom et al (1998), where they investigated the cell secretory index (CSI) of PYY 
(PYY cell secretion rate) and demonstrated no alteration between younger and older mice. My current 
study agrees with this data (Sandstrom et al., 1998); no alteration in PYY content was observed with 
mice in ageing. However Sandstrom et al, (1998) found in addition to no difference in the CSI, an 
increase in PYY-IR cells in older mice. The CSI as described previously (El-Salhy et al., 1997) is 
calculated by  dividing the immunoreactivity stained volume by the number of cells. Therefore the 
increase in the PYY-IR cells but no difference in the CSI may be explained by a reduced sensitivity of 
the cells. The lack of change in PYY concentrations could be explained that the mice were not old 
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enough for an alteration in PYY release to be detected, however, Sandstrom et al (1998), used mice as 
old as 24 months, and no alteration in CSI was detected. 
Evidence in humans suggests that endocrine PYY cell numbers and the CSI  do not change in the 
aged rectum (Sandstrom and El-Salhy, 1999b), but there is no data for the whole colon and this is 
required to draw conclusions about PYY gut content (the whole colon is required thus it is unfeasible 
to collect this type of data in humans). In addition samples from the study by Sandstrom and El-Salhy 
(1999b) study were taken from adults aged 69 years or younger. Data from chapter 4 shows changes 
were only seen in healthy volunteers over 80 years of age, therefore the adults may not have been old 
enough for an alteration to be observed. A suggestion to explain the increase in human plasma PYY 
(observed in chapter 4) and a lack of increase in mice colon PYY content, is that there may be a 
delayed PYY clearance in the plasma in ageing, rather than an increased production within the 
gastrointestinal tract. It is well known kidney function and glomerular filtration rate slows with ageing 
(Shi and Klotz, 2011), potentially resulting in slower PYY clearance. Previous work has shown that 
there is an alteration in CCK concentrations with ageing (Di Francesco et al., 2005), but a lack of an 
alteration in CCK cell numbers and CSI in older humans up to the age of 69 years (Sandstrom and El-
Salhy, 1999a), although more research is required on adults up to 80 years of age. Alternatively it 
could simply be that mice and human PYY release mechanisms with ageing differ.  
GLP-1 concentrations contained in mice colons did not alter with age. To my knowledge, no study to 
date has investigated or demonstrated an alteration in the release of GLP-1 in ageing in rodents and 
humans, it has however been suggested in one study that there is an absence of an inverse relationship 
between GLP-1 and hunger seen in human ageing (MacIntosh et al., 1999) which suggests that there 
may be an alteration in sensitivity to GLP-1 in ageing, rather than total GLP-1 concentrations. 
5.8.5. Limitations and future work 
 
This study used small numbers of mice with an uneven number of mice in each age group. There was 
also an uneven ratio of mice strains and gender within the age categories. The uneven ratio of mouse 
strains, should have not affected the results in this study, as the mouse strains present a normal 
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phenotype, and an abnormal phenotype would only be seen once the gene has been excised. In 
addition, although there is some data to suggest that the appetite regulatory system is different in 
males and females with respect to ghrelin release (Greenman et al., 2004; Greenman et al., 2009), a 
large majority of this data has been seen in human studies and not in mice, therefore it was not 
thought that the differences in gender should affect results. Male mice also live longer than female 
mice and so it is difficult to obtain senescent old female mice in this study. For example in Sandstrom 
et al (1998) none of the female mice survived up to the age of 24 months.  
A power calculation was not conducted, as this study was a pilot study, but the numbers in the young 
and old age group, were reasonable study numbers, only the middle age numbers were low. The most 
important comparison was between the young and the old mice therefore the small numbers in the 
middle age group was thought not to significantly affect the results. 
Rodents do not follow the same growth pattern as humans, where weight increases progressively and 
food intake does not alter largely (Pu et al., 2000). In humans the opposite is seen, in older humans 65 
years and older there is a reduction in food intake and body weight, this makes the animal model 
difficult to extrapolate to humans. It is unfeasible to measure the PYY and GLP-1 colonic content and 
stomach ghrelin content in humans, therefore rodents are the only way to explore this, despite 
differences in growth patterns. The conflicting data coming from animal and human studies of this 
nature suggest that such animal models are not very helpful in the study of human appetite control 
during ageing. 
I was not able to standardise food intake in the mice prior to the extraction of the gut tissue, nor was I 
able to determine the fed state of the mice. Timings of their last meal could have a large effect on 
gastrointestinal hormone release. PYY alterations have only been seen post-prandially in humans (Di 
Francesco et al., 2005) and as observed in chapter 4. If the mice had not eaten for a longer period of 
time an alteration in PYY may not have been detected. However, mice were given ad libitum access 
to food, and so presumably the mice would have eaten fairly frequently, thus eliminating this 
limitation. 
186 
 
I was also unable to obtain plasma samples; it would have been useful to observe and make 
comparisons of gastrointestinal hormones within plasma and tissue. This would have created a clearer 
conclusion on if the animal model is ideal to use as model of ageing. No study to my knowledge has 
previously investigated PYY plasma concentrations in the aged rodent. Finally, I did not measure acyl 
ghrelin concentrations due to a lack of resources, which would have provided a more accurate picture 
of the active ghrelin in the stomach. Future work would require the measurement of the active form of 
ghrelin. 
5.8.6. Conclusions 
 
This data has demonstrated that in ageing mice there is an increase in stomach total ghrelin 
concentrations, with a lack of an alteration in PYY and GLP-1 levels. It conflicts with human data 
where, in plasma, there is either no alteration or a decrease in ghrelin concentrations, and an increase 
in PYY concentrations in plasma. Acyl ghrelin needs to be measured in order for a more accurate 
conclusion on if ghrelin concentrations are altered with age. It could also be possible that the levels 
contained in the stomach and colons do not reflect concentrations in plasma. It would appear that mice 
do not offer a good model for human appetite research.  
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Chapter 6 
THE ASSOCIATION BETWEEN HABITUAL 
PROTEIN INTAKE ON BMI AND HABITUAL 
ENERGY INTAKE IN OLDER AND YOUNGER 
ADULTS 
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6.1. Introduction 
 
It has been suggested that a high intake of protein in the diet can reduce subjective feelings of hunger 
and consequently reduce food intake (Vandewater and Vickers, 1996; Latner and Schwartz, 1999; 
Porrini et al., 1997). A meta-analysis was performed to look at studies that compared the effects of a 
high protein preload and a low protein preload and subsequent energy intake at an ad libitum test 
meal. Out of the 10 studies reviewed, eight demonstrated a reduction in energy intake following the 
high protein test meal condition (Eisenstein et al., 2002). Protein has also been demonstrated to induce 
the most substantial post-prandial response in PYY concentrations compared to high fat or high 
carbohydrate preload meals (Leidy et al., 2010; El Khoury et al., 2010; Batterham et al., 2006). This 
suggests that the reduction in food intake seen following high protein preloads may be due to an 
elevation in the satiety hormone PYY. Weight loss has also been observed with high habitual protein 
intake. In a randomised six month trial comparing ad libitum high protein (25%) low fat diet with 
normal protein (12%) low fat diet for six months, there was a higher weight loss with the high protein 
diet (Skov et al., 1999). 
Di Francesco et al (2005), and results from chapter 4 demonstrated that there is an elevation in post-
prandial PYY in ageing. Therefore, if there is an increase in PYY concentrations after consumption of 
moderate levels of protein (~15%) compared to younger adults, this increase in PYY may be more 
substantial following a high protein meal, meaning that older adults may be more sensitive to the 
satiety effects of protein. If older adults appear to be more sensitive to the effects of protein by a more 
substantial increase in the satiety hormone PYY there could be a further subsequent reduction in 
appetite and food intake. 
It is common practice to supplement undernourished elderly patients with high protein nutrition 
replacement supplements. Therefore, it is important to establish the effect on protein on appetite and 
body weight in older adults. This information would help in the treatment of under nutrition in the 
elderly, by providing information on the type of macronutrient that should be used for optimal energy 
intake and appetite in the older age group. No study to date has investigated the alterations in 
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sensitivity to high protein diets on body weight and energy intake in the older versus the younger 
population. 
This study used the National Diet and Nutrition Survey (NDNS) database to explore the relationship 
between protein intake, BMI and energy intake in older and younger adults. 
6.2. Hypothesis 
 
Increased habitual intakes of protein will result in more of a substantial reduction in energy intake and 
BMI in older adults compared to younger adults. 
6.3. Aims and objectives 
 
6.3.1. Aims 
 
To investigate the effect of high habitual intakes of protein on BMI and energy intake in older (>75 
years) compared to younger adults using the National Diet and Nutrition Survey (NDNS) dataset. 
6.3.2. Objectives 
 
1. To investigate the effect of habitual protein intake on BMI in older versus younger adults. 
2. To observe the impact of habitual protein intake on energy intake in older compared to 
younger adults. 
3. To compare the effects of habitual intakes of other macronutrients; carbohydrate, fat and fibre 
on energy intake and BMI in older compared to younger adults 
6.4. Methodology 
 
The National Diet and Nutrition Survey (NDNS) data from the years 1994 (survey of older adults) 
and 2000 (survey of young adults) was used for the analysis in this study. The NDNS provides a 
snapshot of the diet and nutrition status of people in the UK. The NDNS is used to estimate the 
proportion of individuals with compromised nutritional status, and can be used to monitor progress 
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towards government’s targets. Around 2000 people are interviewed in this survey in England, Wales, 
Scotland and Northern Ireland.  The dataset contains information about eating habits, health and 
lifestyle, food and drink consumption, physical activity, and basic measurements such as height, 
weight and blood pressure. It provides unique information about the nutritional status of the UK. 
Within this dataset there are recordings of weighed food intake from a four day diary as described 
previously (Finch et al., 1998; Henderson et al., 2002). 
6.4.1. Preparation of the NDNS datasheet 
 
In this investigation I wanted to look at both the younger population and the older population, 
therefore I needed to combine the young NDNS dataset (19-64 years) and the old NDNS dataset (65+ 
years) from years 2000 and 1994 respectively. The gap in years between the two datasets used was 
considered as a period of time within the UK where dietary patterns haven’t changed considerably. 
The cut off age for older adults was 75 years, this age was used because literature suggests this is the 
age in which weight loss and body weight loss occurs more frequently (Hickson, 2006). 
The old and young NDNS included a scale of wellness, where a score of 1 described those who were 
unwell with eating affected, and a score of 2 where they were well with eating unaffected. Those who 
reported themselves in the old and young NDNS dataset as unwell were excluded. This was because I 
wanted investigate the appetite and body weight changes in the healthy population. 
In this study I was interested in energy intake, macronutrient intake, body mass index and body 
composition (fat mass and lean mass). I also wanted to control for certain other factors; physical 
activity levels, gender and social class, which all may have a role in energy intake. Any other 
variables were deleted from the datasets. 
The measurement of social class used in both the old and young dataset was gross annual income. For 
a measurement of physical activity levels a z-score of the original data was used. Both the young and 
old dataset provided a score for total physical activity levels on a scale, but the scales used in the two 
datasets were different to one another. A z-score was calculated for both the young and old datasets in 
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order for them both to be combined. The use of the z-score enabled me to control for the most active 
in each cohort in the statistical analysis. 
Measurements of body fat and lean mass percentage were not provided in the NDNS dataset. Body fat 
percentage was calculated using the Deurenberg equation. The Deurenberg equation gives a good 
general estimate of body composition, but individual results from this equation will need to be 
interpreted with caution (Deurenberg et al., 1991). As this investigation is not observing individual 
body compositions and is observing composition in a large cohort, it was deemed as an appropriate 
and the best method to use.  
The Deurenberg equation was developed by regressing BMI against percentage body fat mass 
determined from densitometry and anthropometry in a large population (n1229) which includes older 
men and women. The standard error of the equation is 4% and the coefficient of variation 16% and 
accounts for approximately 80% of the variation in body fat percentage (Deurenberg et al., 1991). 
Deurenberg equation is as follows; 
Body fat percentage = (1.20 x BMI) + (0.23 x Age) – (10.8 – Sex) – 5.4 
Where; BMI is kg/m
2
, Age (years) and sex (male=1, female = 0). 
Lean mass was calculated by subtracting the percentage body fat from 100%. 
6.5. Outcomes 
 
Primary Outcomes: Relationships between habitual protein and BMI and energy intake in older and 
younger adults 
Secondary Outcomes: Relationships of other macronutrients and BMI and energy intake in older and 
younger adults. 
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6.6. Statistical analysis 
 
All data was tested for normality using a Kolminov-Smirnov test for normality. Attempts were made 
to normalise non-parametric data using log transformation, but if after log-transformation data was 
not normally distributed, non-parametric analysis was used. Data was split into age categories, which 
are referred to as ‘interaction terms’ when used in the multiple regression in this study. For 
comparisons of mean values for different characteristics between age groups a Mann-Whitney U test 
was used for non-parametric data, and an independent sample t-test was used for parametric data. 
A non-parametric linear regression analysis (non-parametric regression needed to be used for every 
variable) was conducted to determine the effect of age on BMI and age on calorie intake (kcal) in the 
two different age groups. Linear regression analysis was also performed in the two different age 
categories separately to determine the effect of habitual macronutrient intake on BMI and habitual 
energy intake. Comparisons were made between the slopes (steepness of the line) between the age 
groups. 
A multiple regression was performed to determine if habitual intakes of protein have an independent 
effect on BMI and energy intake in age groups separately and combined. Gender, Social Class, and Z-
score for activity levels were added to the regression as potential interactions. 
The data was analysed using SPSS 18.0 for Windows (SPSS Science, Apache Software Foundation, 
Chicago, IL, USA) and comparisons between the slopes were performed on Graphpad prism 5. 
 
 
 
 
 
193 
 
6.7. Results 
 
6.7.1. Descriptive statistics 
 
Table 6.1 presents the characteristics of the adults in the combined NDNS dataset. Characteristics 
were split into the age groups; 19-74 years and 75+ years. 
Significance was detected in all the characteristics between the age groups. Data is presented in table 
6.1. 
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Table 6.1. Descriptive data from NDNS combined datasets in the 19-74 and 75+ years age range 
Characteristics 19-74 years 75 + years Significance between 
age groups? 
BMI 26.42 
(23.43-29.55) 
n2242 
25.35 
(22.69-28.41) 
n751 
 
p<0.001 
Age 44.39 
(35-61) 
n2781 
82.82 
(78-87) 
n984 
 
p<0.001 
Gender * 46.7% Male (n1298) 
53.3% Female (n1483) 
47.7% Male (n469) 
52.3% Female (n515) 
p<0.001 
Kcal consumed per day 1694.05 
(1400.57-2104.58) 
n2254 
1591.36 
(1315.58-1947.28) 
n984 
 
p<0.001 
Protein % of energy 
intake 
15.38 
(13.60-17.44) 
n2254 
14.49 
(12.77-16.39) 
n984 
 
p<0.001 
Carbohydrate % of 
energy intake ** 
46.53 
(0.15) 
n2254 
50.85 
(0.22) 
n984 
 
p<0.001 
Fat % of energy intake 34.74 
(31.45-39.43) 
n2254 
35.44 
(32.43-39.64) 
n984 
 
p<0.001 
Fibre g per 1000kcal 7.28 
(5.78-9.21) 
n2254 
6.33 
(4.96-8.05) 
n984 
 
p<0.001 
Estimated body fat % 31.45 
(26.82-38.06) 
n2242 
38.26 
(33.11-44.94) 
n751 
 
p<0.001 
Estimated lean mass % 66.74 
(61-94-73.18) 
n2242 
60.36 
(55.07-66.89) 
n751 
 
p<0.001 
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Table 1 continued. Geometric Mean (IQ Range) BMI, Age, Gender, Kcal consumed per day, Protein 
% of energy intake, Carbohydrate % energy intake, Fat % energy intake, Fibre (g per 1000kcal), 
estimated body fat % and estimated lean %. Data obtained from the combined young (19-64 years 
2000) and old (65+ years 1994) NDNS dataset 
* presented as percentage (%) 
** presented as Mean (SD) 
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6.7.2. Correlations 
 
Correlations (without controlling for confounding factors) were performed individually in the two age 
groups, to determine if BMI and calorie intake change with age. 
6.7.2.1. Age and BMI 
In the 19-74 years age group there was significant positive but weak correlation (p=0.001, r= .155) 
between age and BMI, where BMI increased with age (figure 6.1A). However, when the 75+ age 
group was analysed, there was a weak negative correlation (p<0.001, r -.142) between age and BMI, 
where BMI decreased with age (figure 6.1B).  
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Figure 6.1. Correlations between BMI and age in the 19-74 and  75+ years age group. 
                          (A)  
 
 
 
 
 
 
  (B) 
 
 
 
 
 
 
A. Scatter plot with linear regression correlating age and BMI in the 19-74 age group. Significant 
positive correlation (p<0.001, r .155) (n2242). 
B. Scatter plot with linear regression correlating age and BMI in the 75+ age group. Significant 
negative correlation (p<0.001, r -.142) (n751). 
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6.7.2.2. Age and calorie intake 
In the 19-74 years age group there was no significant correlation (p=0.868, r= -.004) between age and 
kcal intake (scatter plot not shown). However, when the 75+ age group was analysed, there was a 
weak negative correlation (p<0.001, r= -.112) between age and Kcal intake, where Kcal intake 
decreased with age (figure 6.2). When calorie intake was controlled for lean body mass (EI/LBM kg) 
a significant positive correlation was seen in the young age group (p<0.001, r=.203) where as age 
increased, energy intake/LBM increased. However, in the 75+ age group, no significance was 
detected (p=0.344, r=-.035) suggesting that energy intake taking into account LBM does not change 
with age. 
 
Figure 6.2. Correlations between Kcal Intake and age in the 75+ years age group. 
 
 
 
 
 
 
 
Scatter plot with linear regression correlating Age and Kcal Intake in the 75+ age group. Significant 
negative correlation (p<0.001, r -.112) (n984). 
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6.7.2.3. Age and body composition 
In the 19-74 years age group there was a significant positive correlation (p<0.001, r= .464) between 
age and body fat percentage (figure 6.3A). When the 75+ age group was analysed, there was also a 
weak positive correlation (p<0.001, r= .192) between age and body fat percentage, where body fat 
percentage increased with age (figure 6.3B), which is interesting considering the drop in BMI. The 
younger age group (19-74 years) had a steeper regression slope than the older people (r= .464 vs. r= 
.192) suggesting that body fat percentage increases to a greater extent in the younger adults. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
200 
 
0 20 40 60 80
0
20
40
60
80
100
Age (years)
B
o
d
y
 f
a
t 
p
e
r
c
e
n
ta
g
e
 (
%
)
70 80 90 100 110
0
20
40
60
80
Age (years)
B
o
d
y
 f
a
t 
p
e
r
c
e
n
ta
g
e
 (
%
)
Figure 6.3. Correlations between estimated body fat percentage and age in the 19-74 and the 75+ 
years age group. 
 
                     (A) 
 
 
 
 
 
                       (B) 
 
 
 
 
 
 
 
A. Scatter plot with linear regression correlating age and estimated body fat percentage in the 19-74 
age group. Significant positive correlation (p<0.001, r .464) (n2781). 
B. Scatter plot with linear regression correlating age and estimated body fat percentage in the 75+ 
age group. Significant positive correlation (p<0.001, r .192) (n751). 
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6.7.3. Habitual intake of macronutrients and BMI 
 
Correlations were conducted to determine if habitual intake of protein and other macronutrients have 
an influence on BMI. 
6.7.3.1. Habitual protein intake and BMI 
 
There was a significant positive correlation in the 19-74 (p<0.001 r .185) age group and the 75+ 
(p=0.021, r .084) age group between BMI and percentage of calories from protein (figure 6.4). The 
regression lines were analysed to compare between the two age groups. Results were approaching 
significance (p=0.053). These results suggest that as protein intake increases, BMI increases, but the 
extent to which BMI increases with protein intake has a trend towards a significant difference 
between older and younger adults, where BMI increases to a greater extent in younger adults with 
higher protein intakes. 
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Figure 6.4. Correlations between percentage energy intake from protein and BMI in the 19-74 and 
the 75+ years age group. 
 
 
 
 
 
 
 
 
 
 
Scatter plot with linear regression correlating percentage energy intake from protein and BMI in the 
19-74 and 75+ age groups. Significant positive correlation in the 19-74 age group (p<0.001, r .185) 
(black circle with red line) (n2076) and in the 75+ age group (p=0.021, r .084)(n=751) (blue triangle 
with green line). Approaching significance in the regression lines between age groups (p=0.053).  
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6.7.3.2. Habitual fat intake and BMI 
In the 19-74 age group it was approaching a significant negative correlation (p=0.055 r -.042) between 
habitual fat intake and BMI but no significant correlation was detected in the 75+ age group (p=0.575, 
r-.02) (figure 6.5). The regression lines were analysed to determine if they were significantly different 
between the age groups. No significance was detected between the lines (p=0.33).  Results suggest 
that habitual fat intakes are not associated with changes in BMI in both the older and younger adults.  
 
Figure 6.5. Correlations between percentage energy intake from fat and BMI in the 19-74 and the 
75+ year age group. 
 
 
 
 
 
 
 
 
 
Scatter plot with linear regression correlating percentage energy intake from fat and BMI in the 19-
74 and 75+ age groups. Approaching significant negative correlation in the 19-74 age group 
(p=0.055 r -.042) (black circle with green line) (n2076) but not in the 75+ age group (p=0.575, r- 
.021) (n=751)(blue box with red  line). No significance detected in the regression lines between age 
groups.  
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6.7.3.3. Habitual carbohydrate intake and BMI 
 
No significant correlations were detected in the 19-74 (p=0.428, r -.017) age group and in the 75+ age 
group (p=0.173, r-0.050) (figure 6.6) between habitual carbohydrate intake and BMI. The regression 
slope lines were analysed to determine if they were significantly different between age groups. No 
significance was detected between the lines (p=0.206).  These results suggest that habitual 
carbohydrate intakes are not associated with a change in BMI in both the older and younger adults. 
 
Figure 6.6. Correlations between percentage energy intake from carbohydrate and BMI in the 19-74 
and the 75+ year age group. 
 
 
 
 
 
 
 
 
Scatter plot with linear regression correlating percentage energy intake from carbohydrate and BMI 
in the 19-74 and 75+ age groups. No significant correlations detected in the 19-74 age group 
(p=0.428 r -.017) (black circle with red line) (n2076) and in the 75+ age group (p=0.173, r- .050) 
(blue triangle with green line) (n=751).No significance detected in the regression lines between the 
age groups.  
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6.7.3.4. Habitual fibre intake and BMI 
 
Fibre was expressed as grams per 1000 kcal, to take into account energy intake. There was a 
significant positive correlation in the 19-74 (p=0.014  r .054) age group and in the 75+ age group 
(p=0.001, r .116) (figure 6.7) between habitual fibre intake and BMI. The regression slope lines were 
analysed to compare between the age groups. No significance was detected between the lines 
(p=0.158).  These results show that with increased fibre intake (g/1000kcal), there is an associated 
increase in BMI in both older and younger adults. 
 
Figure 6.7. Correlations between fibre (g/1000kcal) and BMI in the 19-74 and the 75+ year age 
groups. 
 
 
 
 
 
 
 
 
Scatter plot with linear regression correlating fibre (g/1000kcal) and BMI in the 19-74 and 75+ age 
groups. Significant positive correlation detected in the 19-74 age group (p=0.014 r .054) (black circle 
with red line) (n2076) and in the 75+ age group (p=0.001, r .129) (blue box with green line) (n=751). 
No significance detected in the regression lines between the age groups.  
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6.7.4. Habitual intake of macronutrients and total energy intake 
 
Correlations were also run to determine if habitual intake of protein and other macronutrients have an 
effect on daily habitual calorie consumption. 
6.7.4.1. Habitual protein intake and Kcal consumption 
 
There was a significant negative correlation in the 19-74 (p=<0.001 r -.289) age group and in the 75+ 
age group (p<0.001, r -.296) (figure 6.8) between habitual protein intake and energy intake. 
Significance was detected between two age groups regression lines (p=0.022). These results show that 
as protein intake increases, habitual energy intake decreases in both older and younger adults, but 
there is a greater decline in energy intake with higher protein intakes in older adults (as seen by 
significance between regression lines). 
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Figure 6.8. Correlations between percentage energy from protein and energy intake in the 19-74 and 
the 75+ year age groups. 
 
 
 
 
 
 
 
 
 
Scatter plot with linear regression correlating percentage energy from protein and Kcal in the 19-74 
and 75+ age groups. Significant negative correlation detected in the 19-74 age group (p<0.001 r.-
.289) (black circle with red line) (n2254) and in the 75+ age group (p=<0.001, r -.296) (blue box 
with green line) (n984). Significance detected between the two age groups regression lines (p=0.022.) 
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6.7.4.2. Habitual fat intake and Kcal consumption 
 
There was a significant positive correlation in the 19-74 (p<0.001, r .163) age group and in the 75+ 
age group (p=0.01, r .082) (figure 6.9) between habitual fat intake and Kcal consumption. The 
regression slope lines were compared between age groups. No significance was detected in the 
regression lines between the two age groups (p=0.201). These results show that as energy intake from 
fat increases, there is a subsequent increase in total energy intake in both older and younger adults. 
 
Figure 6.9. Correlations between percentage energy from fat and energy intake in the 19-74 and the 
75+ year age groups. 
 
 
 
 
 
 
 
 
Scatter plot with linear regression correlating energy (kcal) from fat and kcal consumption in the 19-
74 and 75+ age groups. Significant positive correlation detected in the 19-74 age group (p<0.001 r 
.163) (black circle with red line) (n2254) and in the 75+ age group (p=0.01, r .082) (blue box with 
green line) (n984). No significance detected in the regression lines between age groups.  
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6.7.4.3. Habitual carbohydrate intake and Kcal consumption 
 
No significant correlations were detected in the 19-74 (p=0.863  r -.004) age group and in the 75+ age 
group (p=0.767, r -.009) (figure 6.10) between habitual carbohydrate intake and energy intake. The 
regression slope lines were analysed to determine if they were significantly different between the age 
groups. No significance was detected between the regression lines (p=0.664).  These results show that 
habitual carbohydrate consumption (% energy intake) does not influence total habitual energy intake. 
 
Figure 6.10. Correlations between percentage energy from carbohydrate and energy intake in the 19-
74 and the 75+ year age groups. 
 
 
 
  
 
 
 
 
Scatter plot with linear regression correlating energy (kcal) from carbohydrate and kcal consumption 
in the 19-74 and 75+ age groups. No significant correlation detected in the 19-74 age group 
(p=0.863 r -.004) (black circle with green line) (n2254) and in the 75+ age group (p=767, r -.009) 
(blue triangle with red line (n=984)). No significance detected in the regression lines between age 
groups.  
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6.7.4.4. Habitual fibre intake and Kcal consumption 
 
Fibre intake expressed as g/1000kcal was correlated with kcal consumption separately for the two age 
groups. A significant negative correlation was detected in the 19-74 (p<0.001  r -.154) age group and 
in the 75+ age group (p<0.001, r -.160) (figure 6.11). The regression slope lines were compared 
between the two age groups. No significance was detected between the regression lines (p=0.936).  
These results suggest that increased fibre consumption is associated with a reduced habitual energy 
intake in older and younger adults. 
 
Figure 6.11. Correlations between fibre consumption (g/1000kcal) and energy intake in the 19-74 
and the 75+ year age groups. 
 
 
 
 
 
 
 
 
Scatter plot with linear regression correlating fibre consumption g/1000kcal and kcal consumption in 
the 19-74 and 75+ age groups. Significant negative correlation detected in the 19-74 age group 
(p<0.001 r -.154) (black circle with red line) (n2254) and in the 75+ age group (p<0.001, r -.160) 
(blue square with green line) (n=984). No significance detected in the regression lines between the 
age groups.  
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6.7.5. Habitual protein intake and body fat percentage 
 
Body fat percentage and habitual protein intake were correlated against each other to determine if the 
increase in BMI observed with protein intake is due to an increase in body fat percentage or lean 
mass. 
A significant positive correlation was detected in the 19-74 (p<0.001  r .226) age group and in the 75+ 
age group (p=0.015, r .088) (figure 6.12) between habitual protein intake and body fat percentage. 
The regression slope lines were analysed to determine if they were significantly different between the 
age groups. Significance was detected between the lines (p=0.002).   
A resultant significant negative correlation was detected in the 19-74 (p<0.001, r -.226) age group and 
in the 75+ age group (p=0.015, r -.088) when correlating habitual protein intake and lean mass 
percentage. 
The results show that as body fat percentage increases so does habitual protein intake. Difference 
between slopes show that body fat percentage increases to a lesser extent with increasing protein 
consumption in the older age group. 
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Figure 6.12. Correlations between habitual protein intake (% kcal) and body fat percentage in the 
19-74 and the 75+ year age groups. 
 
 
 
 
 
 
Scatter plot with linear regression correlating protein consumption (% kcal) and body fat percentage 
in the 19-74 and 75+ age groups. Significant positive correlation detected in the 19-74 age group 
(p<0.001 r .226) (black circle with red line) (n2076) and in the 75+ age group (p=0.015, r .08 r .088) 
(blue square with green line) (n751). Significance detected between the two age groups regression 
lines (p=0.002) 
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6.7.6. Multiple linear regression 
 
Given the interesting observation that there was a different relationship between protein and energy 
intake and the decline in BMI with age in the over 75 age group, I went on to perform a multiple 
linear regression  to determine the relationship between habitual protein consumption, BMI and 
habitual energy intake. The basic model for the two dependent variables (BMI and energy intake) was 
adjusted for habitual protein consumption, social class (income), physical activity levels and gender. 
Multiple regressions were performed in the age groups separately and combined. The combined age 
group multiple regression was adjusted for the interaction term (age group). Model 1 (table 6.2) 
showed that all variables inputted into the model, including protein intake and the interaction term 
(age group) were significant predictors of habitual energy intake. When regression models were 
conducted separately for younger (table 6.3) and older (table 6.4) adults, again percentage energy 
from protein and all other variables inputted into the model were significant predictors of energy 
intake, with the exception of activity levels in the older age group, in which was not significant. 
Results from the multiple linear regression to determine if percentage energy from protein 
independently influences BMI showed that only percentage energy from protein and interaction term 
(age group) are significant predictors of BMI (table 6.5). However when the two age groups were 
looked at individually, the results showed that gender and percentage energy from protein are 
significant predictors of BMI in the young group (table 6.6), but in the older age group, when all other 
factors are taken into consideration, percentage energy from protein was not a significant predictor of 
BMI, only gender (table 6.7).  
 
 
 
 
214 
 
Table 6.2. Multiple regression to determine the relationship between percentage energy from protein 
and energy intake (combined age groups). 
 Unstandardised Coefficients Standardised 
Coefficients 
t Significance 
Predictor Variable β Std Error Beta 
% energy from 
protein 
-37.99 60.03 -.232 -14.24 p<0.001 
Annual income 66.91 2.67 .130 7.15 p<0.001 
Gender -460.85 9.36 -.425 -25.86 p<0.001 
Activity (z score) 58.21 17.82 .106 6.53 p<0.001 
Interaction term 
(age) 
-130.822 8.91 -.102 -5.62 p<0.001 
 
Final model summary from the multiple linear regression (p<0.001, adjusted R
2
 = 0.318). All 
variables were significant predictors of energy intake. 
 
Table 6.3. Multiple regression to determine the relationship between percentage energy from protein 
and energy intake in adults aged 19-74 years. 
 Unstandardised Coefficients Standardised Coefficients Significance 
Predictor Variable β Std Error Beta t 
% energy from 
protein 
-37.24 3.10 -.224 -12.01 p<0.001 
Annual income 76.75 11.83 .122 6.486 p<0.001 
Gender -480.50 21.14 -.429 -22.74 p<0.001 
Activity (z score) 63.07 10.45 .144 6.03 p<0.001 
 
Final summary from the multiple linear regression (p<0.001, adjusted R
2
= 0.309). All variables were 
significant predictors of energy intake. 
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Table 6.4. Multiple regression to determine the relationship between percentage energy from protein 
and energy intake in adults aged 75+ years. 
 Unstandardised Coefficients Standardised Coefficients Significance 
Predictor Variable β Std Error Beta t 
% energy from 
protein 
-43.62 5.09 -.289 -8.62 p<0.001 
Annual income 44.57 14.37 .107 3.10 p=0.002 
Gender -390.03 32.12 -.419 -12.15 p<0.001 
 
Final models summary from the multiple linear regression (p<0.001, adjusted R
2
=0.323). Percentage 
energy from protein (%), annual income and gender are significant predictors of BMI. Activity levels 
have no significant effect on energy intake (p=0.204). 
 
Table 6.5. Multiple regression to determine the relationship between percentage energy from protein 
and BMI (combined age groups). 
 Unstandardised Coefficients Standardised Coefficients Significance 
Predictor Variable β Std Error Beta t 
% energy from 
protein 
.229 0.029 .149 7.98 p<0.001 
Interaction term -.942 0.206 -.085 -4.58 p<0.001 
 
Final model summary from the multiple linear regression (p<0.001 R
2
=0.031). Percentage energy 
from protein (%),and interaction term (age group) are significant predictors of BMI. Annual income 
(p=0.559), Activity levels (z score) (p=0.239) and gender (p=0.086) has no significant effect on BMI. 
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Table 6.6. Multiple regression to determine the relationship between percentage energy from protein 
and BMI in adults aged 19-74 years 
 Unstandardised Coefficients Standardised Coefficients Significance 
 β Std Error Beta t 
% energy from 
protein 
.267 0.035 .171 7.73 p<0.001 
Gender -.602 0.222 -.060 -2.72 p=0.007 
 
Final model summary from the multiple linear regression (p<0.001, adjusted R
2
=0.031). Percentage 
energy from protein (%), and gender are significant predictors of BMI. Annual income (p=0.235) and 
activity (z score) (p=0.143) has no significant effect on BMI. 
 
Table 6.7. Multiple regression to determine the relationship between percentage energy from protein 
and BMI in adults aged 75+ years 
 Unstandardised Coefficients Standardised Coefficients Significance 
 β Std Error Beta t 
Gender .691 0.323 .078 2.14 p=0.020 
 
Final model summary from the multiple linear regression (p=0.020, adjusted R
2
= 0.006. Gender is a 
significant predictor of BMI. Annual income (p=0.189), activity levels (z scores) (p=0.393) and 
percentage energy from protein (p=0.052) do not significantly predict BMI. 
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6.8. Discussion 
6.8.1. Study overview 
 
The aim of this investigation was to explore the relationship between habitual protein consumption on 
body weight (BMI) and habitual energy intake, and if there is a different effect observed in different 
ages; old (75+ years) and young (19-74 years) using the NDNS dataset.  
6.8.2. Summary of findings 
 
Older adults (people aged 75+ years) had a decline in energy intake, a moderate increase in body fat 
percentage and a reduction in BMI with increasing age. This result is different to the younger 
population where there was an increase in BMI, a larger increase in body fat percentage than older 
people (demonstrated by a steeper regression line) and no changes in energy intake with increasing 
age. This confirms the concept of the ‘anorexia of ageing’ where with age there is a reduction in 
energy intake and body weight reductions (Morley, 1997; Morley and Silver, 1988). Data suggests 
that being slightly overweight (BMI 22-26) is protective in ageing (Kalantar-Zadeh et al., 2007) as 
reductions in body weight and energy intake are associated with an increased risk of mortality 
(Payette et al., 2000; Morley, 2007) highlighting the issue of maintenance of body weight with age. 
As described in chapter 1, an explanation for the reduction in energy intake and reductions in body 
weight with ageing, could be due to an alteration in the appetite regulatory system. Chapter 4 
observed increases in post-prandial PYY levels in ageing. PYY has been shown to be involved in 
protein-induced satiety (Pedersen-Bjergaard et al., 1996; Leidy et al., 2010; El Khoury et al., 2010)  
thus; I wanted to understand the role of protein on body weight and energy intake in older compared 
to younger adults. 
High habitual intakes of protein were positively correlated with BMI in both the older and younger 
populations. However, when other factors were taken into consideration in a multiple regression, a 
significant effect was only seen in the younger persons only. This data disproves my hypothesis as 
this study found no effect of habitual protein consumption on BMI in older people, suggesting that 
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older adults are insensitive to the effects of protein on body weight. The increase in BMI and body fat 
percentage with increased habitual protein intake was also not expected, and does not fit in with 
current literature where reductions in body weight are normally observed with high protein diets in 
younger adults (Due et al., 2004; Weigle et al., 2005). 
Energy intake declined with high habitual protein intake in both age groups confirming previous 
studies (Chapman, 2011; McMinn et al., 2011). Energy intake decreased to a larger extent in the older 
volunteers with high protein consumption than seen in the younger population.  This difference 
between the younger and older population was confirmed by a significant difference in the regression 
lines. In addition when age category (young and old) was inputted into a multiple regression looking 
at protein on habitual energy intake, age appeared to be a significant predictor of alterations in energy 
intake in response to protein consumption. Both the differences in the effect of protein on BMI and 
energy intake in younger and older people suggest that there is a difference in older person’s 
responses to protein. This is the first study to my knowledge that has investigated the role of protein 
on body weight and habitual energy intake between younger and older adults on a population basis. 
An explanation that could be hypothesised for this difference in energy intake response could be due 
to an alteration in the appetite regulatory system. 
Similar findings were also observed with fibre intake, where an increase in BMI and a reduction in 
food intake with high habitual fibre intakes were observed. Unlike protein, no difference was detected 
between the age groups regression lines. Only one other study to date has looked at fibre intake and 
BMI on a population basis in ageing, and observed alternative results, where fibre consumption did 
not influence BMI (Howarth et al., 2007). No effect was observed with high habitual intakes of 
carbohydrate and fat on BMI and energy intake, but was approaching significance in the younger 
volunteers where high habitual fat intakes were associated with increased calorie consumption.  
The increase in BMI, but a decrease in energy intake with high habitual protein intake was not 
expected in this study. It was however expected, confirming my hypothesis,  that the older age group 
would have a different response to habitual protein intakes on BMI and energy intake. More studies 
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need to be conducted in older people to understand the mechanisms behind the alterations that have 
been observed.  
6.8.3. Habitual protein intakes 
 
High habitual consumption of protein was associated with reductions in energy intake in this present 
study. Energy intake appeared to decline more in the 75+ age group, demonstrated by differences in 
younger and older volunteers regression lines. It has already been observed in young adults, that 
following the consumption of a high protein meal there is a reduction in food intake (Vandewater and 
Vickers, 1996; Latner and Schwartz, 1999; Porrini et al., 1997). A few studies have demonstrated that 
high protein diets do not produce a reduction in food intake. In a study by Raben et al (2003) using a 
32% protein meal, there was no difference in food intake compared to equal energy content 
carbohydrate and fat meal (Raben et al., 2003). However, the majority of studies have demonstrated a 
reduction in food intake which remains in line with the results observed in this study. It has been 
shown that protein elicits its appetite suppressing effects via an increased release of gastrointestinal 
appetite hormones GLP-1 and CCK (Bowen et al., 2007; Bowen et al., 2006b; Bowen et al., 2006a; 
Blom et al., 2006), and PYY (Batterham et al., 2006; Pedersen-Bjergaard et al., 1996) and a reduction 
in the hunger hormone ghrelin (Bowen et al., 2007; Bowen et al., 2006b). With the elevation in PYY 
with normal protein intake in older adults seen in chapter 4, it would be of interest to understand if 
protein elicits a more substantial increase in PYY, thus inducing a higher level of satiety, in older 
compared to younger adults, and thus explaining why older adults appear to have different energy 
intake responses to protein in this study. Another explanation for the differences seen between 
younger and older adults responses to protein is that protein may affect different regions of the brain 
that are involved in central control of food intake inducing satiety. The effects of protein on central 
mechanisms of appetite may be heighted in older adults (discussed in more detail in chapter 7.4) 
therefore explaining the age related alterations in response to protein. It has also been previously 
suggested that infusions of protein activate the ileal brake (Meyer et al., 1998), which is mediated by 
PYY, causing increases in feelings of satiety and reducing ad libitum food intake. Older adults have 
been suggested to have an intestinal dysregulation with increased gastric emptying times (Morley, 
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1997; Clarkston et al., 1997) compared to younger adults. With the addition of protein to the diet, this 
effect may be exaggerated, causing a further reduction in food intake. However, not all studies agree 
that there is a reduction in gastric emptying with aging (Madsen and Graff, 2004; Gainsborough et al., 
1993) with the literature around protein on gastric emptying unclear, but this could be an avenue to 
explore in order to understand age related changes in energy intake response to protein in the future. 
What was not expected and does not fit in line with current literature, was that high habitual intakes of 
protein were correlated with an elevation in BMI, which was not seen in the older volunteers when 
taking into account other factors using a multiple regression, suggesting that they may be insensitive 
to the effects of protein on body weight. Previous long-term studies have demonstrated that high 
intakes of protein result in a reduction in body weight in adults. Weigle et al, (2005) demonstrated that 
volunteers that were subjected to 12 weeks of a high protein diet (30%) reduced ad libitum food 
intake and induced weight loss (Weigle et al., 2005). It has also been shown that there is better weight 
maintenance on an 18% energy intake from protein than 15% energy intake from protein (Westerterp-
Plantenga et al., 2004; Lejeune et al., 2005). In a randomised 6 month trial comparing ad libitum high 
protein (25%) low fat diet with normal protein (12%) low fat diet for six months, there was an 
improved weight loss with the high protein diet (Skov et al., 1999). This current study does not 
replicate these results, where higher habitual intakes of protein were associated with an elevated BMI, 
with the effect seen to a lesser extent in the older people. To determine if the effect of protein on 
increased BMI was due to an increase in lean body mass, protein intake was correlated with body fat 
percentage. Body fat percentage increased with protein consumption which goes against current 
literature where it has been demonstrated that protein contributes to the storage of fat free mass (Jean 
et al., 2001) and helps to maintain muscle mass (Phillips et al., 2009; Frestedt et al., 2008). The reason 
for the differences in results may be due to the use of diet diaries for obtaining food consumption. 
Body fat percentage was also an estimate, which may not be the true value, however this was the best 
method that was available to use. The results from the multiple regressions for the younger adults had 
a low R
2
 value of 0.031 which suggests that other factors are more likely to significantly impact on 
BMI more so than protein, suggesting that it is not a strong predictor of BMI. 
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No studies to my knowledge have investigated the effect of protein intake on body weight and energy 
intake in older people on a population basis. These results suggest that habitual protein intake has 
more of an effect on reductions in energy intake in older compared to younger adults. If this is the 
case, a more suitable approach to increasing food intake in older adults may be via the provision of 
using lower protein diets. Research needs to be conducted to investigate further the changes in 
appetite responses of older people to high protein meals. It is beyond the scope of this study to 
determine if there is a difference in sensitivity in older people, but results suggest that there is a 
difference in older and younger people’s response to protein.   
6.8.4. BMI and energy intake decrease’s in older adults 
 
It is well established that the ‘anorexia of ageing’ occurs in older people (refer to section 1.2). This 
study looking at a cross section of the population confirmed this by showing that in the older 
population (75+ years) in the NDNS dataset, there is a reduction in BMI and energy intake with 
increasing age. In the population aged 19-74 years the opposite was observed, where there was an 
increase in BMI and a lack of an alteration in energy intake. The population that was analysed in this 
study was from the healthy population, where only those volunteer’s whose responses to a health 
questionnaire regarded them as well without eating affected were included. This is not the most robust 
method of measuring health, but this was the only available option available to me to use in this 
dataset. It has been demonstrated in section 4 however, using more robust measurements of health 
status (blood samples, questionnaires) that a reduction in energy intake is seen in healthy ageing. 
6.8.5. Habitual fibre intakes 
 
Fibre is a dietary constituent that is not degraded enzymatically to absorbable units in the intestine and 
the stomach. Different types of fibre have been shown to have different effects on satiety (Heaton, 
1973; Touyarou et al., 2011; Vitaglione et al., 2009). It is thought that the increased mastication 
involved in consuming high fibre foods promote satiation by reducing the rate of ingestion (Heaton, 
1973). In this study a significant positive correlation was observed with fibre intake and BMI with no 
difference between regression slopes between the older and younger volunteers, suggesting that older 
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people do not respond differently to younger people to fibre intake. There was also a negative 
correlation between habitual fibre intake and energy intake with no difference between the regression 
lines. This shows similar results to that seen with habitual protein intake where there was a decrease 
in energy intake with high habitual intakes of protein but contradictory results where there was an 
increase in BMI.  There is no definitive answer on if high intakes of fibre affect body weight and 
energy intake. Howarth et al (2001), in a recent review of the recent literature looking at fibre and 
energy intake and body weight demonstrated that out of 26 studies, 14 (54%) showed an absolute 
reduction in energy intake. Different fibre types also demonstrated different effects in energy intake. 
In longer term studies (≥1 week), 24 out of 38 showed a reduction in energy intake. When Howarth 
looked at fibre intake on body weight, out of 66 trials, 39 demonstrated a reduction in body weight 
(59%) (Howarth et al., 2001). Therefore it is not known of the effect of fibre on BMI, but the results 
made it clear in this study that there is not an alteration in the response of different age groups to fibre 
intake on BMI and energy intake. 
Only one other study has investigated the role of fibre on body weight in younger and older adults in a 
population basis. Howarth et al, (2007) using 24 hour food diary recalls from a cross-section of the 
population found that unlike younger adults, older volunteers BMI was not associated with fibre 
density of the diet. Reasons for the differences in results between this present study and Howarth et al 
(2007) may be due to the use of different methodologies. Howarth et al (2007) used regression 
analysis to determine if fibre intake predicted BMI, this present study did not conduct a regression 
analysis for fibre intake and BMI as this was not the primary outcome for the study. Future work 
would use regression analysis to determine if older and younger adults have different body weight 
responses to protein. There was no difference in the regression lines between the younger and older 
adults and therefore I would not expect a difference between the two age groups. Differences in 
results could have also been due to the use of different types of food diaries to obtain results. 
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6.8.6. Habitual carbohydrate intakes 
 
Habitual carbohydrate consumption was not associated with changes in BMI and energy intake in 
both the younger and older adults. The lack of effect seen on body weight and food intake confirms 
the study by Ryan et al (2004), where high carbohydrate in the diet does not affect food intake. The 
results from this study showed that there are no differences between younger and older adults energy 
intake and body weight response to high intakes of carbohydrate.  
This study only analysed total carbohydrate intake. There are many different carbohydrate molecules; 
glucose, maltose, fructose, sucrose and maltodextrin. Carbohydrate polysaccharides have a lower 
glycaemic index (GI). GI relates to the speed at which a fixed amount of ingested carbohydrate raises 
blood glucose. In a review, of 31 short-term studies looking into high GI foods, 15 demonstrated that 
high GI foods reduced appetite and food intake, 14 had no effect and 2 lowered food intake compared 
to a high GI (Raben, 2002). It was not in the scope of this study to measure glycaemic index because 
many factors can affect the GI of a diet, but future work may focus on low GI diets and energy intake 
and BMI in the elderly. 
6.8.7. Habitual fat intake 
 
Habitual fat intake had no effect on BMI and habitual energy intake. However, a correlation between 
habitual fat intake and habitual energy intake was approaching a significant positive correlation in the 
younger age group, where as fat content of the diet increased, energy intake increased. Previous 
studies have shown that high fat meals, compared to low fat meals induce a larger subsequent food 
intake (Astrup et al., 2002; Clegg and Shafat, 2010), the lack of significance may be due to other 
environmental factors, and/ or the quantity of other macronutrients consumed in the diet, and the type 
of fat consumed in the diet. 
Studies have suggested that different types of fats SCFA (short chain fatty acids), MCFA (medium 
chain fatty acids), LCFA (long chain fatty acids), saturated and unsaturated fatty acids may have 
different effects on appetite. Medium chain fatty acids have different effects on satiety that other fatty 
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acids (Stubbs et al., 2000a; Van Wymelbeke et al., 1998; French et al., 2000), but it is not within the 
scope of this study to measure this.  
Di Francesco et al (2010) investigated the differences in appetite gastrointestinal hormone response 
and subjective feelings of appetite in older and younger volunteers to different fat containing meals. 
Volunteers attended two study visits, on one visit they were required to consume a 20% fat meal, and 
on the other occasion a 40% fat meal. Plasma GLP-1 levels were higher following the 40% fat than 
the 20% fat meal in the older but not the younger volunteers, and there was also a reduction in hunger 
in the older age group only following the 40% fat meal. However, this study did not measure ad 
libitum food intake, and so it remains unknown if the elevation in GLP-1 and reductions in hunger 
would result in subsequent reductions in food intake. The lack of significant difference between older 
and younger adults appetite and body weight response to habitual fat intake in this present study 
suggests that older and younger adults have similar appetite responses to fat, which contradicts Di 
Francesco et al (2010) study. The differences in results are likely to be due to the very different 
methodologies used in Di Francesco et al (2010) study and this described study. Short term acute 
investigations are required to determine if there is an alteration in energy intake in response to high fat 
meals between older and younger adults. 
6.8.8. Limitations  
 
Diet diaries are not the most accurate method for the measurement of food intake. A large problem 
with dietary surveys is that people under-report their true habitual food intake. Low energy reporting 
has been shown to be highly prevalent among obese participants, those who smoke, or those of the 
manual social class (Pryer et al., 1997). Low energy reporting has also been seen in both the young 
NDNS dataset (Pryer et al., 1997) and the old NDNS dataset (Cook et al., 2000). However, this is an 
issue that could not be controlled for in this study. 
There are a lot of limitations with running a study using the NDNS dataset with the use of food diaries 
as it only measures relationships rather than true effects. The NDNS dataset is also not designed to 
explore this studies question. However, this study was a preliminary study in order to determine if it 
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would be worthwhile to run a test meal study to investigate the effect of protein on appetite and 
energy intake in older adults. Although no direct answers have been provided to what the actual 
changes are in response to protein, this study provided the answer needed to suggest that further 
investigations are warranted in this area of research.  
6.8.9. Conclusions 
 
The aim of this investigation was to determine if there is a different relationship between older and 
younger people’s responses to dietary protein on body weight and food intake. This study provided 
useful evidence to suggest that there are differences in responses of older people to high protein meals 
which was demonstrated by a difference in the regression line slopes. A multiple regression also 
confirmed that there were differences in responses in older people to protein. There didn’t appear to 
be any differences between older and younger adults for BMI and energy intake in response to 
habitual intakes of any other macronutrients. Further study is now required to understand the 
mechanisms behind the changes in energy intake and BMI response to protein. It could be possible 
that there is a different appetite hormonal response to protein in older people, as high protein foods 
have been demonstrated to increase PYY and other satiating gastrointestinal hormones significantly 
(Leidy et al., 2010; Batterham et al., 2006; Bowen et al., 2006a; Blom et al., 2006). It was observed 
that PYY was higher in my previous study (section 4) in older adults, there may be an increased 
sensitivity of older people to satiety hormones, and an increased ability to increase satiety hormones 
in response to protein. It is also unclear why the energy intake decreased with high protein intake and 
BMI increased. A study looking at appetite and gastrointestinal appetite hormone responses to protein 
needs to be conducted on older and younger people to clarify what effect protein has on appetite in 
older people.  
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7.1. Introduction 
 
Section 1.7. explored the literature on protein, food intake and satiety in younger adults. This section 
provided evidence to suggest that with high intakes of protein there was a greater feeling of satiation 
and satiety, reduced food intake in the short term and even body weight loss in the longer term. In 
addition to this, it was also discovered that the putative satiety hormone PYY is released to a greater 
extent following a high protein meal in young adults (Pedersen-Bjergaard et al., 1996; Batterham et 
al., 2006). No study to date has determined if older adults have a different gastrointestinal appetite 
hormone response to protein than younger adults. It has already been demonstrated that older adults 
appear to have a different response to fat in the diet than younger adults (Di Francesco et al., 2010). 
In chapter 6, using the NDNS dataset, there was some evidence to show that the older population’s 
(+75 years) changes in BMI and habitual energy intake in response to differing habitual protein 
intakes were different to that of the younger population. However, the underlying cause of this 
difference is unclear. Chapter 6 was also unable to provide information on whether there are 
differences in PYY release, food intake and appetite responses in older adults compared to younger 
adults in response to high protein meals. There needs to be further study to clarify what the alterations 
are in ageing in the appetite responses to protein. In chapter 4, results showed a significant increase in 
the satiety hormone PYY with ageing. Therefore, if there is an increase in PYY concentrations with 
moderate levels of protein (~15%) compared to younger adults, this increase may be more substantial 
following a high protein meal, meaning that older adults are more sensitive to the satiety effects of 
protein. If older adults appear to be more sensitive to the effects of protein by a more substantial 
increase in the satiety hormone PYY, and subsequent reductions in appetite and food intake, this 
would provide some useful insight into the type of therapeutic approaches to maintaining energy 
intake to sustain body weight in older adults. 
A cross-over study needs to be designed to compare gastrointestinal appetite hormone (PYY in 
particular) and appetite responses to differing protein meals between younger and older adults to 
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clarify what changes, if any, occur between younger and older adults responses to different protein 
concentrations. 
7.2. Hypothesis 
 
In older adults there will be a larger elevation in post-prandial PYY concentrations and a larger 
reduction in subjective feelings of appetite and food intake following a high protein preload in 
comparison to a low protein preload than what is observed in younger adults. 
7.3. Aims and objectives 
 
7.3.1. Aims 
 
The aim is to compare the response of older and younger volunteers to different protein preloads on 
energy intake, gastrointestinal appetite hormones, and subjective feelings of appetite. 
7.3.2. Objectives 
 
1. To investigate the effect of ageing on post-prandial PYY response to different protein 
containing preloads. 
2. To determine the effect of ageing on food intake following different protein content preloads 
3. To determine the effect of ageing on GLP-1, and acyl ghrelin response to different protein 
content preloads 
4. To determine the effect of ageing on reported appetite scores during the test meal process 
after different protein content preloads. 
5. To investigate if different protein content preloads have a different effect on glucose, insulin 
and gastric emptying in older compared to younger people. 
 
Primary Outcome: PYY concentrations and energy intake at an ad libitum meal in response to 
different protein containing preloads. 
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Secondary Outcomes: Subjective feelings of appetite (VAS), GLP-1, acyl ghrelin, insulin and glucose 
response to different protein containing preloads. 
 
7.4. Methodology 
 
7.4.1. Study design 
 
This study was a cross-over, randomised and single-blinded study, and will involve the consumption 
of a breakfast preload containing differing levels of protein. Differences in food intake and 
gastrointestinal appetite hormone release and subjective feelings of appetite following different 
protein containing preloads will be compared between age groups. 
7.4.1.1. Recruitment 
21 participants were recruited into this pilot study into the following age groups; 20-39 and 65+ years. 
Ten participants were recruited into the 20-39 age group, and 11 participants were recruited into the 
65+ age group. These age groups were chosen based on the human comparison study in section 4 
where there was a significant increase in PYY levels in the over 80’s group in comparison to the 20-
39 age group. The cut off age of 65 years was chosen in order to aid recruitment. As this was a pilot 
study, a power calculation was not performed.  
7.4.1.2. Experimental test meal 
Before the study could commence, the experimental test meals needed to be developed. Whey protein 
isolate of a neutral flavour (Vitaflo, Liverpool) was chosen as it has been seen in a number of studies 
to reduce appetite and food intake (Akhavan et al., 2011; Akhavan et al., 2010; Pal and Ellis, 2011). 
The use of this type of protein was also ideal as it could be added to a meal without altering the taste. 
The experimental test meals consisted of three different protein containing preloads; a high protein 
content meal (60%), a medium protein content meal (30%) or a low protein content meal (15%) 
(control meal). The meals were given to the participants in a randomised order to ensure that they 
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were unaware of the protein content of the test meal given to them. The randomisation was conducted 
simply by asking a volunteer that is not included in the study to pick a folded piece of paper out of a 
box that had 15%, 30%, or 60% written on it. The first paper chosen will be the protein meal for the 
first visit (excluding the sham visit), the second paper drawn will be for the second visit, and so on. In 
this section the 15% protein meal will be referred to as visit B, the 30% protein meal will be referred 
to as visit C and the 60% protein meal will be referred to as visit D. The sham visit is referred to as 
visit A. 
The control (15% low protein) meal was provided on the sham/practice visit. Energy densities of the 
meals were matched for an estimation of 40% of BMR, predicted from the Benedict Equation for 
males and females. The Harris Benedict Equation provides a valid estimation of resting metabolic rate 
at a group level in males and females (De Lorenzo et al., 2001). A measurement of 40% was used 
because it was considered a large enough calorie intake to produce a sufficient hormonal response that 
is considered not too much for an elderly person to eat. 
Harris Benedict Equation: 
Males: BMR= 66 + (13.7 x Weight kg) + (5 x Height cm) – (6.8 x Age)  
Females: BMR = 655 + (9.6 x Weight kg) + (1.8 x Height cm) – (4.7 x Age) 
BMR was estimated for 25 year old and 80 year old males and females based on a 75kg male 175cm 
in height and a 62kg female 168cm in height (average height taken from the study population in 
section 4). 
Total and 40% BMR estimates can be seen in table 7.1 
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Table 7.1. Total and 40% estimated BMR estimates in males and females 
Total BMR estimates  
Female 80 years old 1176.6 kcal 
Female 25 years old 1382.6 kcal 
Male 25 years old 1978.5 kcal 
Male 80 years old 1604.5 kcal 
40% BMR estimates  
Female 80 years old 470.6 kcal 
Female 25 years old 553.0 kcal 
Male 25 years old 791.4 kcal 
Male 80 years old 641.8 kcal 
 
Total and 40% BMR estimates based on a 75kg male and 62 kg female using the Benedicts equation. 
Height was based on the average seen in section 4; 175cm for males and 168cm females. 
 
Due to the relatively small differences in calories needed between the 80 and 25 years age groups an 
average was taken for each gender; 512kcal for females and 716 kcal for males to be consumed in the 
experimental breakfast. Experimental meals were made as close to the calorie content as possible. 
Nutritional composition of the experimental meals can be seen in table 7.2. The meal consists of a 
milk type flavoured pudding (Ensure Crème and Nutricia Forticreme) as these provide high calorie 
palatable meals in smaller quantities that could be easily consumed by elderly people. Whey protein 
of a neutral flavour (Vitaflo, Liverpool) was added to increase protein levels and maltodextrin 
(Vitaflo, Liverpool) a carbohydrate that does not add sweetness to the product was used to increase 
calorie content. The aim was to manipulate the energy and protein content while maintaining the 
flavour and consistency of the pudding to enable blinding of the participants to the macronutrient 
content of the meal. Carbohydrate was used to increase the calorie content of the meal rather than fat 
because it has been demonstrated by Di Francesco et al (2010) that meals containing higher levels of 
fat influence hunger and gastrointestinal hormone response in older adults. Other studies have also 
shown that carbohydrates have the smallest influence on food intake compared to the other 
macronutrients (see section 1.7.6.). Experimental test meals were taste panelled within the 
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Department of Investigative Medicine, Imperial College London to determine its palatability and to 
ensure that people could not detect which meal was a high protein meal.  
Table 7.2. Nutritional composition of protein preload meals provided in the study visits in males and 
females 
 Kcal Protein (g) Fat (g) Carbohydrate (g) 
Females     
15% Protein Meal 512 19.2 13.41 78.4 
30% Protein Meal 514 38.4 13.5 60.1 
60% Protein Meal 516 76.8 10.3 29.1 
Males     
15% Protein Meal 717 26.9 20.1 107.1 
30% Protein Meal 717 53.8 19.1 82.6 
60% Protein Meal 719 107.6 15.0 43 
 
Nutritional content (kcal, protein (g), fat (g) and carbohydrate (g)) of the 15%, 30% and 60% protein 
content preload test meals provided in the study visit. 
 
7.4.1.3. Screening of participants 
Participants were screened prior to taking part in the study. A detailed description of the screening 
process is described in section 2.2 and 2.3 
7.4.2. Study plan 
 
Participants that were eligible to take part in the study signed a consent form and read the information 
sheet sent to them (see appendix 10.9), only once they had done this they were allowed to take part in 
the study. 
Participants attended four ½ day visits lasting around 4 hours, arriving at 8.30am. Participants were 
fasted, having not eaten from 9pm the night before, and had not consumed alcohol and avoided 
excessive exercise the night prior the study visit. Participants were also asked to consume the same 
evening meal the night before the study visit to try and standardise conditions. 
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The first study day was a practice (sham) visit, where exactly the same test meals, number of blood 
samples and VAS were taken. A reduced amount of blood was taken on the sham visit as they were 
not analysed. Gastrointestinal hormones are easily influenced by stress, therefore participants were 
required to attend a sham visit in order for them to become accustomed to the environment (for more 
information please see chapter 2.5). 
The following three study day visits were identical to the sham visit, with the exception that larger 
blood samples were taken for gastrointestinal hormone analysis, and that differing protein content 
preloads were provided. 
On arrival to the study visit (8.30am), participants had an i.v. (intra-venous) cannula placed in a vein 
in their arm for blood sampling. Participants were given 30 minutes following cannulation to become 
accustomed to the environment before any test was undertaken. Blood samples were taken at baseline 
(0 min) for comparison of fasting gastrointestinal appetite hormone levels. A blood pressure reading 
was also taken (see section 2.1.4) as a precautionary monitor of the volunteers health. Immediately 
following the first blood sample participants were asked to consume the experimental test meal (either 
15% protein preload (B), 30% protein preload (C) or 60% protein preload (D)). Participants were 
required to consume all of the experimental test meal for a standard intake of energy and 
macronutrients. Participants were given 15 minutes to consume the standard test meal. At the same 
time that the test meal was to be consumed, participants also drank 250ml of water containing 1.5g of 
soluble paracetamol which was used for the measurement of gastric emptying.  
Blood samples were then taken at 15, 30, 60, 120 and 180 minutes following the standard test meal 
for comparison of release of gastrointestinal hormones in response to the experimental test meals. 
Timeline of the study visit can be seen in figure 7.1. Participants were also asked to fill in VAS to 
assess feelings of hunger, nausea, appetite and satiety with every blood sample taken (see details in 
section 2.8).  
At 180 minutes the cannula was removed and participants were presented with a large ad libitum test 
meal and were invited to eat until they were comfortably full. Comfortably full was described to the 
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participants as a feeling of satisfaction without feeling that they have eaten too much or too little. A 
final VAS was filled in following the ad libitum test meal for subjective feelings of hunger and satiety 
and for an assessment of food palatability. Nutritional composition and description of the test meals 
are described in section 2.4. 
When leaving the study day, participants were given another experimental test meal (same as the 
experimental meal provided on the study day) and a 3 day food diary to fill in. Participants were asked 
to fill in their food diary, starting immediately. Participants were asked to consume the same 
experimental meal received in the study visit the following day for breakfast. They were also asked to 
write down the time that they consumed the breakfast, and were asked to not eat again that day until 
they felt hunger. Hunger was described to the participants as a ‘physiological drive to eat’ i.e. they are 
experiencing ‘hunger pangs’ or other physical symptoms and feelings of hunger. The time of their 
next eating episode was recorded in their food diary along with the quantity and what they ate in 
addition to everything else they consumed for the next two days. The food diary was to observe if 
there were any lasting effects of the experimental meal on longer term food intake. Completed food 
diaries were assessed with Dietplan-5 nutritional analysis software (Forestfield Software, Horsham, 
West Sussex, UK). Participants were also asked to wear the actical activity monitor for a period of 
three days, with one day a weekend at some point during their participation in the study to measure 
energy expenditure. Details on the activity monitor can be seen in more detail in chapter 2.3.6. 
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Figure 7.1. Diagram of overview of study day. Participants were asked to attend four study days 
 
 
 
 
 
 
 
 
 
7.4.3. Measurement of outcomes 
 
Measurement of gastrointestinal hormones, glucose and gastric emptying; Detailed in chapter 2.7. 
Subjective feelings of appetite; Detailed in chapter 2.8. 
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7.5. Statistical analysis 
 
Statistical analysis was performed using SPSS 18.0 for Windows (SPSS Science, Apache Software 
Foundation, Chicago, IL, USA). All data was tested for normality prior to any statistical analysis 
using a Kolmogorov-Smirnov test for normality. Parametric analysis was applied to the normally 
distributed data, and results were presented as Mean (SEM), with the exception of descriptive data 
which was presented as mean (SD). It has been described previously by Segwick et al (2011), that 
descriptive data should ideally be presented as mean (SD). Any data that was non-parametric was log 
transformed to the power of 10 and tested for normality once again.  If data was then normally 
distributed, parametric analysis was applied to the log transformed data, and was presented on a log-
10 transformed axis in graphs as mean (SEM) and as geometric mean (IQ range) in tables. Data that 
was not normally distributed, even following log transformation, was presented as Median (IQ range). 
The aim of this study was to observe the effect of different protein preloads on a number of 
parameters. Comparisons were made using the Area Under Curve (this method was used instead of 
the IAUC because there was no statistical difference between any baseline values in the different age 
groups individually) or mean scores (food diaries, gastric emptying) to compare response to protein 
preloads in each age group (20-39 and 65+) individually. Comparisons were then made using a 
Repeated Measures ANOVA for parametric data and a Friedman Related samples test for non 
parametric data in each age group individually to determine if there is a statistical difference in 
response to the different protein preloads. To compare if there was a difference in response of the 
older and younger volunteers to the three different protein test meal conditions, percentage change 
was calculated between test meal B to C, B to D and C to D and comparisons were made using these 
scores between the 20-39 and 65+ age group using an independent samples t-test for normally 
distributed data and a Mann Whitney U test for non-normally distributed data. Non-normally 
distributed data for percentage change scores could not be log-transformed as some results contained 
negative values. 
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7.6. Results 
 
21 volunteers were recruited in total; 10 in the 20-39 age category (four males, six females) and 11 in 
the 65+ years category (five males, six females).  All 21 volunteers attended all four study visits. 
7.6.1. Descriptive statistics 
 
Descriptive data of the participant’s characteristics can be seen in table 7.3. BMI, body weight and 
body fat percentage was higher in the 65+ age group, but was not statistically significant. Lean body 
mass percentage was lower in the 65+ age group, but again the values between the two age groups 
were not statistically different to each other. 
Table 7.3. Mean and SD values for volunteer’s descriptive characteristics  
 Mean (SD) 
 20-39 years (n=10) 65 + years (n=11) 
 
Age (years) 
 
22 (1.51) 
 
 
76 (7.59) 
 
BMI (kg/m
2
) 
 
23.27 (2.09) 
 
 
23.48 (1.99) 
 
Weight (kg) 
 
 
64.67 (10.12) 
 
66.13 (11.16) 
 
Body Fat (%) 
 
24.01 (5.30) 
 
 
25.90 (8.29) 
 
Lean Mass (%) 
 
20.36 (1.44) 
 
 
19.97 (2.09) 
 
Mean (SD) values for volunteer’s characteristics (Age, BMI, Weight (kg), Body Fat percentage and 
lean body mass percentage) in the 20-39 and the 65+ age group.
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7.6.2. Physical activity levels 
 
Total and physical activity energy expenditure (kcal) measured by the actical monitor was lower in 
the 65+ age group compared to the 20-39 age group, but did not reach significance between the two 
age groups (20-39 and 65+) in total energy expenditure (kcal) and activity energy expenditure (kcal) 
using an independent samples t-test. Mean (SD) values are presented in table 7.4 
 
Table 7.4. Total and activity energy expenditure in the 20-39 and 65+ age groups. 
 20-39 age group 
(n=7) 
65+ age group 
(n=10) 
Significance between 
age groups? 
Mean (SEM) Total energy 
expenditure (kcal) 
2196.16 (378.25) 
 
1947.57 (471.21) p=0.266 
 
Mean (SEM) Activity energy 
expenditure (kcal) 
552.01 (200.11) 
 
396.92 (211.07) p=0.149 
 
Mean (SEM) total and activity energy expenditure (kcal) in the 20-39 and 65+ age group. No 
significance detected between the age groups. 
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7.6.3. Energy intake at the ad libitum test meal 
 
Energy intake was lower following the 60% protein meal in both age categories in comparison to the 
15% and the 30% protein test meals (see table 10.11. in section 10.10. in appendix).  
Significance was detected between the three protein test meal conditions for ad libitum energy intake 
in the 20-39 age group (p=0.002) with the significance detected between the 15% and the 60% meal 
(p=0.006) and the 30% and the 60% meal (p=0.022). No significance was detected between the three 
protein test meals in the 65+ age group (Figure 7.2.) 
 
Figure 7.2 Energy intake (kcal) at the ad libitum test meal in the 20-39 and 65+ age groups following 
protein breakfast test meals B (15%), C (30%) and D (60%). 
 
 
 
 
 
 
 
 
Mean ± SEM energy intake (kcal) at the ad libitum test meal presented on a log
10
 transformed y axis 
in the 20-39 (n=10) (solid bar) and the 65+ (n=11) (patterned bar) age groups following protein 
breakfast test meals B (15%) (blue), C (30%)(red) and D (60%) (green). Significance detected in ad 
libitum kcal intake between the different test meals in the 20-39 age group (p=0.002) B versus D 
*p=0.006, C versus D **p=0.022. No significance detected in the 65+ age group. 
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Percentage change in ad libitum food intake. 
Percentage change in energy intake at the ad libitum test meal between protein test meals B (15%), C 
(30%) and D (60%) were compared between the two age groups to determine if they have a different 
response to protein. Percentages were used in order to make a fair comparison between age groups. 
Significance was detected between percentage change in energy intake following meals B to D 
between the 20-39 and 65+ age group (p=0.018), where the 20-39 age group had a significantly larger 
percentage reduction in food intake at meal D  in comparison to meal B than the 65+ age group. No 
significance was detected between age groups in percentage change scores between kcal consumed at 
the ad libitum meal following test meals B to C and meals C to D. Mean (SEM) values can be seen in 
table 7.5. 
Table 7.5. Percentage change in Kcal intake at ad libitum meal between test conditions B, C and D in 
the 20-39 and 65+ age groups. 
 20-39 (n10) 65 + (n11) Significance 
between age groups 
Percentage change in energy intake at 
ad libitum meal in test condition B 
(15%) to C (30%) 
 
+4.32% (9.71) 
 
+9.79% (6.76) 
 
 
p=0.644 
Percentage change in energy intake at 
ad libitum meal in test condition B 
(15%) to D (60%) 
 
-31.02% (5.78) 
 
-6.96% (7.14) 
 
 
p=0.018 
Percentage change in energy intake at 
ad libitum meal between test condition 
C (30%) and C (60%) 
 
-29.98% (6.98) 
 
 
-14.76% (4.91) 
 
p=0.086 
 
Mean (SEM) percentage change in ad libitum energy intake between test meal conditions B to C, B to 
D, and C to D in the 20-39 (n=10) and 65+ (n=11) age groups. Significance detected in the 
percentage change scores between test meal B and D (p=0.018) between the 20-39 and 65+ age 
group. 
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7.6.4. Food diaries 
7.6.4.1. Total energy intake on test days 
Total energy intake consumed on the study day (including energy intake on the study visit and energy 
intake outside of the laboratory conditions for the rest of the day) was calculated using food diaries. 
There was no significant difference between total energy intake consumed between the three protein 
test days B (15%), C (30%) and D (60%) in the 20-39 age group and in the 65+ age group.  Median 
(IQ range) values can be seen in figure 7.3 and in table 10.12 in appendix 10.10.1. 
 
Figure 7.3. Total energy intake (kcal) consumed on the whole study day in the 20-39 and 65+ age 
group following protein test meal B (15%), C (30%) and D (60%). 
 
 
 
 
 
 
Median (IQ Range) total energy intake (kcal) consumed on the test meal day (including kcal 
consumed at the study visit and kcal consumed on the rest of the day) at test meal B (15%) (blue), C 
(30%) (red)  and D (60%) (green) in the 20-39 (solid bar) and 65+ (patterned bar) age group. No 
significance detected between kcal consumption between the three test conditions in each age group. 
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Percentage change in total kcal consumed  
Percentage change in total kcal consumed between the protein test meals were compared between age 
groups. No significant difference was detected between percentage change in total energy intake 
following test days B to C, B to D and C to D between the 20-39 and 65+ age group. Mean (SEM) 
values can be seen in table 10.13 in appendix 10.10.1. These results show that there is no difference in 
younger and older adults longer term responses to different protein preloads. 
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7.6.4.2. Time to eat next meal 
Volunteers received a protein test meal to take home to consume the next day for breakfast; the meal 
that was taken home was the same experimental test meal that was consumed on that same test day. 
Participants were asked to record down the time that the test meal was consumed for breakfast, and 
they were asked to not eat again until they felt hungry (full explanation described in section 7.4.2). 
The time from consumption of the breakfast and the next meal was calculated for protein meal B 
(15%), C (30%) and D (60%). Time (hours) was compared between test meal conditions individually 
for the 20-39 and 65+ age group. Time to consume next meal was higher following protein test meal 
D (60%) than B (15%) in both the 20-39 age group and the 65+ age group. No significance was 
detected in the 20-39 and in the 65+ age group in time to consume next meal between the three test 
meal conditions (figure 7.4 and table 10.14 in appendix 10.10.1.). 
 
Figure 7.4. Time to eat next meal following protein preloads B (15%), C (30%) and D (60%) in the 
20-39 and 65+ age groups. 
 
 
 
 
 
 
 
Median (IQ Range) time to eat next meal (hours) following protein preloads B (15%) (blue), C (30%) 
(red) and D (60%) (green) in the 20-39 (solid bar) and the 65+ (patterned bar) age groups. No 
significance detected. 
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Percentage change in time to consume next meal 
Percentage change in time to eat next meal between the protein test meals was compared between age 
groups. No significant difference was detected in percentage change in time to eat next meal 
following meals B to D, B to C and C to D between the 20-39 and 65+ age group. This suggests that 
in non-laboratory conditions there is no difference in older and younger adult’s responses to protein. 
Mean values can be seen in table 10.15 appendix 10.10.1.  
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7.6.4.3. Energy intake on day two 
Participants filled out food diaries for the day following the study visit (the day when participants 
were asked to consume the protein preload for breakfast and to not eat again until hungry) and 
calories consumed on these test days were calculated to determine if the protein preload had an effect 
on longer term energy intake in normal living conditions. There was no significant difference in 
energy intake between test meal conditions B, C and D in the 20-39 age group, and also in the 65+ 
age group. See figure 7.5 and table 10.16. in appendix 10.10.1. 
Figure 7.5. Energy intake (kcal) on day two following protein preloads B (15%), C (30%)and D 
(60%) in the 20-39 and 65+ age groups. 
 
 
 
 
 
Mean (SEM) energy intake on day two in test conditions B (15%) (blue), C (30%) (red) and D 
(60%)(green) in the 20-39 (solid bar) and the 65+ (pattern bar) age groups. No significance detected 
between test meal conditions 
 
Percentage change in calorie intake on day two 
Percentage change total kcal consumed on day two between the protein test meals were compared 
between age groups. No significant differences were detected between percentage change in calorie 
intake on day two following meals B to D, B to C and C to D between the 20-39 and 65+ age group. 
The results suggest that there is no difference in older and younger adults long-term responses to 
protein in normal living conditions. Mean values can be seen in table 10.17 in appendix 10.10.1. 
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7.6.5. Visual analogue scales 
 
Comparisons between AUC VAS scores between the three test meal conditions were conducted 
individually for the 20-39 and 65+ age groups. No significance was detected in AUC how hungry, 
how sick, how pleasant to eat and how much can you eat between the three protein test meal 
conditions in the 20-39 and 65+ age groups. Scores for how full do you feel were higher following 
test meal D in the 20-39 age group. Significance was detected in the 20-39 age group between AUC 
fullness scores between the three test meal conditions. Post Hoc tests revealed this significance to be 
between test meal C (30%) and D (60%) (p=0.039), where fullness scores were significantly higher 
following test meal D. No significance was detected in the 65+ age group for AUC how full scores 
between the protein test meal conditions. 
AUC scores for how hungry, how sick, how pleasant to eat and how much can you eat were 
consistently lower in the 65+ age group, and fullness scores were consistently higher in the 65+ age 
group. Data for AUC visual analogue scores between the three test meal conditions in the 20-39 and 
65+ age group can be seen in figure 7.6. and in table 10.18 in appendix 10.10.2 
 
Percentage change in AUC VAS scores. 
Percentage change in AUC hunger, how sick, how pleasant to eat, how much can you eat and how full 
do you feel scores between the protein test meals B (15%), C (30%) and D (60%) were compared 
between age groups to determine if the different age groups have a different appetite response to 
protein. No significance was detected between percentage change in hunger, how sick, how pleasant 
to eat and how much can you eat AUC scores following meals B to C, B to D and C to D between the 
20-39 and 65+ age groups. Significance was detected between percentage change in how full AUC 
scores following meals B to D between the 20-39 and 65+ age group (p=0.032) where the younger 
volunteers had a significantly larger elevation in AUC fullness scores from test meal B to D whereas 
older volunteers AUC fullness scores decreased from test meal B to D. There was also a significance 
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detected between percentage change scores between protein test meal conditions C to D between the 
two age groups (p=0.007), where once again the younger age group had a larger elevation in fullness 
from test meal C to D. No significance was detected in percentage change scores between test meal B 
and C. Mean (SEM) values for how full scores can be can be seen in table 7.6. Percentage change 
scores for all other VAS scores can be seen in table 10.19 in appendix 10.10.2. 
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Figure 7.6. AUC Visual Analogue scores in the 20-39 and 65+ age group following protein test meal B (15%), C (30%) and D (60%). 
(i)                (ii)                (iii) 
 
 
 
 
 
          (iv)              (v) 
     
  
 
 
 
 
Mean ± SEM AUC scores for how hungry (i), how sick (ii), how pleasant to eat (iii), how much can you eat (iv) and how full do you feel (v) following protein 
test meals B (15%) (blue), C (30%) (red) and D (60%) (green) in the 20-39 (n=10) (block bar) and 65+ (n=11) (patterned bar) age groups.                          
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Figure 7.6. continued;  No significance detected between test meal conditions in the 20-39 and 65+ age groups for how hungry, how sick, how pleasant to 
eat and how much can you eat. No significance detected in AUC how full scores in the 65+ age group. Significance detected between test meal conditions in 
the 20-39 age group (p=0.033). Post hoc analysis revealed significance between test meal C (30%) and D (60%) *p=0.039.
250 
 
Table 7.6. Percentage change in how full do you feel AUC scores in test meal conditions B (15%), C 
(30%) and D (60%) in the 20-39 and 65+ age groups 
 20-39 (n10) 
Mean (SEM) 
65 + (n11) 
Mean (SEM) 
Significance 
Percentage change AUC how full do you feel 
scores from test condition B (15%) to C (30%) 
-9.97 
(-45.00 – 19.01) 
-17.19 
(-45.19 –   4.84) 
 
P=0.649 
Percentage change in AUC How full do you feel 
scores from test condition B (15%) to D (60%) 
26.32 
(-4.45 – 76.42) 
-17.36 
(-45.20 –   1.94) 
 
p=0.032 
Percentage change in AUC How full do you feel 
scores from test condition C (30%) to D (60%)* 
30.65 
(11.81 – 77.92) 
-1.5 
(-20.85 – 0.89) 
 
p=0.007 
 
Mean (SEM) percentage change scores for how much can you eat AUC scores in the 20-39 and 65+ 
years age group between protein test meals B (15%), C (30%) and D (60%). Significance detected 
between percentage change scores for B versus D (p=0.032) and C versus D (p=0.007) between the 
20-39 and 65+ age group 
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7.6.6. Plasma gastrointestinal appetite hormone analysis 
 
I wanted to determine if there were any significant differences between PYY, GLP-1 and acyl ghrelin 
AUC responses between protein test meals B (15%), C (30%) and D (60%) in each of the age groups. 
There was no significant difference between PYY, GLP-1 and acyl ghrelin AUC scores following the 
different protein test meals in the 20-39 age group and in the 65+ age group. Data is presented in 
figure 7.7 and in table 10.20 in appendix 10.10.3.   
 
Percentage change in gastrointestinal appetite hormones 
Percentage change in AUC PYY, GLP-1and acyl ghrelin scores between the protein test meals B 
(15%), C (30%) and D (60%) were compared between age groups to determine if the different age 
groups have a different gastrointestinal appetite hormone response to protein. No significance was 
detected between percentage change in PYY, GLP-1 and acyl ghrelin AUC scores following meals B 
to C, B to D and C to D between the 20-39 and 65+ age groups. Data is presented in figure 7.7. and 
table 10.21 in appendix 10.10.3. 
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Figure 7.7. AUC PYY, GLP-1 and acyl ghrelin in the 20-39 and 65+ age group following protein test meal B (15%), C (30%) and D (60%). 
  
    (i)                                                                       (ii)             (iii) 
 
 
 
 
 
 
Mean ± SEM PYY (i) and GLP-1 (ii) AUC scores on a log
10
 transformed axis and Mean ± SEM acyl ghrelin (iii) AUC scores following protein test meals B 
(15%) (blue), C (30%) (red) and D (60%) (green) in the 20-39 (n=10) (block bar) and 65+ (n=11) (patterned bar) age groups. No significance detected in 
AUC scores between protein test meal conditions in the 20-39 and 65+ age groups.  
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7.6.7. Plasma insulin, glucose and insulin resistance 
 
I wanted to determine if there were any significant differences between AUC insulin, AUC glucose 
and post-prandial insulin resistance responses between protein test meals B (15%), C (30%) and D 
(60%) in each of the age groups.  
There was no significant difference between insulin AUC scores between each test meal condition B 
(15%), C (30%) and D (60%) in the 20-39 age group. However, in the 65+ age group it was 
approaching significance (p=0.060) between the three test meal conditions B (15%), C (30%) and D 
(60%). Data is presented  in figure 7.8 (i) and table 10.21. in appendix 10.10.3. 
Plasma AUC scores for glucose declined with increasing protein content of the preload in both the 20-
39 and 65+ age group. There was no significant difference between the three test meal conditions B 
(15%), C (30%) and D (60%) in the 20-39 age group for glucose AUC scores. However in the 65+ 
age group, there was a significant difference (p=0.003) between the three protein test meal conditions. 
This difference was detected between test meal B and D (p=0.003), where plasma glucose AUC 
concentrations were significantly lower following protein meal D (60%) than protein meal B (15%). 
Data is presented in figure 7.8 (ii) and table 10.21. in appendix 10.10.3. 
 
An index of fasting insulin resistance (HOMA) was calculated using the following equation; 
HOMA = (glucose mmol/L * Insulin mU/L) / 22.5  
mU/L = pmol/7.5 (Raben et al., 2001). 
No comparisons were made to look at fasting insulin resistance as I am only interested in post-
prandial response between the test meal conditions. 
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An Index of post-prandial Insulin resistance (HOMA-PP) can be calculated using the following 
equation; 
HOMA-PP =  (IAUC Glucose nmol/L * IAUC Insulin mU/L) / 22.5 (Brynes et al., 2003). 
HOMA-PP scores declined following the higher protein containing preloads in the 20-39 and 65+ age 
groups. There was no significant difference between HOMA-PP scores between the three protein test 
meal conditions B (15%), C (30%) and D (60%) in the 20-39 age group. However, in the 65+ age 
group significance was detected between the three protein test meal conditions B (15%), C (30%) and 
D (60%) (p=0.003). Post-hoc test revealed this significance to be between test meal B (15%) and D 
(60%) (p=0.005) and test meal C (30%) and D (60%) (p=0.013) where HOMA-PP scores were 
significantly lower following test meal D (60%). Data can be seen in figure 7.8 (iii) and table 10.22. 
in appendix 10.10.3. 
 
Percentage change in AUC insulin and glucose 
Percentage change in AUC insulin, AUC glucose and post-prandial insulin resistance scores between 
the protein test meals B (15%), C (30%) and D (60%) were compared between age groups to 
determine if the different age groups have a different response to protein. No significance was 
detected between percentage change in AUC glucose scores between test meals B to C, B to D, and C 
to D between the 20-39 and 65+ age groups. Mean (SEM) values are presented in table 10.22. in 
appendix 10.10.3. 
For insulin, no significance was detected between test meals B to C, but a trend towards a significance 
in percentage chance scores between protein test meal  B to  D (p=0.067) between the 20-39 and 65+ 
age groups. There was a significant difference between percentage change scores in protein test meal 
C to D (p=0.041) between the two age groups. AUC insulin scores increased with increasing protein 
content meals in the 20-39 age group but the 65+ AUC scores demonstrated an opposing result where 
insulin decreased with increasing protein content of the test meal. Data can be seen in table 7.7. 
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Figure 7.8. AUC insulin, AUC glucose and post-prandial insulin resistance in the 20-39 and 65+ age group following test meal B (15%), C (30%) and D 
(60%). 
      (i)                                                                              (ii)                                                                       (iii) 
 
 
 
 
 
Median ± IQ Range AUC insulin (pmol/l) (i) AUC glucose (pmol/l) (ii) and post prandial insulin resistance (HOMA-PP) (iii) scores following protein test 
meals B (15%) (blue), C (30%) (red) and D (60%) (green) in the 20-39 (n=10) (block bar) and 65+ (n=11) (patterned bar) age groups. No significance 
detected in AUC insulin scores between protein test meal conditions in the 20-39 and 65+ age groups. No significance detected between protein test meals in 
glucose AUC scores in the 20-39  age group. Significance detected in AUC glucose between test meal conditions in the 65+ age group (p=0.003). Post hoc 
analysis revealed significance between test meal B (15%) and D (60%) *p=0.003. No significance detected in HOMA-PP scores between test meal conditions 
in the 20-39 age group. Significance detected in HOMA-PP scores between test meal conditions in the 65+ age group (p=0.005). Post hoc analysis revealed 
significance between test meal B (15%) and D (60%) *p=0.005 and between test meal C (15%) and D (60%) *p=0.013
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Percentage change in AUC insulin scores 
Table 7.7. Percentage change in plasma insulin AUC concentrations in test meal conditions B (15%), 
C (30%) and D (60%) in the 20-39 and 65+ age groups 
 20-39 
Median (IQ Range) 
65 + 
Median (IQ Range) 
Significance? 
Percentage change AUC Insulin 
from test condition B (15%) to C 
(30%) 
+6.89% 
(-25.43 – 38.89) 
(n=8) 
+5.31% 
(-0.76 – 21.58) 
(n=11) 
 
p=0.988 
Percentage change in AUC Insulin 
from test condition B (15%) to D 
(60%) 
+0.08% 
 (-7.42 – 23.51) 
(n=8) 
-16.17% 
 (-27.05 – 13.27) 
(n=11) 
 
 p=0.067 
Percentage change in AUC Insulin  
from test condition C (30%) to D 
(60%) 
+19.31% 
 (-18.43 – 53.15) 
(n=10) 
-16.74% 
 (-26.07 - -15.46) 
(n=11) 
 
p=0.041 
 
Median (IQ range) percentage change in insulin AUC concentrations in the 20-39 and 65+ years age 
group between protein test meals B (15%), C (30%) and D (60%).  Significance detected between 
percentage change scores C versus D (p=0.041) between the 20-39 and 65+ age group
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7.6.8. Paracetamol method; gastric emptying 
 
The peak concentration for paracetamol was used as a measurement of gastric emptying. There was 
no significance detected between peak paracetamol concentrations in the 20-39 age group between 
test meal B (15%), C (30%) and D (60%). In the 65+ age group a significance (p=0.038) was detected 
between peak paracetamol concentrations between protein test meals. This significance was detected 
between protein test meal B (15%) and C (30%) (p=0.014) and approaching significance between B 
(15%) and D (60%) (p=0.056) where gastric emptying was significantly faster (time) following test 
meal C (30%) and D (60%) in comparison to test meal B (15%). Data is presented in figure 7.9 and 
table 10.23. in appendix 10.10.23 
Figure 7.9. Gastric emptying (time) using paracetamol method  following protein test meal B (15%), 
C (30%) and D (60%) in the 20-39 and 65+ age groups 
 
 
 
 
 
 
Median ± IQ peak paracetamol concentrations following protein test meals B (15%) (blue), C (30%) 
(red) and D (60%) (green) in the 20-39 (n=10) (block bar) and 65+ (n=11) (patterned bar) age 
groups.  No significance detected in peak paracetamol concentrations between protein test meal 
conditions in the 20-39 age group. Significance detected between peak paracetamol concentrations 
between protein test meal conditions B, C and D (p=0.038). Significance detected between protein 
test meal B and C *p=0.014. 
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Percentage change in peak paracetamol time. 
Percentage change in peak paracetamol time between the protein test meals were compared between 
age groups. No significance was detected between percentage change in gastric emptying time 
between test meals B to C, B to D, and C to D between the 20-39 and 65+ age groups. Median (IQ 
range) values are presented in table 10.24 in appendix 10.10.3. 
7.6.9. VAS following ad libitum test meal 
 
Following the ad libitum test meal participants were asked fill in the normal VAS questionnaire but 
with two additional questions; ‘how tasty was this meal?’ and ‘how pleasant was this meal?’  
All VAS (how hungry, how full, how much can you eat, how pleasant to eat, how sick, how tasty was 
this meal and how pleasant was this meal) following the ad libitum meal were analysed to determine 
if there was any significance between VAS scores between the three test meals B (15%), C (30%) and 
D (60%) in the two age groups individually.  
There was no significant difference between any of the VAS scores (how hungry, how full, how much 
can you eat, how pleasant to eat, how sick, how tasty was this meal and how pleasant was this meal) 
following the ad libitum meal between any of the protein test meals B (15%), C (30%) and D (60%) 
in the 20-39 and 65+ age group. 
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7.7. Discussion 
7.7.1. Overview 
 
The objective of this investigation was to determine if there is an alteration in sensitivity to the 
satiating effects of protein on gastrointestinal appetite hormone release (in particular PYY), energy 
intake and appetite sensations in healthy older compared to healthy younger volunteers. This study 
was a cross-over randomised and single-blinded study. 21 participants were recruited in total. 
7.7.2. Findings 
 
This comparative study confirmed previous data (Skov et al., 1999; Due et al., 2004; Weigle et al., 
2005) where in younger adults there is a reduction in ad libitum energy intake following a high 
protein preload compared to a low protein preload, and an increase in subsequent feelings of fullness 
following the high protein meal. However, in the healthy older volunteers there were no significant 
alterations in food intake and subjective feelings of appetite following the high protein preload 
compared to low protein preloads. This difference in response to protein between younger and older 
adults reached significance, using percentage change scores to compare results. Results showed that 
whilst there was an increase in fullness and a reduction in energy intake in younger volunteers with 
higher protein intake; their response was significantly different to that of the older age group, where 
they did not reduce energy intake at the ad libitum test meal and increase fullness in response to the 
high protein meal to the same extent. There were no significant differences between any other 
subjective feeling of appetite between the three different protein containing preloads, and no 
significant differences in responses to protein measured by percentage change scores between the 20-
39 and 65+ age group. There was also no difference in food intake using food diaries between the 
three protein test meals for longer-term food intake, and between the younger and older volunteers 
longer-term responses to protein using percentage change scores.  
Plasma hormone analysis contradicted previous data (elevation in PYY with high protein intakes) 
(Batterham et al., 2006; Pedersen-Bjergaard et al., 1996) where there were no significant changes in 
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post-prandial PYY release following the different protein containing meals in the younger and older 
adults, with no difference in younger and older volunteer’s PYY responses to the different protein 
meals. However, PYY levels did appear to increase with increasing protein content of the preload in 
the younger age group only, but not the older age group. The lack of significance may be due to the 
small participant numbers recruited in this study, or it could also be due to the 65+ age group not 
being old enough for a difference to be seen (differences only seen in the over 80’s age group in 
chapter 4). Plasma GLP-1 concentrations also appeared to increase with increasing protein intake in 
both the age groups, but did not reach significance. Previous studies have seen elevations in GLP-1 
with high protein intake (Lejeune et al., 2006), the lack of significance could again be due to the small 
population numbers There was also no significant alteration in acyl ghrelin concentrations with 
increasing protein intake, and between the change in acyl ghrelin responses to protein between the 20-
39 and 65+ age group. These results show that GLP-1, PYY and acyl ghrelin may not contribute to 
the age associated changes in appetite in response to protein. 
Interestingly, the glucose AUC levels were significantly lower following the high protein meal than 
the low protein meal (p=0.003) in the 65+ age group, with no significant alteration detected in the 20-
39 age group between the different protein meals, although it was also apparent that levels declined in 
this age group as well. The reduction in glucose with the high protein content meal is likely to be due 
to the lower carbohydrate levels in the test meal. There was no difference in glucose percentage 
change responses to the different protein meals (using percentage change scores) between the 20-39 
and 65+ age group, suggesting that glucose concentrations do not contribute to the reduction in 
sensitivity to protein in older adults. Previous studies have shown whey protein to exert 
insulinotrophic effects (Frid et al., 2005; Nilsson et al., 2004; Nilsson et al., 2007). Insulin AUC 
responses did not appear to change following the different protein containing preloads in the younger 
and older volunteers, but there was a significant difference in AUC insulin percentage change scores 
between the 20-39 and 65+ age group (p=0.041) where insulin AUC increased with higher protein 
intakes in the 20-39 age group, but decreased in the 65+ age group. Insulin has been associated with 
an increase in fullness (Hallschmid et al., 2004). The increase in insulin in younger adults and the 
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absence of an increase in older adults may explain why younger adults felt more full following the 
high protein meal. There was also a significant decrease in post-prandial insulin resistance in the older 
volunteers with high protein intake, but this effect was not seen in the younger volunteers. 
Finally, there was a reduction in gastric emptying time with higher protein intakes, measured by the 
paracetamol method which only reached significance in the 65+ age group (p=0.038), but it was clear 
that the 20-39 age group had a reduction in gastric emptying time also. There was no significant 
difference in responses to the protein test meals between the younger and older volunteers for gastric 
emptying time. This also suggests that gastric emptying does not contribute to the age associated 
changes in response to protein. 
These results suggest that in older adults, there is insensitivity to the satiating effects of protein, where 
older adults are unable to reduce energy intake and increase feelings of fullness in response to a high 
protein meal to the same extent as younger adults. These results oppose my hypothesis where I 
hypothesised that older adults will be more sensitive to the satiating effects of protein. No significance 
was detected in gastrointestinal hormone response to protein, but there appeared to be a non-
significant increase in PYY concentration in the 20-39 age group only. However, as this was not 
significant it may suggest that other mechanisms are involved. This study provides a crucial step to 
understanding the age related alterations in appetite. Only one other study has investigated the role of 
macronutrients on satiety and gastrointestinal appetite hormones in older and younger adults (Di 
Francesco et al., 2010) in which showed that dietary fat elicits a further increase in satiety. Further 
study in response to the results of this study may be required with larger population numbers to find 
out if PYY plays a contributory role to the alterations in responses to protein seen in younger and 
older adults. 
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7.7.3. Older adults are less sensitive to the effects of protein on reductions in 
energy intake compared to their younger counterparts. 
 
Results in this study showed that younger adults eat significantly less following high protein meals, 
but older adults do not significantly reduce their caloric intake in response to higher protein meals. 
This difference in response to the protein test meals reached significance (measured by percentage 
change scores) (p=0.018) between the younger and older age group, suggesting that the older age 
group are insensitive to the satiating effects of protein. This is the first study to my knowledge that has 
provided evidence to suggest that older adults are less sensitive to the satiating effects of protein 
compared to their younger counterparts. The reduction in sensitivity to protein may be due to a 
reduction in sensitivity in the appetite regulatory system to this macronutrient. 
The lack of alteration in food intake could be attributed to the lower food intake generally seen in 
older adults, however the significant difference in percentage change scores for fullness and energy 
intake between younger and older adults, and the evidence seen in chapter 6 may suggest that there is 
an insensitivity in the appetite regulatory system of older adults to the satiating properties of protein. 
Reductions in sensitivity in the appetite regulatory system have been observed previously in older 
adults. Roberts et al, (1994) assessed whether ageing is associated with a reduced response to 
overfeeding and an impaired regulation of food intake. Roberts and colleagues underfed participants 
on a calorie restricted diet for a period of 21 days and then followed this with a period of ad libitum 
feeding. Both the younger and older participants lost weight with the restricted diet, but the older 
people were unable to regain the weight initially lost following the weight loss period. This has also 
been demonstrated by Moriguti et al (2000) in the longer term. Also consistent with this data, another 
study has shown that older adults are less able to compensate for a pre-meal yogurt snack by adjusting 
energy intake during a subsequent meal (Rolls et al., 1995). This suggests an inability in older people 
to up-regulate appetite after periods of under-nutrition and that this may relate to changes in the 
sensations of hunger and fullness perceived by older adults (Morley, 1997; Rolls et al., 1995). 
Additionally, older volunteers have also been suggested to have a reduced sensitivity to the satiating 
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effect of fibre. Howarth et al (2007) looked at 24 hour food diary recalls from a cross-section of the 
population and found that younger, but not older volunteers, had a lower BMI with higher fibre 
intake. This evidence showing an alteration in sensitivity in the appetite regulatory system in older 
adults may explain why the older volunteers in this study have a different response to protein than 
their younger counterparts, as they are unable to differentiate between the high satiating and low 
satiating foods to the same extent as younger adults just like they are unable to compensate for 
reductions in energy intake. This could be due to a multitude of different explanations 
(gastrointestinal appetite hormones, hedonic mechanisms and sensory), in which will be explained 
further in this discussion.  
This present study did not observe any alterations in longer-term food intake between the three 
different protein test meals using food diaries. Participants were asked when leaving the study visit to 
record down everything they ate for the remainder of the day and for an additional two days following 
the study visit. Energy intake was calculated from these food diaries, which included the energy 
intake on the test visits. There was no significant difference in long-term energy intake between the 
three protein test meals in the 65+ and the 20-39 age group on the test day (includes energy intake on 
the study visit and the remainder of the day) and no significant difference between older and younger 
volunteers long term energy intake response to protein. Whilst energy intake in the three ad libitum 
test meal conditions appeared constant in the 65+ age group, the 20-39 age group compensated for 
their reduced energy intake following the high protein test meal later on in the day, making 
cumulative energy intake over the day similar between the three protein test meals. This fits in with 
current literature, where younger adults are able to compensate for reductions in energy intake by 
increasing their food intake at a later time (Roberts et al., 1994). Participants were also asked to take 
home the same experimental test meal that they had on their study visit and eat the next day for 
breakfast. Participants were asked to record down the time that they consumed the test meal and they 
were asked to not eat again until they felt physiologically hungry (see section 7.4.2). There was no 
significant difference in time to eat their next meal between the three different protein preloads in the 
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20-39 and 65+ age groups. It did however appear that there was a trend towards an increase in time to 
eat next meal with increasing protein content of the meal in both the young and the older age group.  
Expectations were that volunteers would feel fuller following the high protein meal, and so there 
would be an increased length of time before consumption of their next meal following the high 
protein meal compared to the low protein meal. There was no significant difference between time to 
eat next meal between the three protein test meal conditions, but there was a trend towards an 
increased length of time with increasing protein intake. The lack of significance may be due to the 
small study numbers. Additionally, there were fewer numbers of volunteers who accurately filled in 
their food diaries which further reduced the power of the analysis. This was due to the volunteers 
either forgetting to record down the time they ate their next meal, or a loss of volunteers due to 
follow-up (explained in further detail in section 7.7.7). As the results were not significant, I cannot 
fully justify that the explanation is due to small sample size. Food diaries are not the most accurate 
method for analysing food intake, and it is documented that both older and younger adults are known 
to under-report and over-report energy intake (Cook et al., 2000; Pryer et al., 1997). Also, a difference 
may not have been detected because in normal living conditions, people may not be willing to change 
their dietary and eating habits and will not adjust their normal eating routine to what was required of 
the participants within this study. Volunteers when outside of the laboratory setting would have been 
able to control their portion sizes irrelevant to how hungry they feel, and would have been more aware 
of their caloric intake. Therefore the best and most accurate way to measure appetite is by using the 
laboratory conditions for a fair comparison, with the most reliable result from ad libitum food intake 
which did demonstrate a significant effect between younger and older peoples response to different 
protein meals. 
The alteration that was seen in short term ad libitum food intake in this study may be due to an 
alteration in the appetite regulatory system. This study did not detect any alterations in responses of 
PYY, GLP-1 and acyl ghrelin in response to the different test meals. It is also unlikely when 
observing the results in this study that it could be due to gastric emptying, which declined in both the 
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older and younger volunteers with increasing protein intake. Increased gastric emptying in ageing has 
been associated with reduced food intake and increased feelings of fullness (Sturm et al., 2004).  
The results from the ad libitum food intake in response to protein were not expected, it was postulated 
that the older population would be more sensitive to the satiating effect of protein. These results 
suggest that older adults are less sensitive to the satiating effects of protein.  
7.7.4. Gastrointestinal appetite hormone responses to different protein 
containing preloads. 
 
Plasma hormone analysis revealed no significant alteration in acyl ghrelin, PYY and GLP-1 release 
following different protein containing preloads. Additionally there was no difference between the 20-
39 and 65+ age group appetite hormone responses to protein, measured by percentage change scores. 
This suggests that the reduction in food intake and the elevation in fullness that was observed with the 
higher protein containing preloads in the 20-39 age group and the lack of alteration in the older 
volunteers cannot be explained by an altered gastrointestinal appetite hormone response. This 
suggests that it might be another mechanism that is causing the older volunteers to be insensitive to 
the satiety effects of protein. 
It was expected that there would be an increase in post-prandial PYY response with high intakes of 
protein, as this has been observed in other studies (Pedersen-Bjergaard et al., 1996; Leidy et al., 2010; 
El Khoury et al., 2010). It was also expected that a high protein intake in older individuals would 
cause a further elevation in PYY (as already elevated with normal protein levels), causing a further 
reduction in appetite. This current study contradicted my hypothesis and found no significant 
alteration in PYY with higher protein intakes. The lack of alteration in PYY response in this study, 
but a reduction in food intake with the higher protein meals suggests that there may be other 
mechanisms involved. A possible explanation could be that rather than protein altering PYY release, 
protein alters the release and expression of neuropeptides, which would then subsequently affect 
feeding behaviour. Kinzig et al (2007) found in rats, that high protein intakes increased the 
anorexigenic ARC POMC expression more so than compared to standard rat chow, which would 
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ultimately reduce food intake more significantly in the high protein condition. Similarly, rats fed a 
high protein diet decreased hypothalamic NPY mRNA levels, and increased hypothalamic mRNA 
POMC levels (Ropelle et al., 2008). It is not possible to measure the effect of high protein diets on 
POMC or NPY expression in humans, but this could provide a potential explanation for the reduction 
in appetite seen in younger adults. This may also provide a reason for the lack of an alteration in food 
intake with different protein meals in older adults. High protein meals may not increase the expression 
of POMC or a decrease expression of NPY receptors in older adults to the same extent as the younger 
adults. It has already been seen in ageing animals that there is a general down regulation of receptors 
involved in the stimulation of food intake, and a lack of an alteration in the expression of receptors in 
the anorexigenic pathways (Kmiec, 2006). Specifically, ageing in rats is associated with a down 
regulation of NPY expression in the hypothalamus. No studies have investigated the effect of high 
protein diets on POMC expression in ageing rodents. However, due to the difficulty in obtaining a 
rodent that follows the same ageing growth pattern as humans and the inability to measure 
neuropeptide expression in humans, this could prove to be quite difficult. 
This study was a pilot study with only a small number of volunteers recruited. In the 20-39 age group 
it did appear there was trend towards higher AUC PYY response following the high protein meal. For 
example, there was a mean increase of 15.9% in AUC PYY response between the 15% protein meal 
and the 60% protein meal. However, in the 65+ age group there was a mean reduction of -2.32% 
between the 15% and the 60% protein meal in AUC PYY response, again suggesting an insensitivity 
in older people to protein by a lack of an increase in PYY. If there was a larger population sample, 
significance may have been detected in these results.  
In addition to PYY there was also a non-significant increase (23.9%) in plasma GLP-1 concentrations 
between the 30% and the 60% protein meal and a mean increase of 14% from the 15% and the 60% 
protein meal in young individuals, in which these percentage increases showed a similar pattern in the 
older age group. This suggests that GLP-1 increases with higher protein intakes in both the younger 
and older adults. Other data has confirmed that with high protein intakes, there is a more substantial 
increases in plasma GLP-1 concentrations compared to other macronutrients (Blom et al., 2006; 
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Lejeune et al., 2006; Raben et al., 2003; Herrmann et al., 1995). But no studies to date have 
investigated the GLP-1 responses to protein in older adults. These results, where GLP-1 is elevated in 
both the younger and older volunteers following the 60 % protein meal compared to the 15% protein 
meal suggests that GLP-1 does not contribute to the lack of decline in food intake following a high 
protein meal in older adults. It would be expected that there would have been a reduction in food 
intake after the 60% protein meal in the older adults as there was an elevation in GLP-1. It could be 
that older adults are insensitive to the anorectic effects of GLP-1, as they did not respond by reducing 
energy intake in response to higher GLP-1 concentrations. It has been suggested that older adults have 
an alteration in sensitivity to GLP-1 (MacIntosh et al., 1999). In addition it has been shown in a recent 
study by Di Francesco et al (2010) that older adults are more sensitive to high fat meals than younger 
adults and the alteration could be related to alterations in GLP-1 release (described in chapter 6). As 
no significant difference was detected in GLP-1 concentrations in this study, other mechanisms as 
mentioned in the previous paragraph may play stronger contributory roles to the alteration in 
sensitivity to protein. With the insensitivity to protein and the reduction in hunger seen in older adults 
seen in this present study, it provides an opportunity where the diet of older adults could be tailored 
by replacing some of the fat in the diet with protein to try and gain optimal food intake. More studies 
are required to determine the role of macronutrients on satiety and its potential success in aiding 
increased food intake in the older population.  
This present study did not observe any alterations in acyl ghrelin levels in response to different 
protein containing preloads, and in addition there was no difference between the younger and older 
volunteers acyl ghrelin responses to protein. Carbohydrate is the most potent form of ghrelin 
suppression (Shiiya et al., 2002; Caixas et al., 2002), consequently it would be expected that the low 
protein meal that had a higher content of carbohydrate would result in a larger suppression of ghrelin. 
This was not seen in this study, where acyl ghrelin concentrations were similar between all the protein 
containing meals. A number of explanations can be provided to explain why this was not seen. Gastric 
emptying was faster following the high protein meal in comparison to the low protein meal, which 
may have subsequently had an effect on gastrointestinal hormone response, including PYY, GLP-1 
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and acyl ghrelin. The amount of carbohydrate in the meal may have not been large enough for a 
response to be seen, for example the majority of studies have seen a large suppression in ghrelin 
following consumption of glucose and carbohydrate alone, and not whilst in a food matrix with other 
macronutrients available (Shiiya et al., 2002; Nakai et al., 2003; Williams et al., 2003). Literature 
surrounding protein and ghrelin release is contradictory where ghrelin has been shown to either be 
unchanged (Greenman et al., 2004), elevated (Erdmann et al., 2003; Erdmann et al., 2006) and even 
reduced (Al Awar et al., 2005) following a high protein meal. Differences in results may be due to 
differences in methodology, lack of measurement of acyl ghrelin and different forms of protein used 
in the investigation. This present study demonstrates that acyl ghrelin concentrations are unaltered 
with differing whey protein containing meals. In addition, no difference was seen between the older 
and younger volunteers acyl ghrelin response to protein. Alterations in acyl ghrelin levels with ageing 
have been contradictory (see chapter one), work in this thesis (see chapter 4) has shown that with 
normal protein concentrations (~15%) there is no difference in acyl ghrelin concentrations in response 
to a test meal, therefore it was expected in this study for there to not be a difference between the older 
and younger volunteers. Although this was not the focus of this study, acyl ghrelin levels were higher 
in the older volunteers, but not significant. This is different to what was seen in chapter 4, where no 
changes in acyl ghrelin were seen. A further discussion of this is provided in the general discussion. 
This study recruited adults in the older category of 65 years and over, with a mean age of 76 years. In 
my previous study, in chapter 4, alterations in gastrointestinal hormone release only occurred in those 
that were of the age of 80 years and older, therefore the older population in this study may not have 
been old enough for an alteration in gastrointestinal appetite hormones to be seen. As this was a pilot 
study, and to aid recruitment, younger older aged volunteers were used, but it is important to notice 
that an alteration in response between younger and older volunteers with respect to energy intake and 
fullness occurred in those that were young older adults (aged 65 years). This effect may be seen to a 
greater extent in those who are over 80 years of age and maybe even with alterations in 
gastrointestinal appetite hormones. There was no difference in energy expenditure between the 
younger and older volunteers in this study, therefore the alteration between younger and older 
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volunteers cannot attributed to energy expenditure. This also reflects how the older adults that were 
recruited were from the healthy older population. It is commonly seen with age that physical activity 
and energy expenditure declines. If the older adults in this study reflected the normal activity levels of 
older adults there may have been more of a substantial difference between older and younger adults 
responses to protein.  
In summary, gastrointestinal appetite hormone response to protein was not significantly different 
between the three different protein meals. Gut hormone response between the 20-39 and 65+ age 
group to protein was also not significantly different, providing no explanation to why there is an 
alteration in sensitivity to protein seen in energy intake and feelings of fullness between the younger 
and older age group. It may be that not enough volunteers were recruited into the study to create a 
significant value as it was apparent the PYY increased in the high protein meal in the young but not 
the old. Another explanation may be due to an alteration in neuropeptide expression, or that the older 
population were simply not old enough for an alteration to be observed. 
7.7.5. Subjective feelings of appetite in response to different protein containing 
preloads. 
 
No significant differences were detected in this study for any VAS measurement with the exception of 
subjective feelings of fullness. In the 20-39 age group, as protein content of the test meal increased, 
feelings of fullness increased. This effect was not seen in the older age group, which subsequently 
resulted in a significant difference in fullness rating responses to protein between the 20-39 and 65+ 
age group. The difference in response to different protein containing meals for feelings of fullness 
correlates with the difference in energy intake responses to the protein test meals between the two age 
groups, and suggests that the explanation the lack of significant reduction in ad libitum food intake in 
response to a high protein meal could be due to the lack of the high protein meal to increase feelings 
of fullness in the older age group. The exact mechanism to why there is difference in response is not 
known, likely explanations for the alteration in appetite sensations is described in section 7.7.3 and 
7.7.4.  
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Although it was not the scope of this study to compare total scores for subjective feelings of appetite 
(aim was to compare response to protein) it was apparent that the younger age group had higher 
scores for nausea than the older age group following the protein test meal B (15%) in particular. 
Scores for nausea declined with increasing protein intake in the 20-39 age group but not in the 65+ 
age group. Although this did not reach significance it would have affected energy intake, hunger, 
desire to eat and how pleasant to eat, as nausea was higher following the 15% than the 60% protein 
meal. The reason for the difference between the younger and older volunteers scores for nausea could 
be that older adults are less sensitive to sweet tastes than younger people (Schiffman, 1997). The 15% 
protein meal was of a slightly sweeter taste and thus it may have affected the younger volunteers 
scores for nausea more so than the older volunteers (i.e. there are insensitive to the sweetness of the 
meal). However, even though there were differences in nausea scores, the difference in responses to 
low and high protein meals was still apparent.  
In summary, older adults do not respond to the satiating effects of protein to the same extent as the 
younger population, the lack of reduction in food intake following a high protein meal may be due to 
the inability to increase feelings of fullness following the high protein meal.  
7.7.6. Glucose, insulin, insulin resistance, and gastric emptying in response to a 
high protein meal 
 
Glucose AUC concentrations in this study declined following the high protein meal more so than the 
lower protein meals in both age groups. The decline in glucose could be explained by the fact that the 
lower protein containing meal had a substantially larger amount of carbohydrate, which could result in 
a more substantial release of glucose into the blood stream. The decline in glucose only reached 
significance in the older age group, the younger age group may not have reached significance as they 
were better able to regulate their glucose levels within a tighter range than the older adults, therefore 
enabling them to lower their plasma glucose levels at a faster rate following the meals with higher 
carbohydrate levels. It is common knowledge that older adults are less able to regulate their glucose 
levels within tighter ranges (Fraze et al., 1987). There was no significant difference between glucose 
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response to protein between the two age groups suggesting that glucose does not play a role in the age 
observed alterations in sensitivity to protein. 
Results showed that plasma insulin concentrations following the three test meals were not 
significantly different in the 20-39 and the 65+ age group. However, there was a significant difference 
between older and younger adults insulin response to protein, this difference was detected between 
test meal B versus D (p=0.041), where insulin levels increased as protein content of the meals 
increased in the 20-39 age group, and insulin levels decreased with the high protein test meal in the 
65+ age group. Elevations in  insulin have been associated with increased fullness (Hallschmid et al., 
2004), the elevation in insulin  in this present study could explain why young volunteers felt more full 
following the high protein meal (i.e. due to the increase in insulin), whereas the lack of elevation in 
insulin would explain why there was no effect on appetite in the older adults. Data around the area of 
insulin and appetite is contradictory and it may be that elevations in glucose cause reductions in 
appetite rather than insulin (Bergmann et al., 1992; Campfield and Smith, 2003). Taking this into 
consideration it is likely that other physiological mechanisms play a role in the alterations in food 
intake and appetite response to protein, but it cannot be completely ruled out.  
Previous studies have shown that whey protein has an insulinotrophic effect whereby it has been 
demonstrated that insulin concentrations are significantly higher following a whey protein meal (Frid 
et al., 2005; Nilsson et al., 2004; Nilsson et al., 2007). This present study used whey protein to 
increase the protein content of the test meals. Insulin appeared to increase in the 20-39 age group, but 
did not reach significance, but there was no increase in the 65+ age group. This suggests that once 
again the older adults are less sensitive to the metabolic effects of whey protein. It is not clear why 
there was a different insulin response to protein. This effect seen cannot be completely discounted 
when trying to explain the difference in appetite responses of older adults to youngers adults 
responses to protein. More studies are required to examine the role of insulin if any, in the alterations 
in appetite to protein. 
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There was a significant reduction in post-prandial insulin resistance in the older age group following 
the high (60%) protein meal, although no significance was seen in the younger age group, it was 
apparent that insulin resistance decreased in the 20-39 age group. The reduction in insulin resistance 
could be due to the high carbohydrate content of the low protein meals. Additionally, other studies 
have suggested that high intakes of protein can improve insulin sensitivity (Pal and Ellis, 2010; 
Ouellet et al., 2007; Arciero et al., 2008) but dietary factors around insulin sensitivity remain 
controversial. The older adults in this study had higher levels of insulin resistance, which is also a 
common feature of ageing. 
Gastric emptying time was significantly shorter following the higher protein meal. This only reached 
significance in the 65+ age group, but it is apparent that gastric emptying time declined in the 20-39 
age group as well. The lack of detection of significance in the young age group could be explained  by 
the small volunteer numbers. The younger and older volunteers did not have a different gastric 
emptying response to protein as detected by no significant difference in percentage change values. 
Subjective feelings of fullness increased and food intake decreased with increasing protein intake, 
therefore you would expect that gastric emptying time would increase with increasing protein content 
of the meal in this study. Previous literature has indicated that increased gastric emptying time is 
associated with increased feelings of fullness and decreased energy intake (Sturm et al., 2004). In 
addition, the meals were of a similar consistency, volume and texture, thus eliminating these factors 
as a reason for accelerated gastric emptying with increased protein intake. Although the evidence is 
limited some authors have suggested that certain protein constituents can have an effect on gastric 
emptying time. It has been shown that protein constituents (amino acids) increase gastrin release 
(McArthur et al., 1983; De Santo et al., 1992; DelValle and Yamada, 1990) which in turn could 
stimulate gastric emptying but data on this subject is limited and still remains relatively unclear. Some 
authors have suggested that there is a decline in gastric emptying with high protein intake (Ma et al., 
2009), further understanding is needed on the role of protein on gastric emptying. 
Another result which did not follow the pattern that was expected was that there appeared to be no 
difference in gastric emptying time between the younger and older volunteers. It is well documented 
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that gastric emptying time in older adults is prolonged compared to their younger counterparts  
(Brogna et al., 2006; Horowitz et al., 1984; Clarkston et al., 1997), and it has been postulated that the 
slowing in gastric emptying time causes the reductions in food intake (Sturm et al 2004). This was not 
the case in this study, and in section 4. The study meal that was provided to the participants was a 
custard type consistency, one study has shown that there is no effect of gastric emptying between 
younger and older volunteers following a liquid meal (Nobles et al., 1991). As the protein test meal 
was not of a solid consistency, and was provided in small energy dense portions this could provide a 
potential explanation. 
To summarise, there was a significant difference in insulin response to protein in the older and 
younger adults. Whey protein is insulinotrophic whereby insulin levels increase with high whey 
protein intakes and insulin resistance declines. The difference in the insulin response between the 
younger and older adults may explain the difference in appetitive responses to protein, however, as 
insulin resistance declined with increasing protein intake in both the age groups which follows the 
pattern that is seen in the literature, it is not likely that it is due to the an alteration in response to the 
insulinotropic properties of whey protein. Gastric emptying and glucose do not explain the age 
observed changes in appetite responses to protein. More studies need to be conducted to define a role, 
if any, on whether insulin plays a significant role in the alterations in sensitivity to protein. 
7.7.7. Limitations 
 
There are many limitations in appetite studies, in which it is difficult to control for all (in more detail 
in section 4.6.12.). In this study it was difficult to control for the compliance of the volunteers, 
ensuring that they consumed all the experimental protein preloads for breakfast the day following the 
study visit, and it was difficult to control for volunteers correct input of data into the diet diaries. 
Parameters were put into place to ensure that the volunteers consumed the meal; I asked participants 
to record down the time that they ate the meal, to return the empty pots that the meal was given to 
them in on the following visit and by questioning participants if they had consumed the meal, 
therefore eliminating the non-compliance as much as feasible. Although participants were given strict 
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guidelines on how to fill in their food diaries, there were still some volunteers who did not record 
down the time of their next meals. Additionally, when volunteers were on their final study visit, they 
were given a stamped addressed envelope to send back their food diaries, in which some volunteers 
did not send back and information was lost. Unfortunately this meant that I did not end up with a full 
set of data for the diet diaries. This is something that could not have been controlled for as every 
attempt was made to try and ensure the participants returned their diet diaries.  
Another limitation to this study is the use of food diaries for the measurement of food intake. Previous 
studies have suggested that both older and younger volunteers under-report food intake in food diaries 
(Cook et al., 2000; Pryer et al., 1997). Under reporting wasn’t measured in this study as the older 
population are known to have a lower energy intake, irrespective of their BMR, therefore using a 
formula to exclude under-reporters could have eliminated the older volunteers who correctly reported 
their energy intake. Participants were reminded throughout their time in the study to report their full 
food intake on a regular basis in order to try and prevent misreporting. Additionally, the volunteers 
that were recruited into this present study were of normal weight. It is more common for overweight 
and obese individuals to under report energy intake (Bandini et al., 1990; Schoeller, 1990; Kempen et 
al., 1995) and the degree to under-reporting is correlated with body mass index (Schoeller at al., 
1990). 
The age of older participants that were chosen was of the age of 65 years and above, with a mean age 
of 77 years. This age may not have been old enough to see an alteration in gastrointestinal hormones 
with higher protein intakes, as an alteration in gastrointestinal hormones was only seen in the age 
group of 80 years and above in chapter 4. Volunteers of the age of 65 years were chosen in order to 
aid recruitment. Even though younger older adults were recruited, an alteration in food intake was still 
observed. Future study would involve the recruitment a cross-section of ages with a larger population 
size of those over the age of 80 years to determine if the alteration in response to high protein meals in 
older adults is further exacerbated in those that are defined in this thesis as ‘old elderly’. 
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The largest limitation in this study was the low participant numbers. This study was a pilot study, to 
enquire if there is an alteration in appetite responses to protein. As this study has seen alterations in 
appetite, this now warrants further investigation.  
7.7.8. Summary 
 
This is the first study to my knowledge that has investigated whether older adults respond differently 
to the satiating effects of protein. This preliminary study revealed that the older age group were in fact 
insensitive to the satiating effects of protein, which could be attributed to the reduced sensitivity of the 
appetite regulatory system with ageing. Older adults did not reduce calorie intake following a high 
protein meal to the same extent as younger adults, and feelings of fullness did not alter, opposing what 
was seen in the younger age group. PYY has been suggested to be released to a greater extent 
following a high protein meal than any other gastrointestinal appetite hormone (see section 1.7), 
however there was no significant difference between PYY scores between the three protein test meals, 
and no significant difference between the older and younger volunteers PYY responses to protein, 
although PYY AUC scores did appear to increase in the young age group only. Further study is 
required with larger population numbers to determine if PYY plays a role. Further study is also 
merited to understand if insulin plays a significant role in the alterations in appetitive responses to 
protein, or if other factors such as cytokines or an alteration in the hedonic mechanisms may play a 
role. Although it is not clear why there is an alteration to the satiating effect of protein in the older age 
group, this study provides a new insight into the alterations in the appetite regulatory system with 
ageing and will provide a crucial step to developing appropriate therapies to help overcome the 
‘anorexia of ageing’. 
7.7.9. Future Work 
 
As this study was a pilot study, no power calculation was performed. A study will need to be 
performed using larger populations sizes and a larger range of age groups to confirm the results of this 
present study where there was a difference in response in older and younger adults to the satiating 
effect of protein, and to see if this effect is further exacerbated in the old elderly aged over 80 years of 
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age. This study would also determine whether using larger population sizes would produce a 
significant difference in PYY response as an explanatory reason for the alteration in sensitivity to 
protein with age. 
Now that evidence is emerging to suggest that older adults have alterations in satiety responses to 
protein, and possibly fat (Di Francesco et al., 2010), future work would also involve the 
experimentation with different macronutrient preloads in order to determine a combination that 
creates the smallest reduction in appetite and the largest subsequent food intake. This would then 
enable me to develop a nutrition replacement formula that creates the largest food intake in older 
adults. 
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8.1. Discussion and Future Work 
 
Undernutrition has been reported to be prevalent in the western society, particularly in older adults 
and those who are suffering from an illness (Elia and Russell, 2009). Undernutrition is a public health 
issue because it is associated with an increase in morbidity and mortality (Corish and Kennedy, 2000; 
McWhirter and Pennington, 1994). The treatments available for the prevention of undernutrition in 
the elderly have failed to make a substantial impact (Milne et al., 2009; Milne et al., 2006), and 
therefore research into other potential therapies is required. A loss of appetite is frequently observed 
with ageing termed; ‘the anorexia of ageing’ (Morley and Silver, 1988). Between the ages of 20 to 80 
there is an average decline in energy intake of 30% in both men and women (Wurtman et al., 1988). 
Increased understanding of the appetite regulatory system has led to research into the alterations in the 
appetite system with ageing and illness. However, the data so far in this research area is very limited 
and rather confusing.   
Gastrointestinal appetite hormones play an influential role in the regulation of appetite (Hameed et al., 
2009) (chapter 1). Previous studies have investigated the role of the hunger hormone, ghrelin, and 
satiety hormones, PYY, GLP-1 and CCK, in the anorexia of ageing (Di Francesco et al., 2006; Di 
Francesco et al., 2008; Di Francesco et al., 2005), but the results from these studies are rather 
contradictory. The reason for the contradictory results may have been due to the methodological 
differences between the studies and the lack of measurement of acyl ghrelin, which is the active form 
of ghrelin (Yang et al., 2008). Thus, a broad aim of this thesis was to explore the mechanisms and 
factors involved in the lack of appetite during ageing. 
Summary of Findings; 
The first aim of this thesis (chapter 3) was to develop an animal model that replicates changes in 
gastrointestinal appetite hormones seen in illness. Taking into consideration evidence published to 
date, I hypothesised that acyl ghrelin, PYY and GLP-1 would be altered which will favour a reduction 
in appetite. Trauma, via a sham cannulation was performed in rats, and gastrointestinal appetite 
hormone response and energy intake were compared between control rats and rats that had received 
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anaesthetics alone (not sure of the effects of anaesthesia on gastrointestinal hormone response) 24 
hours following the procedure. The results of this investigation did not replicate what is seen in 
trauma in humans, where normally there is an increase in PYY concentrations (Di Francesco et al., 
2005), and possible alterations in ghrelin. PYY, GLP-1 and ghrelin (total and acyl) release did not 
alter between the trauma and non-trauma groups. It is not clear why the trauma rats did not follow the 
normal pattern as seen in humans, but a different gastrointestinal hormone profile may have been 
observed in aged animals, as a large proportion of human patients with an altered gastrointestinal 
hormone response in illness are elderly. Due to the results of this study, this line of enquiry was halted 
and efforts focussed on exploring alterations in ageing and in humans, since the rat model tested did 
not replicate what is known.  
Although it is clear that there is a change in the appetite regulatory system with ageing, there is no 
clear consensus on what alterations may occur in gastrointestinal appetite hormone response with age 
(chapter 1). A possible explanation for this inconsistency in results could be due to a difference in 
protocol between the studies and the few volunteers recruited in previous studies. My second study 
(chapter 4) aimed to clarify the age associated alterations in gastrointestinal appetite hormones in 
healthy ageing, recruiting a larger number of volunteers with wide cross section of ages. The results 
from this study confirmed previous data that older adults eat significantly less than younger adults at 
an ad libitum test meal following a standard preload (Di Francesco et al., 2006; Di Francesco et al., 
2008; Di Francesco et al., 2005), and have significantly altered subjective feelings of appetite 
following a preload (Clarkston et al., 1997), feeling less hunger, appetite and desire to eat. 
Gastrointestinal appetite hormone analysis revealed a significant increase in post-prandial PYY 
release in the over 80’s age group, which could explain the reduction in appetite and food intake in 
this age group. There was no difference in any other measured gastrointestinal appetite hormone 
(GLP-1, total ghrelin and acyl ghrelin). There was also no difference in gastric emptying time across 
the age groups. The results from this study suggests that PYY may contribute to the age associated 
reductions in appetite in the very old adults (80+ years), confirming the hypothesis that PYY may 
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contribute to the age associated changes in appetite but rejects the hypothesis that ghrelin and GLP-1 
concentrations contribute to age-associated changes in appetite.  
The next study (chapter 5) used aged mice colons to determine if they have an increased production of 
PYY in the colon compared to young mice. Depending on the results of this study, if it replicates what 
is seen in human plasma in ageing, this animal model can be used to study further the appetite 
regulatory system in ageing. The hypothesis was that there would be an increased PYY release in the 
colons of mice replicating what is seen in human plasma in chapter 4. Previous studies investigating 
colonic PYY release with ageing have presented conflicting results (Sweet et al., 1996; Sandstrom et 
al., 1998; Sandstrom and El-Salhy, 1999b), and no studies to date have looked at the PYY content in 
the whole colon. Stomachs and colons were extracted from young and old aged mice and colonic 
PYY and GLP-1 and stomach ghrelin levels were compared between the age groups. Results of this 
small investigation showed a lack of significant difference in PYY and GLP-1 colonic content 
between the old and young mice, but an increase in stomach ghrelin concentrations in the middle aged 
and older age groups. These results oppose what is seen in plasma in humans seen in chapter 4, 
rejecting my hypothesis. Reasons for this difference may be due to the lack of measurement of acyl 
ghrelin, the levels contained in the stomach and colon not reflecting concentrations in plasma, or 
simply that mice do not offer a good model for human appetite research. 
An economical method of modulating appetite to increase food intake could be by the mode of 
manipulating macronutrients. Protein is considered to be a highly satiating food, and has been shown 
in a number of studies to decrease food intake and body weight (Skov et al., 1999; Johnstone et al., 
1996; Blundell and MacDiarmid, 1997; Marmonier et al., 2000). In addition, it has also been shown 
that protein increases PYY concentrations to a greater extent than other macronutrients (Batterham et 
al., 2006) (see chapter 1). However, we are not aware if these effects are seen in older adults. My final 
aim of this thesis was to explore the role of protein on appetite suppression in older adults. Chapter 6 
and 7 explored this possibility. It was hypothesised that because PYY levels are elevated in older 
adults with normal protein intakes, they may be more sensitive to the effects of protein by an even 
further increase in PYY release. Chapter 6 was a preliminary study to see if there is a different 
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relationship between habitual protein intake, BMI and habitual energy intake between younger and 
older adults, using the NDNS dataset. The results of this study provided useful evidence to suggest 
that there are differences in responses of older people to high protein meals, whereby energy intake 
declined to a greater extent with high protein intake but they appeared insensitive to the effect of high 
protein intakes on BMI. In response to this study, further investigation was needed in order to 
understand why older adults respond differently to protein than younger adults. Thus, my final study 
(chapter 7) was designed to test the hypothesis that in older adults there will be an increase in 
sensitivity to protein via a more substantial increase in PYY and reductions in appetite compared to 
younger adults. This study compared appetite and gastrointestinal appetite hormone responses to 
protein between older and younger adults. Findings revealed that older adults have a different appetite 
response to protein than younger adults, but the results were not what were expected. There was a 
significant reduction in ad libitum food intake and a significant increase in fullness in the young 
adults following a high protein meal, but not the older adults. PYY, GLP-1, acyl ghrelin and glucose 
did not explain any of the age observed differences in response to protein. However, it did appear that 
PYY increased in the younger volunteers only and not in the older volunteers, although not 
significantly. There was a greater insulin response following the high protein compared to the low 
protein meal in the younger but not the older volunteers. There was also a decline in gastric emptying 
rate with the high protein meal but there was no difference between young and older volunteers 
gastric emptying response between the protein meals also suggesting that this does not play a role in 
the age observed reduction in sensitivity to protein. These results suggest that older adults may be less 
sensitive to the satiating effects of protein. 
Discussion of Thesis Findings 
The main outcomes of this thesis were; (i) with ageing there is a reduction in appetite and energy 
intake, (ii) there is a post-prandial increase in the putative satiety hormone PYY in adults over the age 
of 80 years, and (iii) an alteration in sensitivity to the satiating effects of protein in ageing.  
282 
 
Contrary to some published literature, this current thesis found no change in total and acyl ghrelin 
levels with age, providing no evidence to support my original proposed hypothesis that there would be 
a reduction in ghrelin concentrations favouring a reduction in appetite. A detailed discussion was 
included in chapter 1.4.1 (p40), outlining the methodological differences that could have contributed 
to the differences in study results. The study I designed aimed to address these issues. Unlike other 
studies, this study recruited more volunteers, with more standardised conditions, and a strict 
recruitment criterion to create a more robust methodology. It is now known that measurement of acyl 
ghrelin is critical to assess the biological activity of this peptide, few of the previous studies have used 
the measurement of acyl ghrelin.  
Interestingly in chapter 7, although not significant, older adults appeared to have elevated 
concentrations of acyl ghrelin compared to younger adults, opposing the results from the comparison 
study (chapter 4). This could also mean that older adults are insensitive to the effects of ghrelin on 
hunger, because there was a reduced appetite in older adults in chapter 7 compared to younger adults, 
even though acyl ghrelin concentrations appeared to be higher in this age group. It has already been 
observed in animals that there is a reduction in sensitivity to ghrelin (Yukawa et al., 2008; Ariyasu et 
al., 2008). It is also of note that in aged mice, there was an elevation in ghrelin in the stomach in this 
present thesis, future work in this study requires the measurement of acyl ghrelin.  Only one study to 
date has observed an increase in acyl ghrelin concentrations in ageing (Bauer et al., 2010) using a very 
different methodology, and so direct comparisons between this study cannot be made.  
There was an increase in insulin, insulin resistance and glucose in older adults in chapter 4. This 
agrees with published literature that there exists an increase in glucose and insulin resistance with 
ageing (Fraze et al., 1987; Colman et al., 1995; Di Francesco et al., 2006). This data could provide a 
potential explanation for the reduction in food intake observed in older adults, as some studies have 
shown that insulin and glucose reduce appetite and food intake in men only (Hallschmid et al., 2004). 
The differences in adults insulin responses to protein must also not be discounted as a potential 
contributory cause of the alterations in appetite and energy intake responses to protein. The complex 
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interactions between ghrelin, insulin and glucose need to be explored further in age related changes in 
appetite.  
There was no difference in gastric emptying time across the age groups in both the human studies 
(chapter 4 and 7). In this thesis, I used small volume, energy dense meals in order to ensure that the 
older adults with small appetites were able to consume test meals in the required amount of time. 
Delayed gastric emptying times have been seen with large test meals (Brogna et al., 2006; Clarkston 
et al., 1997; Horowitz et al., 1984) in older adults. The test meal provided in this study may not have 
been large enough for such an effect to be seen. The lack of difference in gastric emptying eliminates 
this as a cause in the reduction of food intake and alteration in PYY release in chapter 4 or the 
difference in response of older and younger adults to protein in chapter 7.  
It is of note in this thesis that the populations recruited into the human studies are not representative of 
the general population, as only healthy older adults were recruited, and in the over 80’s age group in 
chapter 4, only females were recruited. Factors such as obesity, illness and medications are known to 
interfere with gastrointestinal appetite hormone response and appetite (Koch et al., 2010; Tschop et 
al., 2001; Carlson et al., 2009; Kadoglou et al., 2010; Jacobsson et al., 2001; Freeman and Roubenoff, 
1994; Womack and Breeding, 1998), therefore in order to determine if the alterations are due 
specifically to ageing, this population had to be excluded. Due to recruitment difficulties in chapter 4, 
no males were recruited in the 80+ age group, however, in separate analysis when only females were 
looked at, post-prandial PYY was still significantly elevated in the 80+ age group, despite the reduced 
power of analysis due to the small participant numbers. A reduction in energy intake was seen in the 
60-79 age group without an alteration in post-prandial PYY, thus other unknown mechanisms may 
also be implicated in the reduction in appetite in older adults, for example changes in the hedonic 
appetite regulatory system.  
Chapters 3 and 5 developed models of ageing and illness associated changes in gastrointestinal 
appetite hormones. Taking into consideration the results from the two rodent studies in this PhD, it 
appears that animal models are not successful in replicating ageing and trauma in humans. Previous 
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research in young healthy rat and mice models has been relatively successful in replicating the 
appetite effects in humans. The trauma model in this thesis may have not been successful in 
demonstrating these effects due to the type of trauma received, the use of anaesthetics and the lack of 
the use of the more commonly seen model of alterations in gastrointestinal appetite hormones such as 
in heart disease and osteoporosis (see chapter one). Carrying out this sort of animal model would be 
difficult and the cost incurred in developing an ageing model is a big issue standing in the way of this 
avenue of research. With respect to the ageing mice model, it appears that relatively few rodent 
studies have been published looking into age associated changes in gastrointestinal appetite hormones. 
It is likely that this is due to it simply not being a good model for appetite in ageing, likely to be due 
to different ageing growth patterns. Unlike humans, rodents follow a different growth pattern whereby 
they continually gain adipose weight with age (explained in chapter 5) which makes comparisons with 
the appetite systems with humans difficult. 
This thesis was the first step to understanding if macronutrient manipulation has potential in helping 
to increase food intake in undernutrition. It was initially hypothesised that older adults would be more 
sensitive to the satiating effects of protein. Other studies have suggested that there is a reduction in 
sensitivity in the appetite regulatory system in older adults, where they have inability to appropriately 
control food intake after under eating in the short- and long- term (Moriguti et al., 2000; Roberts et 
al., 1994). If there was a reduction in sensitivity in the overall appetite regulatory system, this would 
explain why older adults appear insensitive to the satiating effects of protein. This study was a pilot 
study, and in order to aid recruitment, small sample sizes and younger older adults were recruited. In 
chapter 4, where a clear increase in PYY levels were observed, this increase was only seen adults 
aged 80 years and over. Therefore, the inclusion of younger older adults may have altered the results. 
Future work would involve the recruitment of more participants with the separate analysis of the old 
(80+ years) and the young old (60-79) age group. 
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Future Work and Relevance in Management of Undernutrition 
Understanding the changes in the appetite regulatory system is important for the treatment and 
management of undernutrition. This thesis has highlighted the complexity of the reductions in appetite 
in older people whereby older adults have a significantly elevated PYY concentration in response to a 
test meal, but appear to be insensitive to the inhibitory effects of protein on appetite, even though 
evidence suggests that protein is a strong stimulus for inhibition of food intake. It is clear from this 
study, that there is an alteration in the appetite regulatory system with ageing, and the results from this 
thesis adds a new dimension to the already available literature on appetite changes in ageing, by 
demonstrating differences in responses to protein, a finding that has not been seen in the literature to 
date. Due to the complexity of the appetite regulatory system, it may be that a multi-factorial 
approach may be the most impactful in increasing appetite in older adults via the use of macronutrient 
manipulation and manipulation of gastrointestinal appetite hormone levels. For example, an increase 
in PYY was seen in the 80+ age group only, but reductions in food intake were only seen in the 60-79 
age group, suggesting other mechanisms are involved. 
Further study would also be required, with the use of regression analysis to determine if PYY has an 
independent role in the reduction in food intake and appetite in ageing. If PYY does play an 
independent role in the reductions in appetite in ageing, future work can focus on reducing PYY 
levels to increase appetite in older adults. It could be that older adults are insensitive to the satiety 
effects of PYY. An infusion study needs to be conducted to understand further if there is an alteration 
in sensitivity to PYY in ageing. No studies have been conducted of this nature because sensitivity 
studies are particularly challenging since the side effects of high PYY levels are nausea and vomiting, 
and the amount of PYY inducing these symptoms vary considerably, also the expense to manufacture 
the hormones is considerable. If it appears from these investigations that PYY is a strong contributory 
cause of appetite reductions in ageing, future research can focus on this for increasing appetite in the 
elderly. The potential for PYY providing a therapeutic option in future management of under-nutrition 
has some potential. Although data is limited, and far from fully understood, research has shown that 
metalloendopeptidases (enzymes that degrade extracellular matrix proteins) play a role in the 
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breakdown of PYY (Addison et al., 2011), thus if there was a faster rate of PYY breakdown, this 
could result in subsequent increases in appetite. More research is needed in this area as there is very 
little evidence conducted so far for the role of metalloendopeptidases in PYY breakdown, with no 
studies yet having looked at if these enzymes can play a role in increasing appetite. In addition, these 
enzymes have been associated with obesity and obesity related disorders and their use in an at risk 
population may be harmful.   
Further study into the complex roles of ghrelin and insulin may provide an insight into why 
discrepancies are seen in results. Even though there was no data to suggest ghrelin release reduced 
with age, this does not discredit ghrelin’s use for the treatment of undernutrition. Although more 
studies are required, beneficial effects have been seen with the use of a ghrelin mimetic in older adults 
(Nass et al., 2008). Nass et al (2008), in a 2 year double blind study found that the administration of a 
ghrelin mimetic increased fat free mass in older adults, with a decrease in fat free mass when the 
treatment was not administered. Additionally, the use of ghrelin administration may pose an added 
benefit. It has been theorised that ghrelin and PYY interact, and it has been shown in rodents that 
peripheral ghrelin injections attenuate PYY-induced inhibition of food intake (Chelikani et al., 2006), 
which would thus play an additional benefit in increasing appetite in older adults, and may address the 
problem of increased PYY release without the need to manipulate this hormone directly. Not all 
studies have shown such a response and so more research needs to be conducted to understand the 
interactions between PYY and ghrelin before any human studies are conducted.  In addition to 
addressing if there is a difference in sensitivity to PYY, it would also be important to observe if older 
adults are insensitive to the hunger inducing effects of ghrelin. Infusions of ghrelin in younger and 
older adults need to be conducted to see if they have a different response. If older adults appear to be 
insensitive to ghrelin, this would justify the need for a multi-factorial approach to treating 
undernutrition and increasing appetite as ghrelin alone may not produce the desired effects. 
The use of macronutrients for manipulating appetite may also be of significant use in the future, 
particularly because economically it is far cheaper than the use of synthetic gastrointestinal appetite 
hormones. Di Francesco (2010) found that older adults appear to be more sensitive to fat in the diet, 
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whereby they feel fuller following a high fat meal compared to an equicaloric low fat meal.  More 
research studies are required using different combination of macronutrients to assess if there is a 
macronutrient composition of food products that optimise food intake and gastrointestinal hormone 
profile with favours an improvement in appetite in the elderly. The use of high protein, lower fat 
meals may be useful in providing optimal food intake. 
The difficulty of accessing the community with making macronutrient based recommendations for 
increasing food intake, still poses a problem and would require a significant amount of resources to 
educate the elderly population on dietary intake, with other factors such as sociological and 
psychological factors (i.e. bereavement) still a factor that cannot be controlled for, in which case a 
more vigorous approach may be required. In hospital and institutionalised based settings, its use, 
combined with administration of ghrelin or PYY inhibitors could be very successful in addressing 
increasing appetite. Increasing appetite in older adults is important because it will aid with recovery 
from illness and improve quality of life.  
This thesis aimed to understand the alterations in the appetite regulatory system with ageing. The 
overall conclusion from this thesis is that there are reductions in appetite and energy intake which 
may be linked to subsequent increases the satiety hormone PYY in ageing. In addition to increases in 
the putative satiety hormone PYY, there is also an insensitivity to the satiating effects of protein with 
age. The use of animal models have been shown in this thesis to not be a useful model of age related 
appetite research Although more work is required to understand the age associated alterations in the 
appetite regulatory system, this thesis has provided a new insight into the age observed changes in 
which will help focus future research on the treatment and management of undernutrition. 
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10.1. GP Letter sent out to participants, chapters 4 and 7  
 
 
GP headed note paper 
 
Patients name 
Address 1 
Address 2 
Address 3 
Post code 
 
 
 
Dear [patient’s name], 
I am writing to you to ask you to consider taking part in a research study run by researchers at 
Imperial College London.  They are currently recruiting volunteers 80 years and older to take part in a 
study to find out why older people often lose their appetite as they age, and consequently may become 
malnourished. 
As people get older they become more vulnerable to malnutrition (inadequate nutrition). We know 
this as a large proportion of older people have been found with malnutrition both living at home and 
when admitted to hospital. Malnutrition is a major problem which leads to increased risk of illness, 
reduced ability to undertake usual daily activities, and decreased quality of life.  Malnutrition in later 
years of life may be related to changes in appetite control, which means that older people are more 
likely to have a reduced appetite. Appetite is partly controlled by a series of hormones released by the 
gut, which either make you feel hungry or full. With ageing it appears that the release of these 
appetite hormones may be altered, and the ones that make you feel full get released more.  
This study aims to investigate healthy older people to see whether gut appetite hormones are altered 
compared to healthy younger adults.  We are writing to you because you are over 80 years old and 
healthy, according to our records. 
If you decide to take part you will be asked to attend 2 morning study sessions (lasting about 4 hrs) at 
Hammersmith Hospital, Du Cane Road, W12 0HS. The 2 sessions will be 1 week apart and you will 
have blood samples taken. You will be asked to come without having eaten overnight but we will 
provide breakfast and lunch during the test. You will be given travel expenses and compensation for 
your time and inconvenience. 
Your participation is entirely voluntary.  It is up to you to decide whether or not to take part. If you 
decide to take part you are still free to withdraw at any time and without giving a reason. If you are 
interested in taking part and would like to know more about the study please contact the researchers 
directly. 
Charlotte Moss 
E-mail: Charlotte.Moss08@ic.ac.uk 
Phone: 
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10.2. Three Factors Eating Questionnaire, restraint section only 
 
THREE-FACTOR EATING QUESTIONNAIRE 
 
 
Part I  Please circle true (T) or false (F) for each question 
 
1. When I have eaten my quota of calories I am usually good about not  
eating any more        T(+)  F(-)
           
2. I deliberately take small helpings as a means of controlling my weight T(+)    F(-) 
 
3. Life is too short to worry about dieting     T(-)    F(+) 
 
4. I have a pretty good idea of the calories in common food   T(+)    F(-) 
 
5. While on a diet, if I eat food that is not allowed, I consciously eat less  
for a period of time to make up for it.     T(+)    F(-) 
 
6. I enjoy eating too much to spoil it by counting calories or watching my 
 weight.         T(-)    F(+) 
 
7. I often stop eating when I am not really full as a conscious means of  
limiting the amount that I eat .      T(+)    F(-) 
 
8. I consciously hold back at meals in order not to gain weight .  T(+)    F(-) 
 
9. I eat anything I want, any time I want.     T(-)    F(+) 
 
10. I count calories as a conscious means of controlling weight.   T(+)    F(-) 
 
11. I do not eat some foods because they make me fat.    T(+)    F(-) 
 
12. I pay a great deal of attention to changes in my figure.    T(+)   F(-) 
 
 
328 
 
PART II  
Please circle the number above the response that is appropriate to you 
 
13. How often are you dieting in a conscious effort to control your weight? 
 
1   2   3   4 
         rarely (-)       sometimes (-)          usually (+)                   always (+) 
 
14. Would a weight fluctuation of 5lbs affect the way you live your life? 
 
1   2   3   4 
       not at all (-)          slightly (-)       moderately (+)      very much (+) 
 
15. Do your feelings of guilt about overeating help you to control your food intake? 
 
1   2   3   4 
        never (-)            rarely (-)           often (+)           always (+) 
 
16. How conscious are you of what you are eating? 
 
1   2   3   4 
        not at all (-)          slightly (-)       moderately (+)       extremely (+) 
 
17. How frequently do you avoid ‘stocking up’ on tempting foods? 
 
1   2   3   4 
     almost never  (-)         seldom (-)           usually (+)               almost always (+) 
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18. How likely are you to shop for low calorie foods? 
 
1   2   3   4 
        unlikely (-)                 slightly likely (-)    moderately likely (+)         very likely (+) 
 
 
19. How likely are you to consciously eat slowly in order to cut down on how much you eat? 
 
 1   2   3   4 
         unlikely (-)      slightly likely (-)            moderately likely (+)       very likely (+) 
 
 
20. How likely are you to consciously eat less than you want? 
 
1   2   3   4 
        unlikely (-)    slightly likely (-)           moderately likely (+)      very likely (+) 
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21. On a scale of 0 to 5, where 0 means no restraint in eating (eating whatever you want, 
whenever you want it) and 5 means total restraint (constantly limiting food intake and never 
‘giving in’), what number would you give yourself? 
 
                         0 (-) 
eat whatever you want, whenever you want it 
 
1 (-) 
usually eat whatever you want, whenever you want it 
 
2 (-) 
often eat whatever you want, whenever you want it 
 
3 (+) 
often limit food intake, but often ‘give in’ 
 
4 (+) 
usually limit food intake, rarely ‘give in’ 
 
5 (+) 
constantly limiting food intake, never ‘giving in’ 
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10.3. The International Physical Activity Questionnaire 
 
INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
 
We are interested in finding out about the kinds of physical activities that people do as part of 
their everyday lives.  The questions will ask you about the time you spent being physically 
active in the last 7 days.  Please answer each question even if you do not consider yourself to 
be an active person.  Please think about the activities you do at work, as part of your house 
and yard work, to get from place to place, and in your spare time for recreation, exercise or 
sport. 
 
Think about all the vigorous activities that you did in the last 7 days.  Vigorous physical 
activities refer to activities that take hard physical effort and make you breathe much harder 
than normal.  Think only about those physical activities that you did for at least 10 minutes at 
a time. 
 
1. During the last 7 days, on how many days did you do vigorous physical activities 
like heavy lifting, digging, aerobics, or fast bicycling?  
 
_____ days per week  
 
   No vigorous physical activities  Skip to question 3 
 
 
2. How much time did you usually spend doing vigorous physical activities on one of those days? 
 
_____ hours per day  
_____ minutes per day   
 
  Don’t know/Not sure  
 
 
Think about all the moderate activities that you did in the last 7 days.  Moderate activities 
refer to activities that take moderate physical effort and make you breathe somewhat harder 
than normal.  Think only about those physical activities that you did for at least 10 minutes at 
a time. 
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3. During the last 7 days, on how many days did you do moderate physical activities 
like carrying light loads, bicycling at a regular pace, or doubles tennis?  Do not 
include walking. 
 
_____ days per week 
 
   No moderate physical activities  Skip to question 5 
 
4. How much time did you usually spend doing moderate physical activities on one of those days? 
 
_____ hours per day 
_____ minutes per day 
 
  Don’t know/Not sure  
 
 
Think about the time you spent walking in the last 7 days.  This includes at work and at 
home, walking to travel from place to place, and any other walking that you might do solely 
for recreation, sport, exercise, or leisure. 
 
5. During the last 7 days, on how many days did you walk for at least 10 minutes at a 
time?   
 
_____ days per week 
  
   No walking     Skip to question 7 
 
6. How much time did you usually spend walking on one of those days? 
 
_____ hours per day 
_____ minutes per day  
 
  Don’t know/Not sure  
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The last question is about the time you spent sitting on weekdays during the last 7 days.  Include time spent at 
work, at home, while doing course work and during leisure time.  This may include time spent sitting at a desk, 
visiting friends, reading, or sitting or lying down to watch television. 
 
7. During the last 7 days, how much time did you spend sitting on a week day? 
 
_____ hours per day  
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
This is the end of the questionnaire, thank you for participating. 
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10.4. Visual Analogue Scales 
 
(Not to Scale) 
1. How hungry do you feel right now? 
 
 
 
2. How sick do you feel right now? 
 
 
 
3. How pleasant would it be to eat right now? 
 
 
 
4. How much do you think you could eat right now? 
 
 
 
5. How full do you feel right now? 
 
 
 
6. How tasty was this meal? (After Ad Libitum Meal only) 
 
 
7. How pleasant was this meal? (After Ad Libitum Meal only) 
 
 
Not at all Extremely 
Not at all Extremely 
Not at all Extremely 
Nothing A Large Amount 
Not at All Extremely 
Not at All Extremely 
Not at All Extremely 
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10.5. Participant Information Sheet, Chapter 4 
 
Version 3 26/03/10 
THIS INFORMATION SHEET IS VALID FOR USE UNTIL  
 
INFORMATION SHEET FOR PARTICIPANTS 
You will be given a copy of this Information Sheet and a signed 
copy of your consent form to keep, should you decide to 
participate in this study. 
 
COMPARISON OF GUT APPETITE HORMONES IN HEALTHY 
OLDER AND YOUNG ADULTS 
 
You are being invited to take part in a research study. Before you decide, it is important for you to 
understand why the research is being done, and what it will involve. Please take time to read the 
following information carefully and discuss it with friends, relatives and your GP if you wish. Ask us 
if there is anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part. 
If you decide to take part, please let us know beforehand if you have been involved in any other study 
during the last year. You are free to withdraw at any time without explanation. 
Thank you for reading this. 
What is the purpose of this research? 
As we age, we become more vulnerable to malnutrition, as demonstrated by a larger proportion of 
older people who develop malnutrition both living at home and when admitted to hospital.  This may 
be related to changes in appetite control which means that older people are more likely to have a poor 
appetite. Appetite is controlled by a series of hormones released by the gut, which make you feel 
either hungry or full up.  As we age, it appears that, the release of these appetite hormones may be 
altered. A more detailed investigation is needed to clarify what these changes are.  
The purpose of this study is to define whether gut appetite hormone levels are altered in healthy older 
adults prior to or after eating, compared to healthy younger adults. 
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Why have I been chosen? 
Healthy volunteers over the age of 20 are being recruited to take part in this study. 
You should not take part in this study if you: 
- Are breastfeeding 
- Have given blood in the last three months 
- Have any illnesses or are taking medication which we feel make you unsuitable; we will 
discuss this with you before you decide to take part. 
- Smoke 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part, you will be given 
this information sheet to keep and be asked to sign a consent form. If you decide to take part you are 
still free to withdraw at any time and without giving a reason. 
What will happen to me if I do take part? 
If you agree to take part in this study, you will attend a screening visit. At the screening visit we will 
measure your height and weight to calculate BMI, and your body fat percentage calculated using 
Bioelectrical Impedance. You will also be asked to complete a short questionnaire about your eating 
habits. We will also take a small blood sample (about 1½ teaspoons) to test levels of iron in your 
blood. We will also ask you about any current medications you are taking and any illnesses you may 
have had recently. 
Providing the results of these questions and tests are suitable you will be asked to come back to take 
part in the study. You will be asked to wear an activity monitor for a period of 3 days (with one day a 
weekend day). Training on how to use this watch will be provided on the screening visit. The activity 
monitor consists of a waterproof elasticated waistband with a small plastic device attached to it. This 
small plastic device enables us to measure movement, and therefore physical activity levels. 
You will also be asked to attend Ward C2 in Hammersmith Hospital on two occasions. Preferably 
these study days will take place about one week apart. 
Study Day Procedure 
The two study days will follow the same procedures and will be no longer than 4 hours. 
The first study day, will be a practice visit, where we will follow exactly the same procedure as the 
second study day, but smaller volumes of blood will be taken and the blood samples will not be 
analysed. This is because gut hormones are easily influenced by stress and anxiety, therefore a 
practice visit will enable you to become accustomed to the environment. 
You will be asked not to eat or drink anything except water from 9pm the night before the study day 
and you will be asked to abstain from alcohol and strenuous exercise for the 24 hours before each 
visit. 
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When you arrive at 8.30hr you will be asked to sit down and you will have a plastic cannula placed 
into a vein in your arm. You may feel some discomfort while the cannula is being inserted, but it will 
be pain free once inserted. You will remain seated throughout the 4 hours and you will be allowed to 
watch a DVD, read or watch TV. 
Blood samples will be taken from the cannula 6 times during the next 3.5 hours (see the diagram 
below). The amount taken in each blood sample is 10mls (about the same as 2 teaspoons). This means 
you will have no more than 60mls taken on the second study day and about half this amount on the 
practice session. 
Just before each blood sample is taken, you will answer a number of questions on a visual analogue 
scale (VAS). These are lines drawn on a piece of paper with a measure at each end, for example 
ranging from 'I am as hungry as I could possibly be' to 'I am as full as I could possibly be' and you 
will have to mark a point on the scale to indicate how you feel. 
 
Half an hour after the cannula is placed, and immediately after your first blood sample, you will be 
asked to eat a test meal. This will consist of 440ml (a large glass full) Ensure milkshake (flavour of 
your choice), which has to be consumed within 15 minutes.  
At the same time a drink will also be provided that will contain 1.5g of paracetamol which we use as a 
measure of how quickly your stomach is emptying. Paracetamol is not absorbed in the stomach but 
once it is released from the stomach into the small intestines it is absorbed rapidly. By measuring the 
level of paracetamol that appears in your blood we can work out how quickly your stomach empties 
after eating. 
After 3.5 hours, you will be presented with a large meal and invited to eat until you are comfortably 
full, and you will have to answer a number of questions as previously described, for example, ‘How 
hungry do you feel right now?’. The cannula will be removed and that will be the end of the study 
day. 
Figure 1: Diagram of overview of study day. Participants will be asked to attend two study days. 
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Payments and Expenses 
If you decide to take part in this study we will provide a payment to cover your travel expenses and 
inconvenience. This will be about £25 for each study day plus your travel costs. The money will be 
paid into your bank account by Imperial College shortly after completion of the study. If you 
withdraw from the study at any time, you will receive payments for each visit you have attended. 
What are the possible disadvantages of taking part? 
You will be giving up your time and there may be some discomfort as the cannula is placed and in 
some people bruising may occur at the cannula site. 
What are the possible benefits of taking part? 
None. The information we get from this study may help to further our understanding of appetite and 
ageing. 
What happens if something goes wrong? 
If you have a concern about any aspect of this study, you should ask to speak with the researchers 
who will do their best to answer your questions (see contact details at the end of this sheet).  If you 
remain unhappy and wish to complain formally, you can do this through the NHS Complaints 
Procedure.  Details can be obtained from the hospital. 
In the unlikely event that you are harmed due to taking part in this study, there are no special 
compensation arrangements.  If you are harmed due to someone’s negligence, then you may have 
grounds for legal action but you may have to pay for it.  Regardless of this, if you wish to complain 
about any aspect of the way you have been approached or treated during the course of this study, the 
normal NHS complaints mechanism may be available to you. 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept strictly 
confidential. All samples and records will be coded and labelled as such, so you cannot be recognised 
from it. Blood samples at the end of the study will be disposed of. 
What will happen to the results of the research study? 
We will be aiming to publish the results of this study in a scientific journal. Your confidentiality will 
be ensured at all times and you will not be identifiable in any report or papers we write. At the end of 
the study, the results of the study can be made available to you should you wish (please tell the 
researcher at one of your study visits). 
Who is organising and funding the study? 
This study is being organised by the Department of Metabolic Medicine, Imperial College London 
and Imperial College Healthcare NHS Trust. Funding for the study has been obtained from the 
Hammersmith Hospitals Charity Trustees Research Committee. 
 
Who has reviewed the study? 
This study has been reviewed by the Riverside Hospitals Research Ethics Committee. 
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Contact for further information 
If you have any questions you may contact researcher Charlotte Moss preferably via email at 
charlotte.moss08@imperial.ac.uk or by telephone on 07588851564. 
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10.6. Participant Consent Form, Chapter 4 
 
Version 1. 20/08/10 
 
THIS INFORMATION SHEET IS VALID FOR USE UNTIL  
 
PARTICIPANT CONSENT FORM 
 
The effect of protein on appetite and gut hormone 
response in older compared to younger volunteers. 
CI: Dr Mary Hickson 
 
The participant should complete the whole of this form him or herself. 
(please initial each statement if it applies to you) 
 
I have read the Information Sheet for Healthy Volunteers, Version 1, 18.08.10 
 
 
 
I have been given the opportunity to ask questions and discuss this study 
 
 
 
I understand that sections of any of my medical notes maybe looked at by responsible 
individuals from Imperial College, the NHS Trust, or from regulatory authorities where 
it is relevant to my taking part in this research. I give permission to these individuals to 
access my medical records that are relevant to this research. 
 
 
 
I have received satisfactory answers to all my questions 
 
 
 
I have received enough information about the study 
 
 
 
This study has been explained to me by: 
 
Prof/Dr/Mr/Mrs/Ms______________________________________________________ 
 
 
 
I understand that my participation is voluntary and I am free to withdraw from the 
study at any time, without having to give a reason for withdrawing and without 
affecting my future medical care. 
 
 
 
I agree to take part in this study  
 
 
 
 
1 copy to participant, 1 copy to researcher 
 
 
Signed………………………………………………………………………Date…………………........ 
 
(NAME IN BLOCK CAPITALS)………………………………………………………………………... 
 
Investigator’s signature…………………………………………………..Date……………………….. 
(NAME IN BLOCK CAPITALS)………………………………………………………………………... 
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10.7. Chapter 3 plasma gastrointestinal appetite hormone results 
 
 
Table 10.1.  Chapter 3 gastrointestinal appetite hormones in the cannulated, anaesthetics and control 
rats. 
 Cannulation (N=8) Anaesthetics (N=8) Controls (N=8) 
 PYY pmol/L PYY  pmol/l PYY pmol/l 
Geometric Mean  
(IQ Range) 
47.64 
(37.91-56.59) 
58.96 
(47.52-62.97) 
56.14  
(46.03-70.74) 
 GLP-1 pmol/L GLP-1  pmol/l GLP-1 pmol/l 
Mean 
(SEM) 
147.6 
(10.86) 
183.29 
(11.62) 
183.39  
(14.97) 
 Total Ghrelin pmol/L Total Ghrelin  pmol/l Total Ghrelin pmol/l 
Mean 
(SEM) 
502.47 
(20.21) 
511.70 
(22.36) 
520.06 
(23.90) 
 Acyl Ghrelin pmol/L Acyl Ghrelin  pmol/l Acyl Ghrelin pmol/l 
Mean 
(SEM) 
11.81 
(4.15) 
21,47 
(3.16) 
16.10 
(3.66) 
 
Geometric mean (IQ range) plasma PYY concentrations, Mean (SEM) plasma total and acyl ghrelin 
(pmol/L) in the cannulated, anaesthetics and control rats. 
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10.8. Chapter 4 Tables and Results. 
 
10.8.1 Chapter 4 tables for AUC and IAUC Visual Analogue scores  
 
Table 10.2.  Chapter 4 AUC and IAUC VAS scores in the 20-39, 40-59, 60-79 and 80+ age groups 
How hungry do you feel? 
Age group Mean (SEM) AUC Mean (SEM) IAUC 
20-39 (n=18) 7648.33 (862.06) -4401.67 (863.74) 
40-59 (n=18) 5661.67 (520.01) -4028.33 (1335.28) 
60-79 (n=16) 4802.34 (570.34) -980.17 (1198.29) 
80+ (n=6) 3057.50 (1338.92) -572.50 (474.68) 
How sick do you feel? 
Age group Median (IQ Range) AUC Median (IQ Range) IAUC 
20-39 (n=18) 930.00 (180.00 – 3624.28) 0.00 (-75.00 – 1873.13) 
40-59 (n=18) 1125.0 (316.88 – 4031.25) -116.24 (-971.25 – 440.63) 
60-79 (n=16) 600.00 (225.0 – 2955.00) 277.50 (7.50 – 2015.63) 
80+ (n=6) 195.00 (180.00 – 1963.13) 30.00 (0.00 – 768.75) 
How pleasant to eat? 
Age group Mean (SEM) AUC Mean (SEM) IAUC 
20-39 (n=18) 9299.17 (798.99) -3740.83 (645.27) 
40-59 (n=18) 6377.08 (613.77) -4082.92 (1317.73) 
60-79 (n=16) 5667.19 (574.82) -846.56 (1217.05) 
80+ (n=6) 3242.5 (1408.27) -3207.50 (664.11) 
How much can you eat? 
Age group Mean (SEM) AUC Mean (SEM) IAUC 
20-39 (n=18) 9342.50 (751.70) -3237.50 (559.73) 
40-59 (n=18) 6254.17 (514.65) -2875.83 (1115.83) 
60-79 (n=16) 5776.41 (586.14) -422.34 (1010.23) 
80+ (n=6) 3407.50 (1390.35) -2202.50  (623.54) 
How full do you feel? 
Age group Mean (SEM) AUC Mean (SEM) IAUC 
20-39 (n=18) 6692.08 (776.90) 3492.08 (717.96) 
40-59 (n=18) 9708.33 (1166.94) 5608.33 (1166.94) 
60-79 (n=16) 8807.81 (891.53) 2744.06 (1196.51) 
80+ (n=6) 10503.75 (2026.25) 6063.75 (2524.00) 
 
Median (IQ Range) how sick do you feel and Mean (SEM) how hungry, how pleasant to eat, how 
much can you eat and how full IAUC and AUC in the 20-39, 40-59, 60-79 and 80+ age group 
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10.8.2. Chapter 4 table for AUC and IAUC plasma hormone results 
  
Table 10.3.Chapter 4 AUC and IAUC scores for PYY, GLP, acyl ghrelin and total ghrelin in the 20-
39, 40-59, 60-79 and 80+ age groups. 
Plasma PYY 
Age group Geometric Mean (IQ Range) AUC Median (IQ Range) IAUC 
20-39 (n=18) 4877.10 (3624.38 – 6240.08) 1583.18 (540.66 – 2560.58) 
40-59 (n=18) 5410.55 (4684.56 – 5916.49) 1792.73 (853.56 – 3035.89) 
60-79 (n=16) 4715.20 (3556.73 – 5570.66) 1204.46 (97.46 – 1952.83) 
80+ (n=6) 6340.94 (4223.01 – 10565.05) 3640.31 (2620.16 – 4667.53) 
Plasma GLP-1 
Age group Mean (SEM) AUC Mean (SEM) IAUC 
20-39 (n=18) 54163.65 (5500.34) 15389.85 (2962.07) 
40-59 (n=18) 54682.23 (6298.72) 13876.67 (5713.73) 
60-79 (n=16) 55141.43 (4858.08) 18571.50 (2251.96) 
80+ (n=6) 47923.99 (10445.75) 18028.99 (8051.85) 
Plasma Total Ghrelin 
Age group Median (IQ Range) AUC Median (IQ Range) IAUC 
20-39 (n=18) 61925.82    (44469.71 – 82917.71) -21221.70     (-38585 - -14639.83) 
40-59 (n=18) 80576.17    (64356.08 – 138314.08) -43896.53     (-77641.41 - -7477.78) 
60-79 (n=16) 60526.33     (48482.98 – 81717.98) -25887.79     (-43367.00 - -3170.83) 
80+ (n=6) 96290.24    (63678.94 – 159019.88) -38759.55    (-71426.03 - -22712.51) 
Plasma Acyl Ghrelin 
Age group Median (IQ Range) AUC Median (IQ Range) IAUC 
20-39 (n=18) 16440.59     (9471.58 – 24953.82) -23166.56     (-55345.02 - -4941.46) 
40-59 (n=18) 18153.42     (11359.6 – 24993.64) -17278.87     (-33636.22 - -2430.51) 
60-79 (n=16) 15532.93     (8556.80 – 29473.89) -11411.72     (-37305.79 - -308.74) 
80+ (n=6) 14759.26     (9614.43 – 23133.72) -16260.71     (-31519.91 - -6378.08) 
 
Geometric Mean (IQ Range) plasma PYY AUC, Median (IQ Range) plasma PYY IAUC, total and  
ghrelin AUC and IAUC and Mean (SEM) GLP-1 AUC and IAUC levels in the 20-39, 40-59, 60-79 
and 80+ age group 
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10.8.3 Chapter 4 table for AUC and IAUC insulin and Glucose and HOMA scores 
 
Table 10.4. Chapter 4 HOMA and HOMA-PP scores and AUC and IAUC scores for insulin and 
glucose in the 20-39, 40-59, 60-79 and 80+ age groups. 
Plasma Insulin 
Age group Mean (SEM) AUC Mean (SEM) IAUC 
20-39 (n=18) 5993.14 (309.54) 4435.99 (274.04) 
40-59 (n=18) 5806.40 (507.55) 4319.46 (434.03) 
60-79 (n=16) 6775.05 (813.92) 4943.41 (738.95) 
80+ (n=6) 8905.29 (895.98) 5808.90 (725.73) 
Plasma Glucose 
Age group Median (IQ Range) AUC Median (IQ Range) IAUC 
20-39 (n=18) 929.50 (848.70 – 1055.76) 121.05 (32.34) 
40-59 (n=18) 1038.76 (937.76 – 1155.62) 166.82 (50.83) 
60-79 (n=16) 1057.94 (929.38 – 1211.23) 70.82 (59.47) 
80+ (n=6) 1209.09 (1066.29 – 1413.45) 227.11 (46.46) 
Plasma HOMA and HOMA-PP 
Age group Median (IQ Range) HOMA Mean (SEM) HOMA-PP 
20-39 (n=18) 0.20 (0.16 – 0.34) 2599.31 (877.94) 
40-59 (n=18) 0.23 (0.15 – 0.36) 2431.39 (973.15) 
60-79 (n=16) 0.20 (0.16 – 0.38) 4163.55 (2320.05) 
80+ (n=6) 0.59 (0.46 – 0.80) 1317.93 (1317.93) 
 
Mean (SEM) AUC and IAUC insulin and HOMA-PP scores and Median (IQ Range) AUC and IAUC 
plasma glucose and HOMA scores in the 20-39, 40-59, 60-79 and 80+ age groups. 
 
 
 
 
 
 
 
 
 
345 
 
10.8.4 Correlations between energy intake and final VAS score 
 
Table 10.5. Correlations between energy intake and final VAS score in the 20-39, 40-59, 60-79 and 
80 + age group 
Variable 1 Variable 2 Significance R
2 
Energy Intake VAS T180 How Hungry P<0.001 .597 
Energy Intake VAS T180 How Sick N/S -.008 
Energy Intake VAS T180 How Pleasant P<0.001 .704 
Energy Intake VAS T180 How Much Eat P<0.001 .640 
Energy Intake VAS T180 How Full P=0.005 -.360 
Energy Intake Glucose T180 P=0.002 -.394 
Energy Intake Total Ghrelin T180 N/S -.008 
Energy Intake PYY T180 N/S -.141 
Energy Intake GLP-1 T180 N/S -.069 
Energy Intake Acyl Ghrelin T180 N/S .479 
Energy Intake Insulin T180 P=0.003 -.396 
Energy Intake HOMA N/S .243 
Energy Intake HOMA-PP Approaching p=0.06 .312 
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10.8.5. Chapter 4, separate statistics for males and females  
 
10.8.5.1. Energy Intake 
Table 10.6. Chapter 4 Energy intake at ad libitum test meals in males and females seperately in the 
20-39, 40-59, 60-79 and 80+ age groups 
Age Group (years) 20-39 40-59 60-79 80+ Significance? 
Mean (SEM) Kcal 
consumed at test 
meal in females 
885.5 
(106.95) 
n=9 
743.9 
(105.3) 
n=9 
683.9 
(130.4) 
n=7 
415.62 
(72.4) 
n=6 
P=0.005             
(20-39 vs. 80+, 
p=0.032) 
Mean (SEM) Kcal 
consumed at test 
meal in males 
1152.4 
(115.8) 
n=9 
858.3 
(77.4) 
n=9 
603.5 (93.5) 
n=9 
 p=0.002 
(20-39 vs. 60-79, 
p=0.001) 
 
Mean energy intake (kcal) ± SEM at test meal in males and females individually in different age 
categories 20-39, 40-59, 60-79 and 80+ years.  
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10.8.5.2. VAS scores 
Table 10.7.  Chapter 4 AUC VAS Scores in males and females separately in the 20-39, 40-59, 60-79 
and 80+ age groups 
  Mean (SEM) AUC Score  
 Gender 20-39 40-59 60-79 80+ Significance? 
How hungry M 8910.00 
(1145.39) 
6392.50 
(640.19) 
4687.50 
(558.42) 
 p=0.005           
(20-39 vs. 60-79, 
p=0.004) 
 F 6386.67 
(1203.54) 
4930.83 
(778.38) 
4950.00 
(1147.86) 
3057.50 
(1338.91) 
p=0.264 
How sick* M 217.50 
(180.0 – 
3187.50) 
1395.00 
(570.0 – 
4072.5) 
1267.5 
(405.0 – 
3971.25) 
 p=0.426 
 F 1560.00 
(697.50 – 
4207.50) 
517.50 
(277.5 – 
3135.0) 
270.00 
(180.00 – 
630.00) 
195.00 
(180.00 – 
1963.13) 
p=0.086 
How pleasant to 
eat 
M 9990.00 
(1057.56) 
6725.83 
(740.92) 
5855.83 
(535.42) 
 p=0.003           
(20-39 vs. 40-59 
p=0.023) (20-39 vs. 60-
79 p=0.004) 
 F 8608.33 
(1214.67) 
6028.33 
(1010.77) 
5424.64 
(1174.40) 
3242.50 
(1408.27) 
p=0.035           
(20-39 vs. 80+, 
p=0.024) 
How much can you 
eat 
M 10677.50 
(899.19) 
6656.67 
(637.65) 
5721.67 
(501.80) 
 p<0.001           
(20-39 vs. 40-59, 
p=0.001) (20-39 vs. 60-
79, p<0.001) 
 F 8007.50 
(1071.15) 
5851.67 
(823.74) 
5846.79 
(1236.97) 
3407.50 
(1390.35) 
p=0.063 
How full do you 
feel 
M 5743.33 
(984.12) 
9400.83 
(1157.37) 
8888.33 
(1104.05) 
 p=0.053 
 F 7640.83 
(1171.17) 
10015.83 
(1188.10) 
8704.29 
(1564.96) 
10503.75 
(2026.25) 
p=0.486 
* Median (IQ Range) 
Mean (SEM) how hungry, how pleasant to eat, how much can you eat, how full do you feel and 
Median (IQ Range) how sick AUC VAS scores in the 20-39, 40-59, 60-79 and 80+ age group. 
Significance detected; Males how hungry p=0.005 (20-39 v.s.60-79 p=0.004), males how pleasant to 
eat p=0.003 (20-39 vs.40-59, p=0.023. 20-39 vs. 60-79 p=0.004), females how pleasant to eat 
p=0.035 (20-39 vs. 80+ p=0.024), males how much can you eat p<0.001 (20-39 vs.40-59, p=0.001. 
20-39 vs. 60-79, p<0.001). 
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Table 10.8. Chapter 4 IAUC VAS Scores in males and females separately in the 20-39, 40-59, 60-79 
and 80+ age groups 
  Mean (SEM) IAUC Score  
 Gender 20-39 40-59 60-79 80+ Significance? 
How Hungry M -3510.0 
(1441.59) 
-3427.50 
(1738.80) 
-952.50 
(1257.43) 
 p=0.407 
 F -5293.33 
(985.38) 
-4629.17 
(2112.82) 
-990.00 
(2344.06) 
-572.50 
(474.68) 
p=0.149 
How Sick* M 0.00        
(-2392.5 – 
18.75) 
-240.00  
(-2925.0 - 
-7.50) 
547.50 
(52.5 – 
2640.00) 
 p=0.026           
(20-39 vs. 60-79, 
p=0.031) (40-59 vs. 60-
79 p=0.019) 
 F 1380.0    
(-18.75 – 
2587.50) 
180.00    
(-622.50 – 
2580.00) 
90.00 
(0.00 – 
450.00) 
30.00 
(0.00 – 
768.75) 
p=0.754 
How Pleasant to 
Eat 
M -2770.00 
(933.86) 
-3914.17 
(1625.75) 
-224.17 
(1077.72) 
 p=0.123 
 F -4711.67 
(813.55) 
-4251.67 
(2174.77) 
-1646.79 
(2506.64) 
-3207.50 
(664.11) 
p=0.636 
How Much can 
you Eat 
M -2522.50 
(595.80) 
-2703.33 
(1604.54) 
-378.33 
(838.22) 
 p=0.270 
 F -3952.50 
(921.26) 
-3048.33 
(1646.08) 
-478.93 
(2150.91) 
-2202.50 
(623.53) 
p=0.414 
How Full do you 
Feel 
M 3223.33 
(840.88) 
4220.83 
(1592.68) 
688.33 
(1096.97) 
 p=0.129 
 F 3760.83 
(1210.62) 
6995.83 
(1664.18) 
5387.14 
(2011.96) 
6063.75 
(2523.99) 
p=0.580 
 
*Median (IQ Range) 
 
Mean (SEM) how hungry, how pleasant to eat, how much can you eat, how full do you feel and 
Median (IQ Range) how sick AUC VAS scores in the 20-39, 40-59, 60-79 and 80+ age group. 
Significance detected; Males how sick p=0.026 (20-39 v.s.60-79, p=0.031. 40-49 vs. 60-79, p=0.019).  
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10.8.5.3. Plasma gastrointestinal hormones 
Table 10.9. Chapter 4 AUC Scores for PYY, GLP-1, total ghrelin and acyl ghrelin in males and 
females separately in the 20-39, 40-59, 60-79 and 80+ age groups 
 Gender 20-39 40-59 60-79 80+ Significance? 
AUC PYY 
Median (IQ Range) M 4752.75 
(3511.28 –
6320.55) 
5489.40 
(4936.28 
–7341.71) 
3756.98 
(2920.84 
–7270.54) 
 p=0.627 
Median (IQ Range) F 5259.45 
(3460.39 –
6278.78) 
5048.63 
(4116.71 
–5411.55) 
4718.40 
(4100.03 
–5135.25) 
6073.76 
(4924.81 -
10565.05) 
p=0.201 
AUC GLP-1 
Mean (SEM) M 46926.03 
(4901.74) 
51779.64 
(7521.78) 
56866.88 
(7612.07) 
 p=0.577 
Mean (SEM) F 61401.28 
(9563.24) 
57262.31 
(10203.3) 
52922.99 
(5837.18) 
47923.99 
(10445.8) 
p=0.789 
AUC Total Ghrelin 
Mean (SEM) M 58771.46 
(7259.82) 
71166.48 
(13046.9) 
64002.47 
(11772.5) 
 p=0.728 
Mean (SEM) F 77859.60 
(13301.5) 
115480.1 
(14723.7) 
91186.40 
(24890.7) 
105430.5 
(19185.7) 
p=0.422 
AUC Acyl Ghrelin 
Mean (SEM) M 17112.81 
(3977.88) 
14255.82 
(1424.74) 
21928.08 
(4356.12) 
 p=0.312 
Mean (SEM) F 22638.09 
(4805.72) 
32333.23 
(8189.72) 
20251.49 
(6491.47) 
17083.01 
(4705.31) 
p=0.393 
AUC Glucose 
Mean (SEM) M 950.45 
(48.10) 
1068.18 
(86.15) 
1050.28 
(48.76) 
 p=0.385 
Mean (SEM) F 928.84 
(50.14) 
1046.47 
(58.18) 
1112.96 
(117.58) 
1244.11 
(148.26) 
p=0.131 
AUC Insulin 
Median (IQ Range) M 5672.18 
(4609.09 –
7355.48) 
5636.03 
(4598.36 
–8406.15) 
9155.33 
(4918.35 
–9155.33) 
 p=0.668 
Median (IQ Range) F 5510.63 
(4603.88 –
5510.63) 
6015.30 
(4587.60 
–6015.30) 
6675.68 
(6481.50 
–6675.68) 
8835.75 
(7716.90 
–8835.75) 
p=0.034        
(40-59 vs 80+, 
p=0.038) 
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Table 10.9. continued Mean (SEM) AUC PYY, GLP-1, total ghrelin and acyl ghrelin and Median (IQ 
Range) how sick AUC scores in the 20-39, 40-59, 60-79 and 80+ age group. Significance detected; 
Males how sick p=0.026 (20-39 v.s.60-79, p=0.031. 40-49 vs. 60-79, p=0.019).  
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Table 10.10.  Chapter 4 IAUC Scores for PYY, GLP-1, total ghrelin and acyl ghrelin in males and 
females separately in the 20-39, 40-59, 60-79 and 80+ age groups 
 Gender 20-39 40-59 60-79 80+ Significance 
IAUC PYY 
Median (IQ Range) M 1163.25 
(592.39 – 
1812.45) 
1609.80 
(714.64 – 
3295.99) 
1078.13  
(-414.86 – 
2769.56) 
 p=0.406 
Median (IQ Range) F 2232.38  
(-79.16 – 
3661.91) 
1815.60 
(1299.9 – 
2549.70) 
1330.80 
(46.43 – 
2017.65) 
3720.27 
(3332.0 – 
4667.53) 
p=0.007 
IAUC GLP-1 
Mean (SEM) M 11057.83 
(4476.71) 
16612.82 
(9704.16) 
17266.28 
(3199.67) 
 p=0.730 
Mean (SEM) F 19721.88 
(3543.51) 
11444.91 
(6965.43) 
20249.65 
(3254.81) 
18028.98 
(8051.85) 
p=0.644 
IAUC Total Ghrelin 
Mean (SEM) M -27188.14 
(3831.93) 
-27219.73 
(11451.6) 
-24619.33 
(6559.99) 
 p=0.965 
Mean (SEM) F -32802.60 
(11914.1) 
-68990.12 
(15368.8) 
-50257.85 
(36525.4) 
-51089.75 
(18163.1) 
p=0.640 
IAUC Acyl Ghrelin 
Median (IQ Range) M -38249.81 
(-61125.4 
-               
-10931.9) 
-7696.48 
(-18605.2 
-                 
- 1518.29) 
-25247.49 
(-38841.7 
-               
-1442.82) 
 p=0.090 
Median (IQ Range) F -11783.66 
(-34602.2 
– 
4018.65) 
-27825.35 
(-80570.0 
-               
-5109.01) 
-8168.05 
(-25177.1 
– 
1530.79) 
-16260.71 
(-31519.9 
-               
-6378.08) 
p=0.646 
IAUC Glucose 
Mean (SEM) M 102.85 
(47.41) 
152.98 
(88.15) 
117.48 
(71.43) 
 p=0.877 
Mean (SEM) F 139.24 
(45.98) 
180.67 
(56.23) 
10.8 
(101.94) 
227.11 
(46.46) 
p=0.169 
IAUC Insulin 
Median (IQ Range) M 4454.51 
(3548.15 
– 
5524.68) 
3772.16 
(3246.82 
– 
6304.65) 
3872.55 
(3198.75 
– 
6723.41) 
 p=0.933 
Median (IQ Range) F 4860.82 
(3105.60 
– 
6114.15) 
4351.95 
(3387.22 
– 
5361.00) 
4660.05 
(2111.73 
– 
5782.76) 
4960.83 
(4098.90 
– 
7273.85) 
p=0.671 
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Mean (SEM) IAUC  GLP-1, total ghrelin, glucose and Median (IQ Range) IAUC PYY, acyl ghrelin, 
and insulin in the 20-39, 40-59, 60-79 and 80+ age group. Significance detected; Females PYY 
p=0.007 
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10.9. Chapter 7 Study Information Sheet 
 
Version 2 15/11/10 
THIS INFORMATION SHEET IS VALID FOR USE UNTIL  
 
INFORMATION SHEET FOR PARTICIPANTS 
You will be given a copy of this Information Sheet and a signed 
copy of your consent form to keep, should you decide to 
participate in this study. 
 
THE EFFECT OF PROTEIN ON APPETITE AND GUT 
HORMONE RESPONSE IN OLDER COMPARED TO YOUNGER 
VOLUNTEERS. 
CI: Dr Mary Hickson 
You are being invited to take part in a research study. Before you decide, it is important for you to 
understand why the research is being done, and what it will involve. Please take time to read the 
following information carefully and discuss it with friends, relatives and your GP if you wish. Ask us 
if there is anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part. 
If you decide to take part, please let us know beforehand if you have been involved in any other study 
during the last year. You are free to withdraw at any time without explanation. 
Thank you for reading this. 
What is the purpose of this research? 
As we age, we become more vulnerable to malnutrition, as demonstrated by a larger proportion of 
older people who develop malnutrition both living at home and when admitted to hospital. Appetite is 
controlled in part by a series of hormones released by the gut, which make you feel either hungry or 
full up.  Meals high in protein in younger people have demonstrated an increase in hormones that 
make you feel full and a decrease in hormones that make you feel hungry, therefore reducing appetite 
and food intake. No studies have looked at hormone release after a high protein meal in older 
individuals, however, under normal dietary conditions it appears that, the release of these appetite 
hormones may be altered, therefore after a high protein meal, this effect might be more pronounced. A 
more detailed investigation is needed to clarify what these changes are.  
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The purpose of this study is to define whether appetite, food intake and gut hormone levels are altered 
more substantially in healthy older adults compared to healthy younger adults after a high protein 
meal. 
Why have I been chosen? 
Healthy volunteers over the age of 20 are being recruited to take part in this study. 
You should not take part in this study if you: 
1. are breast feeding or pregnant 
2. have given blood in the last three months 
3. have any illnesses or are taking medication which we feel make you unsuitable; 
we will discuss this with you before you decide to take part 
4. Smoke 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part, you will be given 
this information sheet to keep and be asked to sign a consent form. If you decide to take part you are 
still free to withdraw at any time and without giving a reason. 
What will happen to me if I do take part? 
If you agree to take part in this study, you will attend a screening visit. At the screening visit we will 
measure your height and weight and your body fat percentage calculated from Bioelectrical 
Impedance. We will calculate your body mass index (BMI) from your height and weight, which tells 
us how close you are to an ideal weight for your height. Bioelectrical impedance measures the amount 
of fat you have in your body by measuring the passage of a low, safe electrical current through your 
body, and measuring how much resistance there is; fat tissue is more resistant to the current than lean 
tissue. 
You will also be asked to complete a short questionnaire about your eating habits. We will also take a 
small blood sample (about 1½ teaspoons) to test levels of iron in your blood. We will also ask you 
about any current medications you are taking and any illnesses you may have had recently. The 
research team may also review your medical notes to make sure they know about any relevant 
medical history. 
Providing the results of these questions and tests are suitable you will be asked to come back to take 
part in the study. You will be asked to wear an activity monitor for a period of 3 days (with one day a 
weekend day). Training on how to use this watch will be provided on the screening visit. The activity 
monitor consists of a small elasticated waistband with a small plastic device attached to it. The small 
plastic device enables us to measure movement, and therefore physical activity levels. You will be 
asked to attend Ward C2 at Hammersmith Hospital on four occasions. Preferably these study days 
will take place about one week apart. You will have the chance to taste the meals we will ask you to 
eat on the study days so you can say whether or not you can eat them. 
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Study Day Procedure 
The four study days will follow the same procedures and will be no longer than 4 hours. 
The first study day, will be a practice visit, but smaller volumes of blood will be taken and the blood 
samples will not be analysed. This is because gut hormones are easily influenced by stress and 
anxiety, therefore a practice visit will enable you to become accustomed to the environment. 
You will be asked not to eat or drink anything except water from 9pm the night before the study day 
and you will be asked to abstain from alcohol and strenuous exercise for the 24 hours before each 
visit. You will be asked to fill out a 24 hour food diary the day before the study visit and for 3 days 
following the study visit. 
When you arrive at 9.00hr you will be asked for the 24 hour food diary and you will be asked to sit 
down and you will have a plastic cannula placed into a vein in your arm. A cannula is a small plastic 
tube that is inserted into a vein for the use of obtaining blood samples. You may feel some discomfort 
while the cannula is being inserted, but it will be pain free once inserted. The cannula will be removed 
at the end of each study visit. You will remain seated throughout the 4 hours and you will be allowed 
to watch a DVD, read or watch TV. 
Blood samples will be taken from the cannula 6 times during the next 3.5 hours (see the diagram 
below). The amount taken in each blood sample is 10mls (about the same as 2 teaspoons). This means 
you will have no more than 60mls taken on any study day.  
Just before each blood sample is taken, you will answer a number of questions on a visual analogue 
scale (VAS). These are lines drawn on a piece of paper with a measure at each end, for example 
ranging from 'I am as hungry as I could possibly be' to 'I am as full as I could possibly be' and you 
will have to mark a point on the scale to indicate how you feel. 
 
Half an hour after the cannula is placed, and immediately after your first blood sample, you will be 
asked to eat a test meal. This will be either a low, medium or high protein meal in the form of a milk 
type pudding. You will not know which amount of protein the meal contains as it might alter how you 
respond and report hunger signs. 
At the same time a drink will also be provided that will contain 1.5g of paracetamol which we use to 
measure of how quickly your stomach is emptying. Paracetamol is not absorbed in the stomach but 
once it is released from the stomach into the small intestines it is absorbed rapidly. By measuring the 
level of paracetamol that appears in your blood we can work out how quickly your stomach empties 
after eating. 
After 3.5 hours, you will be presented with a large meal and invited to eat until you are comfortably 
full, and you will have to answer a number of questions as previously described, for example, ‘How 
hungry do you feel right now?’. The cannula will be removed and that will be the end of the study 
day. 
You will be given the same test breakfast meal to take home with you to consume for breakfast the 
following day. You will also be asked to abstain from eating your next meal until you feel the 
‘physiological drive to eat’. In other words, until you experience ‘hunger pangs’ or other physical 
symptoms and feelings of hunger. You will be asked to note down the exact time you ate the meal and 
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the time you consumed your following meal and the food type and quantity. You will be asked to 
continue recording food intake for the 3 days following the study day. 
 
Figure 1: Diagram of overview of study day. Participants will be asked to attend four study 
days. 
T0 T15 T30 T60 T120 T180
Cannula Placed
T-30
No BS or VAS
Test Meal
BS, BP, HR and 
VAS time points
Start of Study Day
Second Meal
End of Study Day
VAS only
BS = Blood Sample
BP= Blood Pressure
HR = Heart Rate
VAS = Visual Analogue Scale
 
Payments and Expenses 
If you decide to take part in this study we will provide a payment to cover your travel expenses and 
inconvenience. This will be about £25 for each study day plus your travel costs. The money will be 
paid into your bank account by Imperial College shortly after completion of the study. If you 
withdraw from the study at any time, you will receive payments for each visit you have attended. 
What are the possible disadvantages of taking part? 
You will be giving up your time and there may be some discomfort as the cannula is placed and in 
some people bruising may occur at the cannula site. 
What are the possible benefits of taking part? 
None. The information we get from this study may help to further our understanding of appetite and 
ageing. 
What happens if something goes wrong? 
Imperial College London holds insurance policies which apply to this study. If you experience serious 
and enduring harm or injury as a result of taking part in this study, you may be eligible to claim 
compensation without having to prove that Imperial College is at fault. This does not affect your legal 
rights to seek compensation. 
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If you are harmed due to someone’s negligence, then you may have grounds for a legal action. 
Regardless of this, if you wish to complain, or have any concerns about any aspect of the way you 
have been treated during the course of the study then you should immediately inform the Investigator 
(Charlotte Moss: 07588851564). The normal National Health Service complaints mechanisms are also 
available to you. If you are still not satisfied with the response, you may contact the Imperial AHSC 
Joint Research Office. 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept strictly 
confidential. All samples and records will be coded and labelled as such, so you cannot be recognised 
from it. Blood samples at the end of the study will be disposed of. 
What will happen to the results of the research study? 
We will be aiming to publish the results of this study in a scientific journal. Your confidentiality will 
be ensured at all times and you will not be identifiable in any report or papers we write. At the end of 
the study, the results of the study can be made available to you should you wish (please tell the 
researcher at one of your study visits). 
Who is organising and funding the study? 
This study is being organised by the Department of Metabolic Medicine, Imperial College London 
and Imperial College Healthcare NHS Trust. Funding for the study has been obtained from the 
Hammersmith Hospitals Charity Trustees Research Committee. 
Who has reviewed the study? 
This study has been reviewed by the Riverside Research Ethics Committee (08/H0706/128). 
Contact for further information 
If you have any questions you may contact researcher Charlotte Moss preferably via email at 
charlotte.moss08@imperial.ac.uk or by telephone on 07928123371. 
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10.10. Chapter 7 results  
 
10.10.1. Energy intake  
 
Table 10.11.  Chapter 7 energy intake in the 20-39 and 65+ age groups following 15%, 30% and 
60% protein test meals. 
 20-39 (n10) 65 + (n11) 
Median (IQ Range) Kcal Consumed at ad 
libitum test meal following test meal B (15%). 
723.99* 
(509.68- 1021.33) 
484.71 
(318.61 – 704.00) 
Median (IQ Range) Kcal Consumed at ad 
libitum test meal following test meal C (30%)  
727.57** 
(512.23-1167.61) 
522.61 
(332.96 – 760.00) 
Median (IQ Range) Kcal Consumed at ad 
libitum test meal following test meal D 60%). 
481.36 
(290.62 – 865.23) 
437.04 
(285.39 – 540.58) 
 
Geometric mean (IQ range) kcal consumed at the ad libitum test meal following the 15%, 30% and 
60% in the 20-39 and 65+ age groups. 
*p=0.006 vs. 60% protein test meal 
**p=0.022 vs. 60% protein test meal 
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Table 10.12. Chapter 7 Kcal consumed on whole of the test day in the 20-39 and 65+ age groups 
(includes ad libitum meal, preload and food consumed for the remainder of the day) 
 20-39  65 +  
Median (IQ Range) Kcal Consumed at 
ad libitum test meal following test meal 
B (15%). 
2346 
(2113.25 – 2968.5) 
N=8 
2022.0 
(1790.0 – 2201.5) 
N=9 
Median (IQ Range) Kcal Consumed at 
ad libitum test meal following test meal 
C (30%)  
2248.5 
(2053.25 – 2404.75) 
N=8 
2034.5 
(1788.25 – 2550.0) 
N=10 
Median (IQ Range) Kcal Consumed at 
ad libitum test meal following test meal 
D 60%). 
2713.0 
(2026.0 – 2840.0) 
N=7 
1985.50 
(1504.25 – 2436.25) 
N=8 
 
Median (IQ Range) Kcal consumed on test day following test meal B (15%), C (30%) and D (60%) in 
the 20-39 age group and the 65+ age group. 
 
Table 10.13. Chapter 7 percentage change in total energy intake between test day B (15%), C (30%) 
and D (60%) in the 20-39 and 65+ age groups 
(includes ad libitum meal, preload and food consumed for the remainder of the day) 
 20-39  65 +  Significance 
Percentage change in total energy 
intake on study days, in test condition 
B (15%) versus C (30%) 
 
+1.34% (9.42) 
(n7) 
 
10.19% (7.84) 
(n8)  
 
p=0.479 
Percentage change in total energy 
intake on study days, in test condition 
B (15%) versus D (60%) 
 
-2.42% (5.41) 
(n8) 
 
 
-1.81% (9.07) 
(n6) 
 
p=0.952 
Percentage change in total energy 
intake on study days, in test condition 
C (30%) versus D (60%) 
 
0.77% (8.36) 
(n7) 
 
 
-9.44% (5.85) 
(n8) 
 
p=0.326 
 
Mean (SEM) percentage change in total kcal consumption between test days B (15%) versus C (30%), 
B (15%) versus D (60%) and C (30%) versus D (60%) in the 20-39 and 65+ age group. No 
significance detected between age groups. 
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Table 10.14. Chapter 7 Time to eat next meal following protein test meals in the 20-39 and 65+ age 
groups 
 
 20-39  65 +  
Median (IQ Range) Time to eat next 
meal following test meal B (15%). 
4.0 
(2.75 – 5.38) 
n=9 
4.63 
(4.08 – 5.30) 
n=8 
Median (IQ Range) Time to eat next 
meal following test meal C (30%)  
4.25 
(2.25 – 6.0) 
n=7 
5.25 
(5.0 – 5.88) 
n=8 
Median (IQ Range) Time to eat next 
meal following test meal D 60%). 
5.0 
(4.63 – 6.75) 
n=8 
6.0 
(3.88 – 7.64) 
n=9 
 
Median (IQ Range) time to eat next meal following protein preload B (15%), C (30%) and D (60%) 
on day 2 following study day in the 20-39 and 65+ age group 
 
Table 10.15. Chapter 7 percentage change in time to consume next meal between test meal B, C and 
D in the 20-39 and 65+ age groups. 
 20-39  65 +  Significance 
Percentage change in time to consume 
next meal between test condition B 
(15%) versus C (30%) 
 
-5.12% (8.54) 
(n=7) 
 
+66.11% (45.40)  
(n=7) 
 
p=0.149 
 
Percentage change in time to consume 
next meal between test condition B 
(15%) versus D (60%) 
 
+185.77% (152.74) 
(n=7) 
 
+37.24% (25) 
(n=7) 
 
p=0.354 
 
Percentage change in time to consume 
next meal following the study between 
test condition C (30%) versus D (60%) 
 
+51.38% (21.07) 
(n=6) 
 
+4.86% (12.61) 
(n=7) 
 
p=0.076 
 
 
Mean (SEM) percentage difference in time to consume next meal between test conditions B versus C, 
B versus D, and C versus D in the 20-39 and 65+ age groups. No significance detected between age 
groups. 
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Table 10.16. Chapter 7 total energy intake on day 2 in the 20-39 and 65+ age group 
 20-39  65 +  
Mean (SEM) kcal consumed on day 
2 following test meal B (15%). 
2472.40 (198.42) 
n=10 
1982.00 (138.46) 
n=10 
Mean (SEM) kcal consumed on day 
2 following test meal C (30%)  
2546.77 (198.67) 
n=9 
1921.40 (186.66) 
n=10 
Mean (SEM) kcal consumed on day 
2 following test meal D 60%). 
2254.89 (168.34) 
n=9 
 
1521.11 (127.80) 
n=9 
 
Mean (SEM) kcal consumed on day 2 following test meal B, C and D in the 20-39 and 65+ age group 
 
Table 10.17. Chapter 7 mean (SEM) percentage change in kcal consumed on the day after the study 
visit (day 2) between test meal conditions B, C and D in the 20-39 and 65+ age group 
 20-39  65 +  Significance 
Percentage change in kcal consumed at 
day 2 between test condition B (15%) 
and C (30%) 
 
+9.62% (12.73) 
(n=9) 
 
-2.10% (8.64) 
(n=8) 
 
p=0.470 
 
Percentage change in kcal consumed at 
day 2 between test condition B (15%) 
and D (60%) 
 
-8.45% (8.07) 
(n=10) 
 
-18.69% (5.79) 
(n=11) 
 
p=0.330 
 
Percentage change in kcal consumed at 
day 2 between test condition C (30%) 
and D (60%) 
 
-11.07% (9.18) 
(n=10) 
 
-10.93% (9.07) 
(n=8) 
 
p=0.992 
 
 
Mean (SEM) percentage change in kcal consumed at day two (day following study visit) between test 
meal conditions B versus. D, B versus D and C versus D in the 20-39 and 65+ age groups. No 
significance detected between percentage change scores between the two age groups. 
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10.10.2. Visual Analogue Scales 
 
Table 10.18. Chapter 7 AUC Visual Analogue Scores; how hungry, how sick, how pleasant to eat, 
how much can you eat and how full in the 20-39 and 65+ age group following test meal conditions B, 
C and D. 
 20-39 (n=10) 65 + (n=11)  
Mean (SEM) How Hungry AUC 
AUC following test meal B (15%). 7405.50 (1141.46) 3638.86 (546.90) 
AUC following test meal C (30%)  7887.75 (1217.58) 
 
4264.09 (692.58) 
 
AUC following test meal D (60%). 7493.25 (1408.06) 3405.68 (620.42) 
Mean (SEM) How sick AUC  
AUC following test meal B (15%). 1746.75 (501.91) 646.36 (188.01) 
AUC following test meal C (30%)  1457.25 (457.86) 444.55 (137.40) 
AUC following test meal D (60%). 1137.00 (241.21) 555.68 (150.11) 
Mean (SEM) How pleasant to eat AUC  
AUC following test meal B (15%). 8641.50 (924.43) 4670.45 (730.94) 
AUC following test meal C (30%)  8915.25 (890.63) 4497.95 (788.43) 
AUC following test meal D (60%). 7596.00 (954.59) 4230.68 (725.82) 
Mean (SEM) How much can you eat AUC  
AUC following test meal B (15%). 8152.50 (949.17) 4037.73 (458.32) 
AUC following test meal C (30%)  8831.25 (913.77) 4872.27 (749.29) 
AUC following test meal D (60%). 7902.00 (1122.74) 3745.91 (482.66) 
Mean (SEM) How full AUC  
AUC following test meal B (15%). 6899.25 (867.13) 10323.41 (959.22) 
AUC following test meal C (30%)  6477.75 (1108.19) 8661.14 (1256.65) 
AUC following test meal D (60%). 8400.75 (1026.24) 8695.91 (1348.54) 
 
Mean (SEM) how hungry, how sick, how pleasant to eat, how much can you eat and how full AUC 
following text meal, B, C and D in the 20-39 and 65+ age group. 
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Table 10.19. Chapter 7 Percentage change in VAS scores; how hungry, how sick, how pleasant to eat, 
and how much can you eat following  test meal conditions B (15%), C (30%) and D (60%) in the 20-
39 and 65+ age groups 
 20-39 (n10) 65 + (n11) Significance? 
Mean (SEM) Percentage change in how hungry AUC scores 
Percentage change scores between test 
conditions B (15%) to C (30%) 
 
+14.97% (9.88) 
 
+18.81% (12.27) 
 
p=0.812 
Percentage change scores between test 
conditions B (15%) to D (60%) 
 
+4.01% (12.72) 
 
+2.63% (12.10) 
 
p=0.938 
Percentage change scores between test 
conditions C (30%) to C (60%) 
 
-5.72% (12.93) 
 
-9.75% (11.51) 
 
p=0.818 
Geometric Mean (IQ Range) Percentage change in how sick AUC scores 
Percentage change scores between test 
conditions B (15%) to C (30%) 
-36.42% 
(-61.82 – 104.99) 
0.00% 
(-51.28 – 4.80) 
 
p=0.345 
Percentage change scores between test 
conditions B (15%) to D (60%) 
-18.97% 
(-69.75 – 76.61) 
-16.32% 
(-43.59 – 13.16) 
 
p=0.568 
Percentage change scores between test 
conditions C (30%) to D(60%) 
+45.17% 
(-42.97 – 120.05) 
+9.09% 
(0.00 – 15.79) 
 
p=0.700 
Mean (SEM) Percentage change in how pleasant to eat AUC scores 
Percentage change scores between test 
conditions B (15%) versus C (30%) 
 
+6.37% (7.37) 
 
+2.01% (11.38) 
 
p=0.757 
Percentage change scores between test 
conditions B (15%) to D (60%) 
 
-12.19% (6.47) 
 
-1.58% (11.18) 
 
p=0.434 
Percentage change scores between test 
conditions C (30%) versus D (60%) 
 
-13.01% (9.95) 
 
-0.04% (10.35) 
 
p=0.380 
Mean (SEM) Percentage change in how much can you eat AUC scores 
Percentage change scores between test 
conditions B (15%) to C (30%) 
 
+13.33% (9.16) 
 
+31.85% (19.72) 
 
p=0.420 
Percentage change scores between test 
conditions B (15%) to D (60%) 
 
-2.75% (8.40) 
 
+6.07% (15.54) 
 
p=0.633 
Percentage change scores between test 
conditions C (30%) to D (60%) 
 
-9.87% (10.05) 
 
-11.74% (10.74) 
 
p=0.901 
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Table 10.19. continued Mean (SEM) percentage change scores for how hungry, how pleasant to eat, 
how much can you eat and Geometric Mean (IQ Range) AUC scores in the 20-39 (n=10) and 65+ 
years (n=11) age group between protein test meals B (15%), C (30%) and D (60%).  
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10.10.3. Plasma hormone analysis 
 
Table 10.20. Chapter 7 AUC scores; PYY, GLP-1, Acyl Ghrelin, insulin and glucose following test 
meals B, C and D in the 20-39 and 65+ age group. 
 20-39 (n=10) 65 + (n=11)  
Geometric Mean (IQ Range) PYY AUC 
AUC following test meal B (15%). 4826.44 
(4270.20 – 5534.59) 
4922.54 
(3988.13 – 6641.78) 
AUC following test meal C (30%)  4647.68 
(4149.49 – 5315.78) 
4810.95 
(3168.08 – 7873.65) 
AUC following test meal D (60%). 5285.27 
(4091.68 – 6556.41) 
4570.87 
(3167.70 – 6713.53) 
Geometric Mean (IQ Range) GLP-1 AUC  
AUC following test meal B (15%). 5999.65 
(4603.41 – 8986.50) 
5700.93 
(4213.65 – 6756.98) 
AUC following test meal C (30%)  5461.72 
(4697.10 – 6791.59) 
5791.85 
(3862.35 – 6507.60) 
AUC following test meal D (60%). 6665.13 
(5413.07 – 8703.43) 
6539.55 
(4695.75 - 7882.43) 
Geometric Mean (IQ Range) Acyl Ghrelin AUC  
AUC following test meal B (15%). 20710.03 
(4863.01) 
25964.02 
(4287.21) 
AUC following test meal C (30%)  18366.84 
(3601.61) 
26401.87 
(4101.80) 
AUC following test meal D (60%). 18559.17 
(3810.48) 
27591.22 
(3798.25) 
Median (IQ Range) Insulin AUC  
AUC following test meal B (15%). 7617.49 
(6827.60 – 10134.41) 
7258.18 
(6490.56 – 11118.06) 
AUC following test meal C (30%)  8314.19 
(5303.86 – 11318.52) 
8451.57 
(7232.03 – 12857.42) 
AUC following test meal D (60%). 9167.50 
(6929.45 – 11563.94) 
7054.41 
(6028.39 – 9422.69) 
Median (IQ Range) Glucose AUC  
AUC following test meal B (15%). 930.26 
(863.44 – 975.51)  
1096.58 
(1038.23 – 1183.50) 
AUC following test meal C (30%)  886.69 
(786.45 – 1000.91) 
1005.90 
(945.00 – 1091.40) 
AUC following test meal D (60%). 898.73 
(879.47 – 948.51) 
969.90 
(899.25 – 992.03) 
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Table 10.20. continued. Geometric mean (IQ Range) AUC PYY, GLP-1 and Acyl Ghrelin and Median 
(IQ Range) AUC Insulin and Glucose in the 20-39 and 65+ age group following protein test meals B 
(15%), C (30%) and D (60%). 
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Table 10.21. Chapter 7 percentage change in PYY, GLP-1, acyl ghrelin and glucose scores following 
test meal conditions B (15%), C (30%) and D (60%) in the 20-39 and 65+ age groups 
 20-39 (n10) 65 + (n11) Significance? 
Mean (SEM) Percentage change in PYY AUC scores 
Percentage change scores between test 
conditions B (15%) to C (30%) 
 
+0.39% (7.73) 
 
+2.18% (9.36) 
 
p=0.885 
Percentage change scores between test 
conditions B (15%) to D (60%) 
 
+15.91% (13.91) 
 
-2.32% (6.34) 
 
p=0.233 
Percentage change scores between test 
conditions C (30%) to D (60%) 
 
+12.16% (8.27) 
 
+6.47% (13.17) 
 
p=0.725 
Median (IQ Range) Percentage change in GLP-1 AUC scores 
Percentage change scores between test 
conditions B (15%) to C (30%) 
-6.84% 
(-18.59 – 0.14) 
+3.35% 
(-24.77 – 11.96) 
 
p=0.305 
Percentage change scores between test 
conditions B (15%) to D (60%) 
+14.24% 
(-11.65 – 34.17)  
+23.36% 
(-22.55 – 37.22) 
 
p=0.888 
Percentage change scores between test 
conditions C (30%) to D (60%) 
+23.94% 
(-3.19 – 42.43) 
+24.59% 
(6.34 – 29.88) 
 
p=0.573 
Median (IQ Range) Percentage change in acyl ghrelin AUC scores 
Percentage change scores between test 
conditions B (15%) to C (30%) 
-6.77% 
(-16.59 – 1.53) 
+7.56% 
(-21.54 – 44.12) 
 
p=0.181 
Percentage change scores between test 
conditions B (15%) to D (60%) 
-8.79% 
(-26.82 – 4.65) 
-1.27% 
(-17.44 – 51.32) 
 
p=0.291 
Percentage change scores between test 
conditions C (30%) to D (60%) 
-6.29% 
(-19.11 – 22.12) 
-4.49% 
(-17.25 – 21.46) 
 
p=0.888 
Mean (SEM) Percentage change in glucose AUC scores 
Percentage change scores between test 
conditions B (15%) to C (30%) 
 
-4.61% (5.02) 
 
-8.11% (3.53) 
 
p=0.570 
Percentage change scores between test 
conditions B (15%) to D (60%) 
 
-4.25% (3.72) 
 
-12.82% (2.63) 
 
p=0.071 
Percentage change scores between test 
conditions C (30%) to D (60%) 
 
+1.49% (3.80) 
 
-4.55% (2.46) 
 
p=190 
 
Mean (SEM) percentage change in PYY glucose AUC concentrations  and Median (IQ Range) 
percentage change in GLP-1 and Acyl Ghrelin concentrations in the 20-39 (n=10) and 65+ years 
(n=11) age group between protein test meals B (15%), C (30%) and D (60%).  No significance 
detected between percentage change scores between the 20-39 and 65+ age groups. 
 
368 
 
Table 10.22. Chapter 7 post-prandial Insulin Resistance Scores following test meals B, C and D in the 
20-39 and 65+ age groups 
 20-39 (n=10) 65 + (n=11)  
Median (IQ Range) HOMA-PP 
scores following test meal B (15%). 
2383.88 
(274.94 – 6876.61)  
7427.93 
(1986.17 – 8851.53) 
Median (IQ Range) HOMA-PP 
scores following test meal C (30%)  
2005.08 
(74.61 – 6193.72) 
3319.49 
(1433.73 – 6148.30) 
Median (IQ Range) HOMA-PP 
scores following test meal D (60%). 
1121.97 
(184.61 – 2214.88) 
1095.24 
(285.93 – 2897.34) 
 
Median (IQ Range) HOMA-PP scores in the 20-39 (n=10) and the 65+ (n=11) age group following 
protein test meal B (15%), C (30%) and D (60%). 
 
Table 10.23.  Chapter 7 gastric emptying times following test meal B, C and D in the 20-39 and 65+ 
age group 
 
 20-39 (n=10) 65 + (n=11)  
Median (IQ Range) peak gastric 
emptying time following test meal B 
(15%). 
180.00 
(105.00 – 180.00)  
120.00 
(120.00 – 180.00) 
Median (IQ Range) peak gastric 
emptying time following test meal C 
(30%)  
45.00 
(30.00 – 60.00) 
30.00 
(30.00 – 120.00) 
Median (IQ Range) peak gastric 
emptying time following test meal D 
(60%). 
30.00 
(22.50 – 90.00) 
60.00 
(30.00 – 180.00) 
 
Median (IQ Range) Gastric emptying time in the 20-39 (n=10) and 65+ (n=11) age group following 
test meal B (15%0, C (30%) and D (60%). 
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Table 10.24. Chapter 7 percentage change in peak paracetamol times in test meal conditions B 
(15%), C (30%) and D (60%) in the 20-39 and 65+ age groups 
 20-39 
Median (IQ range) 
65 +  
Median (IQ range) 
Significance? 
Percentage change peak 
paracetamol time in test 
condition B (15%) versus C 
(30%) 
 
-70.83% 
(-83.33 – 12.5) 
(n=10) 
 
-75.00% 
(83.33 – 0.00) 
(n=11) 
 
p=0.892 
Percentage change in peak 
paracetamol time in test 
condition B (15%) versus D 
(60%) 
 
-66.66% 
(-85.4 - -16.67) 
(n=9) 
 
-50.00% 
(-75.00 – 50.00) 
(n=11) 
 
p=0.745 
Percentage change in peak 
paracetamol time test 
condition C (30%) versus D 
(60%) 
 
0.00% 
(-50.0 – 200.00) 
(n=9) 
 
0.00% 
(0.00 – 100.00) 
(n=11) 
 
p=0.678 
 
Median (IQ range) percentage change peak paracetamol time in the 20-39 and 65+ years age group 
between protein test meals B (15%), C (30%) and D (60%).  No significance detected between 
percentage change scores between the 20-39 and 65+ age groups. 
 
 
